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Abstract 
 
Background 
Each year, approximately 10% of people diagnosed with tuberculosis (TB) globally 
have previously received TB treatment, and are prescribed a standardised WHO 
‘Category II regimen’ which includes daily intramuscular injections of streptomycin. 
Treatment success rates on this re-treatment regimen are low,  yet reasons for poor 
outcomes are not well understood. Currently data are lacking about appropriate 
ways to deliver long term injectable agents used as part of TB treatment.  
 
Methods 
The study was conducted in Malawi, a small country in South-Eastern Africa with a 
high TB burden and a generalised HIV epidemic. A cohort study prospectively 
recruited adult patients receiving retreatment regimen. Patients were assessed at 
baseline, 2 and 8 months. Multivariate logistic regression analysis was used to 
determine associations between clinical outcome and microbiologically confirmed 
TB, drug resistance, clinical features at presentation and medical co-morbidities. A 
pragmatic, individually randomised trial assessed hospital versus community-based 
care during the intensive phase of TB retreatment. In the community arm guardians 
were trained to deliver intramuscular injections of streptomycin at home. An 
economic evaluation was conducted from a societal perspective; and a qualitative 
evaluation involved in depth interviews with trial participants, key informant 
interviews, and observations.  
 
Results 
In the cohort study, the prevalence of drug resistance was 9.6%. The prevalence of 
co-morbidity was high (HIV 82.9%; antiretroviral therapy failure 37.5%; severe 
anaemia 22.2%; chronic lung disease 88.2%; renal impairment 33.8%). Ototoxicity 
developed in 35.9% and nephrotoxicity in 14.6%. In multivariate analysis, successful 
outcome was associated only with hypotension at presentation, but not 
microbiologically confirmed TB, drug resistance or other co-morbidities. In the trial, 
93.2% of patients who received community-based care successfully completed 2 
months treatment, compared to 96.0% managed in hospital (RD -0.03; 95%CI -0.09 - 
0.03). The mean cost of hospital-based care was US$ 1546 per person, compared to 
US$ 729.2 in the community. Community-based management reduced risk of 
catastrophic household costs by 84%. Qualitative data demonstrated social and 
financial benefits of community-based care.  
 
Conclusions 
This cohort study demonstrated a low prevalence of drug resistant TB but a high 
burden of medical co-morbidity in patients with recurrent TB in Malawi. Co-
morbidity is likely to be contributing to poor outcomes on TB retreatment regimen. 
A novel community-based model of delivering injectable anti-TB drugs by training 
guardians to do injections at home is shown to be feasible, acceptable and highly 
cost effective. 
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1 Introduction and literature review 
 
1.1 Introduction 
1.1.1.1  
Of the 6.1 million people worldwide reported to have tuberculosis (TB) in 2013, 
600,000 were registered as having previously received TB treatment. These patients 
receive a regimen which has little evidence base, have consistently poor treatment 
outcomes, and are required to have daily intramuscular injections of streptomycin 
for the first 2 months of treatment. It is for these reasons that recurrent TB places a 
disproportionate burden on patients, households and health systems. Although the 
rates of successful completion of TB retreatment are low, no prospective study has 
systematically attempted to address why this is so. Additionally, there is a lack of 
evidence for appropriate approaches to the delivery of injectable agents as a part of 
TB treatment. This thesis therefore addresses two key issues for patients with 
recurrent tuberculosis: why so many fail to complete treatment, and how injectable 
agents can best be delivered using a novel approach to community-based care.  
 
This introductory chapter reviews the current literature on issues relevant to the 
management of recurrent tuberculosis (TB). It begins by providing a general 
summary of key concepts in the epidemiology, clinical features and control of 
tuberculosis both globally and in Malawi, before going on to focus on retreatment 
TB in more detail. A systematic review of the literature on clinical outcomes in 
treatment for recurrent TB is then presented, following which reasons for poor 
outcomes on treatment are explored, such as co-morbidity and toxicity of anti-
tuberculous drugs. Finally, evidence is examined for community and hospital-based 
approaches to the delivery of injectable anti-tuberculosis drugs.    
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1.2 Tuberculosis 
 
Tuberculosis (TB) has plagued humankind since ancient times [1], and is likely to 
have been responsible for killing more people than any other pathogen [2]. Since 
the tubercle bacillus was discovered by Robert Koch in 1882 [3], there have been 
great advances in diagnosis and management of the disease. Yet it remains a global 
public health problem, causing nearly 9 million cases and 1.5 million deaths 
annually [4], predominantly in low and middle income countries (figure 1).  
Tuberculosis still disproportionately affects the poorest and most vulnerable 
members of society - it therefore has implications beyond clinical disease and 
cannot be viewed in isolation from the social and financial burdens with which it is 
frequently associated [5]. 
 
 
Figure 1. Global incidence of tuberculosis. Global tuberculosis report, 2014 [4]. 
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1.2.1 Microbiology and pathogenesis of tuberculosis 
 
The bacterium Mycobacterium tuberculosis is a member of a group of organisms 
known as the M. tuberculosis complex, which also includes its close relatives M. 
africanum and M. bovis [6].  It is transmitted between human hosts by inhalation of 
aerosolised droplets, and once in the lungs predominantly infects alveolar 
macrophages [7]. Following a brief phase of haematogenous spread, a series of 
immunological responses then result in the formation of the characteristic 
tuberculous granuloma whose primary function is to contain replication and 
prevent dissemination of mycobacteria beyond the lungs [8]. In a minority of 
people, symptomatic active disease, usually limited to the thoracic cavity, develops 
at this stage. However, in approximately 90% of infected individuals infection 
remains latent, often for many decades [9]. Disease can reactivate at any time, 
usually in response to immunosuppression by factors such as HIV, 
immunosuppressive drugs, diabetes, alcoholism, malnutrition or stress [10]. During 
active pulmonary disease, granulomas within the lung parenchyma caseate and 
eventually rupture, releasing thousands of infectious bacilli into the airways. This 
causes the infected individual to cough, aerosolising and therefore facilitating 
further transmission of mycobacteria [11].  
 
Figure 2. The pathogenesis of M. tuberculosis. From Rook et al [10] 
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1.2.2 Clinical features, presentation and management of tuberculosis 
 
The clinical features of tuberculosis relate to the site of active disease and are 
frequently accompanied by constitutional symptoms such as fever, night sweats 
and weight loss. Pulmonary tuberculosis classically presents with chronic cough, 
sputum production and haemoptysis. Extra-pulmonary disease occurs in 10 to 42% 
of patients [12], and can affect almost any organ including pleura, central nervous 
system, pericardium, skeleton, lymph nodes, bone marrow, genito-urinary tract, 
gastrointestinal tract and skin [13]. People who are HIV infected are not only at 
increased risk of developing TB, they also present less frequently with classic 
features of pulmonary tuberculosis, and are more likely to have disseminated 
disease (section 1.6.1). 
 
The lack of a good diagnostic tool for tuberculosis has been one of the major 
challenges in TB control. For many years, the diagnosis of tuberculosis depended 
entirely on the demonstration of bacilli in the sputum using the staining technique 
developed by Ziehl and Neelsen in the 1890s [14]. Although relatively inexpensive 
and technically uncomplicated, sputum smear microscopy lacks sensitivity, despite 
advances such as the introduction of LED microscopy [15, 16].  Culture of 
mycobacteria on solid media was developed in the 1930s by Lowenstein and Jensen 
which improved sensitivity, but its application is still hampered by long incubation 
times. Since then, liquid culture techniques have significantly reduced time to 
detection and increased sensitivity further, and are now replacing solid culture as 
the gold standard of TB diagnosis [17]. More recently, ground-breaking discoveries 
in the use of molecular techniques have brought about the Xpert ®MTB/RIF (GXP) 
and Line Probe Assays which offer not only the opportunity of rapid diagnosis but 
also the ability to detect drug resistance in real time [18, 19]. Nevertheless, these 
tests still pose technical and financial challenges and their impact on patient 
important outcomes in operational situations is still debated [20].  
 
Streptomycin (S), the first drug for the treatment of tuberculosis, was developed in 
1946. By 1948 the first randomised clinical trial was conducted by the British 
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Medical Research Council in which streptomycin was shown to reduce mortality 
from tuberculosis [21]. However, it soon became clear that therapy using only a 
single drug rapidly resulted in the development of drug resistance [22], and ever 
since that time anti-tuberculous agents have been used in combination. During the 
following decades, combination ‘short course’ chemotherapy was developed based 
on a series of clinical trials which demonstrated that both rifampicin and 
pyrazinamide were required in the regimen; that rifampicin was sterilizing 
throughout treatment; and that the minimum period for the intensive phase was  
two months [23]. The 2010 World Health Organisation Guidelines for the Treatment 
of Tuberculosis recommend two standardised first-line combination regimens. 
Firstly, all new patients with pulmonary TB should receive a six month regimen 
consisting of a two month ‘intensive phase’ of Rifampicin (R), Isoniazid (H), 
Pyrazinamide (Z) and Ethambutol (E); followed by a four month ‘continuation 
phase’ of RH. Secondly, all patients presenting with tuberculosis who have 
previously received treatment should receive the extended ‘Category II’ or 
‘retreatment’ regimen, which consists of 2RHZES/1RHZE/5RHE [24].  
 
1.2.3 The recent epidemiology of tuberculosis 
 
Over the past three decades, the emergence of Multidrug-resistant TB (MDR-TB) 
has posed a major threat to efforts aimed at controlling TB, particularly in Eastern 
Europe, parts of Sub-Saharan Africa, South America, and Asia [25]. Patients infected 
with a strain of M. tuberculosis which is resistant in vitro to both rifampicin and 
isoniazid require lengthy treatment, which currently consists of one injectable agent 
and at least four other second-line drugs, most of which have poorer efficacy and 
greater toxicity than first line agents [26]. Extensively drug-resistant TB (XDR-TB) is 
defined as MDR-TB plus resistance to any quinolone and any injectable agent, and 
outcomes for people infected with XDR-TB are extremely poor [27].  
 
 
In addition to MDR-TB, the global response to TB has had to face the increasing 
problem of co-infection with HIV, particularly in Sub-Saharan Africa. Whilst it is 
Asian countries which have the highest number of TB cases globally, the HIV 
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epidemic in Sub-Saharan Africa has fuelled the highest incidence rate of in the 
world, where HIV prevalence amongst new TB cases is >50% in many countries 
(figure 3). The close association between TB and HIV led to a peak in global 
incidence rates in 2004, which has been gradually declining since then (figure 4).  
 
A major challenge in TB control is to address the issue that tuberculosis has 
historically been, and still is, strongly associated with poverty.  Currently, of the 22 
high TB burden countries, 17 are classified as low or lower-middle income [28], and 
the incidence rate of tuberculosis has been declining more quickly in countries with 
a higher human development index [29].  Factors which drive the association 
between low socio-economic status and tuberculosis include increased risk of 
transmission because of higher rates of contact with infectious cases; over-crowded 
and poorly ventilated living and working conditions;  increased progression from 
infection to disease driven by factors such as poor nutrition; and reduced access to 
good health care [5, 30-32]. The link between poverty and tuberculosis is further 
driven by the costs of diagnosis and care which frequently worsen already fragile 
economic situations in households affected by tuberculosis [33, 34].  
 
 
Figure 3. HIV prevalence amongst new TB cases [35] 
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Figure 4. TB incidence according to region. Data from Zumla et al [12] 
 
 
  
1.3 Tuberculosis retreatment 
 
Each year, approximately 11% of all people registered for TB treatment have 
previously received treatment [4]. These patients fall into a number of categories 
(table 1) [36]1. In 2013, of the 6.1 million people notified to National TB Control 
Programmes worldwide, 0.3 million were classified as ‘relapse’, and a further 0.4 
million had either failed, defaulted or been previously treated for another reason.  
 
Table 1. WHO definitions of TB retreatment category 
Category Definition 
Relapse A patient previously treated for TB, declared cured or treatment 
completed, who is diagnosed again with smear or culture positive TB 
Treatment after failure A patient who is stared on retreatment regimen after having failed 
previous treatment 
Treatment after default A patient who returns to treatment, positive bacteriologically, following 
interruption of treatment for 2 or more consecutive months 
Other previously treated All previously treated cases that do not fit any of the above definitions. 
e.g. previously treated smear negative cases, previously treated EPTB 
                                                     
1 In 2013, new definitions were produced by the WHO, however the 2006 definitions are used in this 
thesis, as the study protocol was devised prior to publication of the revised guidelines. 
(http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf). 
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Recurrence of tuberculosis can be caused by two distinct mechanisms. Firstly, 
disease can be caused by relapse of the original infecting mycobacterial strain (note 
the difference between this definition and the operational definition of ‘relapse’ in 
table 1). Secondly, patients can be exogenously re-infected with an entirely new 
strain, unrelated to the one which caused their first episode [37]. Molecular 
techniques allow differentiation between re-infection and relapse by analysing 
strains isolated from sputum collected during an initial episode, and comparing 
them to strains isolated from subsequent episodes [38]. Patterns of relapse and 
reinfection are strongly associated with HIV status - work from South Africa [39, 40], 
India [41] and Malawi [42, 43] has consistently demonstrated that HIV infection is 
associated with re-infection, but not with relapse. Possible explanations for this are 
that HIV positive patients remain at increased risk of reinfection because of on-
going impaired immunity and increased exposure (e.g. from frequent contact with 
health care facilities).  
 
It has long been clear that recurrence is most common in the first two years 
following an initial episode [44]. However, once again, genetic analysis of 
mycobacterial strains has meant that it has been possible to distinguish temporal 
patterns of relapse and reinfection. For example, large studies in Northern Malawi 
and Cape Town have recently used genomic sequencing to show that most relapse 
occurs in the first year, but that recurrence due to reinfection is rare during the first 
year [45, 46]. It is perhaps unsurprising therefore that relapse is associated with 
unsuccessful initial treatment and drug resistance [43]; whereas reinfection is more 
likely to suggest inadequate development of protective immunity and on-going 
exposure.  
 
Due to the increased risk of drug resistance in this group, it is crucial that all 
patients being ‘retreated’ for TB have sputum examined for Drug Sensitivity Testing 
(DST), using either genotypic or phenotypic methods [24]. However, in many areas 
of the world, access to DST still poses significant challenges. WHO policy states that 
previously treated patients who are not diagnosed with MDR-TB should receive the 
standardised WHO Category II regimen.  There is a lack of clinical trial evidence to 
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suggest efficacy of this regimen, which was developed by expert consultation in the 
1990s. Additionally, it puts patients at a potentially increased risk of drug toxicity 
due to the longer duration and greater number of drugs; and brings with it 
operational problems of delivering daily injectable agents during the intensive 
phase. Nevertheless, a Global Consultation on Retreatment Regimens in 2009 did 
not suggest the discontinuation of Category II treatment [47], and the most recent 
WHO guidelines in 2010 still recommend the empiric use of routine Category II 
regimen in settings where the prevalence of MDR-TB is low and DST is not available 
[24]. 
 
 
1.4 Tuberculosis in Malawi 
 
1.4.1 Demographic and health indicators in Malawi 
 
Malawi is a land locked country in the south-east of Africa with an area of 
approximately 120,000 square kilometres. In 2013, the population was estimated at 
16,363,000, of whom 84% lived in rural areas [48]. The World Bank recently rated 
Malawi the poorest country in the world, with a GDP per capita of only $253 [49], 
and just over 50% of the population living below the poverty line [50].  The literacy 
rate in people aged 15 years and older is 65%, but is higher in men (74%) than 
women (57%). According to the 2010 Malawi Demographic health survey, 19% of 
women and 11% of men had received no formal education. Only 17% of women 
and 26% of men had completed primary school [51]. Seventy-two percent of 
households have access to improved sanitation facilities; and 79% have access to an 
improved water source, although only 3% have piped water into their dwelling [52]. 
 
Between the years 2000 and 2012, life expectancy at birth increased from 45 years 
to 59 years. However, healthy life expectancy is only 50 years, and 45% of the 
population are under the age of 15 years (figure 5) [48]. Under-five mortality 
remains high at 68 per 1000 live births [53].  
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Figure 5. Population pyramid for Malawi, 2011. [52] 
 
 
Malawi spends 8.4% of its total GDP on health, but The Ministry of Health still relies 
on external donors such as USAID, The Global Fund, and PEPFAR to provide 50% of 
its funding. Despite this support, per capita expenditure on health is still less than 
$20 per annum, and there are only 0.2 physicians per 10,000 people (compared to 
27.7 in the UK) [54].  
 
The public health system in Malawi is four tiered, and consists of community, 
primary, secondary and tertiary care levels. At the community level, care is provided 
by Health Surveillance Assistants. Primary care is accessed through a large network 
of health centres and clinics. Twenty one district hospitals provide secondary care, 
and tertiary services are available at four central hospitals – in Lilongwe, Blantyre, 
Mzuzu and Zomba.  
 
The HIV prevalence in Malawian adults aged 15-49 years is 10.3%, and HIV remains 
the leading cause of death, killing over 48,000 people in 2012 [55]. However, the 
number of new infections has been slowly declining since 2000, and it is estimated 
that 69% of those eligible for ART are on treatment [55]. HIV care is co-ordinated 
centrally using standardised treatment regimens. When ART was initially rolled out 
in 2004, a fixed dose combination of Stavudine, Lamividine and Nevirapine was 
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used. This has since been replaced, first for patients on TB treatment and then for 
the whole population, with a once daily combination of Tenofovir, Lamivudine and 
Efavirenz [56]. 
 
 
1.4.2 Tuberculosis control in Malawi 
 
The incidence of TB in Malawi in 2013 was 156 per 100,000 persons, the lowest it 
has been for over three decades (figure 6) [4]. Due to the increase in population size 
however, this still amounted to nearly 20,000 case notifications. According to 
official reports, it is estimated that the TB case detection rate is 70%, although a 
recent prevalence survey is likely to demonstrate significantly lower case detection 
rates (unpublished data from Malawi NTP). HIV status is known in 92% of patients 
with TB, and the HIV prevalence amongst TB patients is 56%. A major contributing 
factor to the decline in TB incidence seen in figure 6 was presumably the country-
wide roll out of ART in 2004. An initial increase in TB notifications was likely due to 
better detection of TB through scale up of ART services, but the gradual decline in 
incidence is most probably ascribed to the protective effect of ART [57]. Other 
factors which may also have contributed include improved diagnostics and 
improved socio-economic situation of the population. Currently, 88% of HIV positive 
TB patients are on ART, and 90% are prescribed cotrimoxazole preventive therapy.   
 
 
Figure 6. TB incidence in Malawi. WHO Country profile 2014 
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A nation-wide survey conducted in Malawi between 2010-2011 demonstrated a 
very low prevalence of TB drug resistance (table 2). Only 0.4% of new patients and 
4.8% of patients starting retreatment were found to have MDR-TB. 93.3% of new 
patients were infected with a strain of M. tuberculosis which was sensitive to all 
first-line drugs [58].  
 
Table 2. Drug resistance profiles of MTB isolates in Malawi, 2010-2011 
 
 
 
The declining TB incidence, low prevalence of primary drug resistance, and >85% 
successful treatment completion in new patients indicate the strength of the 
Malawi National TB Control Programme. The NTP has historically administered a 
vertical programme, implementing the WHO recommended DOTS strategy since 
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1984 [59]. In line with the Ministry of Health’s Sector Wide Approach to health 
development, the NTP began a process of decentralisation in 2005, aiming to 
increase equity in access to TB care [60]. There are currently 276 smear microscopy 
stations, and 247 registration centres across the country (data from Malawi NTP). 
 
1.4.3 Retreatment tuberculosis in Malawi 
 
Of the 19,539 TB notifications in Malawi in 2013, 2249 (11.6%) patients were 
prescribed retreatment regimen.  Only 669 (29.7%) of these had microbiologically 
confirmed disease and were categorised as ‘relapse’ [4]. NTP policy states that all 
patients starting retreatment should have a sputum sample sent to the Central 
Reference Laboratory in Lilongwe for drug sensitivity testing, and, where available, 
GXP should be performed locally. But in 2013, sputum samples were analysed for 
rifampicin or multidrug-resistance in only 20% of patients who received 
retreatment [4]. All patients are managed with the standard WHO Category II 
retreatment regimen [61]. During the first 60 days of treatment, patients are 
admitted to their local district hospital in order to facilitate the administration of 
daily streptomycin injections. Despite a relatively well run TB control programme in 
Malawi, of previously treated cases in 2013 (excluding relapse) only 57% had 
successful clinical outcome on retreatment regimen [4].  
 
1.5 Clinical outcomes on TB retreatment regimen: A systematic review  
 
 
1.5.1 Background 
 
In 1991 the World Health Assembly set a global target to cure of 85% of patients 
who receive treatment for TB and are sputum smear positive [62]. This was based 
not only on the implications for improving clinical outcomes in individual patients, 
but also on the potential for successful treatment to reduce further transmission, 
and therefore the number of new TB infections [63]. Millennium Development Goal 
number six is to “combat HIV/AIDS, malaria and other diseases.” Encompassed in 
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this goal, two indicators relate specifically to TB: the “prevalence and death rates 
associated with tuberculosis” (indicator 23), and the “proportion of tuberculosis 
cases detected and cured under DOTS” (indicator 24) [64]. The Stop TB Partnership 
endorsed these indicators, and targets set by the Stop TB Strategy state that 
“national programmes around the world must not only reach at least 70% case 
detection and 85% treatment success, but also implement a wider range of 
activities”, including by 2015 a reduction of TB disease prevalence and deaths by 
50% relative to 1990 levels [65]. ‘Success’ in TB treatment is defined as the sum of 
all patients cured and treatment completed (table 3). 
 
Table 3. WHO definitions of treatment outcomes for TB patients [66] 
Outcome Definition 
Cured A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear or culture negative in the last 
month of treatment and on at least one previous occasion 
Treatment completed A TB patient who completed treatment without evidence of failure 
BUT with no record to show that sputum smear or culture results in 
the last month of treatment and on at least one previous occasion 
were negative 
Treatment failed A TB patient whose sputum or culture is positive at month 5 or later 
during treatment 
Died A TB patient who dies for any reason before starting or during the 
course of treatment 
Lost to follow-up A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more 
Not evaluated A TB patient for whom no treatment outcome is assigned. This 
includes cases ‘transferred out’ to another treatment unit as well as 
cases for whom the treatment outcome is unknown to the reporting 
unit 
Treatment success The sum of cured and completed 
 
 
In recent years, great steps have been taken to meet these targets. Globally in 
2011, 87% of new cases successfully completed treatment [35]. In Malawi, TB 
incidence has been slowly falling since the mid 2000s, and the proportion of 
patients being cured has been steadily increasing. However, rates of successful 
treatment are consistently lower in patients prescribed retreatment regimen. 
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According to The Global TB Report 2013, in the Africa region the treatment success 
rate was 82% in new smear positive patients and 76% in new smear negative/extra-
pulmonary patients, but only 68% in patients undergoing retreatment [35]. 
According to official figures, in Malawi in 2010, 86% of new smear positive patients 
were cured, compared to only 77% of patients who were smear positive and on 
retreatment regimen [35], but data published in the medical literature from Malawi 
and other countries suggest that overall success rates in patients on retreatment 
regimen may be even lower.  
 
A metanalysis of studies evaluating outcomes in patients who were retreated for TB 
identified only 6 cohort studies that reported outcomes in patients on TB 
retreatment regimen [67]. These studies demonstrated failure rates of between 0% 
and 27% in patients who were infected with a fully sensitive strain of MTB, but in 
patients with isoniazid monoresistance and mixed or unknown resistance patterns, 
failure rates were even higher at 18-44% and 9-45% respectively. This metanalysis 
only included those patients with microbiologically confirmed TB, and therefore 
excluded a large number of patients prescribed retreatment regimen who were 
smear and/or culture negative, and in whom outcomes were therefore likely to be 
even worse. A study conducted in Malawi that retrospectively examined 
operational data collected by the National TB Control Programme between January 
2006 and December 2008 demonstrated that amongst all types of patients 
prescribed retreatment regimen, only 66% had a successful treatment outcome 
[68]. The remainder were lost to follow up (20%), died (11%), transferred out (2%) 
or failed treatment (1%).  
 
The next section of the thesis describes a systematic review of the literature which 
was performed in order to get a more complete picture of the clinical outcomes on 
TB retreatment regimen, including both microbiologically confirmed and 
unconfirmed cases. This provided the opportunity to examine in more detail 
outcomes in different groups of patients (data not provided in the annual Global TB 
report), and to begin to consider possible factors which may be associated with 
poorer outcomes.  
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1.5.2 Objectives 
 
The objective of this review was to describe the clinical outcomes in patients who 
receive WHO Category II retreatment regimen for Tuberculosis, and begin to 
address some of the gaps in our understanding of why treatment outcomes are 
poor.  
 
The review aimed to answer 4 specific questions: 
 
1. What is the proportion of patients who successfully complete retreatment 
regimen for Tuberculosis?  
2. Does the proportion of patients who successfully complete TB retreatment 
regimen differ by TB category? 
3. Does the proportion of patients who successfully complete TB retreatment 
regimen differ by HIV status? 
4. What is the proportion of patients infected with an isoniazid resistant strain 
who successfully complete TB retreatment regimen? 
 
 
1.5.3 Methods 
 
1.5.3.1 Search strategy 
 
Medscape, Embase and Scopus databases were searched using the terms listed in 
table 4. In addition a manual search of the journal ‘Public Health Action’ was 
performed, as it was a relatively new journal not yet fully referenced, and was 
identified as likely to publish relevant manuscripts. Finally, reference lists of the 
identified studies were examined for further relevant publications. 
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Table 4. Search criteria 
 
 
 
 
 
 
 
 
 
 
1.5.3.2 Study selection 
 
Studies which  met the following criteria were included in the review: 
1. Retrospective and prospective cohort studies or clinical trials reporting on 
clinical outcomes in patients prescribed TB WHO Category II regimen. 
 
Studies which  met the following criteria were excluded from the review: 
1. Studies which report on patients receiving regimens for retreatment other 
than the WHO Category II retreatment regimen. 
2. Studies which do not use standard WHO definitions for reporting TB 
outcomes i.e. ‘cured’, ‘complete’, ‘failed’, ‘died’, ‘lost to follow-up’, ‘not 
evaluated’. 
3. Reports of outcomes in patients on treatment for MDR-TB. 
4. Papers reporting outcomes in patients registered prior to 1991 as this was 
the date the standard retreatment regimen was devised. 
 
After removal of duplicates, the selection of articles for review was performed in 
three stages: study titles, then abstracts and finally full texts of manuscripts were 
reviewed. Two reviewers (DBC and JM) assessed manuscripts independently (see 
acknowledgements table on page v), and where discrepancies arose consensus was 
reached by discussion between the two reviewers and a third, independent 
 MEDSCAPE SCOPUS EMBASE 
1 Tuberculosis (MeSH) Tuberculosis Tuberculosis 
2 Retreat* Retreat* Retreat* 
3 (Category II) (Category II) (Category II) 
4 (Category 2) (Category 2) (Category 2) 
5 #2 OR #3 OR #4 #2 OR #3 OR #4 #2 OR #3 OR #4 
6 #1 AND #5 #1 AND #5 #1 AND #5 
7 Filter Human  Filter English Filter English 
8 Filter English  From 1991 From 1991 
9  From 1991   
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reviewer (SBS).  
 
1.5.3.3 Data extraction and quality assessment 
 
Data were extracted and entered directly into a standardised excel spreadsheet. 
Data extracted included details of the study design, setting, population 
characteristics, treatment regimens, reporting definitions, number of study 
participants, and details of outcomes, including, where possible, outcomes for 
different subgroups including tuberculosis category, HIV status and isoniazid 
sensitivity pattern. The sputum smear status of included patients was also noted. All 
studies reporting on patients receiving retreatment regimen were included, 
regardless of microbiological diagnosis. Any cohort that recruited consecutively 
treated patients was included.  
 
1.5.3.4 Output definitions 
 
The specific endpoint of interest was the proportion of patients in whom an 
outcome of ‘treatment success’ was recorded. Treatment success is a composite of 
‘cured’ and ‘completed’. ‘Cured’ is defined as being smear negative at the end of 
treatment having started smear positive. ‘Completed’ is defined as finishing a 
course of treatment, but not meeting the criteria for cure. Data were extracted to 
determine the proportion of patients who were classified as cured, completed, 
died, lost to follow-up,  failed, or not evaluated in each study (see table 3).   
 
1.5.3.5 Data synthesis and analysis 
 
The proportion of patients successfully completing retreatment regimen was 
calculated for each study. In accordance with WHO reporting standards, all patients 
registered for retreatment were included in the analysis. As such, patients whose 
final outcome was ‘not evaluated’ (including ‘transferred out’ and ‘unknown’) were 
included in the denominator. Extracted data was transferred into STATA version 12 
for statistical analysis.   
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1.5.4 Results 
Figure 7. Summary of study review and selection 
 
 
 
1.5.4.1 Study selection 
 
The results of the literature search are presented in figure 7. In total, 39 full text 
manuscripts met the inclusion criteria and were included in the review. 
Characteristics of the included manuscripts are outlined in table 5.  The majority of 
studies were retrospective cohorts based on analysis of routinely collected data in 
local or national tuberculosis registers. There were only six studies that collected 
data prospectively, and only two of those were with the specific intention of 
examining outcomes on retreatment regimen [69, 70]. The majority of studies were 
conducted in Asia, predominantly India, or Africa.  
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1.5.4.2 Overall outcomes on retreatment regimen 
 
The proportion of patients successfully completing retreatment regimen ranged 
from 27% - 92%. There was significant heterogeneity between studies (I2 = 0.95), 
which precluded calculation of a pooled estimate. The recognised target for 
successful treatment in new smear positive patients is 85%, and only 2/39 (5%) of 
identified studies in retreatment met this target. The treatment success rate was 
less than 75% in 29/39 (74%) of studies, and less than 50% in 4 studies.  
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Table 5. Characteristics of studies included in the review 
Reference * Country Study design n % Success Population under study 
Studies conducted in Asia   
Abeygunawardena, 2014 [71] Sri Lanka RC 160 0.82 All patients registered at a district chest clinic 
Bam, 2007 [72] Nepal RC 118 0.92 Smear positive patients being treated for TB at refugee camps 
Becx-Bleumink, 1999 [73] Indonesia PC 239 0.87 Smear positive patients prospectively enrolled in a pilot of ambulatory treatment  
Burugina Nagaraja, 2011 [74] India RC 202 0.34 Patients from TB registration centres in 7 districts who had failed treatment 
Chandrasekaran, 2007 [75]  India RC 699 0.43 Smear positive patients from all TB registration centres in 1 district 
Chughtai, 2013 [76] Pakistan RC 12656 0.78 All patients registered for treatment of pulmonary TB across the country 
Deepa, 2013 [77] India RC 1077 0.67 Smear positive patients registered at all TB centres in 1 state 
Halim, 2006 [78] Indonesia RC 107 0.70 All patients registered at a central hospital 
Kumar, 2010 [79] India RC 133 0.64 All patients registered at centres in 1 district 
Kumar, 2014 [80] India PC 38 0.55 All HIV positive patients treated for failure, relapse or default at a research centre 
Mehra, 2008 [81] India RC 517 0.70 Patients treated for failure and relapse TB at a single urban chest clinic 
Mukherjee, 2009 [82] India RC 234 0.68 Smear positive patients registered at a regional TB unit 
Mukhopadhyay, 2011 [83] India RC 140 0.69 All patients registered 2 TB units in 1 district (1 urban, 1 rural) 
Pardeshi, 2007 [84] India RC 507 0.66 Smear positive patients registered in 1 district 
Sarpal, 2014 [85] India RC 545 0.81 All patients registered in 1 district 
Sisodia, 2006 [86] India RC 2215 0.74 Smear positive patients registered in 4 districts 
Srinath, 2011 [87] India RC 5365 0.76 All patients registered in 1 state 
Vasudevan, 2014 [88] India RC 133 0.67 All patients registered in 1 district 
Win, 2012 [89] Myanmar RC 3643 0.73 All patients registered across the country 
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Studies conducted in Africa 
   
Akpabio, 2011 [90] South Africa RC 388 0.27 All patients with pulmonary TB registered at a regional TB hospital  
Bohler, 2005 [91] Sudan RC 62 0.68 Smear positive patients registered at 5 TB management units in IDP camps 
Bachmann, 2010 [92] South Africa CT 1385 0.62 All patients prospectively enrolled into the PALSA trial 
Berhe, 2012 [93] Ethiopia RC 22 0.64 Smear positive patients registered at 10 rural & 5 urban districts 
Dooley, 2011 [94] Morocco RC 291 0.73 Smear or culture positive patients registered at 9 urban TB clinics 
Gninafon, 2004 [95] Benin RC 236 0.78 Smear positive patients registered at a large urban referral hospital  
Ige, 2011 [96] Nigeria RC 127 0.74 All patients starting treatment at a University Hospital 
Jones-Lopez, 2011 [70] Uganda PC 288 0.77 Smear positive patients treated as inpatients at a TB referral centre 
Munoz-Sellart, 2010 [97] Ethiopia RC 338 0.66 All patients registered at 7 health centres 
Nakanwagi-Mukwaya, 2013 [98] Uganda RC 105 0.46 All relapse, failure and default patients registered at 3 regional referral hospitals 
Ottmani, 2006 [99] Morocco RC 14635 0.71 All bacteriologically confirmed cases registered across the country 
Salaniponi, 2003 [100] Malawi RC 741 0.65 Smear positive patients registered at non-private health facilities 
Takarinda, 2012 [101]  Zimbabwe RC 225 0.72 All patients registered in 1 district 
Tweya, 2011 [102] Malawi RC 411 0.67 All patients registered across the country 
Wahome, 2013 [103] Kenya RC 46 0.61 All health care workers working at a referral hospital 
Studies conducted in other regions  
Espinal, 2000 [104] Multicentre PC 876 0.57 Survey of DR-TB in Dominican Republic, Hong Kong, Italy, Russia, Korea & Peru 
Furin, 2012 [105] Georgia RC 6633 0.58 All patients registered for TB treatment across the country 
McGreevy, 2012 [106] Haiti RC 153 0.78 All patients registered at a TB-HIV referral centre 
Ponce, 2012 [107] Peru CT 111 0.71 Smear positive patients registered in 3 districts 
Sevim, 2002 [108] Turkey RC 47 0.83 Relapse and default patients registered at 1 referral clinic 
RC retrospective cohort      
PC prospective cohort 
CT clinical trial 
*Studies are listed in alphabetical order by author name 
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1.5.4.3 Outcomes on retreatment regimen by category 
 
 
Figure 8 shows treatment outcomes by TB retreatment category. The mean 
successful completion rate in patients with TB relapse was 70% or above in all 
studies, and confidence intervals around these estimates tended to be small (figure 
8a). On the other hand, there was a lot more variation in the outcome for patients 
registered as having returned to treatment after default or having failed treatment. 
Notably, very few studies specifically report outcome in in patients registered as 
‘other’. The rate of successful treatment in this group varied considerably - from 
61% to 84%.  
 
 
 
Figure 8. Treatment outcomes by TB retreatment category 
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1.5.4.4 Outcomes on retreatment by HIV status 
 
Only five studies compared outcomes on retreatment between HIV positive and HIV 
negative patients (table 6). One further study from India reported 55% successful 
outcome in a cohort of 38 patients, all of whom where HIV positive [80]. Of the 
studies comparing outcomes in HIV positive and HIV negative patients, two were 
conducted in African countries with generalised HIV epidemics (Uganda and 
Zimbabwe); one in Haiti (HIV prevalence <2%); one in Indonesia (HIV prevalence 
0.5%); and one in India (HIV prevalence <0.5%). In four out of the five studies, 
outcomes were worse in HIV-infected patients. In the one study that reported 
higher success rates in HIV positive people, the number of HIV negative patients 
was very small. Jonez-Lopez et al report an adjusted odds ratio of 2.16 (1.01-4.61) 
for unsuccessful outcome in HIV positive patients, with factors associated with 
death in HIV being CD4 count <50 cells/ml, no ART, and Karnofsky score <70 [109]. 
In the study by McGreevy et al, follow up data demonstrated that only 46% of HIV 
positive patients remained alive, in ART care and TB-free after a median of 36 
months of follow up [110].  
 
 
Table 6. Retreatment outcomes by HIV status 
Study 
Success in HIV positive 
% (95%CI) 
Success in HIV negative 
% (95%CI) 
Ige [96] 27/42 
0.64 (0.49-0.79) 
67/83 
0.81 (0.73-0.89) 
Jonez-Lopez [109]  103/140 
0.74 (0.67-0.81) 
118/148 
0.80 (0.74-0.86) 
McGreevy [110] 41/56 
0.73 (0.61-0.85) 
79/97 
0.81 (0.73-0.89) 
Srinath [87] 38/55 
0.69 (0.57-0.81) 
97/111 
0.87 (0.81-0.93) 
Takarinda [101] 101/135 
0.75 (0.68-0.82) 
15/21 
0.71 (0.52-0.90) 
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1.5.4.5 Outcomes on TB retreatment according to isoniazid sensitivity pattern  
 
Outcomes were reported in four studies that had data on isoniazid sensitivity, 
which amounted to a total of only 217 patients.  Three of the four studies were 
conducted in India, and in these the prevalence of isoniazid resistance ranged from 
12% - 28%. The largest of the studies specifically aimed to compare outcomes in 
patients with and without isoniazid resistance, and found that 44% of those with 
isoniazid resistance had poor treatment outcomes, compared to 31% of those 
infected with an isoniazid sensitive strain (aRR 1.46; 95% CI 1.19-1.78) [111]. 
 
Table 7. Retreatment outcomes with isoniazid resistance 
 
Study 
Success in INH resistance 
% (95%CI) 
Burugina-Nagaraga [74] 
5/46 
0.11 (0.04-0.24) 
Deepa [111]  
80/144 
0.56 (0.47-0.64) 
Kumar [80] 
3/4 
0.75 (0.19-0.99) 
Salaniponi [112] 
18/23 
0.78 (0.56-0.93) 
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1.5.5 Discussion 
 
This review demonstrates that rates of treatment completion using the WHO 
Category II regimen for retreatment of tuberculosis are consistently lower than the 
85% treatment success rate target across populations in various settings, regardless 
of HIV status, TB category, or isoniazid resistance pattern. There were only 2 studies 
which achieved greater than 85% treatment success. One of these was conducted in 
a refugee camp - a situation in which there was likely to be little movement of 
people who were living in a well defined space, and for who follow up may 
therefore have been easier. The other was a study of ambulatory care, suggesting 
that this was a particularly well group of patients.  
 
Whilst clinical outcomes on TB retreatment regimen are persistently poor, it is not 
entirely clear why this is so. It is often assumed that the low cure rates are due to 
the increased prevalence of drug resistance in this group, which is associated with 
higher rates of treatment failure, and relapse [113].  
 
A recent survey in Malawi reported that in only 6.7% of new TB patients was any 
form of resistance to first line anti-tuberculous drugs identified, including 0.4% who 
had MDR-TB [58]. In comparison, 19.1% of people undergoing retreatment had drug 
resistant strains of MTB isolated from sputum, with 4.8% having MDR-TB. However, 
an alternative interpretation of these data would conclude: “80% of patients 
undergoing TB retreatment in Malawi are infected with a fully sensitive strain of 
MTB”. This may suggest that in areas of low MDR-TB prevalence, drug resistance 
does not explain all of the unsuccessful treatment outcomes, and that there may be 
other factors accounting for some of the failure to complete retreatment. It is 
important to consider other factors contributing to poor outcomes because if any 
are amenable to intervention, it may be possible to develop additional approaches 
to improving management. 
 
Firstly, it may be that some patients do not have TB at all, in which case the 
misdiagnosis will result in treating for TB and not the true underlying disease. Whilst 
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there have been several studies examining the alternative causes of smear negative 
TB in patients presenting with a first episode of TB, there exist very few data 
exploring this issue in patients being retreated [114, 115]. Secondly, given the fact 
that these patients are having recurrent episodes of TB, it is possible that other co-
morbid conditions, which both predispose to TB and are associated with worse 
outcomes, are prevalent in this group. For example, it has been observed by doctors 
on the TB ward at QECH that there is a particularly high HIV prevalence and a large 
burden of lung disease amongst patients being retreated (personal communication 
Prof H. Mwandumba, MLW). Thirdly, because of prolonged treatment duration and 
the addition of streptomycin to the retreatment regimen, adverse events may be 
common and result in discontinuation or interruption of treatment. Finally, this 
longer and more demanding regimen may be associated with poor adherence and 
increased rates of default from treatment. The following sections review some of 
these factors which may account for poor clinical outcomes in TB retreatment.  
 
1.6 Co-morbidity in patients with Tuberculosis 
 
Tuberculosis has been associated with a number of other medical conditions, such 
as HIV, diabetes and occupational lung disease. Very little is known specifically 
about co-morbidity in patients being treated for recurrent TB. However, the next 
sections review the literature concerning co-morbidity in patients with tuberculosis 
in general, as a background to understanding the potential factors which may play a 
role in those with recurrent TB. It may be suspected that co-morbid medical 
conditions which predispose people to a single event of tuberculosis may be even 
more prevalent in those with repeated episodes.  
 
1.6.1 Tuberculosis and HIV 
 
Between 1990 and 2008 there was a 40% increase in the number of cases of 
tuberculosis globally, which was largely attributable to rises in sub-Saharan Africa 
and driven by the rising epidemic of HIV [116, 117]. By 2013, an estimated 1.1 
million (13%) of the 9 million people who developed tuberculosis worldwide were 
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HIV positive, and there were 360,000 deaths in HIV positive people, accounting for 
one third of all tuberculosis deaths and making tuberculosis the leading cause of 
death amongst people infected with HIV [4]. Currently in the African Region, where 
the burden of HIV is greatest, 41% of all notified cases test positive for HIV, and in 
Malawi that proportion is even higher at 56% [4]. The incidence rate of tuberculosis 
has been estimated to be 20-36 times higher in HIV positive people compared to 
HIV negative people, depending on the characteristics of the local HIV epidemic 
(table 8). 
 
Table 8. Estimated incidence rate ratios for tuberculosis in HIV positive people 
HIV epidemic situation TB Incidence rate ratio 
 
Generalised:  
Prevalence of HIV consistently >1% in pregnant women 
 
 
20.6 (15.4-27.5) 
Concentrated: 
Prevalence of HIV consistently >5% in at least 1 subpopulation  
and <1% among pregnant women in urban areas 
 
26.7 (20.4-34.9) 
Low-level: 
Prevalence of HIV not consistently >5% in any subpopulation 
 
36.7 (11.6-116) 
 
       Adapted from Getahun et al [118] 
 
 
HIV increases the risk of reactivating latent tuberculosis infection, as well as 
increasing the risk of rapid progression of tuberculosis disease following primary 
infection or reinfection [119]. Unlike other opportunistic infections, the risk of 
tuberculosis is increased throughout the course of HIV infection, although risks are 
highest in those with low CD4 counts [120-123]. HIV infection results in impaired 
innate and adaptive immune responses to tuberculosis, and ultimately leads to the 
inability to contain mycobacteria due to poor granuloma formation [124, 125]. The 
HIV virus affects the host immune response to tuberculosis in a number of ways, 
including manipulating macrophage function; destroying CD4+ T cells within 
granulomas; and reducing the ability of T-cells to produce IFN-γ which plays a 
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crucial role in controlling the response to M. tuberculosis [126]. The complexity of 
the relationship between these two infections is heightened by the fact that 
tuberculosis can also affect the course of HIV disease [127]. Tuberculosis has been 
shown to double mortality in HIV infection, regardless of CD4 count [128]; and to 
increase both HIV viraemia and viral heterogeneity [129]. 
 
Altered immune responses to tuberculosis frequently result in atypical clinical 
presentation in patients infected with HIV. HIV positive people more often present 
with smear negative [130], extra-pulmonary [131] and severe disseminated forms 
of tuberculosis [132], particularly as CD4 counts fall [133]. Classical radiological 
features such as consolidation or destructive, cavitatory disease are less common - 
in fact HIV positive people with confirmed pulmonary tuberculosis frequently have 
entirely normal chest x-rays, particularly if they are severely immunosuppressed 
[134-137]. Extrapulmonary and paucy-bacilliary features mean that the diagnosis of 
tuberculosis in those who are HIV positive is an even greater challenge. The lack of 
sensitivity of diagnostic tools has led to the development of a number of screening 
algorithms for detecting tuberculosis in HIV positive people, with variable success 
[138-140]. Diagnosis often remains delayed or missed entirely, potentially 
contributing to poor outcomes.   
 
Once diagnosed, the treatment of new or recurrent tuberculosis is the same 
regardless of HIV status. However, because of the interplays between tuberculosis, 
HIV, and the drugs used to treat the two infections, the management of co-infected 
patients is complex. Although there are a lack of data specifically regarding 
interactions between ART and the Category II regimen, information about the 
significant issues regarding concomitant administration of anti-tuberculous drugs 
and ART can be extrapolated to patients on retreatment regimen as all four first line 
drugs which constitute short course chemotherapy are included in the regimen. 
Drug interactions can result in increased risks of side effects, particularly 
hepatotoxicity [141]; and the enzyme inducing properties of rifampicin can reduce 
the concentrations of anti-retroviral drugs putting patients at risk of developing ART 
resistance [142, 143]. Additionally, ART can be associated with tuberculosis related 
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Immune Reconstitution Inflammatory Syndrome (IRIS) [144, 145], and the high pill 
burden which comes with multiple medications may affect adherence to both 
treatments [146]. However, the benefits of HIV treatment and the associated 
reduction in opportunistic infections outweigh these risks, and early ART has been 
shown to reduce mortality during tuberculosis treatment particularly in those with 
very low CD4 counts [147-149], such that early antiretroviral treatment is now 
recommended for all HIV positive patients with active tuberculosis [150]. 
 
The potential link between drug resistant tuberculosis and HIV is still debated. In a 
systematic review of published studies, Suchindran et al reported that most studies 
from North America showed an association between MDR-TB and HIV, but not a 
single study in Africa demonstrated such an association and results from other 
regions were conflicting [151]. In this and other studies, the increased risk seems to 
be attributable to an increased risk of primary, rather than acquired drug resistance 
[152]. Possible biological explanations for this include poor absorption of drugs 
from the gastrointestinal tract in those infected with HIV, leading to suboptimal 
plasma concentrations of drugs. Alternatively, as previously discussed, a high 
proportion of tuberculosis in HIV positive people is caused by primary infection, 
unlike in HIV negative people. Given the increasing prevalence of drug resistance, it 
is therefore possible that primary disease acquired from recent transmission is 
more likely to be drug resistant. Moreover, HIV positive people are likely to be at 
increased risk of environmental exposure to drug resistant strains, for example 
through frequent contact with health care services. This was demonstrated by the 
extremely high prevalence of HIV in the infamous nosocomial outbreak of XDR-TB in 
Kwazulu-Natal [153].  
 
Multiple studies have shown the devastating effects of co-infection with HIV and 
MDR-TB on treatment outcomes. Mortality estimates range between 32% and 72% 
on treatment, and are consistently higher than in HIV uninfected people treated for 
MDR-TB [154-156]. Despite the conflicting evidence about the role of HIV as a risk 
factor for MDR-TB, the implications for diagnosis, treatment and outcomes in co-
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infected people are such that the management of MDR-TB in HIV deserves 
particular attention [157, 158]. 
 
1.6.2 Post Tuberculosis Lung Disease (PTLD) 
 
Post tuberculosis lung disease (PTLD) is common and respiratory sequelae of 
tuberculosis include airways disease, parenchymal lesions and pleural disease [159, 
160].  
 
The patterns of abnormality seen in pulmonary function testing after tuberculosis 
are variable, and have almost exclusively been described only in patients presenting 
with a first episode of TB. Restrictive defects at the beginning of TB treatment have 
been reported to persist, resolve or become obstructive over time [161]. Much 
research has focussed on the association between tuberculosis and chronic airways 
obstruction (CAO), with a number of retrospective and cross sectional studies 
reporting an association between CAO and a history of tuberculosis [162-165]. The 
mechanisms by which tuberculosis can cause airways obstruction include direct 
damage to endobronchial structures resulting in local obstruction and fibrosis; 
extrinsic compression by enlarged lymph nodes; and parenchymal disease which 
results in reduced pulmonary compliance, peripheral airways collapse and 
subsequent air trapping [166].  
 
The diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is based on 
demonstrating CAO in the context of exposure to recognised risk factors [167], with 
smoking being the most common risk factor but exposure to biomass fuel also 
playing a role, particularly in developing countries [168]. TB is recognised as a risk 
factor for the development of COPD, but the higher rates of CAO after tuberculosis 
have been shown to persist after controlling for smoking [169-171], suggesting that 
tuberculosis is also an independent risk factor for CAO. In a systematic review of the 
association between tuberculosis and CAO, Allwood concludes that “it is debatable 
whether TB-associated CAO should be considered as part of the COPD spectrum, a 
distinct phenotype of COPD, or as an unrelated disease”[172]. 
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Prospective studies have provided evidence for the effects of residual pulmonary 
impairment after an episode of TB on functional ability, morbidity and mortality. A 
prospective study in Indonesia which recruited 200 patients with pulmonary 
tuberculosis and 40 controls, reported the mean FEV1 was 92% of predicted in 
controls compared to 63% in cases at baseline, and 71% in cases after 6 months. 
Despite achieving ‘successful’ treatment outcomes, 27% of patients with 
tuberculosis still had moderate-severe impairment in pulmonary function and 57% 
still had respiratory symptoms at the end of treatment. Moreover, functional ability 
was markedly affected in patients with tuberculosis, and persisted to 6 months 
(6MWT 497m in controls, 408m in cases at baseline (p<0.0001), and 470m in cases 
at 6 months (p=0.02)) [173]. A similar study of 115 patients with tuberculosis found 
that 24.6% had persisting significant lung function impairment at the end of 
treatment, and that this was associated with both reduced exercise tolerance and 
quality of life [174]. In addition to significant impacts on morbidity, impaired lung 
function has also been shown to be associated with increased mortality [175, 176]. 
 
Bronchiectasis can be defined as “permanently dilated airways due to chronic 
bronchial inflammation caused by inappropriate clearance of micro-organisms and 
recurrent chronic infection” [177]. Infections are the most common cause of 
bronchiectasis amongst people with non-cystic fibrosis bronchiectasis [178]. The 
pathogenesis of bronchiectasis is thought to be explained by the vicious cycle of 
host mediated inflammatory response to foreign material and organisms causing 
damage to airways, which in turn results in abnormal mucous clearance and further 
bacterial colonisation [179]. The association between tuberculosis and 
bronchiectasis has been recognised since the 1800s [180], and the proportion of 
cases of bronchiectasis due to tuberculosis has been estimated at between 1% and 
32% [166]. Extensive bronchiectasis can cause airflow obstruction; hence there is a 
significant overlap between bronchiectasis, CAO and tuberculosis [166, 181].  
 
Tuberculous Destroyed Lung (TDL) is extensive, progressive destruction of the lung 
parenchyma secondary to tuberculosis [182], and can result in progressive 
dyspnoea, recurrent infections, decline in respiratory function and cor pulmonale 
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[183, 184]. TDL is associated with high morbidity from worsening breathlessness, 
repeated acute exacerbations and multiple hospital admissions. It also carries with 
it a high mortality with one study reporting a median survival of 39 months [185]. 
A well-recognised complication of PTLD is infection with the fungus Aspergillus. 
Aspergillus is a ubiquitous fungus which can cause a range of pathologies, but in 
PTLD is associated with Chronic Pulmonary Aspergillosis (CPA). There are various 
patterns of presentation of CPA [186]. Some patients present with rapid 
development of symptoms and consolidation with or without cavitation on imaging. 
More commonly, CPA presents with slowly evolving, single or multiple lung cavities 
that may or may not contain a fungus ball (aspergilloma). Less well recognised is the 
phenomenon of ‘tracheobronchial aspergillosis’ which causes only minimally 
invasive, local disease. A study in Uganda has shown that 60/200 (15%) post-TB 
patients have both chronic symptoms and x-ray changes consistent with CPA [187], 
and it has been estimated that in 2007 alone, 372 000 people globally developed 
CPA following an episode of tuberculosis [188]. 
 
 
1.6.3 Tuberculosis and diabetes 
 
An association between tuberculosis and diabetes mellitus has been postulated 
since the early twentieth century [189]. Interest in the interaction between the two 
diseases has resurfaced recently, particularly since the projected epidemic of 
diabetes has come to light [190]. According to the International Diabetes 
Federation, the number of people with diabetes is set to increase from 387 million 
to 592 million by 2035, with over 75% of these people living in low and middle 
income countries [191].  
 
There have been a number of reports demonstrating that co-affliction with 
tuberculosis and diabetes mellitus (TB-DM) is common, although all of these 
concentrate on the interaction amongst patients presenting with a first TB episode 
[192-195]. In 2008, Jeon et al published a systematic review of 13 observational 
studies which concluded that diabetes mellitus was associated with tuberculosis 
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(relative risk 3.11), however the majority of these studies were retrospective, many 
were based on self reported diagnoses, and none were conducted in Africa [196]. 
None the less, growing interest in the association resulted in The Union, The WHO 
Stop TB Department and the World Diabetes Foundation convening a joint 
consultation meeting in 2009 which highlighted the need for further efforts to 
combat the impact of TB-DM [197]. Although predictions based on diabetes 
prevalence and TB incidence forecast a large rise TB-DM in South Africa [198], 
primary data have only recently begun to emerge from the continent as a whole. 
Cross sectional studies have reported the prevalence of DM in groups of patients 
starting TB treatment, and there is a suggestion that this may be higher than in the 
general population [199, 200]. Only one case control study from the continent, 
conducted in Tanzania, has demonstrated that diabetes is associated with 
tuberculosis (OR 2.2, 95% CI 1.5-11.6), but this was dependent on HIV status, with 
no significant association shown in those who were HIV infected [201].  
 
In addition to increasing the risk of tuberculosis, it is possible that diabetes affects 
the clinical presentation and course of TB, and that outcomes on TB treatment are 
worse in people who have diabetes.  A metanalysis has reported that the risk of 
death during TB treatment is higher in patients with diabetes (RR 1.89), as is the risk 
of relapse (RR 3.89) [202]. It is unclear whether poorer outcomes are due entirely to 
TB related factors, or also to direct complications of diabetes and other associated 
morbidities, however there are some data to suggest that diabetes is linked with 
more severe TB disease. For example, a large study conducted in Taiwan 
prospectively enrolled over 1200 patients with culture positive Pulmonary TB and 
found that compared to patients without DM, those with TB-DM were significantly 
more likely to have opacity over the lower lung fields, extensive parenchymal 
lesions, and cavitatory disease [203]. Additionally, a number of studies have 
reported longer time to smear or culture conversion in patients with diabetes [204-
206]. Of particular relevance in patients being retreated for TB is the possibility of 
an interaction between diabetes and drug resistant TB, although data so far do not 
support such an association [207, 208].  
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The pathological mechanism underlying the TB-DM association is likely to be 
multifactorial, involving multiple components of the host immune response. 
Defence against tuberculosis is dependent on both innate and adaptive immune 
responses [8, 10]; and diabetes is well known to result in impaired immune 
response to infection [209]. Examination of the direct immunological responses to 
tuberculosis in diabetes has highlighted the importance of impaired macrophage 
function and phagocytosis in both mouse models [210] and human studies [211]. 
Data also suggest that adaptive responses to tuberculosis are altered in individuals 
with diabetes, but changes in IFNγ responses to tuberculosis vary across studies 
[212]. 
 
1.6.4 Tuberculosis and Anaemia 
 
Anaemia is common in patients with tuberculosis, with prevalence estimates 
ranging between 32% and 86% [213-216]. The pathogenesis of anaemia in 
tuberculosis is multifactorial, with components of both iron deficiency anaemia 
(which can resolve with iron supplementation) and anaemia of chronic disease, or 
‘anaemia of inflammation’ (which can resolve on treatment for tuberculosis) [215, 
217, 218]. The interaction between tuberculosis, anaemia and HIV is complex, as 
anaemia is common in both tuberculosis and HIV. However, it has been shown that 
anaemia is a strong independent predictor of tuberculosis amongst HIV positive 
people [219], and that anaemia is associated with HIV infection in patients with 
tuberculosis [220]. The presence of anaemia in tuberculosis is associated with 
reduced rates of sputum smear conversion at 2 months [214], as well as increased 
risk of recurrence [218], adverse drug reactions [221] and higher overall mortality 
[222, 223]. 
 
1.6.5 Tuberculosis and nutrition 
 
It has long been recognised that under-nutrition is a key risk factor for the 
development of Tuberculosis. For example, much of the decline in tuberculosis 
incidence in industrialised countries prior to the introduction of anti-microbials has 
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been attributed to improved nutritional status of the population [224]. A systematic 
review of the literature has reported a reduction in tuberculosis incidence of 13.8% 
per unit increase in BMI [225]; and the relative risk of tuberculosis for people with 
under-nutrition has been estimated to be 3.2 (95% CI3.4-14.2)[226]. The risk is 
thought to be due to lack of both macro- and micro-nutrients, with deficiency in 
vitamin D being of particular importance [227]. A model which assumes that the 
goal to end hunger by 2035 is met, estimates that the global tuberculosis incidence 
would be reduced by 18% [228].  
 
In addition to playing a role in the risk of developing tuberculosis, failure to gain 
weight during the course of tuberculosis treatment is a strong predictor of poor 
treatment outcome [229]. However, the benefits of nutritional supplementation 
alongside anti-tuberculous treatment are limited [230]. Nevertheless, because of 
the clear link between tuberculosis and under-nutrition, the WHO has published 
guidelines on ‘Nutritional care and support for patients with tuberculosis,’ which 
recommends that “an adequate diet, containing all essential macro-and micro-
nutrients is necessary for the well-being and health of all people, including those 
with TB,” therefore “nutrition screening, assessment and management are integral 
components of TB treatment and care.”[231] 
 
 
1.7 Toxicity of anti-tuberculous drugs 
 
 
Adverse Drug Reactions (ADRs) are experienced in 5 – 40% of patients on first line 
anti-tuberculosis drug treatment, and vary according to clinical setting and 
definition [232-235]. In a prospective cohort of 430 patients on first line anti-
tuberculous drugs, Yee et al report an overall incidence of 0.55 ADRs per 100 person 
months follow up, with reactions to pyrazinamide being the most common, 
followed by reactions to Isoniazid, Rifampicin and Ethambutol (1.48, 0.49, 0.43 and 
0.07 events per 100 person months respectively) [233]. The frequency of ADRs is 
persistently reported to be higher in women, older people, and HIV positive people 
[233, 235, 236]. There are several implications of major adverse reactions to anti-
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tuberculous drugs. Serious reactions may themselves result in significant morbidity 
and mortality [237, 238]. Additionally, discontinuation of treatment due to adverse 
events may result in periods of no treatment or suboptimal dosing, prolonged 
treatment duration and in some cases may ultimately require substitution with less 
potent, potentially more toxic second-line drugs.  
 
The most common severe ADRs associated with anti-tuberculous treatment are skin 
reactions and hepatotoxicity; other side effects include gastrointestinal disturbance, 
isoniazid associated peripheral neuropathy, pyrazinamide associated arthralgia, and 
ethambutol associated optic neuritis [238]. However, as drugs are given in 
combination and have many overlapping toxicity profiles, it is often difficult to 
confidently establish which is responsible for a particular ADR. Drug Induced Liver 
Injury (DILI) is associated with rifampicin, isoniazid and pyrazinamide and causes 
hepatocellular necrosis with or without cholestasis [239]. In cases where the patient 
develops clinical hepatitis, or there is a significant rise in serum levels of 
transaminases and/or bilirubin, anti-tuberculous treatment must be stopped and 
reintroduced either stepwise or at full dose [240]. Shang et al describe a 9-fold 
increase in the risk of unsuccessful TB outcome in patients who develop 
hepatotoxicity, and a 2-fold increase in the risk of prolonged treatment [241].  
 
Cutaneous adverse drug reactions (CADR) can be caused by all five of the first line 
anti-tuberculous drugs and usually develop within the first few months of 
treatment. The range of cutaneous manifestations encompasses a spectrum from 
mild rash to severe life threating reactions such as Steven’s Johnsons Syndrome 
[242].  In severe cases of CADR, all anti-tuberculous drugs must be stopped and 
reintroduced, but patients offen suffer reintroduction reactions which can also be 
severe [243].  
 
In areas of high HIV prevalence the interactions between HIV and TB, as well as the 
interactions between drugs used to treat them, makes the diagnosis and 
management ADRs even more complex.  ADRs on anti-tuberculous drugs are more 
common in HIV infected people, with one study from South Africa reporting ADRs in 
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26.7% of HIV-infected people, compared to 13.3% of HIV-uninfected people [244]. A 
further study in the same country found that of 71 cases with TB-ART DILI, 39 were 
due to anti-tuberculous drugs, 12 to ART, and 20 to both. Overall 3-month mortality 
in this group was extremely high at 35% [245]. Risk factors for HIV positive people 
developing hepatotoxicity due to anti-tuberculous drugs have been shown to 
include low BMI, disseminated tuberculosis, low CD4 count and WHO stage IV HIV 
disease [246]. As well as DILI, the risk of CADRs has also been shown to be higher in 
HIV infected people [242, 247].  
 
In addition to RHZE, patients prescribed retreatment regimen are exposed to the 
increased risks posed by toxicity from streptomycin. Streptomycin is an 
aminoglycoside antibiotic, and the nephrotoxic and ototoxic effects of this class of 
drug have been well described [248-250]. Aminoglycosides cause ototoxicity by 
destruction of the hair cells within the cochlear and vestibule. This leads to high 
frequency hearing loss and vestibular damage that are usually irreversible [251, 
252]. Nephrotoxicity caused by aminoglycosides is due to necrosis of the proximal 
tubules, and, unlike ototoxicity, is usually reversible [253, 254]. Data concerning the 
long-term use of aminoglycosides in tuberculosis tend to be focussed on side effects 
of treatment for MDR-TB rather than streptomycin [255-259], and there is no 
information specifically regarding streptomycin toxicity in Africa. Nevertheless, the 
rate of aminoglycoside toxicity in patients on tuberculosis treatment seems to be 
high. A study of 110 patients in the Netherlands who were prescribed amikacin, 
kanamycin or streptomycin reported that 18% developed hearing loss, whilst 7.5% 
developed nephrotoxicity. Toxicity was associated with longer duration of 
treatment and larger total doses [260].  
 
The high incidence and irreversibility of ototoxicity mean that hearing loss is likely 
to contribute the largest burden of morbidity related to aminoglycoside toxicity in 
the treatment of tuberculosis. Features of hearing loss in patients prescribed 
aminoglycosides for the treatment of MDR-TB have been summarised in a review by 
Seddon et al who report rates of ototoxicity ranging from 8-28% in studies which 
used standardised methods for assessing ototoxicity, and 1-50% where 
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unstandardised methods were used [261]. Limited data exist on risks of ototoxicity 
on streptomycin. A case series of patients from Brazil reported that 75% of patients 
on streptomycin had hearing loss, although no baseline assessments were 
performed [262]. Further data from a series in the USA demonstrated ototoxicity 
developed in 28% of patients who received streptomycin (compared to 56% on 
kanamycin and 59% on amikacin) [263]. Risk factors for the development of hearing 
loss on anti-tuberculous treatment are not well defined, although genetic mutations 
predispose a proportion of patients to streptomycin ototoxicity [264], and it is 
possible that HIV positive patients on treatment for MDR-TB are also at higher risk 
of developing hearing loss [265].  
 
1.8 Models for the delivery of injectable anti-tuberculous drugs 
 
In addition to poor clinical outcomes and high rates of medical co-morbidity, 
patients on retreatment regimen are faced with the problem of having to receive 
daily injections of streptomycin. This issue is also a problem for those being treated 
for MDR-TB who need injectable agents for even longer, usually eight months. 
Different approaches exist to delivering injectable drugs to patients who require 
them long term. Traditionally, patients are admitted to hospital in order to receive 
their treatment from a health care professional, but more recently community 
based approaches to delivering parenteral drugs have been developed for TB and 
other conditions.  
 
1.8.1 Disadvantages of hospital admission for tuberculosis 
 
1.8.1.1 Nosocomial transmission of infection 
 
Hospital admission puts patients at risk of acquiring nosocomial infections. Health 
Care Associated Infections (HCAI) are linked with increased morbidity and mortality, 
prolonged admission times, and increased use of resources [266]. A recent review 
has reported the prevalence of HCAI in developing countries is 15.5 per 100 
patients, which is significantly higher than proportions reported from Europe and 
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the US [267]. Few data exist on HCAI in Africa, however it appears that the 
prevalences of methicillin-resistant S. aureus and resistant enterobacteriaceae are 
increasing [268]. Factors associated with HCAI include prolonged use of invasive 
devices and antibiotics, high-risk procedures, immuno-suppression and insufficient 
application of isolation procedures [267]. Patients on TB retreatment admitted to 
hospital in settings such as Malawi are therefore at high risk of acquiring HCAIs, as 
the majority are HIV positive, they are all on prolonged antibiotics, and most are 
managed on open wards with shared facilities.  
 
It also is well established that there are significant levels of TB transmission 
associated with health care facilities [269, 270]. Transmission occurs between 
patients, visitors and health care workers putting large numbers of people at risk of 
becoming infected. Of particular concern is the risk of transmission of MDR and 
XDR-TB,  which was highlighted by the outbreak of XDR-TB associated with a health 
facility in South Africa [153]. It is therefore recommended that whenever possible, 
patients with MDR-TB are placed on active treatment and managed in the 
community [26, 271]. With this in mind, it is important to recognise that the highest 
burden of drug-resistant tuberculosis is amongst patients starting retreatment 
regimen. For these people to be admitted to hospital, a large reservoir of 
potentially infectious drug resistant TB is being created, particularly given the delays 
often associated with the diagnosis of drug resistance and institution of appropriate 
management [272, 273].  
 
1.8.1.2 Social and economic effects on patients and households 
 
Admission to hospital is associated with large economic burdens for patients and 
their families. Costs to users include direct costs of medical care, other out of 
pocket expenses such as food and transport, as well as lost earnings [33, 34]. 
Although TB care is provided free in Malawi, there are still many direct and indirect 
costs associated with diagnosis and treatment [274]. It is becoming increasingly 
recognised not only that households frequently incur catastrophic health costs as a 
result of tuberculosis, but also that these catastrophic costs can be associated with 
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poor clinical outcomes [275]. Due to these concerns, in 2013, the World Health 
Organisation set a target that no families would face catastrophic costs due to TB by 
2030 [276]. Multiple studies have demonstrated higher user costs associated with 
facility-based management during the intensive phase of standard short course 
therapy (table 9). 
 
Table 9. User costs of facility-based and community-based management during TB treatment 
Reference Setting 
Cost per person of  
facility-based 
management (US$) 
Cost per person of  
community-based 
management (US$) 
Floyd et al [277] 
 
South Africa 272 91.60 
Floyd et al [278] 
 
Malawi 228 95 
Moalosi et al [279] 
 
Botswana 720 551 
Nganda et al [280] 
 
Kenya 297 89 
Okello et al [281] 
 
Uganda 91 62 
Wandwalo et al [282] 
 
Tanzania 43 19 
 
 
In many Sub-Saharan African countries, if a patient is admitted to hospital they are 
accompanied by a ‘guardian’ – a lay person, usually a family member or friend, who 
looks after them and provides much of their basic care including washing, dressing, 
feeding, collecting and often giving patients oral medications [283]. In effect, this 
often results in two adult members of a household being away from home, 
therefore unable to provide and care for the family, and having to rely on friends 
and family for help so that the financial burden of illness also becomes a social 
burden [284]. The psychological effects of prolonged admission to hospital have 
also been recognised, and data from a survey conducted on the TB ward at QECH 
demonstrated that 40% of patients screened positive for common mental health 
disorder or depression (data presented at Malawi College of Medicine Research 
Dissemination Conference 2007, Dr R. Stewart). 
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1.8.1.3 Financial burden on the health system 
 
A number of studies have reported the high healthcare costs associated with 
hospital admission for TB treatment (table 10), and they have consistently 
demonstrated that it is more cost effective to manage patients in the community. 
The high costs of facility-based treatment are primarily due to the costs associated 
with in-patient admissions.  
 
Table 10. Provider costs of facility-based and community-based management during TB treatment 
Reference Setting Cost facility-based 
management (US$) 
Cost community-based 
management (US$) 
Floyd et al [277] 
 
South Africa 1,775.70 649.30 
Floyd et al [278] 
 
Malawi 228 106 
Migliori et al [285] 
 
Italy 16,703 5,946 
Moalosi et al [279] 
 
Botswana 2,206 1,106 
Nganda et al [280] 
 
Kenya 294 120 
 
Okello et al [281] 
 
Uganda 419 289 
Wandwalo et al [282] 
 
Tanzania 102 75 
Weis et al [286] 
 
USA 15,670 700 
 
 
 
1.8.2 Community-based models for the delivery of injectables 
 
Community-based directly observed therapy for patients receiving oral short course 
chemotherapy for TB has a long established and successful history in Malawi and 
many other countries [287]. Until recently however, there were no published data 
on the management of patients in the community who require injections as part of 
their TB treatment. With the advent of MDR-TB, community based models have 
been developed. These models were recently summarised in a systematic review, 
which identified 10 publications evaluating community-based care in the 
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management of MDR-TB. The models used a variety of approaches, which included 
patients travelling daily from the community to a health facility, or a professional 
health care worker visiting patients in their homes [288]. Treatment outcomes in 
these studies were comparable to other studies which have looked at MDR-TB 
management, with 65% of patients successfully completing treatment.  
 
There are a number of potential problems with the current models of community-
based care for patients requiring injectables. The first model, of nurses visiting 
patients at home, is likely to be more cost effective than hospital-based care for 
health systems in the long run because of the large overhead costs of providing in-
patient care. However, the organisation of daily visits by nurses to the community 
often requires the institution of a separate funding stream. Only one study in the 
review specifically  reported nurses delivering injections in patients’ homes. In this 
case, nurses were compensated $2 per day, and the mechanism used to support 
this was described as ‘philanthropic funds’ [289]. Partners in Health, a large 
American NGO, has established very successful community based MDR treatment 
programmes in Peru, Russia and Lesotho which, although run in conjunction with 
local NTPs, still rely heavily on PIH for support in terms of both finances and 
expertise [290]. 
 
The  Malawi Guidelines for the community-based management of MDR-TB were 
adapted from the successful MDR-TB programmes in Peru and Lesotho. Personnel 
from the local health centre are trained to visit patients at home and deliver 
treatment on a daily basis. However, it is the experience of the operational 
programme in Malawi, which has less direct external support, that nurses often do 
not achieve this. Reasons have included lack of fuel, lack of N95 masks, lack of 
incentives (particularly for weekend visits) and being too busy at the health centre.  
 
An alternative approach has been for patients to travel daily to a health facility in 
order to receive injections.  A number of projects delivering MDR care have been 
run in this way [289, 291, 292]. However, the financial burden of daily travel to the 
health facility has not been fully assessed, and it is now well recognised that costs of 
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transport are a barrier to adherence [293]. Experience of this model of ambulatory 
care in Malawi for patients on retreatment has been disappointing. This has 
primarily been because patients frequently run out of funds and therefore miss 
doses due to lack of transport; but there have also been a few instances in which 
health care workers were reluctant to deliver injections without receiving additional 
financial incentives (personal communication; Dr J Mpunga, Programme Manager, 
Malawi NTP). As such, the community-based model of ambulatory care was 
abandoned and all patients are now admitted to hospital for the full 60 days of 
injections. 
 
Over recent years in industrialised countries, programmes of outpatient parenteral 
antibiotic therapy (OPAT) have been developed and successfully instituted [294]. 
These programmes have employed various methods of care delivery, including 
patients attending a health facility daily and nurses visiting patients at home. 
Increasingly, family members are being trained to give parenteral medications to 
patients at home [295, 296]. Evidence is that these services are safe, well received 
by users, and highly cost effective [297]. The approach has been so successful that 
guidelines for OPAT services now exist in both the USA [298] and the UK [299]. 
Diabetic patients in poor countries are frequently prescribed insulin and 
successfully administer sub-cutaneous injections at home [300], however no model 
of  carer-administered intramuscular or intravenous treatment has yet been 
developed in Africa.  
 
1.9 Conclusion 
 
 
This chapter has summarised the features and global epidemiology of tuberculosis, 
and has described TB control in Malawi. A systematic review of the literature on 
outcomes using the WHO Category II retreatment regimen has demonstrated low 
success rates across a number of settings and populations. Data which evaluate 
factors associated with poor outcomes specifically in patients on TB retreatment 
are lacking. However risks factors for TB and associations with poor outcome on TB 
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treatment in general such as HIV co-infection, diabetes and chronic lung disease 
have been outlined. The cohort study presented in chapter 3 of this thesis 
addresses the issue of poor outcomes on Category II retreatment regimen by 
examining TB factors such as microbiologically confirmed TB and drug resistance; as 
well as non-TB factors such as medical co-morbidity and drug toxicity. 
 
Not only is retreatment TB associated with poor clinical outcomes, it also requires 
daily injectable anti-tuberculous drugs for the first 60 days of treatment, for which 
there is no good model of delivering care. Hospital-based care is associated with the 
problems of nosocomial infections; economic burdens for users and providers;  and 
substantial social disruption for families and households. Community-based models 
for TB treatment are preferable but few successful programmes for delivering 
injections as part of TB treatment have been developed that have been entirely 
embedded in local systems. There is therefore a gap in the evidence for provision of 
care which is locally adaptable, cost effective and affordable. Increasingly in well 
resourced settings, family members are being trained to administer parenteral 
antibiotics to patients in their homes. If injectable treatment for TB is to be 
delivered reliably and efficiently in Africa, it must be through a model of care which 
is financially and operationally sustainable within existing healthcare structures. The 
TB-RROC trial evaluated a novel mechanism for the delivery of long term injectables 
in TB treatment by training guardians to administer streptomycin. Clinical, 
economic and qualitative evaluations of this model of care delivery are presented in 
chapters 4, 5, 6 and 7 of this thesis; and the following chapter 2 outlines the 
methodological approach taken to performing the evaluation.  
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2 Thesis overview 
 
2.1 Overall objectives 
 
Given the complexities surrounding TB retreatment outlined in chapter one, the 
overall goal of this thesis was to gain a better understanding of the problems faced 
by patients receiving TB retreatment in Malawi, and to explore areas which might 
be amenable to interventions which could improve care. The thesis addressed two 
main issues, both relating to the management of patients prescribed TB 
retreatment regimen.  
 
Firstly, in order to provide a better understanding of the clinical context, factors 
which may be associated with poor clinical outcomes on retreatment regimen were 
investigated. The overall aim of this study was to answer the question: “Why are 
health outcomes poor in adult patients prescribed retreatment regimen for 
tuberculosis in Malawi?.” 
 
Second, the issues associated with prolonged hospital admission were addressed. In 
an attempt to alleviate the problems of in-patient management during the intensive 
phase of TB retreatment, a community-based model of care was developed in 
which guardians were trained to administer streptomycin to patients at home 
during the intensive phase of TB retreatment. The overall aim of the study was to 
evaluate whether this approach would provide a better alternative to hospital-
based management.  
 
Based on these two objectives, the project was named the “TB-Retreatment 
Regimen: Outcomes and Care-delivery Study” (TB-RROC Study). The next section of 
this thesis takes some time to provide a detailed overview of the range of 
approaches to evaluating complex interventions followed by a justification of the 
approach that was taken in evaluating the new model of community-based care. 
Finally there is a brief outline presented of the methods used in the TB-RROC Study.  
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2.2 Approach to Evaluation 
 
2.2.1 A theoretical approach to evaluation: Realistic evaluation  
 
Evaluating a social or public health intervention is complicated by the multiple 
components which need to be accounted for. Studies which are targeted at groups 
of people involve changing behaviours, which makes them hard to control and 
complicated to measure. Traditionally though, evaluation of public health 
interventions has involved experimental approaches such as individually or cluster 
randomised controlled trials. ‘Realist evaluation’ was a new paradigm advocated by 
Pawson and Tilly in the 1990s, in which they critique this experimental method and 
propose a new  approach based on realist principles [301].  
 
The classic experimental design involves taking two similar groups of people; 
measuring both groups at the beginning; applying treatment to one group and not 
the other; measuring changes after the treatment; and comparing changes between 
the groups. Any changes which occurred in the treated group but not the untreated 
group can be put down to the impact of the treatment. This is represented by the 
shorthand “OXO”: Observe the system (O1), introduce a treatment (X) to one group, 
observe the system again (O2). Pawson and Tilly argue that this OXO methodology 
fails to produce useful information in the evaluation of social interventions for the 
following reasons: 
 
1. Experiential methods subscribe to a ‘successionist’  view of causation. In other 
words, that we do not and cannot observe causal forces at work, and that 
causation can only be inferred from that which can be observed. Cause and 
effect is therefore established by observing repeated succession of one event by 
another (‘constant conjunction’). In contrast, ‘generative’ theory holds that 
there is a real connection between events which are connected causally. 
Elucidating these internal mechanisms (which may be observed or unobserved), 
is what allows us to determine causation. This is demonstrated using the 
example of the prisoner who was rehabilitated. The external observable cause 
for this might have been a prisoner education programme. But, crucially, there 
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is also an internal feature that is changed – the disposition of the prisoner, 
which resulted in his rehabilitation. It is this internal change which allows us to 
make sense of the causal relationship between education programme and 
rehabilitation. As the aim should be to understand causal mechanisms rather 
than establish constant conjunction patterns, the use of the counterfactual in 
experimental models is misguided. Instead, investigations should be driven by 
the development of sound theory about which causal mechanisms may operate 
to produce observed outcomes.  
2. Invariably experimental designs show that interventions ‘work’ sometimes but 
not all the time. This is fundamentally because social interventions involve the 
complex interaction of people with systems and depend on the choices people 
make, which vary considerably according to individual preferences, experience 
and circumstance. It is not the programme which ‘works’ but the way people 
respond to resources, practices and ideas that programmes introduce which 
influence outcome. Findings from different studies are therefore frequently 
inconsistent, leaving it hard for policy makers to interpret results. Evaluators 
should therefore not be aiming to answer the question ‘does it work?’, but 
rather to help unravel the questions of ‘How does it work, for whom and in 
what circumstances?’  
 
Pawson and Tilly’s response to these issues is to suggest an alternative ‘realist’ 
mode of evaluation [302]. They argue that crucial to determining what works, for 
who, and in what circumstances, is recognising that variations in outcome are 
determined by the fact that different mechanisms acting in different contexts will 
result in different outcomes. In other words, Context (C) + Mechanism (M) = 
Outcome (O). In order to understand outcomes, rather than following the OXO 
approach, it is necessary to design programmes which explore theories of which 
‘CMO’ patterns are operating in any given intervention or programme. This is in 
keeping with the generative theory of causation and underpins the realist approach 
to evaluation (figure 9). 
 
 50 
In order to illustrate the approach, Pawson and Tilley provide an example of the 
effect of a social intervention on crime rates on an estate. They identify different 
contexts within the estate, which combine with various social mechanisms to 
produce a variety of outcomes, some examples of which are summarised in table 
11.  
 
 
 
 
Adapted from Pawson and Tilley [301] 
 
 
 
Table 11 Examples of context, mechanism and outcome configurations 
Context                         + Mechanism            = Outcome 
Area A: poor-quality 
housing; lack of tenant 
involvement in estate 
management 
+ 
Improved housing and increased 
involvement in management create 
increased commitment and increased 
stability 
= 
Reduced 
burglary 
prevalence 
Area B: poor-quality 
housing; lack of tenant 
involvement in estate 
management 
+ 
Increased involvement in management 
created increased territoriality, 
unattractive housing maintains high 
turnover, retraining vulnerable families 
= 
Stable burglary 
prevalence 
Area C: Tower blocks 
occupied mainly by the 
elderly, lack of tenant 
involvement in estate 
management 
+ 
Concentration of elderly residents creates 
vacancies taken up by young, formerly 
homeless, who have little inclination for 
informal social control & generate an 
estate subculture 
= 
Increased 
burglary 
prevalence 
Adapted from Pawson and Tilley [301] 
Figure 9. Generative causation - the basis for the realist experiment 
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By definition, the approach to designing an evaluation must depend on the theories 
underpinning it and the purpose of data collection is to confirm, falsify or refine 
theory. Thus, the chosen methodology for data collection must be aligned with this 
purpose. Realist theory traditionally rejects the RCT as a tool for assessing complex 
social interventions [303]. Berwick highlights their deficiencies [304], suggesting 
that public health programmes involve “complex, multicomponent interventions – 
essentially a process of social change. The effectiveness of these systems is sensitive 
to an array of influences: leadership, changing environments, details of 
implementation, organisational history, and much more. In such a complex terrain, 
the RCT is an impoverished way to learn.” However, there have been suggestions 
that in fact combining realist theory with randomised trials can produce valuable 
insights.  
 
Whilst agreeing that intervention research should be theory-driven, Bonnell et al 
disagree with Pawson and Tilley about the value of RCTs in evaluating complex 
interventions [305]. They argue that counterfactuals are necessary when 
researching social interventions “precisely because these sorts of experiments 
involve much more complex causality, where is it not possible to isolate the effects 
of one causal factor from another.” They also point out that, if designed properly, 
‘realist RCTs’ can be used to address questions of what works for whom and in 
which circumstances, by, for example using multi-arm studies and performing 
stratified sub-group analyses [306]. What is more, RCTs are able use theory-driven 
approaches to examine mechanisms of change by evaluating different components 
of an intervention as well as overall outcomes. They recommend that realist RCTs 
should not only focus on processes but also on the development and validation of 
theories of intervention which aim to explain how contexts and mechanisms 
interact. All of these components should employ mixed quantitative and qualitative 
methods in order to provide robust data.  
 
The view that realist RCTs can provide the data required to influence policy has 
underpinned this work. Some of the key ‘CMO’ configurations which this study 
 52 
aimed to examine are outlined in table 12. The theories underpinning these 
interactions have been reviewed in section 1.8, but are presented here again within 
a realist framework. In evaluating a community-based intervention for providing 
care during TB retreatment, the outcomes of importance were identified as falling 
into three broad domains: clinical, social and economic.  
 
Table 12. Contexts, mechanisms and outcomes evaluated in the TB-RROC Study 
Context                         + Mechanism            = Outcome 
    Clinical 
Poorly resourced 
government-run health 
services in Malawi 
+ 
Trained guardians learn to 
safely  deliver streptomycin in 
the community 
= 
Clinical outcomes are as 
good as hospital-based 
care 
Poorly resourced 
government-run health 
services in Malawi 
+ 
Guardians are unable to safely 
administer streptomycin; sick 
patients unable to access care 
= 
Clinical outcomes are 
not as good as hospital-
based care 
High rates of default 
from TB treatment and 
HIV care 
+ 
Control over health decisions 
means patients and guardians 
more invested in own health 
= 
More engagement in 
healthcare results in 
lower default rates  
    Social 
Patients & guardians 
affected by TB have 
strong social networks 
+ 
Community & family able to 
offer support more easily as 
burden of travel to hospital is 
relieved 
= 
Patients & guardians 
maintain community 
relationships more 
easily 
Families affected by TB 
have children who are 
left at home when 
patients are admitted 
+ 
Patients and guardians are 
able to care for children when 
managed at home 
= 
Children receive better 
support & are able to 
attend school 
Patients are confined to 
overcrowded TB wards  
+ 
Patients and guardians can live 
in their own homes and 
continue normal activities 
= 
Dignity and 
independence are 
maintained 
    Economic 
Households suffer 
economic burden of 
hospital admission 
+ 
Less money spent on food and 
transport after patient 
discharged from hospital 
= Reduced costs to 
patients & households 
Patients & guardians are 
unable to work whilst in 
hospital.  
+ 
Patients & guardians are able 
to continue working. 
Livelihoods are not disrupted. 
= 
Reduced lost earnings 
for patients and 
households 
Overcrowded TB wards 
due to  large numbers 
admitted for injections 
+ Fewer patients on TB wards = Reduced health system 
costs 
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2.2.2 A  practical approach to evaluation: MRC guidelines  
 
In 2008, the Medical Research Council (MRC) updated their 2000 guidelines for 
developing and evaluating complex interventions [307]. Complex interventions are 
usually described as interventions which are “built up from a number of 
components, which may act both independently and interdependently” [308]. 
However, they may have other characteristics (box 1) and it is fair to say that there 
“is no sharp boundary between simple and complex interventions…few 
interventions are truly simple, but the number of components and range of effects 
may vary widely” [309]. 
 
Box 1. What makes an intervention complex? 
 Number of interacting components within the experimental and control elements 
 Number and difficulty of behaviours required by those delivering or receiving the intervention 
 Number of groups or organisational levels targeted by the intervention 
 Number and variability of outcomes 
 Degree of flexibility or tailoring of the intervention permitted 
From MRC guidelines for developing and evaluating complex interventions [307] 
 
 
Although the TB-RROC intervention involved a single component (teaching 
guardians to deliver streptomycin injections), it nevertheless fulfils many of the 
other criteria of a complex intervention, and as such lessons can be learnt from 
guidelines regarding these types of interventions. For example, guardians were 
required to attend training and follow a series of instructions which they then had 
to adapt and implement in their home environment; both patients and guardians 
were expected to participate and work together; a number of different outcomes 
were assessed including clinical, economic and social; and the intervention was 
flexible, always tailored around the needs of the patients and guardians (e.g. the 
number of days of training varied considerably according to guardians availability 
and competency). 
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The basic outline of the MRC guidance is shown in figure 10 and consists of four 
stages. It begins with development and then piloting, before evaluating and finally 
implementing the intervention.  
 
Figure 10. Key elements of the development and evaluation process 
 
From MRC guidelines for developing and evaluating complex interventions [307] 
 
The MRC views randomised methods as generating the strongest type of evidence, 
however the new guidelines recognise that “good theoretical understanding is 
needed of how the intervention causes change, so that weak links in the causal 
chain can be identified and strengthened” and identifying theory is a component of 
the development stage of the process. However, they have been criticised for not 
providing clear guidance on how to develop such theory [310]. They also state that 
“ensuring strict standardisation may be inappropriate: the intervention may work 
better if a specified degree of adaptation to local setting is allowed for” [309].  
 
The 2008 MRC guidelines on evaluation also stress the importance of evaluating the 
processes involved in the programme, not simply the outcomes. It is important not 
to confuse ‘process’ – the actions which happen within a programme, and 
‘mechanism’ – the explanation for why things do or don’t happen within a 
programme. The evaluation of process is a concept which has been central to 
evaluation since it’s early days, when Avedis Donabedian proposed that the key 
components of assessing quality of care were ‘structure’ – the attributes of the 
settings in which care occurs, including resources, staff and organisational 
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structure; ‘process’ – what is actually done in the giving and receiving of care, for 
example the waiting time for consultations, or the number of investigations 
performed; and ‘outcome’ – the effects of health care on the health status of 
patients and populations [311]. Once again, the guidelines have been accused of 
not providing enough detail on how to evaluate process, and further work has 
provided additional guidance [312].  
 
In summary, this thesis draws on the values outlined in the realist approach to 
evaluation, in particular emphasising the importance of developing theory and 
understanding how interventions work by the examination of both context and 
mechanism. Although randomised experiments are shunned by purist realist 
evaluators, newer guidance from the MRC and others has begun to recognise the 
importance of many of the principles advocated by the realist camp. Thus 
recommendations for the conduct of RCTs now include strong reference to both 
theory and context. The TB-RROC study therefore begins with a cohort study which 
aimed to examine the clinical context of TB retreatment more closely. Published 
literature was reviewed in order to build theories to explain the mechanisms which 
are important for clinical, social and financial outcomes in the context of TB care in 
Malawi. The intervention of training guardians which aimed to improve social and 
economic outcomes of TB retreatment was then evaluated using multiple data 
collection methodologies to test these theories.  
 
 
2.2.3 Pragmatic trials in evaluation 
 
It is clear that the context in which a programme is implemented is a central 
component of the way in which it is evaluated. By imposing strict limitations on the 
design of a trial in order to maximise internal validity, many explanatory trials have 
been criticised for not providing information which is applicable to operational 
situations [313]. Most RCTs aim to establish efficacy, in other words, whether a 
treatment can work in ideal conditions. Many exclude patients who are deemed to 
be at high risk of non-compliance or adverse events (e.g. pregnant women, patients 
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with co-morbidity), and study staff are usually expected to follow strict protocols in 
order to make it simpler to demonstrate efficacy. As a consequence, the results of 
many RCTs are hard to generalise beyond such strict confines and are difficult 
interpret when working in standard clinical settings [314]. The objective of 
pragmatic trials is “to assess whether treatments work in conditions more 
appropriate to routine practice” [315]. The term ‘pragmatic’ in reference to 
interventions was proposed by Schwartz and Lellouch who described ‘explanatory’ 
trials as those which test a causal research hypothesis and ‘pragmatic’ trials as 
those which help users to choose between options of care [316]. There are few 
instances in which a trial is fully pragmatic or fully explanatory, and most lie 
somewhere on the pragmatic-explanatory continuum [317]. However, there are 
some features which characterise pragmatic trials, and these can be used to assess 
where on this spectrum a study lies. Where a trial lies, or should lie, on the 
spectrum will depend very much on the intended purpose of the study (decision-
making v explanation).  
 
In 2009, Thorpe et al published “A pragmatic-explanatory continuum indicator 
summary (PRECIS): a tool to help trial designers” [318]. The aim of the tool is to help 
researchers examine the extent to which their trial design aligns with their stated 
purpose and therefore adjust the design to be more in line with the aims of the 
project. It can also be used by policy makers and implementers to assess how 
generalisable the results of the study are and therefore how applicable they may be 
to a particular setting. The tool consists of 10 domains which determine the extent 
to which an intervention is pragmatic or explanatory. These domains are presented 
in a wheel with the explanatory end of the spectrum at the centre (E).  
 
There are a number of features of the TB-RROC study which were specifically 
designed in order to make the trial as far towards the pragmatic end of the 
continuum as possible (figure 11): 
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1. Eligibility criteria  
There were no strict clinical criteria for entry into the study. No blood tests were 
necessary prior to enrolment, and the only clinical requirement was for a clinician 
to declare the patient fit for discharge. This was based on national guidelines and 
our own personal experiences of the health system in Malawi in which blood tests 
are not routinely performed on patients with TB (even those receiving retreatment) 
unless there is a specific clinical indication for doing so. Pregnant women were 
excluded because streptomycin is contraindicated in pregnancy, and they should 
therefore not be receiving standard Category II regimen. Likewise, although 
patients with identified rifampicin resistance or MDR-TB, patients without a 
guardian, and patients not well enough for discharge were all excluded, these 
exclusion criteria would also always apply in routine practice, as it would never be 
appropriate for these people to receive community-based management for TB 
retreatment. 
 
 
Figure 11. TB-RROC trial PRECIS diagram 
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2. Flexibility of the experimental intervention 
The intervention was designed to accommodate the needs of the study 
participants. For example, patients were able to nominate their guardian and 
training and follow up were arranged for the convenience of the participants. 
Although provided with some basic training tools, the style and content of the 
training sessions were essentially left to the discretion  of the study nurses.  
 
3. Practitioner expertise (experimental) 
During consultation with the Malawi NTP in the initial development stage it was 
established that should the intervention be adopted as policy, routine follow up 
visits would be carried out by health surveillance assistants. Therefore, follow up 
visits in the trial were conducted by fieldworkers with a level of training and 
experience comparable to that of HSAs. Both nurses employed full time on the 
study were highly experienced research nurses, however at both sites the sister in 
charge of the TB ward (employed by Ministry of Health) was also a full member of 
the study team, attending all training, receiving a monthly stipend, and running the 
study when the research nurse was unavailable. It was anticipated that nurses at 
this level would deliver the intervention in routine settings were it to be successful.   
 
4. Flexibility of comparison intervention 
Participants in the comparison group received standard of care, delivered by the 
medical and nursing staff on the TB wards at the two sites. The addition of a study 
doctor to each of the wards during the study period may have resulted in an 
enhanced level of care for patients in hospital. However the doctors were members 
of the medical team delivering care to all patients on the TB wards, regardless of 
their participation in the TB-RROC study, and were therefore simply part of the 
standard care for all patients with TB during that period, and functioned in the 
same way as other doctors at the same level function on the wards.  
 
5. Practitioner expertise (comparison) 
Participants in the comparison arm received routine care from staff on the wards, 
with little additional input from the study team.  
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6. Follow-up intensity  
Despite concerns from some academic colleagues that no Therapeutic Drug 
Monitoring (TDM) was being performed in order to assess adherence, TDM was not 
carried out in the study. Performing TDM on patients in the community would alter 
the applicability of the results for two reasons: i) a nurse would have to perform the 
follow up visits (see point 3), and ii) having blood tests would likely alter 
participants’ behaviour, making the results difficult to interpret in a setting where 
TDM would not routinely be done. The follow up schedule of visits at 1, 3, 5 and 7 
weeks post discharge was again derived from discussions with collaborators at the 
NTP and based on what they considered would be practical for a district TB office to 
implement. All follow up visits were performed by fieldworkers visiting study 
participants at home, but it became apparent that this may not always be possible 
under routine conditions. In practice, it may be that patients would be asked to 
attend the health facility for some follow up visits, which would constitute slightly 
less intense follow up.  
 
7. Outcome measure  
The outcome measure of the study was an outcome which is measured routinely in 
TB reporting. If a patient was still alive and attending the hospital for treatment at 
the end of the intervention period, it was considered a treatment success. Whilst 
microbiological tests formed a component of the secondary outcomes, this was not 
the primary outcome of the study as sputum culture is not routinely performed 
after 2 months of TB retreatment in Malawi.  
 
8. Participant compliance 
The importance of adherence in TB treatment cannot be overlooked in any TB 
intervention. Adherence to treatment was closely monitored in both control and 
intervention arms, but this is entirely in line with operational practice.  
 
9. Practitioner adherence to study protocol 
Study staff were expected to follow a basic set of guidelines for recruitment, 
training of guardians, follow up of study participants, reporting and management of 
 60 
adverse events. However they had autonomy in deciding, along with study 
participants, exactly how training and follow up visits were organised.  
 
10. Primary analysis   
The primary analysis was intention to treat, in line with the principle that the aim of 
the study should not be to establish efficacy under ideal conditions, but rather to 
assess the effectiveness of the intervention in practice.  
 
Reporting of this study followed a published extension to the CONSORT statement, 
specifically for reporting pragmatic trials. This extension was published in order to 
help researchers present data in a standardised format to aid the interpretation and 
therefore use of pragmatic trails in decisions about health care [319].  
 
2.2.4 Applied health research and evidence for decision-making 
 
Evaluations of public health interventions are only valuable if they are used by 
decision-makers to improve the health of populations, and research which is 
inaccessible and irrelevant to those who can implement change rarely has impact 
[320, 321]. Rather than developing new health technologies, applied health 
research aims to maximise the impact of health technologies on populations by 
enhancing the health systems through which they are implemented and improving 
their delivery to populations who are most in need. A number of terms are used to 
describe this type of research, but this summary will focus on the definitions 
proposed by Remme et al who propose three research domains: ‘Operational’, 
‘Implementation’ and ‘Health System’ (table 13) [322].  
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Table 13. Defining research to improve health systems 
Research 
Domain 
Primary Characteristic Example 
Focus of research Users of research Utility of outputs 
Operational Operational issues 
of specific health 
programmes 
Healthcare 
providers, 
programme 
managers 
Local Which of the current ART 
payment strategies in use 
in Nairobi should be 
retained in the new 
integrated programme? 
Implementation Implementation 
strategies for 
specific products 
or services 
Programme 
managers, R&D 
managers 
Local/broad How to deliver ivermectin 
for onchocerciasis control 
and ensure high treatment 
coverage in isolated rural 
communities?  
Health system Issues affecting all 
or some of the 
building blocks of a 
health system 
Health system 
managers, policy 
makers 
Broad To what extent do health 
services reach the poor? 
How can this be improved?  
 
Adapted from Remme et al [322] 
 
The utility of research outputs refers to how amenable the research is to adaptation 
and use in other contexts. For example, operational research is targeted at finding 
specific solutions for local healthcare problems and is focussed entirely on the 
context of that particular situation. It therefore has limited applicability beyond the 
setting in which it is conducted (although if the context is well evaluated and 
described, it may still provide important lessons for other settings). On the other 
end of the spectrum, health system research addresses much broader questions 
which are not disease specific but rather pertain to issues which have repercussions 
for the health system as a whole. The WHO/UNICEF/World Bank Special Programme 
for Research and Training in Tropical Diseases defines implementation research as 
that which “addresses implementation bottlenecks, identifies optimal approaches 
for a particular setting, and promotes the uptake of research findings,”  once again 
stressing the importance of understanding the specific context in which the 
implementation is carried out [323].  Implementation research is intervention 
specific but, unlike operational research, it aims to provide information which is 
applicable beyond the local area in which it is conducted. The TB-RROC study 
evaluates a specific new model of care delivery relevant to the local contexts in 
Lilongwe and Blantyre, but it also provides information applicable to other settings 
both nationally and potentially further afield, particularly in settings where it is 
 62 
standard to admit patients requiring injectables for retreatment or MDR-TB [324]. 
According to the definitions discussed, the TB-RROC study is therefore best 
categorised as ‘implementation research’.  
 
The driving force behind any applied health research is its potential for translation 
into practice [325]. In order for this process to be successful, it is important that 
research is designed appropriately. In order to help produce strong evidence to 
support decision-making in tuberculosis programmes, Mann et al developed the 
‘Impact Assessment Framework’ [326]. The IAF proposes five layers of evaluation 
which together will provide a comprehensive assessment of the potential impact of 
an intervention (figure 12).  
 
Figure 12. Impact Assessment Framework 
 
Adapted from Mann et al [326] 
 
The TB-RROC study incorporated layers of the IAF which were practical given the 
available resources and time. Effectiveness was assessed primarily by conducting an 
RCT, although some aspects of safety were also addressed in a qualitative 
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evaluation. In terms of equity, the effects of the intervention on the poor were of 
particular interest and this was examined by analysing user costs for different 
quartiles of wealth, as well as addressing issues of poverty in the qualitative 
analysis. The potential effects of scale up on costs to patients and providers were 
evaluated in a full economic analysis which estimated both user and health system 
costs.  
 
It is recognised by the developers of the IAF that “evidence alone is often not the 
only driver of policy change”. In addition to evidence, other important factors 
include developing partnerships for capacity building; and collaborating with policy 
players in order to understand political context and external influences [325]. In 
recent years there has been a move away from viewing the interaction between 
research and policy as a one way linear process, requiring transfer of knowledge 
from researcher to policy maker [327]. The assumption that there is a clear divide 
between researchers and policy makers has also been challenged [328]. Instead, the 
whole relationship is now seen as a much more complex and dynamic process, and 
there has been a surge of literature about the research-policy interface [329-333]. A 
key piece of work which sets out set out a broad framework for the practical 
translation of research into policy is The RAPID (Research and Policy in 
Development) framework developed by The Overseas Development Institute (ODI). 
 
The ODI points out that “better utilisation of research and evidence in development 
policy and practice can help save lives, reduce poverty and improve quality of life” 
[334]. The RAPID framework identifies a range of inter-related factors which can be 
used to determine the likelihood of evidence being adopted by decision-makers 
(figure 13). Four broad issues in the research-policy interface are outlined: the 
political context (which shapes the relationship between research and policy); the 
evidence (in particular the quality, relevance and communication of evidence); links 
(with communities, networks and intermediaries which are crucial in affecting 
policy change); and finally external influences (such as donors and funders who 
invariably have influence on policy).  
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Figure 13. The RAPID framework 
 
                                      From ODI [335] 
 
 
Although the TB-RROC project was a relatively small scale evaluation forming the 
basis of a PhD fellowship, attempts were still made at all stages to incorporate best 
practice recommendations for generating evidence and working with decision 
makers to optimise the potential for impact. As such, the Malawi NTP was involved 
in the development of the project from the pre-protocol stages. An initial meeting 
was held in April 2012 in which the basic components of the project were discussed 
and agreed upon. The meeting was used to ensure that the intervention was 
designed to be as representative of the operational situation as possible, and that 
relevant evidence required for decision-making by the NTP was generated. The 
Lilongwe site was managed by the programme’s Care and Treatment officer who 
was seconded by the NTP to be the co-PI at Bwaila hospital. This ensured not only 
theoretical but also practical involvement of the NTP throughout the project, and 
helped to form a strong link between the project and the NTP. The views of other 
stakeholders were also incorporated into the project by convening a Community 
Advisory Board which met throughout the study (figure 14); and by involving 
Ministry of Health nurses working on the TB wards as part of the study teams at 
both sites. Finally, at the conclusion of the study, a feedback session was held with 
study participants in which the results of the project were presented and discussed 
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(figure 15). Evidence was presented and discussed at regular intervals with both the 
NTP and the CAB, and as the final results of the project are being generated, 
discussions with the NTP are on-going. The terms of reference for the CAB are 
outlined in appendix 1.  
 
 
Figure 14. Community Advisory Board 
 
 
 
Figure 15. Participant feedback 
 
 
 
It was clear that in order to answer a broad range of questions concerning issues 
relating to effectiveness, safety, context, equity and costs, it would be necessary to 
use a number of different research tools to evaluate the TB-RROC intervention. It is 
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well recognised that applied health research is often strengthened by the use of 
multiple methodological approaches, in order to obtain rich data from different 
perspectives which can add value individually or be used in conjunction to 
‘triangulate’ findings [305, 322, 336]. In addition to quantitative methods such as 
RCTs, ‘mixed methods’ studies use qualitative methods to provide data which 
cannot easily be captured by quantitate methods, such as information about 
context, experiences, beliefs and attitudes [337, 338]. Applied health research 
studies are also increasingly including economic evaluations in order to assess the 
financial impact of health interventions for both service users and policy makers 
[339]. 
 
2.3 Summary of TB-RROC Study methods 
 
2.3.1 Investigating reasons for poor clinical outcomes on TB retreatment 
 
In order to examine factors associated with poor clinical outcome on TB 
retreatment regimen, a prospective cohort study was conducted. Patients starting 
TB retreatment were recruited from QECH. The primary outcome of the study was 
successful completion of the 8 month course of treatment. The exposure of interest 
was microbiological confirmation of TB by sputum smear, culture or GXP. Other 
variables which it was hypothesised would be associated with TB treatment 
outcome were co-morbid medical conditions (such as chronic lung disease and HIV), 
drug toxicities, burden of TB infection and drug resistance. Patients were reviewed 
at baseline, after 2 months of treatment and at completion of 8 months of 
treatment.  
  
2.3.2 Evaluation of a community-based model of care during TB retreatment 
 
A mixed methods approach was taken to the evaluation of a community-based 
intervention which involved training guardians to deliver streptomycin in patients’ 
homes. A pragmatic, individually randomised trial assessed effectiveness by 
comparing clinical outcomes at 2 months in patients randomised to community-
based management to clinical outcomes at 2 months in patients randomised to 
 67 
receive hospital-based management. The trial was powered to detect non-
inferiority in the intervention arm. Patients were recruited from QECH in Blantyre 
and Bwaila Hospital in Lilongwe. The importance of examining how the intervention 
might work for different groups of users was recognised. However, the time 
available did not allow for recruitment of a large enough cohort into the RCT which 
would enable formal statistical sub-groups analysis.  Further evaluation consisted of 
a formal qualitative study which aimed to describe the experiences of patients and 
their guardians during the intensive phase of TB retreatment (context), and how 
these experiences were affected by community-based care (mechanisms of the 
intervention). The qualitative evaluation was used to gather detailed information 
about the experiences of a wide variety of study participants and key informants.  
Finally, an economic evaluation was performed in order to a) provide cost data 
which would be relevant to decision-makers, b) explore the consequences of 
community and hospital-based care during TB retreatment on costs to households, 
and c) describe the financial consequences of undergoing TB retreatment in 
different groups, particularly the poor.  
 
In these ways, the multi-method evaluation provided a comprehensive 
understanding of the clinical, social and financial impacts of the intervention with 
the aim of affecting a change which worked for individuals, families and 
communities. Relevant data alongside engagement with decision makers 
throughout all stages of the project aimed to ensure that the study was conducted 
in a way which was relevant to policy and also had local context at the forefront. By 
addressing the challenge of providing long term injectables to patients with 
tuberculosis in the community using an entirely new approach in resource limited 
settings, the study addressed a crucial gap in research and practice.  
 
2.4 Study sites and population 
 
The TB-RROC Study was conducted across two sites. Queen Elizabeth Central 
Hospital (QECH) in Blantyre is the largest hospital in Malawi, and admits over 
10,000 adult patients a year. It serves as the tertiary referral unit for the southern 
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region of Malawi and is attached to the country’s only medical school. TB care in 
Blantyre is managed by the TB office based on the TB ward at QECH, and also by the 
District TB Officer, based at the local District Health Office located close to the 
hospital. Since 2011, a process of decentralisation has meant that there are now 11 
TB registration centres based at primary health centres around Blantyre. All 
patients requiring retreatment regimen are referred to QECH for hospital admission 
in order to receive streptomycin injections delivered by nurses on the ward. The 
organisation of TB care in Lilongwe follows a slightly different model. Bwaila 
Hospital is run by the Lilongwe District Health Office and there is no emergency 
adult care facility. Patients are admitted to the TB ward at Bwaila via a number of 
pathways. Those who present acutely to Kamuzu Central Hospital in Lilongwe (the 
tertiary hospital serving the central region) are transferred to Bwaila Hospital for 
further TB care once they have been clinically stabilised. Patients diagnosed with 
recurrent TB from any of the health centres around Lilongwe or at the integrated 
TB-HIV clinic based on site are referred directly to the ward at Bwaila for admission. 
In 2010, there were approximately 300 registrations in Blantyre and 350 
registrations in Lilongwe for TB retreatment regimen (data from Malawi NTP).  
 
At both centres, a study office was established on the TB ward. At QECH, this was a  
room off the main corridor of the ward, next to the TB office. At Bwaila, this was an 
office adjacent to the nurses’ office which was positioned between the two free-
standing (male and female) TB wards. The study teams were based permanently at 
these offices and were therefore well integrated into the day to day activities of the 
wards.  
 
The TB-RROC Trial was conducted at both sites. The cohort study recruited patients 
only from QECH as this was the site with access to resources such as spirometry, 
audiology and CT scanning. 
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2.5 Data management 
 
Data were managed at the Malawi Liverpool Wellcome Centre and followed MLW 
standard operating procedures in relation to data handling and consent. All data 
collected, stored and shared were GCP compliant [340].  
 
Patients recruited to the study were assigned a study number at the time of 
recruitment, and from this point all data were anonymised. The study team  
collected data on paper Case Record Forms (CRFs). Original paper records including 
CRFs and consent forms were stored securely in locked filing cabinets in the 
research offices.  
 
Data were captured to electronic form using Teleform® scanning software (Cardiff 
Software Inc). Data from the Blantyre site was scanned directly using Teleform® 
scanning equipment. Data from the Lilongwe site were scanned to electronic file 
and then transported to Blantyre for transfer into the Teleform® system. Data were 
verified at regular intervals and discrepancies resolved. Data were then exported 
automatically to a secured database in Microsoft Access. Data files were exported 
to STATA 12 for analysis. Access to the study database was password protected, and 
the number of people with access to the database was limited to the principal 
investigator, study supervisors and co-investigators at the NTP.  
 
2.6 Ethical considerations 
 
Written informed consent 
Written (or witnessed in the case of participants who were illiterate) informed 
consent was obtained from both patients and guardians. Consent was obtained 
separately for participation in the trial, the cohort study, and the qualitative study. 
Each participant should have the right to decline entry into the study without 
influence. Therefore patients and guardians were each asked separately to provide 
informed consent for participation in the trial. They were both given the chance to 
ask questions and to discuss between themselves prior to being asked to provide 
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consent. It was made clear that participation in any part of the study was voluntary 
and that consent to participate could be withdrawn at any time without affecting the 
care of the patient.  
 
Ensuring privacy and confidentiality for participants 
All consultations involving study participants aimed to maintain privacy and were 
performed in a private room wherever possible. Consultations during the trial and 
cohort studies took place in the study offices based on each ward. For the qualitative 
evaluation, interviews were conduced in a private room away from the ward. Patients 
recruited to the study were assigned a study number at the time of recruitment, and 
from this point data were anonymised.  
 
Ethics Committees & Trial Registration 
The studies were approved by the Institutional Review Boards at College of 
Medicine, Blantyre, Malawi (COMREC) and Liverpool School of Tropical Medicine, 
Liverpool, UK. The Trial was registered under the identifier ISRCTN05815615. 
 
2.7 Conclusion 
 
This chapter has reviewed approaches to evaluation, with a particular focus on the 
theory of ‘realist evaluation’ as described by Pawson and Tilley. The ideas 
underpinning the TB-RROC evaluation have been presented in the context of realist 
evaluation and the methodology described in line with the MRC guidelines for the 
evaluation of complex interventions. The TB-RROC evaluation aimed to provide data 
which would be of use for decision makers and hence the trial was designed 
pragmatically, and evaluated using mixed methods to holistically assess the new 
model of care delivery.  
 
In addition to providing an overview of the methods used in evaluation of the TB-
RROC trial, this chapter has briefly described the methods used in a cohort study 
which investigated clinical outcomes on TB retreatment. The thesis now goes on to 
describe each of these studies in detail.  
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3 The TB-RROC Cohort Study 
 
3.1 Introduction 
 
It is well recognised that clinical outcomes on Category II retreatment regimen for 
TB are poor, and further data to support this has been presented in a systematic 
review of the literature in chapter 1 of this thesis. Reasons for the low rates of 
successful treatment completion are not well established, but may include drug 
resistance, poor adherence, drug toxicities and medical co-morbidities. This chapter 
describes a prospective cohort study which was performed in Blantyre in order to 
examine in detail factors which may be associated with poor treatment outcome on 
Category II regimen.  
 
3.2 Aims and objectives 
 
The overall aim of this study was to answer the research question:  
 
“Why are health outcomes poor in adult patients prescribed retreatment regimen 
for tuberculosis in Malawi?”  
 
Specific objectives were: 
 
1. To determine the prevalence of smear, culture or GeneXpert (GXP) 
confirmed TB in patients receiving TB retreatment regimen, and to 
compare health outcomes in patients with confirmed TB to those 
without confirmed TB. 
2. To describe the following features in patients on TB retreatment 
regimen and determine if any are associated with poor health outcome: 
 Burden of TB infection (by bacillary load) 
 Resistance to drugs used in the retreatment regimen 
 Infectious and non-infectious co-morbidities 
 Adverse events associated with anti-tuberculous drugs 
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It was believed that the presence of microbiologically confirmed TB would be the 
explanatory variable most predictive of clinical outcome [341, 342]. It was for this 
reason that the primary objective of the study (and therefore basis of the sample 
size calculation) was to determine whether there was an association between 
microbiologically confirmed TB and clinical outcome. Data about other clinical 
features in patients recruited to the study were also collected in order to evaluate 
whether there were additional explanatory variables that were associated with 
poor health outcome.  
 
3.3 Methods 
 
3.3.1 Study design 
 
This was a prospective cohort study, which recruited consecutive patients starting 
TB retreatment regimen at QECH. Those recruited had a number of clinical 
assessments during the course of their treatment, which aimed to identify factors 
that may be associated with clinical outcome. Patients were assessed at three time 
points: at the start of TB treatment, after 2 months of treatment, and at completion 
of treatment after 8 months  (table 14).  
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Table 14. Data collection schedule for TB-RROC cohort study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Outcome measures 
 
The primary outcome measure was:  
 
 “Successful 8-monthTB treatment outcome”.  
 
The definition of ‘successful 8-month treatment outcome’ was based on the WHO 
definition of successful TB outcome, which includes those who are cured and those 
who complete treatment but do not fulfil the definition of cure (table 3) [66]. 
Unsuccessful outcome therefore comprised those who died, those who defaulted 
treatment and those who were transferred out or whose treatment outcome was 
unknown.  
 
 
 Month 0 
(Enrolment) 
 
Month 2 
(End of 
streptomycin) 
Month 8 
(Completion of 
treatment) 
Demographics     
Medical history     
Clinical examination     
Smoking history     
Alcohol history     
Audiological assessment     
Blood tests    
    Creatinine, ALT, Bilirubin     
    HbA1c     
    HIV test +/- CD4 & VL     
Urine dipstick      
Sputum examination    
    AAFB smear       
    GXP      
    MGIT culture     
    DST     
Radiological assessment     
    Chest X-ray     
    CT scan thorax     
Lung function testing      
Audiological assessment       
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3.3.3 Eligibility 
 
Inclusion criteria 
 Adults ≥ 16 years of age starting TB retreatment regimen 
 Patients able to give informed consent 
 
Exclusion criteria 
 Patients identified as having MDR-TB on phenotypic drug sensitivity 
testing, or being treated for MDR-TB on the basis of Rifampicin 
resistance detected using GXP (these patients were referred to the NTP 
MDR treatment programme) 
 Pregnant women 
 Patients unable to give informed consent 
 
Patients were only recruited from QECH. The eligibility criteria for enrolment into 
the TB-RROC cohort study overlapped significantly with those for enrolment into 
the TB-RROC trial. In fact the criteria for entry to the cohort study and the trial were 
essentially the same, with the exception of two points. Firstly, some patients did not 
come to the attention of the study team on the day they started TB treatment, for 
example if they bypassed the TB ward by being admitted to the intensive care or 
high dependency unit. As clinical assessments were required at baseline for the 
cohort study, patients who were screened having completed 10 or more days of TB 
treatment were excluded from the cohort study, whereas these patients could still 
be enrolled into the trial. Secondly, not having a guardian willing and able to 
participate in the study was not an exclusion criterion for enrolment into the cohort 
study. Those patients admitted to hospital with TB who do not have a guardian are 
likely to be a different subset of the population to those who do; for example they 
may be more likely to be from a lower socioeconomic background. Therefore to 
have excluded those patients with no guardian from the cohort study may have 
resulted in recruitment bias.  
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3.3.4 Laboratory procedures 
 
All laboratory tests were performed at the MLW research laboratory or the 
MLW/COM TB laboratory in compliance with Good Clinical Laboratory Practice. The 
results of any tests performed in real time were made available to the clinicians 
caring for patients in order to aid decision-making and improve clinical care.  
 
Biochemical & haematological testing 
 
Serum creatinine, ALT and bilirubin levels were measured in real time using the 
Beckman Coulter Synchron CX® 5 PRO Clinical System. Creatinine clearance was 
estimated using the Cockcroft-Gault Equation: 
 
 CrCl = ((140-Age) x (Weight in kg) x constant) / Serum creatinine in μmol/L 
 
* Constant = 1.23 for men; 1.04 for women 
 
Renal function was measured at baseline and after completing 2-months of 
streptomycin. There is no accepted classification for renal injury occurring over this 
period of time, therefore the RIFLE classification of acute kidney injury was adapted 
for use in the study [343]. It was felt that this was the most appropriate 
classification on which to base the definition of kidney injury, because it takes into 
account both serum creatinine and CrCl. As a large proportion of patients in this 
cohort were likely to have low or very low body weight, the addition of CrCl should 
be more representative of renal function than serum creatinine alone. Kidney injury 
was therefore defined as an increase in serum creatinine of 1.5 fold, or a reduction 
in CrCl by ≥ 25% from baseline. Renal impairment at baseline was defined as 
Creatinine >115μmol/L or CrCl <90 mL/min. Urine analysis was performed using 
Mission® Urinalysis Reagent Strips (ACON Laboratories), as per manufacturers 
instructions.  
 
Drug induced liver injury was diagnosed if the ALT increased to >200 IU/L; there was 
a rise in bilirubin to >40 μmol/L; or a patient became clinically jaundiced [344-346].  
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Full blood count was performed in real time using the Beckman Coulter HmX® 
haematology analyser. Anaemia was defined as Hb <8g/dL [347]. Samples for HbA1c 
testing were batched and performed periodically using the AU480 Beckman 
Coulter® analyser.  A diagnosis of diabetes was made if a patient had an HbA1c level 
of ≥6.5% [348]. 
 
Assessment of HIV related parameters 
 
In patients found to be HIV positive using the standard testing protocol in Malawi 
(serial testing using Determine 1/2™, Alere, Waltham, USA and Uni-Gold™ 
Recombigen® HIV, Trinity Biotech, Bray, Ireland), CD4 count was performed using 
the CyFlow® Counter (Sysmex Partec GmbH, Gorlitz, Germany). In line with Malawi 
national guidelines, HIV viral load was performed at the QECH laboratory using the 
Abbott m2000 RealTime System for the detection of HIV-1 RNA (Illinois, USA) in all 
patients who had been on ART for longer than one year. ART failure was diagnosed 
based on a viral load of >5000 copies/ml, and patients who met this criteria were 
referred to their nearest ART clinic for initiation of second-line ART.  
 
TB laboratory procedures 
 
Sputum samples were decontaminated with 3% sodium hydroxide, mixed and left 
to stand for 15 minutes, vortexing twice at 5-minute intervals. The action of sodium 
hydroxide was neutralized by adding sterile phosphate buffer, following which the 
sample was mixed and then centrifuged at 3700rpm for 20 minutes. The 
supernatant was discarded; the pellet re-suspended in PBS, and a drop of sediment 
was placed on a slide. Once dry, slides were fixed and then stained with Auramine 
O; decolorized with 0.5% acid-alcohol; counterstained with Acridine Orange or 
Potassium Permanganate; and examined for bacilli using florescence microscopy. 
All positive smears were confirmed by Zeihl Neelsen staining. 0.5ml of concentrated 
sputum was added to a mycobacterial growth indicator tube containing 0.8ml of 
MGIT PANTA and OADC; and incubated using the BACTECTM MGITTM 960 
Mycobacterial Detection System (Becton, Dickinson and Company, New Jersey, 
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USA) for up to 44 days. All positive samples were confirmed by ZN staining. The 
presence of M. tuberculosis was distinguished from Mycobacteria Other Than TB 
(MOTT) by examining for the presence of cording; testing using SD BIOLINE TB Ag 
MPT64 Rapid antigen test for M. tuberculosis (Standard Diagnostics Inc., Republic of 
Korea); and incubating samples on LJ slopes at 45oc, 37oc and 25oc as well as PNB at 
37oc for 3 weeks. Xpert®MTB/RIF assay (Cepheid Sunnyvale, USA) was performed 
on raw sputum samples according to manufacturers instructions. Indeterminate 
results were repeated on a fresh sputum sample. 
 
Phenotypic drug susceptibility testing was performed at the University of North 
Carolina research laboratory in Lilongwe using the BACTEC MGIT ® AST SIRE kit, 
according to their standard operating procedures. Briefly, each of the four 
antibiotics streptomycin, isoniazid, rifampicin and ethambutol were suspended in a 
MGIT tube. Organism suspension was added to each antibiotic tube as well as a 
growth control tube and the tubes were incubated at 35-37oc. If the drug-
containing tube did not fluoresce within two days of onset of fluorescence in the 
growth control tube, the MGIT result was interpreted as susceptible. If the drug-
containing tube fluoresced on or within two days of the onset of fluorescence of the 
growth control tube, the result was interpreted as resistance to that drug.  
 
3.3.5 Radiological procedures 
 
Chest radiographs were performed at the start of TB treatment. CT thorax was 
performed on the SOMATON Sensation 16 scanner (Siemens) using the pre-
programmed Lung Low Dose protocol as per manufactures instructions. DICOM 
images were transferred to a password protected electronic storage device and 
read using OsiriX HD software. It was planned that CT scans of the thorax would be 
performed on a subgroup of 100 patients after 2 months of treatment. This time 
point was chosen because the primary purpose of doing CT thorax was to identify 
patients with chronic lung disease, therefore obtaining images 2 months after the 
initial acute event would provide most relevant information. Chest radiographs 
were used in the reporting of acute lung pathology because CT scan is not always 
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reliably available in Blantyre, and it could not be guaranteed that all patients would 
have access to CT during the acute phase of their illness.  
 
Two qualified radiologists (EJ and SG) independently reviewed and reported all 
chest x-ray and CT thorax images. They then used a consensus approach to decide 
on an agreed interpretation of each radiograph and CT series. Primary analysis was 
performed on the consensus interpretation of the images. The purpose of this study 
was not to test the sensitivity of a radiological technique but rather to provide an 
accurate description of respiratory pathology found on imaging. As such, 
radiologists had access to basic clinical information (age, sex, HIV status, duration of 
illness, sputum smear status, smoking history) in order to aid interpretation of the 
films. All reports were recorded on standardised reporting proformae (appendix 2). 
Initially, detailed descriptions of the images were recorded using a classification 
developed from guidelines for the reporting of Thoracic Imaging published by the 
Fleischner Society [349]. Based on these purely descriptive findings, images were 
further reported according to pre-defined diagnostic categories. 
 
3.3.6 Audiological procedures 
 
Trained audiologists from the Department of ENT at QECH performed audiological 
assessments on patients at baseline, 2 months and 8 months. A brief history of 
symptoms that may have indicated possible ototoxicity was ascertained. Following 
this, otoscopy was performed to rule out common causes of impaired hearing 
resulting from abnormality in the auditory canal or tympanic membrane such as 
wax in the canal or tympanic perforation. Patients in whom pathology was 
identified on otoscopy were referred to the ENT department for further 
management.  
 
Transiently Evoked Otoacoustic Emissions (TEOAEs) were tested using the Sentiero 
hand held device (PATH Medical Solutions, Guymark, UK) and assessed in each ear 
at frequencies between 1000 and 4000 kHz. Results were graded as ‘valid response’ 
(indicating normal hearing) or ‘no valid response’ (indicating impaired hearing). 
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Pure Tone Audiometry (PTA) was performed in a quiet room using the KUDUwave 
5000 audiometer (eMoyoDotnet (Pty) Ltd, Randburg, South Africa).  PTA thresholds 
were obtained at frequencies between 250 and 1600 kHz. In line with guidelines 
published by the American Speech-Language-Hearing Association [350, 351] 
significant change in behavioural hearing sensitivity was defined as: 
 
 ≥ 20 dB change from baseline at any one test frequency; or 
 ≥ 10 dB change from baseline at any two consecutive frequencies. 
 
In order to improve specificity for ototoxicity, this definition was further refined to 
include only those with change in hearing at high frequency (>8000 kHz). Vestibular 
assessment was performed in those patients who reported a history of imbalance 
or dizziness. Vestibular assessment included: 
 Romberg’s test 
The patient is asked to stand with their feet together and their arms folded. 
They are then asked to close their eyes. Balance loss or increased sway (side 
to side and/or back and forth movement of the whole body) indicates 
bilateral vestibular functional loss. 
 Head thrust test 
The patient is asked to look straight ahead. The examiner moves the head 
slowly from side to side. The head is then moved quickly to one side. The 
development of nystagmus indicates vestibular pathology.  
 Clinical test of sensory integration of balance (CTSIB) 
The patient is asked to sand bare foot on a firm surface. They are asked to 
fix their eyes on a point ahead, and then to close their eyes. The procedure 
is repeated with the patient standing on a mattress or sponge. A patient 
with bilateral vestibular pathology falls. 
 
3.3.7 Lung function testing 
 
Spirometry was performed on patients at 2 and 8 months. Baseline lung function 
was not assessed for two reasons. Firstly, spirometry performed during the acute 
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phase of a respiratory illness is unlikely to be representative of a patient’s true 
respiratory capacity. Secondly, the risk of TB transmission posed to operators was 
likely to be significantly reduced after patients had been on TB treatment for 2 
months.  
 
Spirometry was performed using the EasyOneTM spirometer (ndd Medical 
Technologies, MA, USA), according to manufacturers instructions. All operators 
attended training run by Spirometry Training Services Africa CC. Machines were 
calibrated using a 3L calibration syringe before each session. Participants were 
actively encouraged during the procedure to exhale maximally, and for at least 6 
seconds. For each patient, it was attempted to obtain 3 reproducible, technically 
acceptable readings. Comparison to predicted levels used NHANES III reference 
ranges. The investigator interpreted all spirographs, and a second reader reviewed 
20% of all tests as a quality control measure.  
 
The following definitions were used to interpret lung function [352]: 
  
Table 15. Interpretation of pulmonary function tests 
Classification Spirometry findings 
Normal     FEV1/FVC ≥ 70%  
   FVC ≥ 80% predicted  
   FEV1 ≥80% predicted 
Obstructive 
 
   Further classified as: 
   FEV1/FVC <70% 
 
                Mild:  FEV1 ≥80% of predicted 
 Moderate: FEV1 <80%, ≥50% predicted 
 Severe:                 FEV1 <50%, ≥30% predicted 
 Very severe: FEV1 <30% predicted 
Restrictive    FEV1/FVC ≥70%  
   FEV1 <80% predicted 
 
 
3.3.8 Sample size 
 
The sample size calculation for this study was based on the primary outcome 
variable and that which was believed to be most associated with successful 
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treatment outcome - confirmation of TB by smear, culture or GXP. It was estimated 
that approximately 50% of all patients on retreatment regimen would be culture 
positive. This was based on the assumptions that: 
 
1. 58% of patients with pulmonary TB would be culture positive 
(unpublished data, Prof E.L. Corbett). 
2. No patients with EPTB would be culture positive. 
 
It was also estimated that approximately 85% of patients with culture positive TB 
would have a successful end of treatment outcome, and that approximately 65% of 
patients with culture negative TB would have a successful treatment outcome. 
Using openepi software (http://www.openepi.com/) it was calculated that 158 
patients were therefore needed in order to detect this difference with a power of 
80% at a significance level of 5%.  
 
 
3.3.9 Statistical Methods 
 
Primary analysis 
 
Univariate analysis of associations with the primary outcome of 8-month treatment 
success was performed using logistic regression and presented as unadjusted odds 
ratios with 95% confidence intervals.  Multivariate analysis was performed using a 
logistic regression model to produce adjusted odds ratios with 95% confidence 
intervals. The model was adjusted for the predefined variables: age group, gender, 
HIV status and variables which were associated with outcome at a significance of 
<0.1 were then added to the model, and likelihood ratio tests performed to 
determine the best fit model.   
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Analysis of co-morbidities 
 
Time to culture positivity and drug sensitivity of M. tuberculosis isolates 
Chi2 test for trend was used to examine the association between time to positivity 
of sputum culture and clinical outcome. Univariate logistic regression models were 
used to derive unadjusted odds ratios, the 95% confidence intervals and associated 
Wald p-values for the presence of drug resistance and clinical outcome.  
 
HIV infection 
Univariate logistic regression models were used to derive unadjusted odds ratios, 
the 95% confidence intervals and associated Wald p-values for the associations 
between clinical outcome  and ART, length of time on ART, CD4 count and viral 
load. 
 
Lung pathology  
Cohen’s kappa statistics were calculated to assess inter-reader correlation of x-ray 
and CT scan reporting. Simple proportions describing the patterns of acute and 
chronic lung disease on x-ray and CT scan were calculated. Fishers exact test was 
used to explore associations between patterns of acute lung disease and sputum 
smear and culture status, HIV status, gender, age and smoking.  Univariate logistic 
regression models were used to derive unadjusted odds ratios, the 95% confidence 
intervals and associated Wald p-values for the presence of bronchiectasis, and 
successful TB treatment outcome. Multivariate logistic regression models were 
used to explore independent clinical predictors of bronchiectasis, and the 
associations between chronic lung disease and TB treatment outcome. Variables 
included in both of these models of chronic lung disease were predefined as age, 
gender, HIV status, TB status (confirmed or unconfirmed microbiologically) and 
smoking history. The logistic regression models were used to determine odds ratios, 
the 95% confidence intervals and associated Wald p-values for treatment outcomes 
in patients with chronic lung disease and the presence of bronchiectasis on CT 
thorax. The same predefined variables were used in multivariate analysis of the 
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associations with restrictive lung disease as well as analysis of the associations 
between chronic lung disease on CT thorax and abnormal spirometry.  
 
Analysis of drug toxicities 
 
Univariate logistic regression was used to derive unadjusted odds ratios, 95% 
confidence intervals and associated Wald p-values for ototoxicity and 
nephrotoxicity according to age, gender, BMI, HIV status, baseline renal function 
and ART status. Predefined variables used in a multivariate analysis of factors 
associated with ototoxicity were BMI, age, gender, HIV status and baseline renal 
function. Predefined variables in a multivariate analysis of factors associated with 
nephrotoxicity were BMI, age, gender HIV, and ART. All predefined variables in the 
study were chosen on the basis that there was a biological basis on which to 
suspect that they would be associated with outcome.  
 
3.4 Results 
 
3.4.1 Study participants 
 
Between June 2013 and September 2014, 230 patients starting retreatment 
regimen for tuberculosis were screened for eligibility. After excluding 72 patients, 
158 were enrolled in the study. The prevalence of microbiologically confirmed 
tuberculosis in the study population was 58% (figure 16).  
 
Table 16 shows the baseline characteristics of the study population. The median age 
was 37 years, and 64.6% of patients were male. The majority (83.5%), had 
pulmonary TB, but the prevalence of extra-pulmonary TB was high in the group 
without confirmed TB at 34.8%. The category of treatment most commonly 
registered was ‘other’ (53.2%), and 95.5% of patients without a microbiological 
diagnosis fell into this category. Most patients had had one previous episode, 
although 3 patients were on at least their fourth episode of TB treatment. The HIV 
prevalence was 82.9%. The median CD4 count in the whole HIV positive study 
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population was 171 cells/mm3, but it was lower in the group without a confirmed 
TB diagnosis (151 v 177 cells/mm3). The prevalence of alcohol excess was high at 
17.1%, and 26.6% of patients had a history of smoking. 
 
 
 
Figure 16. Study enrolment 
 
 
  
 85 
Table 16. Study population baseline characteristics 
ART failure = Antiretroviral failure, defined as HIV viral load >5000 copies/ml 
HR = Heart rate; RR = Respiratory rate; SBP = Systolic blood pressure; BMI = Body mass index 
 
Total study 
population 
n = 158 (%) 
 
TB confirmed 
n = 92 (%) 
 
TB not confirmed 
n = 66 (%) 
Patient age (median, IQR) 37 (31-43) 38 (31-43) 35.5 (31-41) 
Patient sex (% male) 102 (64.6) 64 (69.6) 38 (57.6) 
TB Class  
     Pulmonary 
     Extra-pulmonary 
 
132 (83.5) 
26 (16.5) 
 
89 (96.7) 
3 (3.3) 
 
43 (65.2) 
23 (34.8) 
TB Category 
     Relapse 
     Treatment after default 
     Fail 
     Other 
        Smear negative 
        Extra-pulmonary 
 
62 (39.2) 
7 (4.4) 
5 (3.2) 
84 (53.2) 
57 (36.0) 
27 (17.1) 
 
62 (67.4) 
4 (4.6) 
5 (5.4) 
21 (22.8) 
17 (18.5) 
4 (4.3) 
 
0 (0.0) 
3 (4.5) 
0 (0.0) 
63 (95.5) 
40 (60.6) 
23 (34.8) 
No. of previous TB episodes 
     1 
     2 
     >2 
 
138 (87.3) 
17 (10.8) 
3 (1.9) 
 
78 (84.8) 
11 (12.0) 
3 (3.2) 
 
60 (90.9) 
6 (9.1) 
0 (0.0) 
HIV status 
     Negative 
     Positive 
 
27 (17.1) 
131 (82.9) 
 
17 (18.5) 
75 (81.5) 
 
10 (15.2) 
56 (84.5) 
CD4 count (median, IQR) 171 (61-324) 177 (45-309) 151 (75-327) 
ART failure (n=64) 24 (37.5) 11 (32.4) 13 (43.3) 
Karnofsky score at baseline (median, IQR) 90 (80-100) 90 (80-90) 90 (90-100) 
HR >100bpm 95 (60.1) 58 (63.0) 37 (56.1) 
RR >20bpm 37 (23.4) 17 (18.5) 20 (30.3) 
SBP <100mmHg 50 (31.7) 35 (38.0) 15 (22.7) 
BMI 
     ≥18.5 
     16-18.4 
     <16 
 
36 (23.7) 
75 (49.3) 
41 (27.0) 
 
14 (15.9) 
49 (55.7) 
25 (28.4) 
 
22 (34.4) 
26 (40.6) 
16 (25.0) 
Anaemia 34 (22.2) 16 (17.8) 18 (28.6) 
Diabetes 5 (3.3) 5 (5.6) 0 (0.0) 
Renal impairment 52 (33.8) 33 (36.7) 19 (29.7) 
Chronic Lung disease on CT Thorax (n=102) 90 (88.2) 57 (93.4) 33 (80.5) 
Pulmonary function testing (n=103)   
     Normal 
     Obstructive 
     Restrictive  
 
34 (33.0) 
6 (5.8) 
62 (61.2) 
 
19 (32.2) 
1 (1.6) 
41 (67.2) 
 
15 (35.7) 
5 (11.9) 
22 (52.4) 
Smoker 
     Never 
     Former 
     Current 
 
116 (73.4) 
41 (26.0) 
1 (0.6) 
 
65 (70.7) 
26 (28.3) 
1 (1.1) 
 
51 (77.3) 
15 (22.7) 
0 (0.0) 
History of alcohol excess 27 (17.1) 15 (16.3) 12 (18.2) 
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3.4.2 Factors associated with clinical outcomes on TB retreatment 
 
Patients with a microbiologically confirmed diagnosis of TB were not more likely to 
successfully complete TB retreatment (66.3% v 71.2%; OR 0.80, 95% CI 0.40-1.58). 
In the study cohort as a whole, 24.1% of patients died before completing treatment, 
but only 1.3% failed treatment and only 6.4% were lost to follow up or not 
evaluated (table 17).  
 
 
Table 17. 8-month treatment outcomes in patients with confirmed and unconfirmed TB 
  
Total study 
population 
n = 158 (%) 
 
TB confirmed 
n = 92 (%) 
 
TB not confirmed 
n = 66 (%) 
Treatment success 108 (68.4) 61 (66.3) 47 (71.2) 
Cured 40 (25.3) 40 (43.5) NA 
Treatment completed 68 (43.0) 21 (22.8) 47 (71.2) 
Treatment failed 2 (1.3) 1 (1.1) 1 (1.5) 
Died 38 (24.1) 22 (23.9) 16 (24.2) 
Lost to follow-up 8 (5.1) 6 (6.5) 2 (3.0) 
Not evaluated 2 (1.3) 2 (2.2) 0 (0.0) 
 
 
 
In univariate analysis, baseline anaemia and systolic hypotension were both 
significantly associated with poor end-of-treatment outcome (table 18). A likelihood 
ratio test suggested that a multivariate model which included hypotension and 
anaemia fit the data better than one which included only the predefined variables 
of age, gender and HIV (LRT p-value 0.01). After adjusting for age, gender, HIV 
status hypotension, and anaemia, hypotension but not anaemia remained 
significantly associated with outcome.  Outcomes were worse in the categories ‘Fail’ 
and ‘Other’, but this difference was not statistically significant.  
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Table 18. Features associated with clinical outcome on TB retreatment 
 
Successful outcome 
n (%) 
 
p-value 
 
OR (95% CI) 
 
p-value 
 
aOR (95% CI) 
Confirmed TB 
  No 
  Yes 
 
47/66 (71.2) 
61/92 (66.3) 
 
 
0.51 
 
 
0.80 (0.40-1.58) 
 
 
0.55 
 
 
0.80 (0.37-1.70) 
TB site 
  Pulmonary 
  Extra-pulmonary 
 
93/132 (70.5) 
15/26 (57.7) 
 
 
0.20 
 
 
0.57 (0.23-1.36) 
 
 
- 
 
 
- 
TB Category 
   Relapse 
   TAD 
   Fail 
   Other 
 
47/63 (74.6) 
5/7 (71.4) 
3/5 (60.0) 
53/83 (63.9) 
 
 
0.86 
0.48 
0.17 
 
 
0.85 (0.15-4.83) 
0.51 (0.08-3.34) 
0.60 (0.29-1.24) 
 
 
 
- 
- 
 
 
 
- 
- 
Age  
  <30 
  30-35 
  36-45 
  >45 
 
22/32 (68.8) 
28/43 (65.1) 
39/56 (69.6) 
19/27 (70.4) 
 
 
0.74 
0.93 
0.89 
 
 
0.85 (0.32-2.25) 
1.04 (0.41-2.67) 
1.08 (0.35-3.29) 
 
 
0.92 
0.74 
0.85 
 
 
1.06 (0.36-3.11) 
1.20 (0.40-3.57) 
1.12 (0.34-3.66) 
Gender 
  Female  
  Male 
 
34/56 (60.7) 
74/102 (72.6) 
 
 
0.13 
 
 
1.71 (0.86-3.41) 
 
 
0.32 
 
 
1.48 (0.69-3.20) 
HIV status 
  Negative 
  Positive 
 
21/27 (77.8) 
87/131 (66.4) 
 
 
0.25 
 
 
0.56 (0.21-1.50) 
 
 
0.60  
 
 
0.74 (0.24-2.30) 
HR >100bpm 
   No 
   Yes 
 
47/63 (74.6) 
61/95 (64.2) 
 
 
0.17 
 
- 
0.61 (0.30-1.24) 
 
 
- 
 
 
- 
RR>20bpm 
  No 
  Yes 
 
64/95 (67.4) 
44/63 (69.8) 
 
 
0.74 
 
- 
1.12 (0.56-2.23) 
 
 
- 
 
 
- 
SBP<100mmHg 
   No 
   Yes 
 
82/108 (95.9) 
26/50 (52.0) 
 
 
0.003 
 
 
0.34 (0.17-0.70) 
 
 
0.02 
 
 
0.41 (0.19-0.87) 
BMI 
     ≥18.5 
     16-18.4 
     <16 
 
23/36 (63.9) 
58/75 (77.3) 
24/41 (58.5) 
 
 
0.14  
0.63 
 
 
1.93 (0.81-4.60) 
0.80 (0.32-2.00) 
 
 
- 
- 
 
 
- 
- 
Anaemia  
  No 
  Yes 
 
88/119 (74.0) 
18/34 (52.9) 
 
 
0.02 
 
- 
0.40 (0.18-0.87) 
 
 
0.11 
 
 
0.50 (0.22-1.17) 
Chronic Lung Disease 
on CT 
  No 
  Yes 
 
11/12 (91.7) 
71/90 (78.9) 
 
 
0.32 
 
 
0.34 (0.04-2.80) 
 
 
- 
 
 
- 
Abnormal Spirometry 
  No 
  Yes 
 
32/34 (94.1) 
56/69 (81.2) 
 
 
0.10 
 
 
0.30 (0.06-1.27) 
 
 
- 
 
 
- 
Diabetes 
  No 
  Yes 
 
101/146 (69.2) 
4/5 (80.0) 
 
 
0.61 
 
 
1.78 (0.19-16.4) 
 
 
- 
 
 
- 
Renal impairment  
  No 
  Yes 
 
74/102 (72.5) 
31/52 (59.6) 
 
 
0.11 
 
 
0.56 (0.28-1.13) 
  
 
- 
* adjusted for age, gender, HIV, confirmed TB, hypotension, anaemia 
ART failure = Antiretroviral failure, defined as HIV viral load >5000 copies/ml 
HR = Heart rate; RR = Respiratory rate; SBP = Systolic blood pressure; BMI = Body mass index 
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3.4.3 M. tuberculosis burden and drug sensitivity patterns 
 
 
The median time to sputum culture positivity was 7.8 days (IQR 4.9-9.9 days). There 
was no significant association between time to culture positivity and clinical 
outcome (table 19).  
 
Table 19. Time to sputum culture positivity 
 
Successful outcome  
n (%) 
p-value OR (95% CI) 
TTP (days) 
  ≤ 3  
  3-7  
  >7 
 
5/8 (62.5) 
19/29 (65.5) 
26/36 (72.2)* 
 
 
0.87 
0.59 
 
 
1.14 (0.22-5.78) 
1.56 (0.31-7.78) 
  * Chi2 test for trend p-value 0.499 
 
 
Of the patients who were sputum culture positive, 52 isolates were successfully 
recovered for phenotypic drug sensitivity testing (table 20). Only five patients 
(9.6%) had M. tuberculosis isolates cultured from sputum which showed any drug 
resistance on testing. The commonest drug resistance was to ethambutol (5.8%) 
and isoniazid (3.9%). After screening for rifampicin resistance with GXP, there was 
no undiagnosed rifampicin resistance. No streptomycin resistance was detected, 
and no isolates had resistance to more than a single drug.  
 
 
Table 20. Drug sensitivity patterns and TB treatment outcomes 
Resistance 
Total 
n = 52 
Successful outcome 
with sensitive isolate 
n (%) 
Successful outcome 
with resistant isolate 
n (%) 
p-value OR (95% CI) 
Rifampicin 0 (0.0) 36 (69.2) - - - 
Isoniazid 2 (3.9) 35 (70.0) 1 (50.0) 0.56 0.43 (0.25-7.31) 
Ethambutol 3 (5.8) 34 (69.4) 2 (66.7) 0.92 0.88 (0.07-10.50) 
Streptomycin 0 (0.0) 36 (69.2) - - - 
Any resistance 5 (9.6) 33 (70.2) 3 (60.0) 0.64 0.64 (0.10-4.23) 
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3.4.4 Co-morbidity in patients on TB retreatment 
 
The prevalence of baseline co-morbidity in patients on TB retreatment according to 
TB diagnosis is summarised briefly in table 16. Baseline anaemia was common 
(22.2%), and associated in univariate but not multivariate analysis with poor 
treatment outcome (table 18). The prevalence of baseline renal impairment was 
33.8%, but this was not associated with poor treatment outcome (OR 0.56, 95% CI 
0.28-1.13). Diabetes was only present in 3.3% of patients, and was not associated 
with unsuccessful treatment outcome either (OR 1.78, 95% CI 0.19-16.4).   
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3.4.4.1 HIV infection 
 
HIV prevalence in this cohort of patients on TB retreatment was high at 82.9%. 
Although not significant on statistical testing, it is of note that only 66.4% of HIV 
positive patients successfully completed treatment compared to 77.8% of HIV 
negative patients. Factors associated with treatment outcome amongst HIV positive 
patients are shown in table 21. Only 55.4% of patients with CD4 count <100 
cells/mm3 successfully completed treatment, compared to 72.6% of those with CD4 
count ≥100 cells/mm3. Patients with ART failure had only a 50.0% chance of 
successful treatment outcome, in comparison to 70.1% for patients who were not 
diagnosed with ART failure (OR 0.43 (95% CI 0.17-1.05; p-value 0.09).   
 
Although there was no difference in treatment outcome between patients who 
were and who were not on ART, there is a suggestion that length of time on ART 
may be associated with risk of unsuccessful TB treatment.  Both patients who had 
been on ART for less than 6 months and those on ART longer than 12 months had 
lower (but not significant on statistical testing) probability of treatment success 
than those who had been on ART for between 6 and 12 months (65.4%, 63.5% and 
76.9% respectively). 
 
Table 21. Factors associated with clinical outcome amongst HIV positive patients 
 
Successful outcome  
n (%) 
OR (95% CI) p-value 
ART 
  No 
  Yes 
 
20/29 (68.9) 
67/102 (66.7) 
 
 
0.86 (0.35-2.09) 
 
 
0.74 
Length of time on ART 
  <6 months 
  6 – 12 months 
  >12 months 
 
17/26 (65.4) 
10/13 (76.9) 
40/63 (63.5) 
 
 
1.76 (0.39-8.09 
0.88 (0.34-2.29) 
 
 
0.47 
0.80 
CD4 count 
  <100 
  ≥100 
 
26/47 (55.4) 
61/84 (72.6) 
 
 
2.14 (1.01-4.53) 
 
 
0.06 
Viral load 
  Not detectable 
  Detectable 
 
75/107 (70.1) 
12/24 (50.0) 
 
 
0.43 (0.17-1.05) 
 
 
0.09 
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3.4.4.2 Lung Disease 
 
A total of 102 CT thorax scans and 146 chest x-rays were performed. Reasons why 
imaging was not performed included primarily that the patient was not well enough 
or died prior to an x-ray or CT being performed; and that there were long periods 
when the CT scanner was not working. All CT and plain x-ray images were reviewed 
by two radiologists. The kappa statistics for agreement between the two reporters 
were 0.60 for acute lung disease on CXR; 0.66 for the presence of changes 
consistent with active TB on CXR; and 0.45 for chronic lung disease on CT. Results 
presented are based on consensus reports compiled by discussion between the two 
radiologists.  
 
Acute Lung Disease 
 
Acute changes on plain chest x-ray were seen in 124/146 (84.9%) of patients. The 
commonest finding was multifocal pneumonia (55.9%), followed by lobar 
pneumonia (24.1%); pleural effusion (12.4%); atypical pneumonia (4.4%); miliary 
pattern (0.7%) and other forms of acute lung injury (6.2%).  All 4 cases of miliary TB 
which were seen on CT thorax were not visible on plain chest x-ray. Figure 17 
demonstrates the frequency of acute lung disease seen on chest x-ray according to 
HIV status. The patterns of acute lung disease did not vary significantly according to 
HIV status, age or gender. Multifocal pneumonia was more common in people with 
a history of smoking (73.7% v 49.5%; RR 1.48 95%, CI 1.13-1.95; p-value 0.01), but 
smoking was not associated with any other acute chest x-ray changes. 
 
 92 
Figure 17. Acute lung disease on chest x-ray according to HIV status 
 
 
Chronic Lung Disease 
 
Of 102 patients who had CT thorax performed, 88 (86%) were shown to have some 
form of chronic lung disease. Bronchiectasis was present in 62 patients; features of 
emphysema in 22; scarring in 20; destroyed lung in 19; and features consistent with 
pulmonary artery hypertension in 2. Of the 62 patients with bronchiectasis on CT 
scan, 55% had peripheral disease, 7% had central disease and 38% had both 
peripheral and central disease. In 47% of cases, bronchiectasis was associated with 
traction, and in 45% it was associated with volume loss (figure 18). The majority 
(71%) of bronchiectasis was classified as cystic type bronchiectasis (figure 19). CT 
thorax was able to help distinguish changes consistent with active cavity formation 
from patterns of chronic cystic bronchiectasis (figure 20).  Patients with 
bronchiectasis were more likely to have changes consistent with acute pulmonary 
disease on chest x-ray than those without bronchiectasis (95.2% v 71.1%, p-value 
0.002). In 8/19 (42%) of patients with destroyed lung, more than 25% of the lung 
parenchyma was affected (figure 21). Of those with lung scarring on CT, the changes 
were consistent with post-TB scarring in 82% (figure 22). 
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There were 36 (35%) patients who had evidence of pleural thickening on CT thorax, 
of whom 8 had bilateral disease. Apical disease was present in 18 patients, basal 
disease in 16, and 2 patients had both basal and apical pleural thickening. Only 1 
patient, a 44 year old HIV-positive man with culture-negative TB, had pleural 
plaques.  
 
32/62 (52%) of patients with bronchiectasis on CT thorax had no evidence of 
bronchiectasis on plain chest x-ray (figures 23 & 24). Similarly, 9/22 (41%) of 
emphysema (figure 22); 29/79 (37%) of scarring; and 5/19 (26%) of destroyed lung 
seen on CT was not visible on plain x-ray.  
 
 
 
 
 
 
Figure 18. Coronal CT images demonstrating cystic bronchiectasis in the                                                
left upper lobe with volume loss. 
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Figure 19. Axial image showing bilateral cystic bronchiectasis, demonstrating connection between 
large cysts and dilated airway (white arrows) as well as smaller cysts (black arrows). In addition, 
active nodular disease is seen in the apex of the left lower lobe (striped arrow).   
 
 
 
Figure 20. Axial and coronal CT images showing bilateral upper lobe cavitation, with surrounding 
nodular consolidation, consistent with active disease. 
 
 
Figure 21. Axial and coronal images of a destroyed left upper lobe, involving approximately 25 – 
50% of the lungs. Nodular and consolidative active disease is present in the right lung                    
and left lower lobe. 
 
 
 95 
Figure 22. Chest X-ray showing hyperinflation and corresponding CT images of panlobular 
emphysematous change (white arrows), as well as chronic nodular and linear scarring in the right 
upper lobe (black arrows). 
 
 
Figure 23. Chest X-ray and coronal reformat of CT. There is bilateral upper lobe central cylindrical 
bronchiectasis (white arrows), which are not visible on the Chest X-ray. There is also dense 
nodular and linear scarring on CT images which are not seen on Chest X-ray (black arrows). 
 
 
Figure 24. Chest X-ray and coronal CT image of extensive, longstanding cystic bronchiectasis in the 
left upper lobe, which is not visible on Chest X-ray. 
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Figure 25 shows the proportions of patients with different types of chronic lung 
disease on CT thorax according to their baseline sputum culture result. There were 
no significant differences in the rates of chronic lung disease between those 
patients who were sputum culture positive and those who were sputum culture 
negative. Overall 92 % of patients with culture positive TB and 97% of patients with 
culture negative TB had some form of chronic lung disease. Of note, the proportion 
of patients with bronchiectasis was higher amongst patients with culture positive 
TB (78%) than culture negative TB (59%) (RR 1.90, 95% CI 0.99-3.69; p-value 0.08) 
The patterns of chronic lung pathology were similar when analysed by sputum 
smear status.  
 
Bronchiectasis was associated with being HIV negative, having confirmed TB and 
with a history of smoking (table 22). The associations remained significant after 
additionally adjusting for age and gender. No other pattern of chronic lung disease 
was associated in multivariate analysis with HIV status, TB status, smoking, age or 
gender.  
 
 
Figure 25. Proportion of patients with chronic lung disease according to baseline TB culture 
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Table 22. Factors associated with bronchiectasis 
 
Bronchiectasis  
n (%) 
 
p-value 
 
OR (95% CI) 
 
p-value 
 
aOR* (95%CI) 
Age 
  <30 
  30-35 
  36-45 
  >45 
 
13/18 (72.2) 
14/31 (45.2) 
23/37 (62.2) 
12/16 (75.0) 
 
 
0.07 
0.46 
0.85 
 
 
0.32 (0.09-1.11) 
0.63 (0.19-2.16) 
1.15 (0.25-5.33) 
 
 
0.36 
0.79 
0.63 
 
 
0.46 (0.09-2.36) 
1.25 (0.24-6.40) 
1.56 (0.25-9.58) 
 
Gender 
  Male 
 Female 
 
48/74 (64.9) 
14/28 (50.0) 
 
 
0.17  
 
 
1.85 (0.76-4.46) 
 
 
0.44 
 
 
1.55 (0.50-4.60) 
Smoking 
   Never 
   Former/current 
 
37/71 (52.1) 
25/31 (80.6) 
 
 
0.01 
 
 
3.83 (1.40-10.46) 
 
 
0.02 
 
 
4.60 (1.35-15.67) 
Confirmed TB 
   No 
   Yes 
 
17/41 (41.5) 
45/61 (73.8) 
 
 
0.001 
 
 
4.00 (1.71-9.23) 
 
 
0.01 
 
 
3.60 (1.38-9.36) 
HIV  
  Negative 
  Positive 
 
18/21 (85.7) 
44/81 (54.3) 
 
 
0.01 
 
 
0.20 (0.05-0.73) 
 
 
0.04 
 
 
0.19 (0.04-0.95) 
* Adjusted for age, gender, smoking, HIV, confirmed TB 
 
 
Table 23. Associations between chronic lung disease patterns and clinical outcome 
 
Successful 
outcome  
n (%) 
 
 
p-value 
 
OR (95% CI) 
 
p-value 
 
aOR* (95% CI) 
Any CLD  
   No 
   Yes 
 
11/12 (91.7) 
71/90 (78.9) 
 
 
0.32 
 
 
0.34 (0.04-2.80) 
 
 
0.24 
 
 
0.26 (0.03-2.45) 
Bronchiectasis 
   No 
   Yes 
 
35/40 (0.88) 
47/62 (0.76) 
 
 
0.15  
 
 
0.45 (0.15-1.35) 
 
 
0.17 
 
 
0.41 (0.19-1.47) 
Emphysema 
   No 
   Yes 
 
64/80 (0.80) 
18/22 (0.82) 
 
 
0.85 
 
 
1.13 (0.33-3.79) 
 
 
0.91 
 
 
0.93 (0.25-3.42) 
Destroyed lung 
   No 
   Yes 
 
70/83 (0.84) 
12/19 (0.63) 
 
 
0.04 
 
 
0.32  (0.11-0.96) 
 
 
0.08 
 
 
0.32 (0.09-1.13) 
Scarring  
   No 
   Yes 
 
18/20 (0.90) 
64/82 (0.78) 
 
 
0.24 
 
 
0.40 (0.08-1.86) 
 
 
0.09 
 
 
0.23 (0.04-1.28) 
* Adjusted for age, gender, smoking, HIV, confirmed TB 
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The study was not powered to detect significant associations between lung disease 
and clinical outcome. However, table 23 demonstrates that although not 
statistically significant, the probabilities of successful treatment outcome were 
lower for patients with any chronic lung disease, bronchiectasis, scarring. Destroyed 
lung was associated with unsuccessful clinical outcome on univariate analysis but 
after controlling for age, gender, smoking, HIV and confirmed TB the adjusted OR 
was 0.32 with 95% CI 0.09-1.13. 
 
Chronic Lung Disease in relation to Pulmonary Function 
 
103 patients had spirometry performed after 2 months of TB treatment. Only 34 
(33%) had normal pulmonary function: 63 (61.2%) had restrictive pulmonary deficit 
and 6 (5.8%) had obstructive deficit. Restrictive pulmonary function was not 
significantly associated with age, sex, BMI, smoking, HIV or number of previous TB 
episodes (table 24). The prevalence of restrictive pulmonary function in patients 
with BMI less than 16 was 77%, which was higher than in those with BMI between 
16 and 18.5 or in those with BMI greater than 18.5 (57.1% and 56.0% respectively), 
however this difference was not statistically significant (chi2 test for trend p-value 
0.15). Similarly, the prevalence of restrictive pulmonary deficit was higher in 
smokers (72.4% v 56.8%), but the difference was not statistically significant.  
 
Of the 6 patients with obstructive pulmonary deficit, only one had a history of 
smoking. Half of the patients were male; 4/6 were HIV positive; 4/6 had BMI greater 
than 16; and 3/6 were older than 45 years. 
 
Successful treatment outcome was seen in 52/63 (82.5%) of patients with 
restrictive pulmonary deficit, in comparison 36/40 (90.0%) without restrictive deficit 
(OR 0.52, 95% CI 0.15-1.78; p-value 0.39). There were few patients with obstructive 
deficit, however the treatment success rate in this group was 4/6 (66.7%) compared 
to those without obstruction in whom 84/97 (86.6%) successfully completed 
treatment (OR 0.31, 95% CI 0.05-1.86; p-value 0.21). 
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Table 24.Factors associated with restrictive pulmonary deficit 
 
Restrictive                
pulmonary  deficit 
n (%) 
p-value OR (95% CI) p-value aOR* (95% CI) 
Age 
  <30 
  30-35 
  36-45 
  >45 
 
14/21 (66.7) 
20/27 (74.1) 
19/35 (54.3) 
10/20 (50.0) 
 
 
0.58 
0.36 
0.28 
 
 
1.43 (0.41-4.99) 
0.59 (0.19-1.82) 
0.50 (0.14-1.77) 
 
 
0.81 
0.32 
0.29 
 
 
1.19 (0.28-4.99) 
0.49 (0.12-2.00) 
0.47 (0.12-1.92) 
Gender 
   Female 
   Male 
 
21/36 (58.3) 
42/67 (62.7) 
 
 
0.67  
 
 
1.20 (0.52-2.74) 
 
 
0.78  
 
 
1.16 (0.42-3.21) 
Smoking 
   Never 
   Former/current 
 
42/74 (56.8) 
21/29 (72.4) 
 
 
0.15 
 
 
2.00 (0.79-5.10) 
 
 
0.12 
 
 
2.39 (0.79 – 7.16) 
BMI 
   ≥ 18.5 
   16.18.4 
   <16 
 
14.25 (56.0) 
32/56 (57.1) 
17/22 (77.3) 
 
 
0.92 
0.13 
 
 
1.05 (0.40-2.71) 
2.67 (0.75-9.53) 
 
 
0.92 
0.22 
 
 
1.06 (0.37-3.02) 
2.34 (0.60-9.11) 
Confirmed TB 
   No 
   Yes 
 
22/42 (52.4) 
41/62 (67.2) 
 
 
0.13 
 
 
1.86 (0.83-4.18) 
 
 
0.11 
 
 
2.11 (0.85-5.20) 
HIV  
   Negative 
   Positive 
 
11/19 (57.9) 
52/84 (61.9) 
 
 
0.75 
 
 
1.18 (0.43-3.25) 
 
 
0,46 
 
 
1.64 (0.07-4.06) 
* Adjusted for age, gender, smoking, HIV, confirmed TB 
 
Of patients who had spirometry performed at 2 months, repeat testing was done 
after 8 months of TB treatment in 58. Out of the 33 patients in this group who had 
restrictive pulmonary function at 2 months, 19 (57.6%) still had restrictive deficit at 
8 months; 4 had developed evidence of obstructive disease; and 10 had normal 
spirometry. Obstructive pulmonary function remained in 3 out of the 4 who had 
had obstruction at 2 months. There were 21 patients who had normal spirometry 
on initial testing, of whom 2 developed obstruction and 1 developed restriction.  
 
There were only 77 patients who had both CT thorax and spirometry at 2 months, 
therefore the study lacked power to determine whether spirometry was a useful 
predictor of radiologically confirmed chronic lung disease. Nonetheless, the data 
examining these associations are presented in table 25, and they suggest that 
patients with either bronchiectasis or destroyed lung were more likely to have 
abnormal pulmonary function. Of patients with bronchiectasis, 75.0% had abnormal 
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spirometry, compared to 55.2% without; and of patients with destroyed lung, 92.3% 
had abnormal spirometry, compared to 62.5% without.  
 
 
 
Table 25. Associations between chronic lung disease patterns on CT thorax and                                       
abnormal respiratory function 
 
Abnormal 
spirometry 
p-value OR (95% CI) p-value aOR* (95% CI) 
Bronchiectasis 
   No 
   Yes 
 
16/29 (55.2) 
36/48 (75.0) 
 
 
0.08 
 
 
2.43 (0.91-6.50) 
 
 
0.07 
 
 
3.06 (0.91-10.36) 
Emphysema 
   No 
   Yes 
 
40/60 (66.7) 
12/17 (70.6) 
 
 
0.76 
 
 
1.20 (0.37-3.88) 
 
 
0.64 
 
 
1.35 (0.38-4.76) 
Destroyed lung 
   No 
   Yes 
 
40/64 (62.5) 
12/13 (92.3) 
 
 
0.07 
 
 
7.2 (0.88-58.90) 
 
 
0.13  
 
 
5.53 (0.62-49.51) 
Scarring  
   No 
   Yes 
 
9/12 (75.0) 
43/65 (66.2) 
 
 
0.55 
 
 
0.65 (0.16-2.65) 
 
 
0.59 
 
 
0.64 (0.13-3.26) 
* Adjusted for age, gender, smoking, HIV, confirmed TB 
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3.4.5 Drug toxicities associated with TB retreatment  
 
Overall 80/158 (50.6%) patients experienced at least one drug side effect during the 
first 2 months of TB retreatment, with streptomycin toxicity being common (table 
26).  Six patients (4.4%) experienced drug induced liver injury, and 1 had Stevens 
Johnsons Syndrome requiring interruption of treatment.  There were no significant 
associations between treatment outcome and nephrotoxicity or ototoxicity. Four 
out of the six patients with drug induced liver injury died (RR for death 5.78, 95% CI 
2.75-12.10; p-value 0.004). 
 
 
Table 26. Drug toxicity during the first 2 months of TB retreatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total  
n (%) 
Successful 
outcome with 
no toxicity 
n (%) 
Successful 
outcome with 
toxicity 
n (%) 
p-
value 
OR (95% CI) 
Ototoxicity 28/78 (35.9) 43/50 (86.0) 23/28 (82.1) 0.65 0.75 (0.21-2.63) 
Nephrotoxicity 19/130 (14.6) 88/111 (79.3) 15/19 (79.0) 0.97 0.98 (0.30-3.24) 
Neuropathy 51/127 (40.2) 62/76 (81.6) 40/51 (78.4) 0.66 0.82 (0.34-1.99) 
DILI 6/136 (4.4) 104/130 (80.0) 2/6 (33.3) 0.02 0.13 (0.02-0.72) 
SJS 1/158 (0.6) 107/157 (68.2) 1/1 (100.0) 1.0 - 
DILI = Drug Induced Liver Injury 
SJS = Stevens Johnsons Syndrome 
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3.4.5.1 Ototoxicity 
 
Results of audiological evaluation on 78 patients who were assessed at baseline and 
2 months demonstrated that 28 (35.9%) developed high frequency hearing loss 
during the period in which they received streptomycin. Vestibular function was 
assessed in 27 patients, of whom 3 (11.1%) developed features suggestive of 
vestibulotoxicity in addition to high frequency hearing loss. The development of 
ototoxicity was not associated with BMI, age, gender, HIV status or baseline renal 
impairment (table 27). Hearing loss was measured again at 8 months in 46 patients. 
Of the 14 patients in this group who had developed ototoxicity whilst on 
streptomycin, 6 (42.9%) still had high frequency hearing loss at the end of 
treatment, 6 months after completing streptomycin.  
 
Table 27. Risk factors associated with ototoxicity 
* adjusted for BMI, age, gender, HIV status, and baseline renal function 
 
 
 
 
 
Ototoxicity 
n (%) 
p-value OR (95% CI) p-value aOR* (95% CI) 
BMI 
   >=18.5 
   16.18.4 
   <16 
 
8/21 (38.1) 
13/41 (31.7) 
7/16 (43.8) 
 
 
0.62 
0.73 
 
 
0.75 (0.25-2.26) 
1.26 (0.34-1.75) 
 
 
0.57 
0.48 
 
 
0.70 (0.21-2.39) 
1.70 (0.39-7.46) 
Age 
  <30 
  30-35 
  36-45 
  >45 
 
8/15 (53.3) 
7/25 (28.0) 
8/25 (32.0) 
5/13 (38.5) 
 
 
0.11 
0.19 
0.43 
 
 
0.34 (0.09 -1.30) 
0.42 (0.11-1.54) 
0.55 (0.12-2.47) 
 
 
0.41 
0.59 
0.57 
 
 
 
0.52 (0.11-2.45) 
0.65 (0.12-3.16) 
Gender 
   Female 
   Male 
 
12/28 (42.9) 
16/50 (32.0) 
 
 
0.34  
 
 
0.63 (0.24-1.63) 
 
 
0.11 
 
 
0.37 (0.11-1.26) 
HIV  
   Negative 
   Positive 
 
7/12 (58.3) 
21/66 (31.8) 
 
 
0.09 
 
 
0.33 (0.09-1.17) 
 
 
0.10 
 
 
0.26( 0.05-1.29 
Baseline renal function 
   Normal 
   Abnormal 
 
20/60 (33.3) 
8/18 (44.4) 
 
 
0.39  
 
 
1.6 (0.55-4.68) 
 
 
0.96 
 
 
0.97 (0.11-1.26) 
 103 
3.4.5.2 Nephrotoxicity 
 
Renal function was assessed at the start of treatment and after 2 months in 130 
patients, of whom 19 (14.6%) developed renal impairment. Nephrotoxicity was not 
associated with BMI, age, gender, HIV status or ART (most patients were on 
tenofovir containing regimens which are known to be associated with kidney 
disease) (table 28). 
 
 
 
Table 28. Risk factors associated with nephrotoxicity 
* adjusted for BMI, age, gender, HIV status and ART  
 
 
 
 
 
 
 
 
 
 
 
 
Nephrotoxicity 
n (%) 
p-value OR (95% CI) p-value * aOR (95% CI) 
BMI 
   >=18.5 
   16.18.4 
   <16 
 
3/31 (9.7) 
10/67 (14.9) 
6/32 (18.8) 
 
 
0.48 
0.31 
 
 
1.64 (0.42-6.43) 
2.15 (0.49-9.51) 
 
 
0.36 
0.19 
 
 
2.13 (0.42-10.69) 
3.24 (0.56-10.80) 
Age 
  <30 
  30-35 
  36-45 
  >45 
 
5/26 (19.2) 
4/39 (10.3) 
7/43 (16.3) 
3/22 (13.6) 
 
 
0.31 
0.75 
0.61 
 
 
0.48 (0.12-1.99) 
0.82 (0.23-1.90) 
0.66 (0.14-3.16) 
 
 
0.39 
0.92 
0.83 
 
 
0.51 (0.11-2.42) 
1.10 (0.22-5.25) 
0.83 (0.15-4.53) 
Gender 
   Female 
   Male 
 
9/44 (20.5) 
10/86 (11.6) 
 
 
0.18 
 
 
0.51 (0.19-1.37) 
 
 
0.08 
 
 
0.36 (0.12-1.14) 
HIV  
   Negative 
   Positive 
 
4/25 (16.0) 
15/105 (14.3) 
 
 
0.83 
 
 
0.88 (0.26-2.91) 
 
 
0.89 
 
 
0.88 (0.15-5.28) 
On ART at start 
   No 
   Yes 
 
8/49 (16.3) 
11/81 (13.6) 
 
 
0.67 
 
 
0.81 (0.30-2.17) 
 
 
0.44 
 
 
0.59 (0.15-2.25) 
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3.5 Discussion 
 
This study has demonstrated once again that outcomes on Category II retreatment 
regimen are poor with only 68.4% of patients successfully completing treatment, 
but, more importantly, it also provides new insights into some of the reasons which 
may explain these poor outcomes. In contrast to the assumption made during the 
design of the study, microbiological confirmation of TB was not associated with 
unsuccessful treatment outcome (66.3% successful treatment in patients with 
confirmed TB compared to 71.2% successful treatment in patients without 
confirmed TB). A key finding of the study is that the prevalence of drug resistance in 
this cohort of patients on TB retreatment was low, and not associated with poor 
outcome. After adjusting for age, gender and HIV status the only factor associated 
with unsuccessful treatment outcome was hypotension at presentation. However, 
the prevalence of medical co-morbidities which may contribute to poor treatment 
outcomes was high, with 82.9% of patients being HIV infected, 88.2% having chronic 
lung disease on CT thorax, 33.8% having baseline renal impairment, and 22.2% 
having anaemia. The incidence of drug toxicity during the first two months of 
treatment was also high, with 50.6% of all patients experiencing at least one drug 
side effect. The incidence of  streptomycin induced toxicity is of particular concern 
as 35.9% of patients developed ototoxicity and 14.6% developed nephrotoxicity.   
 
The high mortality (24.1%) seen in this cohort is alarming, and higher than many  
previous studies. Of the studies included in the systematic review of outcomes on 
TB retreatment in chapter 1, mortality rates varied between 6%- 25%. Only one 
study reported a mortality rate of higher than 20% [112], and interestingly this 
study was also conducted in Malawi. The high death rate can perhaps be viewed in 
conjunction with the very low rates of default and undocumented treatment 
outcomes.  In studies which have followed up patients recorded as having defaulted 
from TB and/or HIV treatment in Africa, the true outcome is frequently death [353, 
354]. It is possible that because this was a prospective study, in which patients and 
guardians built good relationships with the study team, the documentation of 
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treatment outcome was more accurate and death as a true outcome was more 
reliably determined.  
 
3.5.1 Microbiological factors 
 
Unlike many other countries with a high TB incidence, Malawi has a low prevalence 
of drug resistant tuberculosis. This was demonstrated in a national survey of drug 
resistance conducted in 2010 [58], and has been shown again 4 years later in this 
study. Of the 52 samples which were tested for drug resistance, only 3 (5.8%) had 
ethambutol resistance and 2 (3.9%) had isoniazid resistance. In the debate 
surrounding the management of patients with recurrent TB, the level of drug 
resistance in a particular setting is  a crucial factor - it determines not only how to 
manage the risk of MDR-TB and which empirical drug regimen should be used for 
patients with recurrent TB who do not have MDR-TB, but also how likely it is that 
drug resistance accounts for poor clinical outcomes. Here, it is seen that not only  
was the prevalence of any form of drug resistance only 9.6%, but also that drug 
resistance was not associated with poor outcome (although numbers may have 
been too small to demonstrate any association). After using GXP to detect 
rifampicin resistance in sputum samples collected at the start of treatment, no 
additional cases of rifampicin resistance were found using phenotypic drug 
sensitivity testing, which is reassuring. It is unexpected that no streptomycin 
resistance was found, as it was the second commonest drug resistance pattern after 
isoniazid in the recent survey of drug resistance in Malawi. It must be noted as a 
weakness of the study that after storage, transport and re-culture of samples, only 
52 isolates were tested for resistance, and it is possible that patterns in those 
samples not re-cultured may have been different.  
 
It is perhaps surprising that microbiologically confirmed TB was not predictive of 
clinical outcome, as a number of previous studies have found that patients with 
smear and/or culture negative TB did worse than those with laboratory confirmed 
TB [341, 342]. The difference in outcomes has always been ascribed primarily to the 
fact that patients treated empirically for tuberculosis may not have TB, but rather 
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have other conditions which remain undiagnosed and therefore untreated [114]. 
The possibility of ‘false positive’ TB diagnoses is of particular importance in the 
group of patients classified as ‘other’ in whom fewer than 5% had a confirmed TB 
diagnosis, and in whom treatment outcomes were particularly poor (63.9% success 
rate). Without microbiological evidence of tuberculosis, it is impossible to know 
how many people prescribed treatment empirically actually have tuberculosis, and 
it is important to recognise the potential for harm caused by both undertreating the 
true pathology and exposing patients to toxic anti-tuberculous drugs.  
 
One possible explanation for the discrepant result in this study is that, compared to 
new patients, patients on retreatment regimen have a high prevalence of multiple 
concurrent diagnoses, regardless of whether or not they have confirmed 
tuberculosis, and that co-morbid disease is common even in those who do have 
definite TB. In settings with high HIV prevalence, another reason for poorer 
outcomes in patients without microbiologically confirmed TB is the fact that HIV is 
associated with being sputum smear/culture negative and also with poorer clinical 
outcome due to other HIV related pathology [355, 356]. As the HIV prevalence in 
this cohort was so high (82.9%), and similar in both groups, the potential for HIV to 
have a differential effect on outcomes in those with and without confirmed TB  was 
probably less significant. Nevertheless, patients who are sputum smear/culture 
negative are more likely to have disseminated disease and therefore do worse. 
Indeed extra-pulmonary disease was more common in those without a 
microbiological diagnosis (43.8% v 3.3%), and although not significantly associated 
with outcome, 70.5% of patients with pulmonary TB completed treatment, 
compared to only 57.7% with extra-pulmonary disease. Patients in this study were 
defined as having EPTB according to their TB registration status, but were not 
further categorised into those who simply had TB affecting an extra-pulmonary site 
and those who had truly disseminated disease. Had mycobacterial blood cultures 
been routinely performed it might have been easier to make this  distinction, and to 
explore the spectrum of ‘extra-pulmonary’ disease further.   
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Unlike previous studies [357, 358], an association between time to positivity of 
sputum cultures and clinical outcome was not demonstrated in this study. It would 
be predicted that the higher mycobacterial load which is represented by early TTP 
would cause a more aggressive clinical picture. In this study data on TTP was 
available for only 73 samples, which may explain why the statistical test for trend 
was not significant. A different explanation might be that HIV prevalence in this 
cohort was high. HIV may affect the TTP, as it has previously been associated with 
delayed increase in TTP over time [359]. 
 
3.5.2 Medical co-morbidity 
 
The finding that hypotension at presentation is predictive of poor clinical outcome 
is in keeping with previous literature [360, 361]. In tuberculosis, there are several 
potential mechanisms underlying the development of hypotension. Low blood 
pressure is likely to be associated with disseminated disease, although in this cohort 
hypotension was prevalent both in patients with microbiologically confirmed TB and 
those treated empirically (prevalences of hypotension being 38.0% and 22.7% 
respectively). Mycobacterium tuberculosis septic shock has been defined as ‘positive 
identification of mycobacteria by microscopy or culture from sputum, body fluids 
and tissues as well as the absence of another more plausible pathogen in 
combination with sepsis syndrome and appropriate clinical suspicion,’ and has been 
associated with an in-hospital mortality of 79.2% in one study [362]. It is also well 
reported that co-infection with other bacteria is common in patients with 
tuberculosis, many of which may cause bacteraemia and septic shock, and 
contribute to poor clinical outcomes [363, 364]. Finally, direct infection of the 
adrenal glands by M. tuberculosis can result in Addison’s syndrome, which presents 
with hypotension [365, 366]. A study previously performed in Blantyre did not 
demonstrate a high prevalence of adrenal insufficiency in new smear positive 
patients [367], but another from Tanzania reported 32% of patients with chronic 
tuberculosis had an impaired cortisol response and that this was associated with 
hypotension [368]. In general, it is to be expected that patients who present acutely 
unwell with TB will do worse than those who are ambulatory, and a study 
 108 
conducted at QECH in 2011 found that low BMI and high respiratory rate at 
presentation were independently associated with poor outcome during the 
intensive phase of treatment [364].  A number of studies have demonstrated that 
poor functional status at presentation is a predictor of unsuccessful treatment 
outcome, with higher mortality rates in sicker patients [369, 370].  
 
Severe anaemia, defined as Hb <8g/dL was common, affecting 22.2% of patients 
overall, and was more prevalent in patients with extra-pulmonary disease (28.6% v 
17.8%). Had anaemia been defined in the study protocol as Hb <10g/dL as some 
previous studies have done [219, 223], the overall prevalence of anaemia would 
have been  even higher at 44.4%. Severe anaemia was associated with poor 
outcome on univariate but not multivariate analysis at a significance level of 0.05. 
However, it is possible that the study was simply underpowered in this respect, as 
multiple other studies have shown anaemia to be independently associated with 
poor outcome on TB treatment in both HIV positive and HIV negative patients [218, 
369, 371]. Baseline renal impairment was also prevalent (33.8%), but not 
associated with outcome. Once again, it is possible that the study was 
underpowered to detect an association, as the absolute treatment success rate was 
higher in those with renal impairment (72.5% compared to 59.6%).   
 
Only five patients had diabetes mellitus (3.3%). All five had microbiologically 
confirmed tuberculosis, which is in keeping with previous literature suggesting that 
diabetes is associated with increased cavitation and smear positivity [203, 205]. 
Only three out of the five patients were HIV positive. However, the low prevalence 
of diabetes in this cohort conforms to the suggestion that the TB-DM association is 
not as much of a concern in Africa as it is in Asia, America, and Europe. Other 
research has reported that TB studies conducted in Africa tend to recruit younger 
patients in whom non-communicable diseases such as diabetes are less prevalent 
[372, 373]. Nevertheless, the  implementation of a programmatic approach TB-DM 
which is currently being advocated [374, 375] needs to be specifically evaluated in 
the African context where other drivers of TB, such as HIV co-infection, are likely to 
be playing a much greater role than diabetes.  
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3.5.3 HIV factors 
 
The prevalence of HIV in this cohort was particularly high at 82.9%, which is more 
than the reported 56% prevalence in adult patients with TB in Malawi [376].  There 
are a number of possible explanations for this. One consideration is that the study 
recruited from a large central hospital in an urban area. HIV prevalence is often 
higher in urban areas [377], and was double that in rural areas according to the 
most recent Malawi Demographic Health Survey [51]. However, HIV prevalence in 
patients starting TB treatment for the first time is still only approximately 65% in 
Blantyre (unpublished data, Prof E.L. Corbett), and patients requiring retreatment 
are referred to QECH from the whole of Blantyre district including both urban and 
rural areas, suggesting that in fact there is a true difference in HIV burden between 
new and retreatment patients. Given that HIV increases the risk of TB at all stages 
and CD4 counts [120, 378], and that a single episode of TB does not confer 
immunity [10],  it is to be expected that HIV positive people will have more TB 
episodes in a lifetime than HIV negative people, particularly in areas of high TB 
transmission. People established on ART can live for many years, but remain at 
increased risk of TB throughout that time, thereby increasing their chances of 
having more than one episode [379, 380]. As more and more people are initiated on 
ART in Malawi and other African countries, a growing pool of HIV-positive people 
living at risk of TB for many years, and therefore at risk of recurrent episodes of TB, 
may develop.  
 
TB treatment success rates are lower in people infected with HIV. This association 
was is also seen patients on TB retreatment, as presented in the systematic review 
in chapter 1 of this thesis. The increased risk of poor outcome in HIV on TB 
retreatment is demonstrated once again by this cohort study, in which only 66.4% 
of HIV positive people had successful treatment outcome, compared to 77.8% of 
HIV negative people. The finding that patients with CD4 count of <100 cells/mm3 
did worse than those with higher CD4 counts (55.4% success v 72.6% success; OR 
2.14, 95% CI 1.01-4.53) is also in keeping with previous literature [381, 382].  
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The high proportion of patients with ART failure seen in this cohort is a major 
concern. HIV viral load testing was only performed once patients had been on ART 
for at least a year, and ART failure was defined as having an HIV viral load of >5000 
copies/ml. Both of these thresholds are rather conservative (newer WHO guidelines 
recommend testing 6 months after initiation of ART and using a threshold of 1000 
copies/ml [150]), but were chosen to be in line with local policy in order to avoid 
difficulties in management if patients did not meet local criteria for second line ART. 
Had viral load been measured after 6 months on treatment, even more ART failure 
may have been detected. It is possible that ART failure is common in patients on TB 
retreatment because this is a group in whom adherence to both ART and TB drugs is 
poor, putting them at risk of both ART failure and recurrent TB. Although patients 
with detectable HIV viral loads were given adherence counselling and referred to 
ART clinic for management, comprehensive assessments of ART adherence were 
not recorded in a systematic way as part of this study. Similarly, although only 7 
(4.4%) of patients were registered as having TB treatment after default, in depth 
assessment of previous adherence to TB treatment was not carried out. An 
alternative explanation relates back once again to the issue that patients on ART for 
a long time will be at increased risk of developing more than one episode of TB. For 
many ‘new’ patients who have not previously been treated for TB, TB is their 
presenting HIV diagnosis following which they initiate ART. On the other hand, 
patients who have previously received TB treatment are likely to have been 
diagnosed with HIV during their first episode and therefore already have been on 
ART for some time prior to the current episode. This will result in a higher 
proportion of the patients on TB retreatment being at risk of ART failure. Clinical 
outcomes on second line ART are worse than  those on first line HIV drugs [383, 
384], and in the long term are likely to contribute to poor outcomes in patients with 
recurrent TB.  In this study, only 50.0% of patients with detectable viral load 
successfully completed TB treatment.  
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3.5.4 Chronic Lung Disease  
 
Of particular interest is the finding of an extremely high burden of chronic lung 
disease in patients on TB retreatment. Previous literature had gone some way to 
describe the features of post-tuberculous lung disease, however none has 
specifically assessed the burden of lung disease in patients entering TB care at the 
point of a recurrent episode. The key issue is that if the vast majority of patients 
starting TB retreatment regimen have underlying chronic lung disease, it may not 
be sufficient simply to treat their respiratory disease with anti-tuberculous drugs.  
 
The commonest finding was bronchiectasis, which was present in 62/102 (60.8%) of 
patients who underwent CT thorax. Being HIV negative, having microbiologically 
confirmed TB, and a history of smoking were all independently associated with 
bronchiectasis.  TB and smoking are well recognised risk factors for bronchiectasis 
[179, 385], however the association with being HIV negative requires some 
exploration. Bronchiectasis has been shown to be common in HIV infected children 
and adolescents in Sub-Saharan Africa [386], as well as in HIV infected adults in the 
USA [387]. However, in the case of TB associated bronchiectasis, it can be 
postulated that a certain degree of inflammatory response to infection is required 
in order to produce destructive pulmonary changes, and that HIV infected adults 
are less capable of  mounting such an immune response. This is in keeping with the 
well recognised finding that HIV positive patients with TB have fewer cavitatory 
lesions on imaging than those who are HIV negative and are less likely to be sputum 
smear positive [130, 135, 137]. The finding that bronchiectasis is so prevalent in this 
group of patients is important because it is a diagnosis for which appropriate 
interventions may improve outcome. Interventions known to affect the prognosis in 
bronchiectasis include appropriate antibiotic management of infectious 
exacerbations and regular postural drainage [177, 388, 389], both of which could be 
easily implemented in low-resource settings. In this cohort of patients, it is possible 
that those with bronchiectasis were more likely to have super-added acute bacterial 
infection, which may contribute to more severe presentations and even explain a 
proportion of the hypotension seen at presentation. Further research to determine 
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the microbiological aetiology of infectious exacerbations of bronchiectasis in African 
settings would help to inform management.  
 
Tuberculous destroyed lung results in large sections of non-functional lung 
parenchyma as tissue is destroyed by bronchiectasis, scaring and volume loss, and 
has previously been associated with poor TB outcomes. In this study, TDL was seen 
in 19% of patients and associated with poor outcome on univariate analysis, with 
successful outcome seen in only 63% of patients, compared to 84% in those without 
TDL. After adjustment of age, gender, smoking, HIV and confirmed TB the odds ratio 
for successful treatment outcome in people with TDL remained 0.32, but 95% CI 
was 0.09-1.13 (p-value 0.08). In fact, treatment outcomes were worse for all 
categories of chronic lung disease except emphysema, but once again none of these 
differences reached significance at a 0.05 level, possibly due to the small numbers 
of patients.   
 
Emphysema was seen in 22% of patients, although only 27% of the cohort reported 
ever having smoked. In a setting such as Malawi, it is likely that emphysematous 
changes are associated with exposure to biomass fuels [390], although data about 
possible biomass exposure and indoor air pollution were not collected as part of 
this study. Many of the emphysematous changes seen were mild, which is likely to 
explain the relatively good outcomes in patients with radiological evidence of 
emphysema.  
 
Of the 102 patients who had CT thorax performed, 77 also had spirometry after 2 
months of TB treatment. Abnormal spirometry was more common in patients who 
had  bronchiectasis (75% had abnormal spirometry compared to 55.2% without 
bronchiectasis) and destroyed lung (92.3% had abnormal spirometry compared to 
62.5% without TDL). In practice, the greatest potential for the use of spirometry 
would be to screen for bronchiectasis in settings where CT thorax, which is the gold 
standard for diagnosis, is not routinely available. The data have already shown the 
weakness of plain chest X-ray in diagnosing CT confirmed bronchiectasis, and X-ray 
facilities are often only available at central hospitals, limiting their usefulness at 
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community level. If spirometry were to perform better than X-ray in predicting 
bronchiectasis, it may be valuable as an additional screening tool for picking up 
patients for whom interventions such as postural drainage might be of benefit. 
Using the data from this cohort study with a bronchiectasis prevalence of 60%, the 
positive predictive value for CT diagnosed bronchiectasis using spirometry would be 
0.69, and the negative predictive value would be 0.86, suggesting it may have some 
use in settings where the prevalence of bronchiectasis in patients on TB 
retreatment was high.   
 
As well as there being a large number of radiologically diagnosed respiratory 
abnormalities, pulmonary function testing also demonstrated a high level of 
respiratory pathology, with only 33% of patients having normal respiratory function. 
The high prevalence of restrictive deficit compared to obstructive defect was an 
unexpected finding, for which there may be several explanations. The first 
explanation is that there truly is a high prevalence of restrictive lung pathology, 
caused mostly by bronchiectasis, TDL and scarring. However, alternative 
explanations include secondary restriction caused by reduced lung expansion. 
Impaired lung expansion can be due to a number of factors such as rib cage 
deformity, obesity or muscle weakness [391]. In this cohort of patients with 
multiple acute and chronic medical problems in whom malnutrition is common, it is 
possible that their ability to perform spirometry was hindered by intercostal and 
diaphragmatic weakness. This theory is perhaps supported by the fact that 
restrictive pulmonary deficit was more common in those who were severely 
malnourished – the prevalence of restrictive deficit being 77.3%, 57.1% and 56.0% 
in patients with BMI <16, 16-18.4, and ≥18.5 respectively. Lastly, it must be 
acknowledged that, despite training and strict protocols, it is possible that the 
technique of patients when doing spirometry was suboptimal, as this would also 
result in a restrictive-looking picture. In keeping with previous literature, the 
progression of restrictive lung defect was variable, with the majority (57.6%) still 
having restriction on pulmonary function at 8 months, but others improving and a 
small number developing obstructive deficits.   
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Overall, it is clear that there is a huge burden of chronic respiratory pathology in  
patients with recurrent tuberculosis, a large proportion of which is directly 
attributable to the effects of tuberculosis on the lung. However, there are some 
elements which may have improved the investigation of respiratory disease in this 
study. Additional insights may have been gained by more longitudinal follow-up of 
patients. The fact that previous imaging and respiratory function testing were not 
available makes it hard to differentiate pulmonary disease associated with the 
current TB episode from disease caused by previous episodes. Similarly, although 
spirometry was repeated after 8 months, repeat imaging was not performed due to 
resource constraints. Although many findings on CT are clearly irreversible (such as 
scarring and large, cystic bronchiectasis) repeated measures would provide the 
opportunity to assess progression of disease over time. Although it was planned 
that all patients would have CT thorax after 2 months of treatment, due to technical 
problems with the CT scanner in Blantyre, patients had CT performed at different 
time points during treatment. This may have meant that the amount of chronic 
change was underestimated in those who had CT early in the course of disease, and 
more prevalent in those who had CT later on. Although many of the CT findings in 
this cohort would be consistent with chronic aspergillus infection, aspergillus 
serology was not performed. Further investigation of the prevalence and features of 
aspergillus infection in patients with recurrent TB would be an interesting area for 
further investigation. Additional issues which need to be explored in order to assess 
the impact of respiratory disease on patients with recurrent TB would involve 
longitudinal follow up of patients, and in particular focus on the functional and 
social impacts of chronic lung disease.  
 
3.5.5 Drug toxicity 
 
Drug toxicity was common in this cohort, and mostly caused by streptomycin. 
Whilst on streptomycin, 35.9% of patients developed ototoxicity. This is in keeping 
with previous literature about the incidence of aminoglycoside ototoxocity [261, 
392], but it provides the largest dataset specifically concerning streptomycin, and 
the first from a prospective cohort of patients on streptomycin in Africa.  A more 
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unusual finding is that the ototoxocity resolved in over half of patients at 8 months, 
as previous data have suggested that aminoglycoside ototoxocity is irreversible 
[251]. However the follow-up numbers in this study were small, and only 14 
patients with ototoxicity after 2 months had repeat testing at 8 months.  Risk 
factors for streptomycin induced ototoxicity are not well defined, although one 
study from South Africa has suggested that hearing loss was greater in HIV positive 
patients than HIV negative patients on treatment for MDR-TB [265]. In contrast, 
data in this study suggest that ototoxicity may be less common in HIV positive 
patients, with only 31.8% developing hearing loss, compared to 58.3% of HIV 
negative patients. The explanation for this is not obvious, but may be associated 
with differences in the pharmacokinetics of streptomycin, which is a question for 
further exploration.  
 
The importance of ototoxicity is it’s affect on peoples functional ability. Much of the 
ototoxocity diagnosed on formal testing was subclinical. A subgroup of 78 patients 
in the cohort study were also enrolled in the TB-RROC trial, in which regular 
screening for hearing loss using the CALFRAST test was performed (see chapter 5 
[393]. Of these 78 patients, 14 had abnormal audiometry but only 1 stopped 
streptomycin due to presumed ototoxicity. Nevertheless, ototoxicity in this group is 
very common and mild hearing loss may still have subtle affects on peoples’ daily 
activities. Therefore, if streptomycin is used as part of the Category II retreatment 
regimen monitoring for ototoxicity should be considered, although the optimal 
approach to this in poor resource settings needs to be determined.  
 
Nephrotoxicity developed in nearly 15% of patients. This may well be an 
underestimate, as blood tests were not performed in a number of patients who 
died whilst on streptomycin, particularly those who deteriorated or died out of 
working hours when the study team was not available. It may also explain the lack 
of association between kidney injury and clinical outcome. There were no factors 
associated with the development of nephrotoxicity, and it is especially reassuring 
that patients on Tenofovir containing ART were not at greater risk of developing 
renal impairment whilst on streptomycin.   
 116 
3.5.6 Study limitations 
 
This study had a number of weaknesses, many of which have already been 
discussed whilst addressing specific aspects of the data. However, it is worth noting 
two overarching limitations. Firstly, the study was not powered to detect 
associations between treatment outcome and all of the potential risk factors. 
Hence, whilst it was possible to demonstrate high prevalence of co-morbidity and 
high incidence of toxicity, the study was frequently unable to show that these were 
statistically associated with poor outcome. Nevertheless, clinical issues are 
highlighted and it seems unlikely that such a high burden of disease is not 
contributing to poor outcomes in this group.  
 
A second drawback is that the study did not recruit a control group with which to 
compare the prevalence of other medical conditions, for example patients receiving 
TB treatment for the first time or a sample from the general population. Instead, 
comparisons are made to published data which limits the interpretation of results. 
Nevertheless the complexity of medical problems in this group of patients is clearly 
demonstrated, and from a practical perspective, if the aim is to improve 
management for patients on retreatment this is not dependent on comparison with 
other groups.   
 
Thirdly, a major drawback of this study is that cause of death was not determined. 
In determining factors which may be contributing to poor outcome, autopsy 
findings confirming cause of death would have been valuable information. 
However, it was beyond the scope of the study to perform autopsy on study 
participants who died for two reasons. Firstly, the local ethics board in Malawi 
(COMREC) at the time was not granting permission for any post-mortem 
examinations to be performed as part of research studies, as it was in the process of 
revising its policy on the matter. Secondly, discussion with other investigators at 
MLW suggested that previous attempts to use verbal autopsy had not been useful 
in this setting for determining cause of death due to difficulties in differentiation 
between TB and HIV related conditions (personal communication Dr P 
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MacPherson). The WHO Verbal autopsy tool focuses on respiratory, gastrointestinal 
and neurological symptoms, all of which are common in both HIV and tuberculosis, 
hence making the distinction very difficult [394].  
 
Finally, there was no systematic documentation of the management of medical co-
morbidity in this cohort of patients. Although the burden of co-morbidity is shown 
to be high, the impact of this burden is difficult to assess given the lack of autopsy 
data and the inability to assess the role of medical interventions applied to address 
the co-existing medical problems. There is little standardisation of management in 
Malawi for many of the co-morbid conditions seen - clinical decisions are made by a 
broad range of clinicians with varied levels of training and experience; and access to 
both diagnostic and therapeutic resources are intermittent and unpredictable. 
Therefore, although it would have been possible to document additional treatment 
received by patients in the study, the data would have been imprecise and difficult 
to interpret. For example, all patients underwent chest x-ray, but the clinical 
management of problems identified on chest x-ray such as lung abscesses, 
bronchiectasis or pleural disease would have been very variable, and these 
management decisions may have impacted clinical outcome. This is particularly 
important as the care received by patients in this cohort study was almost certainly 
enhanced by the presence of additional clinical input from members of the research 
team.  
 
 
3.6 Conclusion 
 
In this cohort of patients, fewer than 10% were infected with a strain of MTB which 
had any form of drug resistance and this was not associated with poorer outcome, 
yet 24% of patients died whilst on treatment. Patients who have an acute 
presentation with hypotension are particularly likely to do badly. The high 
prevalences of anaemia, HIV, ART failure and chronic lung disease are likely to 
contribute not only to mortality but also to morbidity in this group of patients. The 
additional burden of ototoxicity will further impact on the lives of patients 
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prescribed retreatment regimen. If clinical outcomes are to be improved for 
patients being treated for recurrent episodes of TB, it will be necessary to manage 
not only their TB disease, but also to address the entire spectrum of medical 
complications with which they present. The potential for interventions to reduce 
the impacts of co-morbidity and drug toxicity are discussed in the final chapter of 
the thesis.  
 
This cohort study has described the clinical context of recurrent TB in Malawi, 
demonstrating that patients prescribed retreatment regimen are a complex group 
with multiple medical issues. It was on the background of this context that the 
intervention of community-based management during the intensive phase of TB 
retreatment was designed, piloted and evaluated.  
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4 Intervention pilot study 
 
4.1 Introduction 
 
 
In line with MRC guidelines, the first steps after conception of the TB-RROC 
intervention were to review the literature, develop theories of how the planned 
intervention might impact on outcomes, and engage with the Malawi NTP and 
other stakeholders. Following this,  a pilot study was performed in order to explore 
the feasibility of training guardians to deliver injections.  
 
A pilot study can be defined as a ‘small study for helping to design a further 
confirmatory study’ [395]. Pilot studies are an important preparatory stage in the 
development of trials, and as such form a key component of the Medical Research 
Council’s Guidelines for Developing and Evaluating Complex Interventions [307].  
 
There is some discrepancy regarding the differentiation between ‘pilot studies’ and 
‘feasibility studies’. Whilst some authors claim little distinction between the two 
[396], others describe subtle differences [397]. The National Institute for Health 
Research Evaluation, Trials and Studies Coordination Centre (NETSCC) defines a 
pilot study as: 
 
“a smaller version of the main study used to test whether the components of 
the main study can all work together. It is focused on the processes of the 
main study, for example to ensure recruitment, randomisation, treatment, 
and follow up assessments all run smoothly’’ [398]; 
 
whereas they define a feasibility study as: 
 
“a piece of research done before a main study in order to answer the 
question ‘Can this study be done?’. It is used to estimate important 
parameters that are needed to design the main study. For instance standard 
deviation of the outcome measure, willingness of participants to be 
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randomised, willingness of clinicians to recruit participants, number of 
eligible patients, characteristics of the proposed outcome measure, follow-up 
rates etc, availability of data needed or usefulness of a particular database, 
time needed to collect and analyse data” [398] 
 
Many pilot studies clearly address questions of ‘feasibility’ and therefore the 
terminology is in some respects academic. As this initial study included an 
evaluation of the intervention proposed for the main study, the term ‘pilot’ has 
been used.  
 
Although they can play a role in many types of study [399], pilot studies are of most 
relevance in the planning of a Randomised Controlled Trial (RCT). Essentially, the 
overall aim of a pilot study is to maximise the chances of a trial being successful, 
and to optimise the potential of a full scale RCT effectively and efficiently being able 
to answer a research question. Thabane et al [396] describe various reasons for 
conducting pilot studies: 
 
 Process: This assesses the feasibility of the steps that need to take place as 
part of the main study. Examples include determining recruitment rates, 
retention rates etc 
 Resources: This deals with assessing time and budget problems that can 
occur during the main study. The idea is to collect some pilot data on such 
things as the length of time to mail or fill out all the survey forms.  
 Management: This covers potential human and data optimisation problems 
such as personnel and data management issues.  
 Scientific: This deals with the assessment of treatment safety, determination 
of does levels and response, and estimation of treatment effect and its 
variance.  
 
Pilot studies should be conducted with the same rigour as definitive trials. They 
should have clearly defined objectives and methodologies and be carried out 
according to principles of good practice. Criteria for the assessment of feasibility 
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should be pre-defined and clearly laid out [395, 400]. In general, pilot studies are 
stand-alone pieces of work separate from the main study. In certain cases, such as 
adaptive designs, the data obtained from a pilot can be incorporated into the main 
study, but caution needs to be taken as pilot data may result in the alteration of 
study methodology in the subsequent trial [401]. Pilot studies are not designed to 
test hypotheses, and do not produce data to which statistical tests of significance 
can be applied, rather descriptive data should be presented which directly address 
predefined feasibility criteria [402-404].  Likewise, sample size calculations are not a 
requirement of a pilot study, as these studies are not aiming to provide a definitive 
answer to a question of efficacy. Instead, a pilot study must recruit a sample that is 
representative of the target population; have eligibility criteria that are in line with 
those intended for the main study; and recruit a sufficient number of participants to 
provide the information required to address the objectives of the study [396].  
 
The intervention that was being evaluated in this study was an entirely new 
approach to the delivery of long-term injectables to patients with recurrent TB in 
Malawi. Although community based models of care for patients on TB treatment 
have previously been evaluated, the idea of training guardians in Malawi to deliver 
injections was novel. Therefore, it was felt that an initial evaluation of the safety of  
the intervention was warranted prior to committing to a larger trial. Additionally, as 
the process of delivering care in this way had not previously been tested, a pilot 
study would also provide an opportunity to refine the procedures involved in the 
intervention.  Finally, it was recognised that the main study was being run on a 
strictly limited budget and time scale, as it formed the basis of a PhD fellowship. 
Therefore it was important to establish what recruitment rates to the trial were 
likely to be, in order to establish whether it would be feasible to conduct the 
definitive RCT within the resource constraints.  
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4.2 Aims and objectives 
 
The overall aim of this pilot study was to provide information that would be used to 
inform the design of a randomised controlled trial planned to evaluate a community 
based model of care during the intensive phase of TB retreatment.   
 
The main research question was: 
 
Is it feasible to train guardians to deliver streptomycin to patients in the community 
during the intensive phase of the tuberculosis retreatment regimen?  
 
In line with the classification proposed by Thabane et al, the specific objectives of 
this pilot study were: 
 
1. To assess the feasibility of training guardians to administer intramuscular 
streptomycin (Process and scientific).  
 
2. To identify obstacles in the training of guardians in the technique of 
intramuscular injection, in order to optimise the training procedures prior to 
commencing the main study (Resources). 
 
3. To trial data collection and management tools in order to optimise procedures 
prior to commencing the main study (Management).  
 
These objectives were designed in order to determine whether the intervention 
was safe, whether the planned study was feasible within the constraints of available 
resources and likely rates of recruitment, and to optimise the processes and 
management of the main study.  
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4.3 Methods 
 
4.3.1 Study design 
 
A pilot study was performed in which a small cohort of patients was prospectively 
recruited and managed as per the intervention planned for the main trial. It was 
planned that all patients starting retreatment regimen for tuberculosis at QECH 
during a one-month period were screened for eligibility. In stage 1 of the study, the 
guardians of all those who enrolled were trained in the technique of intramuscular 
injection. In stage 2, a consecutive subgroup of those who successfully completed 
the training were discharged and managed in the community (figure 26). There was 
no randomisation process. Patients in the community were followed up until 
completion of the intensive phase of treatment. Eligibility criteria, follow up 
procedures and data management procedures were in line with those planned for 
the main study. 
 
Figure 26. Pilot study flow diagram 
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4.3.2 Outcome measures 
 
Outcome measures were designed to determine the feasibility of the planned 
intervention.  
 
The primary outcome measure was: 
 
The proportion of patients managed in the community who developed serious 
adverse events as a direct complication of the intramuscular administration of 
streptomycin. 
 
‘Serious adverse events as a direct complication of the intramuscular administration 
of streptomycin’ were defined as:  
 
 Deep soft tissue infection at an injection site, or  
 Sciatic nerve palsy 
 
These are well known but uncommon complications of intramuscular injection. For 
the purposes of this study, a deep soft tissue infection was defined as an infection 
at an injection site that required surgical drainage or intravenous antibiotic therapy. 
Sciatic nerve palsy was determined by examination for unilateral sensory loss in the 
distribution of enervation by the sciatic nerve (below the knee), or unilateral 
weakness of the lower leg, particularly foot drop.  
 
It is worth noting that the primary outcome in this pilot study was not the same as 
that planned for the main trial. The primary outcome in the main trial was ‘still alive 
and on treatment at the end of the intervention’. However, the proportion of 
patients predicted to be ‘still alive and on treatment’ at 2 months was 87% (based 
on unpublished data from the TB register at QECH). Therefore, in a small pilot study 
the uncertainty around the estimate would be too large to be able to make an 
assessment of feasibility [405]. Rather, it was felt that a direct assessment of 
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guardians’ ability to deliver injections without complication would be of more value 
in determining whether the intervention was safe.   
 
The secondary outcome measure was: 
 
The proportion of patients starting retreatment regimen whose guardians 
reach competency in the technique of intramuscular injection following 
training.  
 
Competency was assessed using a standard proforma consisting of 10 specific tasks 
(appendix 3). Guardians were required to complete all 10 steps correctly in order to 
be considered competent to safely perform the procedure of intramuscular 
injection.  
 
It was judged that the main study would be feasible if: 
 
No more than one patient managed in the community developed a serious 
adverse event as a direct complication of the intramuscular administration of 
streptomycin. 
 
AND 
 
65% of the guardians of patients starting retreatment regimen reached 
competency in the technique of intramuscular injection following training.  
 
The baseline rates of these complications were unknown. There are no published 
data that prospectively describe the incidence of either sciatic nerve palsy or 
abscess following intramuscular injection in Malawi or a similar setting. However, 
considering these are complications that are well known to arise from the 
procedure in a broad range of situations [406-408], it was reasonable to expect 
there might have been a small number of events during the course of the study. A 
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very conservative feasibility threshold for adverse events in the pilot study was 
chosen in order to emphasise and ensure patient safety.  
 
Recruitment to the main trial was intended to run for 18 – 20 months. Given that 
approximately 20-25 patients per month register for TB retreatment at each of 
QECH and Bwaila Hospital, it was estimated that in order to reach the target sample 
size in the main trial, at least 65% of all guardians of patients who were screened 
would have to reach competency in the technique of intramuscular injection. 
 
 
4.3.3 Sample size 
 
No formal sample size calculation was undertaken as this was a pilot study [400]. 
Rather, the number of participants was determined by deciding on a minimum 
number that would be required to provide sufficient data to optimize the processes 
in the planned trial. On average during a one-month period in 2010, 26 patients 
were started on retreatment regimen at QECH (data from Malawi NTP records). It 
was believed that by recruiting participants during a one-month period, the data 
from training 20-30 guardians in injection technique and following up a subgroup of 
10 patients in the community would generate enough information that could be 
used to help optimise the main study.  The pilot was designed to ensure that the 
sample recruited would be representative of the sample recruited to the main trial.  
 
 
4.3.4 Eligibility 
 
It was anticipated that the main study would be run as a pragmatic trial (see 
chapter 2) [315], and as such all patients eligible for retreatment regimen according 
to Malawi NTP guidelines would be eligible for initial entry [61]. The pilot study was 
therefore designed to be consistent with this approach and aimed to reflect the 
situation in both the planned trial and routine practice in Malawi. Eligibility criteria 
were defined as follows: 
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Inclusion criteria 
 
 Adults >16 years starting TB retreatment regimen 
 Able to give informed consent 
 Able to identify a suitable guardian 
 
Exclusion criteria 
 
 Patients identified as having MDR-TB on phenotypic drug sensitivity testing, or 
being treated for MDR-TB on the basis of Rifampicin resistance detected using 
GXP (Patients in whom MDR-TB is diagnosed were referred to the NTP MDR 
programme). 
 Pregnant women  
 Unable to give informed consent 
 Unable to identify a suitable guardian 
 
 
4.3.5 Data collection process 
 
There was a 2-stage enrolment and recruitment process. In the first stage, all 
patients starting retreatment regimen were approached to identify a guardian 
willing to participate in the study. The guardian was then trained in the technique of 
intramuscular injection. In the second stage, only a subgroup of those who were 
deemed clinically fit for discharge and whose guardian became competent at 
injection technique were discharged from the hospital in order to complete the 
intensive phase of treatment in the community.  
 
 
4.3.5.1 Recruitment: stage 1 
 
Patients starting retreatment regime were identified each weekday by reviewing 
the TB register and TB ward register at QECH. All eligible patients were approached 
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to take part in the study, and those who agreed were asked to identify a guardian. 
Initial consent to participate in this phase of the study was obtained separately 
from both the patient and the guardian. Logs were kept of all patients screened and 
all participants enrolled into stage 1. Baseline demographic, socio-economic and 
clinical data were collected on a standard Case Record Form (CRF). Whilst the 
patient was admitted to the ward, the guardian was trained in the technique of 
intramuscular injection. During the training period, a small reimbursement for 
transport was available to guardians, based on standard costs of transport 
depending on the distance they lived from the hospital. The study nurse instructed 
guardians daily during weekdays on a one-to-one basis. Once the study nurse 
believed that a guardian was capable of performing the injection using the correct 
technique, the guardian underwent a structured competency assessment (appendix 
3). The competency assessment was devised by carefully breaking down the 
components involved in performing intramuscular injection. Discussion amongst the 
study team and ward nurses identified the crucial steps involved in administering 
injections. This process was aided watching training videos and by the development 
and piloting of the pictorial instruction card (appendix 4). Once the essential steps 
had been established, the assessment form was developed.  
 
Following the competency assessment, patients continued to receive routine 
clinical care under their admitting medical team and had no further involvement in 
the study unless enrolled into stage 2. These participants formed the cohort for 
analysis of the secondary outcome (the proportion of guardians successfully trained 
in injection technique).  
 
4.3.5.2 Recruitment: stage 2 
 
It was planned that the first 10 patients who were clinically fit for discharge and 
whose guardians passed the competency assessment would be discharged from 
hospital in order to complete the intensive phase of TB retreatment at home, 
including daily streptomycin being delivered by their guardian. Prior to discharge, 
additional consent to participate in the second stage of the study was obtained. A 
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log was kept of all patients participating in the second stage of the pilot study. 
These patients formed the cohort for analysis of the primary outcome.  
 
4.3.5.3 Follow up 
 
Follow up procedures for those enrolled into stage 2 of the study were in line with 
those described in detail for the main trial (Chapter 5). Briefly, routine follow up 
was conduced at weeks 1, 3, 5, and 7 post discharge from the ward. Participants 
were also able to contact the study team at any time if they had concerns. These 
events were recorded as unplanned follow up and logged as adverse events. All 
patients were reviewed at the end of the intervention i.e. at completion of the 2-
month intensive phase of retreatment. Following completion of the intervention, 
patients re-entered routine TB clinical care provided at QECH or their local TB 
registration centre.  
 
4.3.5.4 Adverse event monitoring and reporting 
 
Adverse events, serious adverse events and unexpected serious adverse events 
were defined as per the protocol in the main trial (see chapter 5).  For the duration 
of the pilot study, all adverse events were reported immediately to the PI. The PI 
and study nurse jointly reviewed all patients experiencing adverse events, and 
completed an adverse event form for each episode. Considering the small number 
of participants in the pilot study, adverse events were compiled and reported at the 
end of the study period.  
 
4.3.5.5 Statistical methods 
 
This was a pilot study involving a small number of participants and was not 
designed to produce data for the statistical analysis of effect. Rather, the proportion 
of guardians reaching competency and the number of serious adverse events were 
reported in order to determine whether the pre-established feasibility criteria were 
met.  
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4.4 Results 
 
The study recruited participants from 9th January 2013 – 13 March 2013. A total of 
24 patients starting retreatment regimen were screened (figure 27).  
 
4.4.1 Primary outcome: Adverse events 
 
Ten patients and their guardians were enrolled into stage 2 of the study, discharged 
from hospital and completed the intensive phase of TB retreatment at home. The 
characteristics of the patients and guardians are shown in table 29. There were no 
serious adverse events directly related to the administration of intramuscular 
streptomycin in those patients discharged to the community.  
 
One patient died on day 60 of treatment. She was a 28 year old HIV positive woman 
being treated for presumed extra-pulmonary TB. Following discharge to the 
community, she had been readmitted to hospital with fever, anaemia and 
splenomegaly. No definitive diagnosis was made but she initially responded to 
empirical treatment for a presumed episode of bacterial sepsis and was discharged 
back to the community. She later died at home on the last day of her course of 
streptomycin, after a further short febrile illness of undetermined aetiology. The 
guardian did not report any symptoms suggestive of intramuscular abscess or sciatic 
nerve injury.  
 
4.4.2 Secondary outcome: Proportion of guardians trained to inject 
 
There were 19 participants enrolled into stage 1 of the study. Seventeen guardians 
who began training successfully completed training and passed the competency 
assessment. The median time taken by guardians to reach competency was 3 days 
(range 2 – 10 days). Given that 24 patients were screened for eligibility into the 
study, the overall proportion of guardians who reached competency was 70.1%.  
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Figure 27. Participant recruitment to Pilot Study 
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Table 29. Characteristics of participants enrolled into the TB-RROC pilot study 
 
 
 
 
 
  
Characteristic 
 
n 
 
Patient characteristics 
 
 
 Age (mean, yrs) 36.1 
 Sex 
  Male 
  Female 
 
6 
4 
 TB classification 
  Pulmonary 
  Extra-Pulmonary 
 
8 
2 
 TB category 
  Relapse 
  TAD 
  Fail 
  Other 
 
6 
0 
0 
4 
 Number of previous TB episodes 
  1 
  2 
 
9 
1 
 HIV status 
  Positive 
  Negative 
 
8 
2 
 ART status amongst HIV+ 
  On ART 
  Not on ART 
 
 
7 
1 
 Guardian Characteristics 
 
 
 Age (mean, yrs) 37.0 
 Sex 
  Male 
  Female 
 
4 
6 
 Relationship to patient 
  Spouse 
  Sibling 
  Parent 
  Aunt/Uncle 
  Niece/Nephew 
 
4 
2 
1 
2 
1 
 Occupation 
  Paid employee 
  Self-employed 
  Unemployed 
 
 
4 
4 
2 
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4.5 Discussion 
 
4.5.1 Feasibility 
 
There were no serious adverse events as a direct complication of intramuscular 
injection, and more than 65% of guardians were successfully trained to administer 
intramuscular streptomycin. As both feasibility criteria were met, it was concluded 
that a larger trial would be feasible.  
 
There was one serious adverse event - the death of a patient on day 60 of 
treatment. The case was reviewed and it was concluded that the event did not 
occur as a result of the intervention. There was no suggestion that her illness was 
caused by a direct complication of having received injections from the guardian. The 
intercurrent, recurring episodes suggest a possible additional underlying pathology. 
Although she eventually died in the community, she had had a previous readmission 
to hospital from which she recovered sufficiently to be discharged home. Mortality 
in this group of patients is known to be high, with 11% of patients at QECH in 2011 
dying within the first 2 months of TB retreatment (unpublished data from QECH TB 
register). Therefore, 1 death amongst 10 patients managed in the community was 
within the expected mortality and not thought to be a contraindication to proceed 
to the main trial.  
 
Recruitment to the pilot study was considerably slower than anticipated. In order to 
enrol 10 patients into stage 2 of the study, recruitment had to be extended beyond 
the planned one month, so that the recruitment period ran from 9th January to 13th 
March 2013.  
 
The pilot was seriously affected by an interruption in the supply of streptomycin, 
which occurred countrywide during the first three months of 2013. This had major 
implications for both recruitment and retention of participants. Of greatest 
significance was the fact that only 24 patients were screened during a period of 
more than 2 months. This is in contrast to the mean number of patients registering 
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for TB retreatment at QECH in 2011, which was 26 per month. From observation 
and discussion with health care providers, it was evident during this period that 
fewer patients were being referred to QECH for TB retreatment. This was likely to 
be because it was known amongst those working at TB registration centres across 
the region that streptomycin was not available at the central hospital. Additionally, 
some patients and guardians on the ward who may otherwise have participated in 
the study were unable or unwilling to participate. There were a number of 
occasions where training was interrupted and participants became frustrated and 
withdrew from the study, or where guardians were competent to do injections but 
there was not sufficient stock of streptomycin to be able to discharge patients with 
an adequate supply. Of the 17 guardians who became competent in injection 
technique, 7 did not enter stage 2 of the study. Of these, 4 were not discharged due 
to reasons directly related to the inconsistent supply of streptomycin: 2 guardians 
withdrew, 1 patient withdrew, and in 1 case although both were still willing to 
participate there was insufficient supply of streptomycin.  
 
The lack of streptomycin was an unprecedented event, with supplies of TB drugs in 
Malawi having been consistent for many years [409]. The exact reasons for the 
interruption in supply remain unclear but are likely to be multifactorial. It was 
thought that although unlikely to happen again, the possibility of further 
interruptions in drug supply, which would hinder the trial, needed to be considered. 
Key components of the World Health Organisation’s Stop TB Strategy are that 
governments should provide a standardised treatment TB regimen and ensure 
effective drug supply and management systems for TB [65]. So, whilst the possibility 
of the study procuring streptomycin to be used in emergency situations was 
debated, it was decided that this should only be considered as a last resort. 
Strategies whereby the study could support the sourcing of drugs through local 
systems (for example assisting with transport to collect streptomycin from other 
Ministry of Health facilities in the region) were considered as preferable 
alternatives.   
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4.5.2 Training technique 
 
The processes by which guardians were taught to administer intramuscular 
injections were optimised. Tools devised included (see figure 28): 
 
 Foam pads were designed for use when practicing injection technique. 
 Illustrated instruction cards were developed (appendix 4). 
 DOT cards for participants to complete whilst receiving treatment in the 
community were optimised (appendix 5). Dates of upcoming visits and study 
team contact details were added to the original design of these cards.   
 
 
Figure 28. Materials developed for training guardians 
to deliver streptomycin injections 
 
 
 
 
In addition to improving the one-to-one training delivered to guardians, the pilot 
study provided an opportunity to sensitise staff on the TB ward to the study. 
Clinicians, nurses and TB officers were made aware of the study and became 
familiar with the processes involved in recruiting and training participants.  
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4.5.3 Data collection and management 
 
Data were collected using paper CRFs and captured using Teleform scanning 
software. A number of changes were made to the data management procedures, 
including: 
 
 In addition to variable names, each variable was given a unique letter and 
number linking it to the form and the position on the form on which it could 
be found.  
 Questions to which there could be more than one response were not 
captured accurately by the Teleform system during the pilot. Adjustments 
were made so that each answer was entered into the database as a separate 
variable.  
 Barcodes were found not to be useful. They did not scan well into the 
system and as there was no parallel recruitment (only one study nurse 
enrolling at each site at any one time) they were not thought to be 
necessary. The participant study number on each page was found to be 
sufficient.  
 During the pilot study participants were allocated both a screening number 
and an enrolment number, which resulted in confusion on a number of 
occasions. It was also recognised that there was potential for further 
complication during the main study as patients were going to be screened 
for entry into a cohort study as well as the trial and would be enrolled into 
one, both or neither of the studies. Therefore it was decided to allocate one 
study identification number to each participant, which would remain their 
unique identifier throughout the screening, enrolment and follow up 
processes, hence simplifying the system.  
 
Following presentation of the pilot data to research colleagues, an additional 
variable was added which captured the education level obtained by the guardians 
who were trained. Questions were asked about guardian’s occupation during the 
pilot study. However, one of the concerns about this intervention had been 
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whether guardians who were illiterate would be able to learn to deliver injections. 
Asking guardians about their educational attainment better captured this 
information.  
 
A number of issues that were discussed with patients during the process of data 
collection were of a potentially sensitive nature. Furthermore, the questions asked 
in one questionnaire had the potential to affect answers to questions subsequently 
asked in another questionnaire. For example, asking a patient about whether they 
had had thoughts of suicide and feelings of worthlessness (as part of the SRQ 
screening for depression) may have affected the answers they then provided for the 
EQ-5D quality of life measurement. It was therefore established that during 
enrolment to the study the questionnaires should be administered in the following 
order: 
 
1. Baseline clinical data 
2. Demographic information 
3. EQ-5D quality of life assessment 
4. SRQ 
 
All amendments to training and data collection procedures were incorporated into 
the protocol and standard operating procedures for the main trial.  
 
4.6 Conclusions 
 
In summary, this pilot study demonstrated that progression to a larger randomised 
trial was justified, as both predefined feasibility criteria were met – there were no 
complications as a direct result of guardians administering streptomycin in the 10 
patients discharged to the community, and more than 65% of those screened had a 
guardian who successfully learnt to administer intramuscular injections. The study 
also provided the opportunity to improve data management systems and optimise 
the procedures involved in the planned intervention.  
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5 The TB-RROC Trial 
5.1 Introduction 
 
Having established in a pilot study that it was feasible to train guardians to deliver 
streptomycin in the community, a definitive trial of the intervention was conducted. 
This, the first component of a multi-method evaluation of the TB-RROC 
intervention, primarily aimed to assess clinical outcomes. A pragmatic, individually 
randomised trial of hospital versus community-based management during the 
intensive phase of TB retreatment was performed.  
 
5.2 Aims and objectives 
 
The overall aim of this study was to determine the optimal setting for the delivery 
of streptomycin during the intensive phase of TB retreatment regimen in Malawi.  
 
The specific objective was to assess the feasibility and safety of training guardians 
to administer streptomycin to patients at home during the intensive phase of TB 
retreatment regimen.  
 
5.3 Methods 
 
5.3.1 Study design 
 
The study was an individually randomised controlled clinical trial conducted across 
two sites in Malawi – Queen Elizabeth Central Hospital in Blantyre and Bwaila 
Hospital in Lilongwe. In order to maximise the usefulness of the data to policy 
makers in Malawi, the trial adopted a pragmatic design in which operational 
conditions were replicated as far as possible. It aimed to detect non-inferiority in 
the intervention arm as it was believed that if clinical outcomes were shown to be 
no worse in patients managed at home, and the intervention demonstrated 
potential social and economic benefits, the recommendation would be to adopt the 
new method of care delivery. The primary outcome of the trial was ‘still alive and 
on treatment at the end of 2 months of TB treatment.’ The study employed a 2-
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stage enrolment and randomisation process: patients starting retreatment regimen 
were screened for eligibility, and asked to identify a guardian. Only once guardians 
were trained in injection technique and patients fit for discharge were participants 
randomised and formally enrolled in the trial. 
 
5.3.2 Outcome measures 
 
The primary outcome was: 
 “Successful treatment at the end of the 2 month intervention period” 
 
The definition of successful treatment was adapted from the WHO and Malawi NTP  
operational reporting guidelines, which state that successful treatment includes 
patients who have been cured and those who have completed treatment [61, 66]. 
Unsuccessful treatment includes all patients who have died, defaulted or whose 
outcome is unknown. For the purpose of this study successful treatment included 
all those “still alive and on treatment at the time of assessment after 2 months 
treatment.” A primary outcome at two months was chosen because it was believed 
that the potential for impact would be greatest during the period during which 
patients were actually receiving intramuscular injections as part of the intervention. 
Additionally, although it is recognised that end of treatment (8 month) outcomes 
are of primary importance in tuberculosis control, the project was confined by the 
timeline of the PhD fellowship, which was too short to allow an additional six 
months of follow up.  
 
Secondary outcomes were: 
 2-month culture conversion in those culture positive at baseline 
 8-month programmatic TB outcome  
 Serious Adverse Events during the intensive phase of treatment 
 Karnofsky score at 2 months 
 Mental Health status at 2 months  
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5.3.3 Eligibility 
 
Inclusion criteria 
 Adults ≥ 16 years of age starting TB retreatment regimen 
 Patients able to give informed consent 
 Patients able to identify a suitable treatment supporter 
 
Exclusion criteria 
 Patients identified as having MDR-TB on phenotypic drug sensitivity testing, 
or being treated for MDR-TB on the basis of Rifampicin resistance detected 
using GXP (these patients were referred to the NTP MDR treatment 
programme) 
 Pregnant women 
 Patients not planning to stay in Blantyre/Lilongwe for the 2-month duration 
of the intervention 
 Patients unable to give informed consent 
 Patients unable to identify a suitable guardian 
 
5.3.4 Study procedures 
 
5.3.4.1 Initial screening and enrolment 
 
Patients starting retreatment regimen were identified each weekday by reviewing 
the TB and ward registers at each site. All eligible patients starting retreatment 
regimen were approached to take part in the study, and those who agreed were 
asked to identify a guardian for training. Consent to participate in this phase of the 
study was obtained from both patients and their guardians. Logs were kept of all 
patients screened and all patients enrolled into the first stage of the study. Baseline 
demographic, socio-economic and clinical data were collected on a standard Case 
Record Form (CRF). Mental health status was assessed at baseline and again at the 
end of the intervention using a Chichewa validated self-reporting questionnaire 
(SRQ). This tool was developed by the WHO to be used in screening for common 
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mental disorder, and consists of 20 questions which explore symptoms of 
depression and anxiety [410]. Patients scoring 8/20 or higher were classified as 
having common mental disorder [411]. 
 
5.3.4.2 Training guardians 
 
Whilst patients were admitted to the ward, the study nurse trained recruited 
guardians in the technique of intramuscular injection. This involved daily instruction 
and supervision, and included training in all aspects of streptomycin administration 
including injection procedure, sterile technique and safe disposal of sharps. Once it 
was thought that the guardian was able to safely perform the injection, they 
underwent a structured competency assessment. Guardians were given three 
attempts to pass the competency assessment. Whilst on the ward, all other aspects 
of TB care remained unchanged. All patients were offered HIV counselling and 
testing, and were referred to Antiretroviral Therapy (ART) clinic as appropriate. 
 
5.3.4.3 Randomisation 
 
Participants were randomised to receive hospital or community based care once 
the guardian had passed the competency assessment and the patient was declared 
fit for discharge by a clinician. Randomisation was carried out by the data team at 
MLW who were not involved in the conduct of the trial in any other form. Block 
randomisation using variable block sizes of 4 or 6 was performed using a computer 
random number generator to produce an equal allocation ratio. Allocation 
concealment was ensured by using sequentially numbered opaque sealed 
envelopes that were prepared by an independent person and opened only after 
participant details had been written on the envelope. Given the nature of the 
intervention, there was no blinding.  
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5.3.4.4 Follow up of study participants 
 
Patients were reviewed either at home or on the ward 1, 3, 5 and 7 weeks post 
randomisation. Reviews were conducted by the study fieldworker. At each review 
the following took place: 
 Assessment for adverse events, including: 
- Assessment of hearing using CALFRAST test 2 
- Assessment of urine output, by enquiring if the patient had passed urine 
during the previous 24 hours 
- Assessment for sciatic nerve injury, by asking the patient about 
unilateral leg weakness or numbness 
- Assessment of the injection site, by asking about symptoms and 
examination for swelling, redness and discharge 
- Documentation of any medications prescribed by a clinician in the 
intervening period since the last review 
 Documentation of Karnofsky score  
 
For patients managed in the community, the following also took place at each visit: 
 
 Collection of all used equipment 
 Delivery of all equipment required for the next two weeks of treatment, 
including needles, syringes, gloves, sharps disposal boxes, drug vials and 
water for injection 
 Adherence assessment by self-report and ‘vial count’ (equivalent to ‘pill 
count’ employed as a standard means of assessment of adherence to ART) 
 At the first visit, injection technique was also assessed to ensure 
competence was maintained in the home environment 
 
                                                     
2 The ‘calibrated finger rub auditory screening test’ (CALFRAST)  has been validated in the USA as a 
routine diagnostic screening tool for hearing loss. It involves the examiner holding their arms out to 
either side of the patient’s head; rubbing the fingers strongly on one side; and asking the patient 
which side they hear a sound. This is repeated 3 times. If the patient is able to hear a strong finger 
rub, the procedure is repeated using a faint finger rub. 393. Torres-Russotto, D., et al., Calibrated 
finger rub auditory screening test (CALFRAST). Neurology, 2009. 72(18): p. 1595-600. 
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5.3.4.5 Unplanned follow up 
 
If participants encountered problems between routine visits there were clear 
procedures by which they could contact the study team. Patients and guardians 
were given a telephone number to call the study team and if necessary, a visit to 
the patient or review at the health facility was arranged. Adverse events were 
recorded on a standard proforma (appendix 6). 
 
5.3.4.6 Withdrawal from the intervention 
 
Readmission to the TB ward was arranged immediately for any patient in the 
community who, at any point during follow up was deemed unable to safely 
continue participating in the intervention for any reason, including: 
 
 Inability to continue administration of TB treatment e.g. if trained guardian 
was no longer available 
 Any illness requiring admission to hospital 
 Patient or guardian’s unwillingness to continue in the study 
 
In a situation where a patient was admitted for management of an acute clinical 
event from which they fully recovered, they were able to return home and continue 
to receive injections delivered by their guardian if it was clinically appropriate to do 
so. If the guardian was unable to continue safely administering injections (including 
direct complication as a result of the injection i.e. abscess at an injection site or 
sciatic nerve injury), the patient would have been withdrawn permanently from the 
intervention and completed their course of streptomycin in hospital.  
 
5.3.4.7 Completion 
 
All patients were reviewed at the end of the intervention period i.e. at completion 
of the 2-month intensive phase of treatment. Clinical and socio-economic data were 
captured using standard CRFs. Following the completion of the intervention, 
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patients re-entered routine TB care under the NTP and completed treatment on an 
outpatient basis as per standard practice. Final outcomes were recorded from the 
TB register after patients had completed the 8 month course of retreatment.  
 
5.3.5 Adverse events monitoring 
 
As the trial was designed pragmatically in order to provide appropriate, meaningful 
data for making policy decisions about scale up of the intervention in Malawi, there 
was an emphasis on maintaining a research environment as representative of the 
‘real-life’ situation in Malawi as possible. The adverse event monitoring in this study 
therefore aimed to be a realistic reflection of standard practice within the routine 
health-care system, whilst maintaining patient safety as a priority at all times.  
 
5.3.5.1 Definitions 
 
In order to reflect the particular situation of a community based intervention in 
which adverse event monitoring is necessarily different from monitoring in a 
therapeutic drug trial, definitions of adverse events were adapted from standard 
definitions [412] (table 30). 
 
5.3.5.2 Identification  and management of adverse events 
 
There were three methods by which adverse events could be identified. Firstly, 
during a routine follow up visit; secondly by a participant contacting the study team 
between scheduled reviews; and lastly if a participant failed to attend a routine 
review. Patients presenting with clinical adverse events were reviewed by the study 
PI or another nominated clinician. Blood-borne virus exposures were managed by 
the study team according to Malawi Ministry of Health guidelines, including 
providing post-exposure prophylaxis for HIV if necessary, and recorded as an SAE. If 
a patient missed more than 2 doses of TB treatment between routine review visits, 
an adherence adverse event was recorded. Adherence counselling was provided 
and the participants were reviewed after one week. At the one-week follow up visit, 
if the patient had missed more than one dose, they were readmitted to the TB ward 
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for completion of the intensive phase of treatment (therefore constituting an SAE).  
If participants did not attend a scheduled routine follow up visit, all attempts were 
made to contact them by telephone and community visits. If a successful follow up 
visit was not completed within 2 weeks of the missed appointment, this constituted 
a default event which was automatically classified as an SAE. All adverse events 
were reviewed and recorded by the study clinician at each site.  
 
 
Table 30. Definitions of adverse events 
 
 
  
  
Adverse event 
(AE) 
 
Any untoward medical occurrence in a study participant 
   Clinical event Any illness or clinical injury, including possible infection at an 
injection site, possible sciatic nerve injury, possible renal 
impairment, possible hearing loss, prescription of any new 
medication  
 
   PEP event Any possible blood-borne infection exposure occurring in relation to 
administration of streptomycin, including needle-stick injuries, 
which may or may not require post exposure prophylaxis (PEP) for 
HIV  
 
   Adherence event Any situation in which the guardian does not administer daily 
streptomycin injections, and includes missed doses identified by 
self-report or vial count at routine review, or the guardian being 
unavailable to give the dose for any other reason (e.g. travelling 
away) 
 
   Default event Any missed routine follow up visit 
  
Serious Adverse Event 
(SAE) 
Any adverse event that: 
i. Results in death 
ii. Is life-threatening 
iii. Requires hospitalisation or prolongation of existing         
hospitalisation (including readmission because of any clinical, 
adherence, safety or PEP event) 
iv. Results in persistent or significant disability or incapacity 
(including sciatic nerve injury or ototoxicity) 
v. Results in a patient being lost to follow up 
vi. Results in any caregiver requiring Post Exposure Prophylaxis 
following possible exposure to blood-borne virus  
 
Unexpected Serious Adverse 
Event (USAE) 
Any SAE that, for any reason, is deemed to be unexpected and 
requires expedited review 
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5.3.6 Study oversight, monitoring and administration 
 
5.3.6.1 Data and Safety Monitoring Board 
 
A data and safety monitoring board (DSMB) was established which consisted of 
three independent people, all of whom were senior academics with experience of 
research in Malawi (Prof Neil French (Chair), Prof Stephen Gordon, Dr Mas 
Chaponda). Considering the trial did not involve an investigational medical product 
in terms of usage, dose or indication, an appropriate reporting mechanism was 
devised. Rather than determining rates and features of adverse reactions due to a 
study drug, the aim of this reporting mechanism was to ensure safety of the new 
method of delivering care. Reporting therefore focussed on monthly rates of SAEs, 
particularly those that could be associated with the incorrect delivery of 
intramuscular injections by guardians in the community i.e. sciatic nerve palsy and 
abscess at the site of intramuscular injection. Reports of all SAEs were compiled and 
sent to the sponsor and DSMB each month . Any Unexpected Serious Adverse Event 
were reported through an expedited reporting mechanism within 48 hours.  
 
The primary concern regarding community based management was the possibility 
of unsafe delivery of intramuscular injections by guardians i.e. incorrect technique 
which resulted in intramuscular abscess or sciatic nerve palsy. There were no 
prospective data on which to base any planned evaluation, and events were likely 
to be rare. Therefore, in conjunction with the DSMB, a ‘halting rule’ was devised 
which would trigger a review of procedures should there be an excess of absolute 
numbers of complications in the community group. It was planned that if the 
combined number of sciatic nerve palsies and abscesses in the home group 
exceeded the number in the hospital group by more than 3, recruitment to the 
study would be halted, pending review by the DSMB and TSC who would advise 
whether there were any steps which could be put into place to avoid further 
incidents, or whether the study should be stopped (see appendix 7 for DSMB terms 
of reference and interim monitoring report).  
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5.3.6.2 Trial Steering Committee 
 
A Trial Steering Committee (TSC) consisting of an independent chair experienced in 
running clinical trials in Malawi (Dr Kamija Phiri); two independent Malawi-based 
clinical researchers (Prof. Malcolm Molyneux, and Prof Henry Mwandumba) and a 
representative from the Malawi NTP (Mr Kruger Kaswaswa) was established to 
provide independent advice and monitoring.  
 
5.3.6.3 Monitoring and Audit 
 
External audits were carried out by the Research Support Centre at the Malawi 
College of Medicine at both study sites. The first audits were during the first six 
months of recruitment at each site, and subsequent audits were conducted 
annually during the remainder of the study period. The PI was responsible for 
ensuring that problem areas identified during the audits were rectified and for 
circulating details of actions taken to the TSC.  
 
5.3.6.4 Community Advisory Board 
 
A Community Advisory Board (CAB) was established in Blantyre which consisted of 6 
members including a patient who had recently received TB retreatment and the 
guardian of a patient on TB retreatment, as well as health workers involved in TB 
care and lay community members. The members of the CAB were identified 
through personal contacts at QECH and by the Science and Communications officers 
at MLW who had experience of running an established CAB within the organisation 
and who were involved in a large community-based TB intervention in Blantyre. The 
CAB met once prior to submission of the protocol to the ethical committees; once 
following completion of the pilot study but before the start of the main trial; and 
once towards the end of the study.  
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5.3.7 Sample size 
 
It was assumed that 87% of patients managed in hospital would still be alive and on 
treatment at the end of the 60 day intervention period3. It was also assumed that 
the rate of successful outcome would be slightly, but not meaningfully, lower in the 
intervention group and therefore that the proportion being still alive and on 
treatment at 60 days would be 82% in the intervention group. The sample size was 
calculated based on a non-inferiority margin of 6%. This margin was chosen because 
a 6% change in outcome was judged not to be clinically meaningful, and because it 
is less than half the estimated rate of unsuccessful outcome (13%) from previous 
data. Using a one-sided alpha at a level of 0.05, in order to achieve a power of 80%, 
it was calculated that a sample size of 268 would be required.  
 
5.3.8 Statistical analysis 
 
The primary analysis performed was based on Intention to Treat. In this strategy 
participants were included in the analyses according to the arm that they were 
randomised to, irrespective of the actual intervention received. If participants were 
randomised in error without having met the criteria for randomisation (the 
guardian being competent to administer streptomycin and the patient being 
declared fit for discharge by a clinician), they were not included in the analysis but 
reported as protocol deviations.  Secondary Per Protocol analysis was planned as a 
sensitivity analysis, and for this purpose a protocol deviation was defined as any 
participant who was randomised to community management but was not 
discharged from hospital by the time they completed 60 days of streptomycin. Any 
readmissions to hospital did not constitute protocol deviations, as admission to 
hospital may form part of the intervention. Likewise, incorrect administration of 
streptomycin was not considered a protocol deviation, but instead defined as an 
adverse event.  
 
                                                     
3 An unpublished evaluation of TB records at QECH in 2012 demonstrated that 87% of patients 
started on retreatment regimen were still alive and on treatment after 2 months.  
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A single planned interim analysis was conduced after 130 (approximately half of the 
study participants) had been recruited. Based on a binomial probability with an 
expected probability of 10%, it was stated the trial would stopped if the p-value for 
difference in mortality between the hospital and community groups was less than 
0.01. 
 
Efficacy outcomes are presented as proportions and compared using the Fishers 
exact test for the comparison of two proportions. The risk difference for 
unsuccessful treatment outcome was estimated with 95% confidence intervals. Risk 
ratios with 95% confidence intervals for key 2-month outcomes (death, default and 
culture conversion) and detailed 8-month outcomes were calculated. The median 
Karnofsky scores and IQRs at the end of the intervention was estimated for each 
group. There were no planned subgroup analyses.  
 
 
5.4 Results 
 
5.4.1 Study participants 
 
Between June 2013 and February 2015, 456 patients starting TB retreatment 
regimen were screened. Of those screened, 278 had guardians who began training 
to administer streptomycin. After further withdrawals during the period of training, 
a total of 204 participants were randomised – 103 to the intervention arm and 101 
to receive standard of care (figure 29). One patient was randomised in error prior to 
being declared fit for discharge by a clinician. Of the 204 participants randomised, 
144 were enrolled in Blantyre and the remaining 60 in Lilongwe. Of the 144 patients 
enrolled into the trial in Blantyre, 78 also participated in the cohort study.  
 
A meeting of the Trial Steering Committee was held in February 2015, at which it 
was decided to stop recruitment of the trial early due to futility. At the time of the 
meeting, 200 patients had been recruited. The event rate in the trial was much 
lower than the 0.13 which had been projected - 0.0645 in the intervention arm and 
0.0426 in the control arm (risk difference -0.0219). Assuming that the proportion of 
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success remained the same in both arms, it was projected that in order to establish 
a risk difference with 95% confidence intervals which were within the -0.06 non-
inferiority margin, recruitment would need to continue until at least 600 
participants had been recruited (figure 30), and that this was not feasible given the 
resources available.  
 
Figure 29. Trial recruitment 
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Figure 30. Risk difference with 95% confidence intervals at different sample sizes 
 
 
Characteristics of the study participants are summarised in table 31. Overall, the 
median age of patients was 36.5 years (IQR 30.0 - 44.0 years), and 69.6% were 
male. The majority of patients (89.2%) had pulmonary TB, which was classified most 
commonly as relapse (48.5%) or ‘other’ (41.7%). The HIV prevalence was 80.4%  
(median CD4 count 177 (IQR 82-423) cells/mm3), of whom 131 (80.9%) were on ART 
prior to starting TB retreatment. The proportion of patients in Lilongwe who were 
HIV positive was 73.3%, compared to 83.3% in Blantyre; but 90.9% of HIV positive 
patients in Lilongwe, compared to only 77.1% in Blantyre were on ART prior to 
presenting with TB. The median age of guardians was 32 years (IQR 26-40 years), 
and 30.4% were male. 56.4% of guardians had no formal education beyond primary 
school level.  
 
Table 32 shows the characteristics of the study population according to 
randomisation arm. A lower proportion of patients randomised to receive 
community-based care were male (64.4 % v 74.8%); a higher proportion had 
pulmonary tuberculosis (95.2% v 83.2%); and the median CD4 count in the 
community arm was higher (255 v 161 cells/mm3), however none of these 
differences were statistically significant. The characteristics of guardians enrolled 
into each group were similar.  
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Table 31. Characteristics of trial participants by study site 
 
 
 
 
 
 
 
 Total study 
population 
n = 204 (%) 
 
Blantyre 
n = 144 (%) 
 
Lilongwe 
n = 60 (%) 
Patient characteristics 
   
  Patient age (median, IQR) 36.5 (30.0-44.0) 36.0 (31.0-43.5) 37.5 (28.5-44.0) 
  Patient sex (% male) 142 (69.6) 97 (67.4) 45 (75.0) 
  TB Class  
     Pulmonary 
     Extra-pulmonary 
 
182 (89.2) 
22 (10.78) 
 
125 (86.8) 
19 (13.2) 
 
57 (95.0) 
3 (5.0) 
  TB Category 
     Relapse 
     TAD 
     Fail 
     Other 
 
99 (48.5) 
5 (2.5) 
15 (7.4) 
85 (41.7) 
 
60 (42.7) 
5 (3.5) 
4 (2.8) 
75 (52.1) 
 
26 (43.3) 
0 (0.0) 
0 (0.0) 
34 (56.7) 
  HIV positive 164 (80.4) 120 (83.3) 44 (73.3) 
  Established on ART if HIV positive 131 (80.9) 91 (77.1) 40 (90.9) 
  No. of previous TB episodes 
     1 
     2 
     >2 
 
174 (85.3) 
28 (13.7) 
2 (1.0) 
 
121 (84.0) 
21 (14.6) 
2 (1.4) 
 
53 (88.3) 
7 (11.7) 
0 (0.0) 
  Baseline Karnofsky score (median, IQR) 90 (80-100) 90 (80-90) 90 (80-90) 
  History of alcohol excess 47 (23.7) 30 (20.8) 20 (33.3) 
Guardian characteristics 
   
  Guardian age (median, IQR) 32 (26-40) 30.0 (25.0-40.0) 33.0 (29.0-40.0) 
  Guardian sex (% male) 62 (30.4) 45 (31.3) 17 (28.3) 
  Guardian level of education 
     None 
     Standard 1-4 
     Standard 5-8 
     Form 1-2 
     Form 3-4 
     University 
 
4 (2.0) 
33 (16.2) 
52 (25.5) 
42 (20.6) 
45 (22.1) 
28 (13.7) 
 
3 (2.1) 
12 (8.3) 
38 (26.4) 
36 (25.0) 
36 (25.0) 
19 (13.2) 
 
1 (1.7) 
21 (35.0) 
14 (23.3) 
6 (10.0) 
9 (15.0) 
9 (15.0) 
  Guardian relationship to patient 
     Spouse 
     Sibling 
     Parent 
     Child 
     Aunt/Uncle 
     Niece/Nephew 
     Friend/neighbour 
 
74 (36.3) 
56 (27.5) 
16 (7.8) 
19 (9.3) 
14 (6.9) 
9 (4.4) 
16 (7.8) 
 
48 (33.3) 
41 (28.5) 
6 (4.2) 
17 (11.8) 
11 (7.6) 
8 (5.6) 
13 (9.0) 
 
26 (43.3) 
15 (25.0) 
10 (16.7) 
2 (3.3) 
3 (5.0) 
1 (1.7) 
3 (5.0) 
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Table 32. Characteristics of trial participants according to study arm 
 
 
 
 
 
 Total study 
population 
n = 204 (%) 
Hospital-based 
Management 
n = 101 (%) 
Community-based 
management 
n = 103 (%) 
Patient characteristics 
   
  Patient age (median, IQR) 36.5 (30.0-44.0) 37.0 (30.0-44.0) 36.0 (30.0-43.0) 
  Patient sex (% male) 142 (69.6) 77 (74.8) 65 (64.4) 
  TB Class  
     Pulmonary 
     Extra-pulmonary 
 
182 (89.2) 
22 (10.78) 
 
84 (83.2) 
17 (16.8) 
 
98 (95.2) 
5 (4.8) 
  TB Category 
     Relapse 
     TAD 
     Fail 
     Other 
 
99 (48.5) 
5 (2.5) 
15 (7.4) 
85 (41.7) 
 
44 (43.6) 
2 (2.0) 
5 (5.0) 
50 (49.5) 
 
55 (53.4) 
3 (2.9) 
10 (9.7) 
35 (34.0) 
  Sputum culture positive 80 (39.2) 38 (37.6) 42 (40.8) 
  HIV positive 164 (80.4) 87 (86.1) 77 (74.8) 
  Established on ART if HIV positive 131 (80.9) 70 (81.4) 61 (80.26) 
  CD4 count (cells/mm3; median, IQR) 177 (82-423) 161 (68-339) 225 (117-560) 
  No. of previous TB episodes 
     1 
     2 
     >2 
 
174 (85.3) 
28 (13.7) 
2 (1.0) 
 
88 (87.1) 
12 (11.9) 
1 (1.0) 
 
86 (83.5) 
16 (15.5) 
1 (1.0) 
  Baseline Karnofsky score (median, IQR) 90 (80-100) 90 (80-90) 90 (90-100) 
  History of alcohol excess 47 (23.7) 21 (21.1) 26 (26.3) 
Guardian characteristics 
   
  Guardian age (median, IQR) 32 (26-40) 33 (28-39) 30 (25-40) 
  Guardian sex (% male) 62 (30.4) 28 (27.7) 34 (33.0) 
  Guardian level of education 
     None 
     Standard 1-4 
     Standard 5-8 
     Form 1-2 
     Form 3-4 
     University 
 
4 (2.0) 
33 (16.2) 
52 (25.5) 
42 (20.6) 
45 (22.1) 
28 (13.7) 
 
4 (4.0) 
20 (19.8) 
26 (25.7) 
18 (17.8) 
20 (19.8) 
13 (12.9) 
 
0 (0.0) 
13 (12.6) 
26 (25.2) 
24 (23.3) 
25 (24.3) 
15 (14.6) 
  Guardian relationship to patient 
     Spouse 
     Sibling 
     Parent 
     Child 
     Aunt/Uncle 
     Niece/Nephew 
     Friend/neighbour 
 
74 (36.3) 
56 (27.5) 
16 (7.8) 
19 (9.3) 
14 (6.9) 
9 (4.4) 
16 (7.8) 
 
37 (36.6) 
28 (27.7) 
9 (2.9) 
7 (6.9) 
7 (6.9) 
3 (3.0) 
10 (9.9) 
 
37 (35.9) 
28 (27.2) 
7 (6.8) 
12 (11.7) 
7 (6.8) 
6 (5.8) 
6 (5.8) 
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5.4.2 Successful completion of the intensive phase of treatment 
 
At the end of the intensive phase of treatment, 97 (96%) of patients in the hospital 
arm and 96 (93.2%) of patients in the community arm were sill alive and on 
treatment (RD -0.03 (95% CI -0.09 – 0.03); p-value 0.538). Only an intention to treat 
analysis was performed, as all randomised patients received the form of treatment 
to which they are assigned. There were 7 deaths in the community arm, and 2 in the 
hospital arm (RR 3.43; 95% CI 0.73 – 16.13) (table 33). Deaths were reviewed at a 
meeting of the DSMB  in September 2014, and it was concluded that none were 
either directly or indirectly related to the intervention. Of the 7 deaths which 
occurred in the community arm, 6 occurred after the patient had been readmitted 
to hospital (see table 34 for clinical details of all deaths). Two patients defaulted 
from hospital-based care, but none defaulted from community-based care. 
 
 
Table 33. Treatment outcomes at 2 months 
 
Hospital-based 
management 
n = 101 (%) 
Community-based 
management 
n = 103 (%) 
 
p-value 
 
RR (95% CI) 
Alive and on TB treatment 97 (96.0) 96 (93.2) 0.54 0.97 (0.91-1.03) 
Death 2 (2.0) 7 (6.8) 0.17 3.43 (0.73-16.13) 
Default 2 ( 2.0) 0 (0.0) 0.24 NA 
 
 
 
Table 34. Details of deaths during the intensive phase of treatment 
Details of event Location 
Community-based treatment arm 
 
  Stevens Johnsons syndrome 2 weeks after starting TB treatment, 1 week after starting ART Hospital 
  End stage heart failure with dilated cardiomyopathy; on treatment for presumed TB pericarditis Hospital 
  Acute febrile illness with jaundice; treated for presumed bacterial sepsis Hospital 
  Disseminated Kaposi Sarcoma, pancytopenia, ascites, splenomegaly Hospital 
  Headache, dysphasia, hemiparesis; treated for presumed cerebral toxoplasmosis 
  Cryptococcal meningitis 
Hospital 
Hospital 
  Sudden death Community 
Hospital-based treatment arm 
 
  Died whilst receiving bowel prep for colonoscopy; presumed electrolyte imbalance Hospital 
  Jaundice; presumed drug induced liver injury Hospital  
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5.4.3 Secondary outcomes 
 
End of TB treatment outcomes 
 
Before the close of the study, the first 162 patients enrolled to the trial had 
completed 8 months of follow up and therefore had registered TB treatment 
outcomes. Clinical outcomes of these patients are shown in table 35. Of the 
patients who received community-based care during the intensive phase, 67/83 
(80.7%) successfully completed the 8 month course of treatment, compared to 
61/79 (77.2%) who received hospital-based care. The proportion of patients in the 
community arm who were cured was 49.4%, compared to 32.9% in the hospital arm 
(RR 1.50 (95% CI 1.02-2.20) p-value 0.04). There were no significant differences 
between the two groups in the numbers who failed, died or defaulted treatment.  
 
 
Table 35. 8 month treatment outcomes 
 
Hospital-based 
management 
n = 79 (%) 
Community-based 
management 
n = 83 (%) 
 
p-value 
 
RR 
(95% CI) 
Successful treatment 61 (77.2) 67 (80.7) 0.70 1.05 (0.89-1.23) 
   Cure 26 (32.9) 41 (49.4) 0.04 1.50 (1.02-2.20) 
   Complete 35 (44.3) 26 (31.3) 0.12 0.71 (0.47-1.06) 
Fail 1 (1.2) 1 (1.2) 1.00 0.95 (0.06-14.96) 
Death  11 (13.9) 13 (15.7) 0.83 1.12 (0.54-2.36) 
Default 4 (5.1) 2 (2.4) 0.43 0.48 (0.09-2.53) 
Transfer out 2 (2.5) 0 (0.0) 0.24 NA 
 
 
Two-month culture conversion 
 
Of 80 patients who had sputum which was culture positive for M. tuberculosis at 
the start of treatment, repeat sputum culture was performed in a subgroup of 43 
patients who were able to provide a sample after 2 months of treatment. In the 
group who received community-based care, 21/23 (91.3%) went from being sputum 
smear positive to sputum smear negative at 2  months, compared to 15/20 (75.0%) 
who culture converted in the hospital-based care group (RR 1.22 (95%CI 0.91-1.61); 
p-value 0.22).  
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Karnofsky score at the end of the intensive phase of treatment 
 
The median Karnofsky score at the end of the intervention period was 100% in both 
groups. Of patients still alive at the end of the intensive phase of treatment, 84.4% 
in the community group and 79.2% in the hospital group had a Karnofsky score of 
100% (figure 31). One patient in the hospital arm had a final Karnofsky score of 70, 
and one patient in the community arm had a final score of 80.  
 
Figure 31. Final Karnofsky scores 
 
 
 
 
 
Mental health status at the end of the intensive phase of treatment 
 
All but one of the 21 patients who were identified as having common mental health 
disorder at baseline no longer scored above 7 on the SRQ after 2 months of 
treatment. The one patient who continued to screen positive for depression at the 
end of the intervention period had received hospital-based care.  
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5.4.4 Adverse events 
 
There were 56 adverse events in 36 patients who received hospital-based care and 
34 adverse events in 20 patients who received community-based care (table 36). All 
events were clinical events. One patient reported a missed dose of streptomycin 
and two patients missed a single dose by ‘vial count’, but there was no episode 
which met the pre-defined criteria for an adherence event. There were no needle 
stick injuries in either arm. Adverse events that resulted in death or default are 
reported as part of the primary outcome, hence are not discussed here. There were 
8 serious adverse events in the hospital arm and 5 in the community arm. Both 
adverse events which resulted in potential disability were as a consequence of 
presumed ototoxicity and occurred in the hospital arm.    
 
 
Table 36. Adverse events during the intensive phase of treatment 
 Hospital-based 
management 
n = 101 
Community-based 
management 
n = 103 
Total Adverse Events  56 34 
Serious Adverse Events  8 5 
  Life threatening illness  6 0 
  Hospitalisation  0 5 
  Significant disability 2 0 
  Needle stick injury  0 0 
 
 
5.5 Discussion  
 
 
This trial demonstrated that 93.2% of patients who received community-based care 
during the intensive phase of TB retreatment successfully completed 2 months of 
treatment, compared to 96.0% of those managed in hospital  (Risk difference -0.03 
(95% CI -0.09 - 0.03); p-value 0.538). There was no difference between the two 
study arms in terms of successful 8 month completion of TB treatment (80.7% in 
the community v 77.2% in the hospital); or the rate of 2 month culture conversion 
(91.3% in the community v 75.0% in the hospital), suggesting that overall outcomes 
at the end of treatment were comparable in the two groups.   
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5.5.1 Primary outcome 
 
The risk difference between the two groups in the primary outcome of ‘still alive 
and on treatment at 2 months’ was only 3%. However, the confidence intervals 
around this estimate reached 9%, therefore non-inferiority cannot be concluded at 
a margin of 6% which was the pre-defined non-inferiority limit. These figures are 
open for interpretation and discussion. Firstly, a non-inferiority margin of 6% was 
rather conservative. The choice of non-inferiority margin is essentially subjective, 
with many other trials setting margins of 10% - 15% [413-416]. Had this trial chosen 
a higher margin, not only the point estimate for the risk difference, but also the 95% 
confidence intervals around that estimate may well have fallen within the limit set 
for non-inferiority.  
 
Second, it is worth noting that the point estimate of 3% difference in risk is low, and 
that it is only the 95% confidence intervals which cross the chosen non-inferiority 
margin. The confidence intervals around this risk difference are wide primarily 
because the event rate in the study was low. This in itself is important to note - that 
the absolute rate of unsuccessful treatment in the community at 2 months was only 
7%. This is a high rate of treatment ‘success’, with previous estimates of 
unsuccessful retreatment at 2 months in Malawi being as high as 13%.  
 
Finally, in trying to assess “what works, for who, and in what circumstances?”, it is 
important to consider “what didn’t work, for who, and in what circumstances?”. 
Whilst there were 7 deaths in the community arm of the study, compared to only 2 
in the hospital arm (relative risk 3.43, 95% CI 0.73-16.13), the circumstances of 
these deaths need to be carefully examined. There could be a number of 
explanations for what may be a higher mortality rate in the community arm. The 
first explanation is chance: there is no statistical difference in the mortality rates 
between the two groups. Nevertheless, it is important not to ignore the fact that 
the absolute number of deaths in the community was nearly 3.5 times higher than 
in the hospital, and consider possible reasons for this. A higher death rate may have 
been as a direct consequence of guardians administering injections. However, none 
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of the deaths were related to unsafe administration of an intramuscular injection, 
such as overwhelming sepsis originating from an infection at the site of infection. 
Additionally, there is no evidence that adherence to treatment in the community 
arm was a problem, as both measures of adherence suggested very few missed 
doses of streptomycin; the rate of sputum culture conversion at 2 months was 
similar in both groups; and all of the deaths were due to conditions other than TB. A 
third possible reason for an increased death rate in the community may be that 
patients at home may suffer as a consequence of having less medical attention 
during the intensive phase of treatment. As has already been demonstrated in 
chapter 3, patients on TB retreatment are a complex group with multiple medical 
co-morbidities, and it may be that they benefit from regular clinical reviews whilst 
admitted to hospital, with community-based management having the effect of 
decreasing the level of care patients receive. Some evidence for this may be 
suggested by the higher number of adverse events in the hospital arm compared to 
the community arm, although this may have been expected as any prescription of 
medication by a physician was classified as an adverse event. However, it is well 
recognised that over-prescription of antibiotics and other drugs by clinicians in 
common [417, 418], and because patients were reviewed twice a week on the 
ward, it is unsurprising that they were prescribed medications more frequently. An 
alternative explanation for the higher number of prescriptions in the hospital group 
is the transmission of nosocomial infections, and further limitation of this study was 
its inability to accurately capture data about confirmed hospital acquired infections.  
 
An indirect effect of community-based care also seems unlikely though for other 
reasons. Of the seven deaths in people randomised to the community arm, six 
happened only following readmission to hospital. In 5 out of 6 of these patients, the 
death took place after they had been receiving appropriate treatment as an in-
patient for at least 7 days. For example, it is hard to see how a patient with 
cryptococcal meningitis who complained only of mild headache and was well 
enough to walk into the ward for readmission but deteriorated despite appropriate 
treatment with fluconazole, amphotericin and therapeutic lumbar punctures, would 
have had any different outcome had she been managed in the hospital. Similarly, a 
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patient treated for ‘TB pericarditis’ who was later found to have end-stage dilated 
cardiomyopathy and treated with intensive diuresis as an in-patient for 2 weeks 
prior to his death, was likely to have had a poor outcome in any setting.  
 
5.5.2 Secondary outcomes 
 
Whilst analysis of the primary outcome is open to interpretation, the data on 
secondary outcomes in this study are very encouraging. Crucially, end-of-treatment 
programmatic outcomes at 8 months were the same in both groups. Ultimately, it is 
the successful completion of the full course of TB treatment, rather than an 
intermediate outcome after 2 months, which is important from both individual and 
programmatic perspectives. In this case, a primary outcome at 2 months was 
chosen only because the time constraints of the PhD fellowship did not allow for an 
additional 6 months of patient follow up for all patients. Of the total cohort, 8-
month treatment outcome was known in 79%, and the proportion who successfully 
completed treatment was 80.7% in the community arm, compared to 77.2% in the 
hospital arm. There were no significant differences in treatment outcome group 
between patients in the two study arms, apart from a higher cure rate in the 
community arm, which is difficult to explain. Overall Karnofsky scores and SRQ 
scores were high in both groups throughout the study, precluding any meaningful 
assessment of the differences in changes in performance status and mental health 
between the groups.  
 
5.5.3 Study limitations 
 
The major limitation of this study was its failure to demonstrate statistical non-
inferiority and the decision of the TSC to stop the trial early due to futility. The 
reasons for this are two-fold. Although every effort was made to predict the 
expected event rate by conducting a review of the QECH TB register prior to starting 
the study, the eventual event rate was much lower than had been predicted. This 
can be explained by the fact that the trial recruited a cohort of patients who were 
less sick than the general group registering for retreatment, as by definition they 
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had to be well enough to be discharged. As evidenced by the very low rate of 
default before completion of treatment (5.1% in the hospital group and 2.4% in the 
community group), this trial also recruited a self-selected group of participants who 
were motivated to be involved in their own health care and take an active role in 
their treatment.  Additionally, it is common for clinical outcomes in a trial setting to 
be better than those in routine practice, due to increased input from the study 
team. Despite intentions to maintain routine conditions, this may also have played a 
role in improving outcomes across the board in patients recruited to the TB-RROC 
trial.  
 
A possible source of bias in this study is that despite randomisation there were 
some slight differences in baseline characteristics between the two groups. The HIV 
prevalence in the community arm was 74.8% compared to 86.1% in the hospital 
arm, with a median CD4 count of 225 cells/mm3 compared to 161 cells/mm3; and 
the proportion of patients with pulmonary TB was 95.2% compared to 83.2% in the 
hospital arm. These differences were small and none were significantly different on 
statistical testing, never the less it is important to recognise them. 
 
According to realist approaches to evaluation, it is important not simply to present 
an overall statistical analysis of an intervention, but rather to examine some of the 
mechanisms underlying outcomes in order to understand how and why the 
intervention has impact. In this instance, a realist evaluation may have examined 
how community-based management worked differently for different people, and 
perhaps performed subgroup analyses according to gender, HIV status or study site. 
A further limitation of the study from a realist perspective is that it was not 
sufficiently powered to perform subgroup analyses which would have made this 
possible, and instead these issues are addressed in the economic and qualitative 
evaluations (Chapters 6 and 7).  
 
When trying to decide who an intervention does not work for, an important group 
to consider is those who were not recruited. This study had a higher rate of non-
uptake than predicted in the development stage or suggested by the pilot study, 
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with only 44.7% of those initially screened for eligibility eventually randomised. 
There were no differences in age or gender between those who were and those 
who were not randomised. As the low recruitment rate was not predicted, data 
were not collected about any additional characteristics which may have shed light 
on the reasons people did not participate. The commonest reasons for non-
enrolment were that either the patient or the guardian declined to participate. It 
has long been recognised that recruitment rates to trials are frequently lower than 
predicted. In the 1970s, Louis Lasagna, an American pharmacologist, recognised the 
phenomenon which became known as ‘Lasagna’s Law.’ The law states that “the 
incidence of patient availability sharply decreases when a clinical trial begins and 
returns to its original level as soon as the trial is completed” [419]. It is not 
uncommon for clinical trials to fail to reach recruitment target, with one review of 
studies published in the Lancet and British Medical Journal demonstrating that 
nearly 60% of trials either failed to meet the target recruitment or required an 
extended period of recruitment [420]. A number of potential barriers to 
recruitment to clinical trials have been described and include a lack of trust in 
medical research, poor understanding of the medical diagnosis and/or intervention, 
and practical issues such as time commitment or transportation [421, 422]. 
Strategies which are thought to increase recruitment to clinical trials include 
unblinded studies, monetary incentives and culturally appropriate study designs 
[423], as well as telephone reminders and opt-out strategies [424]. The current 
study was unblinded and designed specifically to be employed in a Malawian 
setting. Monetary incentives were considered, however it was believed that as this 
was not something which would be offered under routine conditions, it was not 
appropriate to offer incentives during the study. As many of the recognised barriers 
to recruitment are specific to the research process, it is always interesting to 
consider what might happen if the intervention were introduced in a non-research 
setting, which may be an argument for additional evaluation under programmatic 
conditions in this instance.  
 
The low recruitment rate to the TB-RROC trial may impact on the generalisability of 
the results, as they only apply to fewer than half of the patients who started TB 
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retreatment during the period of recruitment. In addition to patients and guardians 
declining to participate, a significant proportion of patients were not recruited 
because they were never clinically stable enough to be discharged. As well as the 21 
patients who were medically unfit and the 10 patients who died following 
enrolment, a number of those who were recorded as having declined to participate 
did so because they were not well enough to do so. However, it was never intended 
for the intervention to be applicable to all patients who are prescribed TB 
retreatment, and even under routine conditions only those well enough to go home 
would be considered for community-based management. In other respects, the trial 
was designed to be as generalisable as possible, and the pragmatic approach to its 
design has already been discussed in some detail in chapter 2.  
 
5.6 Conclusion 
 
Although there are many published evaluations of community-based management 
for patients receiving standard 6 month short course chemotherapy and patients 
being treated for MDR-TB, this is the first evaluation specifically concerned with 
community-based management of  patients on retreatment regimen. It is also the 
first study to investigate training guardians (lay people) rather than health 
professionals to deliver parenteral antibiotics in a low resource setting. The results 
of this study are in keeping with the literature in showing that adherence to 
treatment in the community is good; guardians are able to deliver injections safely 
with out causing infection or sciatic nerve injury; and outcomes at completion of TB 
treatment are comparable to hospital-based care.  
 
Ultimately in non-inferiority studies, it is the job of decision makers to assess 
whether they are willing to accept the possible risks involved in the new 
intervention. In the current situation, their question would be: “is a 3% (or, worst 
case, 9%) increased risk of death or default during the first 2 months of TB 
retreatment a risk worth taking, given similar outcomes at the end of TB treatment, 
and the potential advantages of community based care?” The main theory driving 
the evaluation of this intervention is that there are indeed benefits for both 
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patients and health systems of community-based care during the intensive phase of 
TB retreatment, and the next two chapters of this thesis investigate those potential 
financial and social benefits. The final chapter then combines the data from all 
modalities of evaluation to make an overall assessment of the intervention, provide 
recommendations and make suggestions for further work.  
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6 The TB-RROC Trial Economic Evaluation 
 
 
6.1 Introduction 
 
 
Having examined the clinical outcomes of hospital and community-based 
management during the intensive phase of TB retreatment, this chapter moves on 
to look at the economic consequences of the TB-RROC intervention. A full economic 
analysis from a societal perspective was performed in order to provide data for use 
in decision-making, as well as to evaluate the financial outcomes of community-
based management on study participants and their households.  
 
6.2 Aims and objectives 
 
 
The broad aim of this study was to evaluate the health economic consequences of 
hospital and community based management of patients during the intensive phase 
of TB retreatment in Malawi.  
 
The primary objective was: 
To determine the cost effectiveness of a community based model of care 
using guardians to deliver streptomycin to patients during the intensive 
phase (first 2 months) of TB retreatment in Blantyre, by performing a trial 
based economic evaluation of community versus hospital based care.  
 
Secondary objectives were: 
1. To assess health utility at the end of the intensive phase of TB retreatment, 
and compare health utility in patients who received community-based 
management to those who received hospital-based management.  
2. To estimate costs and health care resource use during the continuation 
phase of TB retreatment; and to compare costs and resource use between 
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participants who received hospital-based and those who received 
community-based care during the intensive phase of TB retreatment. 
3. To document broader economic consequences for households of people 
receiving retreatment regimen for TB in Blantyre and Lilongwe, including 
catastrophic costs.   
 
6.3 Methods 
 
 
6.3.1 Study design 
 
The main study was a trial-based economic evaluation, nested within the TB-RROC 
trial. It took a societal perspective, and total costs were broken down into health 
system and user costs. Results are presented using incremental cost effectiveness 
ratios and expressed in terms of incremental costs per patient successfully 
completing 2 months of treatment [425]. Additional data on 8 month costs, 
financial effects on households, and usage of health facilities were also collected 
from trial participants, and examined in separate analyses. The household economic 
consequences of an episode of TB retreatment were evaluated according to the 
socioeconomic position of the study participants.  
 
6.3.2 Estimating user costs 
 
User costs of community-based care were estimated by interviewing study 
participants at the end of the 2 month intervention period. Data were collected 
using a standard proforma. This had been developed based on a tool for 
determining user costs during TB care which has previously been used extensively in 
Malawi [426].  User costs included only costs incurred after the start of TB 
treatment - it was assumed that costs associated with the process of being 
diagnosed with TB were the same in both arms of the trial, as the intervention 
began only after a diagnosis had been made. Costs were broken down into direct 
medical and non-medical costs. Direct non-medical costs included costs of food, 
transport and linen. Additionally, indirect costs (productivity losses) for the patient 
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and guardian were calculated by multiplying the number of days of admission (for 
patients) or days of missed work (for guardians) by reported daily income. As part 
of the questionnaire, study participants were asked what their average weekly 
income was prior to the onset of illness, from which an estimate of average daily 
income was derived. For participants in the community arm, direct and indirect 
costs from additional visits to health care facilities after discharge were estimated 
for both the patient and guardian.  
 
6.3.3 Estimating provider costs 
 
6.3.3.1 Estimating provider costs of the intervention 
 
Costs were calculated using a ‘bottom up’ ingredients approach. All resource use 
was prospectively documented during a defined period of the trial. Values were 
determined for each unit of resource, and then total cost was calculated by 
multiplying the total resource use by the cost per unit.  
 
The health system costs of community based care were broadly divided into (1) 
costs of training staff; (2) costs of training guardians to deliver intramuscular 
streptomycin; (3) costs of routine follow up in the community; (4) costs of 
unscheduled attendances (adverse events); and (5) costs of TB drugs (figure 32). For 
each of these units, resource use was estimated prospectively, and the value of 
each resource item calculated using the tools outlined in tables 37-40. The cost of 
training staff was added to staff salaries for analysis. Data were used to calculate 
the total costs of care for all patients during the period of evaluation, from which an 
estimate was derived for the cost per patient successfully treated. Overhead costs 
were estimated as a proportion of the total costs of running a medical ward, based 
on the staff time spent on training and follow up of patients managed in the 
community. Staff salaries were estimated using data from QECH for staff at the 
equivalent level (e.g. fieldworker costs were estimated using the salary of a TB 
officer/HSA at QECH). Drug costs were calculated based on the 2013 MSH 
International Drug Price Indicator Guide [427]. 
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Figure 32. Components of health system costs of community based care 
 
 
 
 
Table 37. Resource use and costs of training study staff 
Staff protocol training 
   
       Method to estimate resource use Method to estimate resource cost 
Staff time (doctor 
delivers training) 
Training timetable: hours spent 
training; plus preparation time  
Doctor (lecturer) salary at Malawi CoM 
Staff time (study 
staff get trained) 
Training timetable: hours spent 
training 
QECH staff salary scale  
Stationary Number of training folders produced Costs of items at MLW stores 
Refreshments Training timetable: one lunch break Costs of lunch allowance at MLW 
 
 
 
 
Table 38. Resource use and costs of training guardians to do injections 
Training guardians 
   
       
Method to estimate resource use Method to estimate resource cost 
Consumables Records kept prospectively by study 
nurse during training of guardians 
Cost of items purchased through MLW 
or WTTC as applicable 
Nurse time Records kept prospectively by study 
nurse during training of guardians 
QECH staff salary scale 
Hospital 
admission 
Data recorded routinely as part of 
TB-RROC trial 
Cost of admission day for retreatment 
(See section 6.3.3.2) 
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Table 39. Resource use and costs of routine community follow up 
Routine follow up 
   
       
Method to estimate resource use Method to estimate resource cost 
Consumables Records kept by fieldworker whilst 
doing community visits  
Cost of items purchased through MLW 
or WTTC as applicable  
Fieldworker 
time 
Records kept by fieldworker whilst 
doing community visits  
QECH staff salary scale 
Transport Records of minibus usage kept by 
fieldworker on community visits 
Records of minibus cost kept by 
fieldworker on community visits 
 
 
 
Table 40. Resource use and costs of adverse events in the community 
Adverse events 
  Method to estimate resource use Method to estimate resource cost 
Staff time Records kept prospectively by staff       
(fieldworker, nurse, clinician)  
QECH staff salary scale 
Admission 
time 
Records kept of number of days in 
hospital following readmission 
Cost of admission day for retreatment 
(See section 6.3.3.2) 
Transport Records of minibus usage kept by 
fieldworker on community visits 
Records of minibus cost kept by 
fieldworker on community visits 
Tests Records kept prospectively by study 
nurse/clinician of all tests performed 
Costs of tests at QECH 
(See section 6.3.3.2) 
Drugs Records kept prospectively by study 
nurse/clinician of all drugs, dosages 
& duration prescribed 
Most up to date version of 
International Drug Price Indicator 
Guide (supplier median price) 
 
 
 
 
6.3.3.2 Estimating provider costs of standard of care 
 
The costs of providing hospital-based care during the intensive phase of TB 
retreatment were only estimated at the Blantyre site (QECH). A full hospital costing 
study of patients admitted to QECH (The Cost HTC Study) was being undertaken by 
a collaborator at MLW (Dr H Mahesweran) at the same time as the TB-RROC trial 
was being conducted. The Cost HTC Study recruited a sample of 1 in 5 admissions to 
the adult medical wards at QECH in order to estimate the costs of admission for 
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specific medical conditions, including tuberculosis.  The Cost HTC study population 
was enriched for patients receiving TB retreatment by additionally including all 
patients randomised in the TB-RROC trial to receive hospital-based care during a 
one year period. The methods employed to estimate the costs of a hospital 
admission were as outlined by Dr Mahesweran below.  
 
Medical data extraction 
 
A medical doctor reviewed the notes of all participants and extracted data about 
the medical care which the patient received using a standard proforma which had 
been developed by discussion with doctors at QECH and piloted before use. The 
duration and outcome of admission and were noted. Data were extracted about 
which investigations and procedures were performed and how often they were 
performed. For prescriptions, drug name, dosage, frequency, route of 
administration and duration were recorded.   
 
Cost analysis 
 
The costs for all medical resources used were determined based on the UNAIDS 
costing guidelines [428]. A bottom-up approach was used to estimate the cost of 
medical resource outputs at QECH (e.g. a day of admission, a full blood count). The 
first step in the process was to generate a list of medical resource outputs. 
Secondly, interviews were conducted with medical and administrative personnel to 
identify the individual resource inputs (e.g. needles, syringes) required to produce 
each medical resource output. Thirdly, financial data from the hospital 
administration systems, in combination with national and international resources, 
were used to value the individual resource inputs. These data were then used to 
calculate the cost of each medical resource output. Finally, the estimated resource 
output costs were used to generate the total health provider cost for each patient.  
 
A top-down method was also used to allocate the additional costs of support 
services for each medical resource output. Interviews were undertaken with central 
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support services to estimate the total cost of support services for the hospital, 
which included the costs of central administration, cleaning, portering, security, 
laundry and catering services. The total costs of these support services were then 
divided amongst the departments involved in providing care to adult medical 
patients i.e. medical wards, laboratory, radiology and pharmacy. This was done by 
dividing the number of staff working in each department by the total number of 
staff working in the hospital and allocating costs proportionately.  
 
In order to estimate the cost of a day of admission to an adult medical ward, 
interviews were conducted with the nurse in charge of each ward. Data were 
obtained about the number of staff on the ward and the hours they worked; as well 
as consumable use and equipment on the ward. The total costs per year were 
estimated, and the costs of central support services were added to this cost (see 
above) in order to estimate the total annual cost of running the ward. During the 
period of the Cost HTC Study, the number of patients on each ward was recorded 
daily. By dividing the total annual cost of running the ward by the total number of 
patient days, the average ward stay cost for one day of admission was estimated.  
 
A similar process was employed to estimate a prescription cost for drugs dispensed 
from the hospital pharmacy. By interviewing staff in the pharmacy department, the 
total cost of resource inputs was estimated, to which the costs of central support 
services was added. The pharmacy has a record of all drugs it supplies, which was 
then used to calculate the average cost per drug dose dispensed.  
 
Direct and indirect costs of investigations performed at the laboratory and radiology 
departments were estimated. Direct costs included the costs of consumables, 
equipment and personnel time involved in the procedure; and were estimated 
based on interviews with the staff involved. Indirect costs were estimated based on 
the total annual cost of running the department plus central support services. The 
annual cost of running the department was once again based on interviews with 
staff, which established the amount of time staff spent at work but not directly 
involved in performing specific procedures, as well as the total consumable and 
 174 
equipment use. The indirect costs of each procedure were estimated by dividing the 
total number of procedures performed in a year by the total indirect annual costs.  
Adding the direct and indirect costs of each procedure produced an estimate of the 
average cost for each procedure. For procedures performed by clinicians on the 
wards, only the direct costs were estimated. For investigations performed outside 
QECH, the cost charged to QECH was used (e.g. CT scans, MRI scans).  
 
For all the costing, staff salaries were obtained from the QECH human resources 
department and included employer contributions and fringe benefits. The costs of 
consumables and equipment were obtained from the Malawi Ministry of Health 
price catalogue. For costs that were not available in the catalogue, international or 
reference prices were used. For this, first local suppliers were contacted to obtain 
costs, and if not available, international suppliers and manufacturers were 
contacted. Equipment costs were annuitized over their useful life with an annual 
discount rate of 3%. For large laboratory and imaging equipment,  useful life was 
assumed to be 5 years. This assumption was based on discussions with laboratory 
and radiology staff on time before equipment would be replaced. For all other 
equipment’s, including general office equipment, useful life was assumed to be 3 
years. 
 
 
6.3.4 Estimating outcomes of the intensive phase of TB retreatment 
 
6.3.4.1 Effectiveness outcome 
 
The outcome of interest for the primary analysis was successful completion of the 
intensive phase of TB retreatment. Patients who died or defaulted during the 2 
month study period were classified as having an unsuccessful outcome; all those 
who were still alive and taking treatment after 2 months were deemed to have 
successfully completed the intensive phase of retreatment. The cost per person 
successfully completing 2 months of TB retreatment was estimated. These clinical 
outcome data were routinely collected as part of the TB-RROC trial. 
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6.3.4.2 Health-related quality of life outcome 
 
A secondary analysis evaluated the health-related quality of life in each arm of the 
study. Utility scores for study participants were generated using a Chichewa 
validated version of the EQ-5D approved by the EuroQol group.  The EQ-5D consists 
of two components: a 5-point descriptive scale in which participants are asked 
about their mobility, self-care, daily activities, pain and anxiety; and a visual 
analogue scale (VAS) in which patients are asked to score their health status by 
marking on a scale between 0 and 100 [429]. Descriptive scores provide individual 
health states for each participant, which are then converted to utility scores using  
conversion tariff sets which have been validated using national surveys of the 
general population. Estimation of the index values in this study was performed 
using the Zimbabwe-specific value set, as there is currently no validated tariff for 
Malawi and Zimbabwe is the country with a validated scale whose characteristics 
most closely resemble those of Malawi. Individual components of the descriptive 
scale are also presented individually. They were first converted into binary 
outcomes: “some problems” or “no problems” because the frequency of any 
problems with each modality was low.  
 
6.3.5 Estimating costs and outcomes at the end of TB retreatment 
 
Successful 8 month treatment outcome was assessed according to operational 
definitions as set out by the WHO. The standard definition of successful TB 
treatment comprises ‘cure’ or ‘treatment complete’. These outcomes were 
determined by reference to the TB register. Where data in the TB register were 
incomplete, patients were actively followed up by the study team using locator 
information provided at recruitment.  
 
Data were collected from participants when they completed treatment at 8 months 
by administering a standard questionnaire. The questionnaire was similar to the 
one performed at 2 months, and was used to collect data from study participants 
about costs incurred during the six month period in which they were on 
 176 
continuation phase TB treatment. They were asked about additional days of 
hospital admission, as well as outpatient attendance at the TB office, ARV clinic, 
Health Centre and Hospital outpatient or emergency department. Direct medical 
and non-medical user costs, as well as income lost due to additional days in hospital 
were calculated using the same methods applied to evaluating user costs during the 
intervention period. Participants were asked about overall costs of an average visit 
to each outpatient department, and these were multiplied by the total number of 
visits.  
 
The evaluation of provider costs during the continuation phase of treatment was 
not within the scope of this study. The number of days of readmission as well as the 
number of attendances at ART clinic, TB office, out-patient department and A&E 
were documented. If the number of additional contacts with health services was 
similar in both groups, it was assumed that provider costs were likely to be similar 
in the two groups.  
 
6.3.6 Evaluating Catastrophic household costs 
 
The household economic situation of study participants was assessed at 2 months. 
Data were collected from participants at both sites. Total costs were defined as 
both direct medical and non-medical costs as well as indirect costs, and were 
calculated as a proportion of total annual household income. Total household 
income was estimated by multiplying the monthly household income by 12.  
 
The term ‘catastrophic cost’ is used to describe healthcare costs which force 
households to reduce expenditure to a level which is below a basic minimum. There 
is not a currently a universal definition of what constitutes a ‘catastrophic cost’ and 
options have incorporated financial shock mechanisms (selling or borrowing) – 
sometimes referred to as ‘dissaving’ [430]; thresholds of total household income; 
and thresholds of ‘capacity to pay’ (the effective income for non-food expenditure). 
In this study, the primary definition of catastrophic cost was total health associated 
costs ≥10% of annual household income as this is a quantifiable measure which is 
 177 
commonly used [34, 431, 432]. In a limited sensitivity analysis, data are also 
presented for the proportion of participants experiencing health expenditure of 
≥20% or more of their total household income, given that this has been shown to 
correlate with poor tuberculosis treatment outcomes and may therefore be a more 
appropriate measure for patients with TB [275].  
 
Wealth quartiles were generated using Principal Component Analysis [433, 434]., 
with the fourth quartile being the poorest and the first being relatively the richest. 
Components included in the analysis were based broadly on those in a proxy means 
test for poverty derived from the Malawi 1998 DHS [435], and are shown in table 
41. Wealth scores were generated separately for participants living in urban and 
rural areas. Patients were asked to describe if they lived in a rural area, using the 
term ‘Kumudzi’ in Chichewa, which roughly translates to ‘home village’, and broadly 
connotes rural dwelling. The proportion experiencing catastrophic costs are 
presented for each wealth quartile.  
 
Dissaving activities are described in detail. The proportion of participants who 
borrowed money is reported, as well as descriptions of the loans including from 
whom people borrowed, and whether they were required to pay interest. 
Additionally, details of any property that was sold whilst the patient was on TB 
treatment are reported.  Dissaving mechanisms are examined according to study 
arm and associations with wealth are described. Finally, the associations between 
dissaving and experiencing catastrophic costs are explored by calculating risk ratios 
for catastrophic costs in those who borrowed money or sold property in order to 
cover healthcare associated costs.   
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Table 41. Variables included in wealth score for principle component analysis 
Rural  Urban 
HH cooks over collected firewood HH owns a fridge 
Household size Household size 
Education level of household head Age of head of household 
No. of salaried HH members Education level of household head 
HH owns a bicycle No. of salaried HH members 
HH owns a car or motor cycle HH owns a car or motor cycle 
HH owns a fridge HH gets lighting from electricity or gas 
Purchased sugar in the last 2 weeks HH owns a bed 
Total acreage cultivated  
HH grows tobacco  
HH owns a bed  
No. cattle owned  
       * HH = Household 
 
 
 
6.3.7 Currency, price and date conversion 
 
Costs were recorded as the expenses incurred by the trial in Malawi Kwacha,  
Pounds Sterling or US dollars, and the year the cost was incurred was noted. The 
costs were adjusted to the year of reporting using the Gross Domestic Product 
deflator index, provided by the World Bank. All costs were converted into 2014 US 
Dollars using the market exchange rate.  
 
6.3.8 Statistical analysis 
 
For all cost data, means with corresponding 95% confidence intervals are 
presented. As cost data and EQ-5D scores were skewed, non-parametric bootstrap 
methods were used to derive 95% confidence intervals for the mean differences 
between these values in the two study arms.  
 
Factors associated with incurring catastrophic costs were evaluated in univariate 
analysis and then multivariate analysis using a logistic regression model and 
controlling for pre-defined variables age, gender, HIV status, residence and wealth. 
The associations between catastrophic cost and clinical outcome were assessed 
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using a logistic regression model and adjusted for wealth. When it became clear 
that HIV was independently associated with incurring catastrophic costs, the model 
was adapted to also control for HIV. Risk ratios and 95% confidence intervals were 
calculated for the risk of incurring catastrophic costs according to study arm.   
 
6.4 Results 
 
6.4.1 Cost effectiveness of community-based management  
 
6.4.1.1 User costs 
 
Data about user costs during in the intervention were available for 188 out of the 
204 (92.2%) participants enrolled into the trial. There were 11 patients no longer in 
care two months after starting treatment (9 patients died and 2 defaulted 
treatment); and a further five who were unable or unwilling to provide information.  
 
Costs incurred by patients and guardians during the first two months of TB 
retreatment are presented in table 42, and the distribution of total costs in figure 
33. The mean cost to participants who received standard of care was US$ 271.6, 
compared to a mean cost of US$ 101.8  for those who received community-based 
care. The mean difference between hospital and community-based care was US$ 
169.8 (95% CI US$ 128.9 - US$ 210.7). The biggest out-of-pocket expense was food. 
The mean expenditure on food was 2.7 times higher for patients (US$ 69.8 v US$ 
26.7) and 1.4 times higher for guardians (US$ 17.7 v US$ 13.6) in the group 
managed in hospital.  Similarly, mean transport costs were higher for both patients 
and guardians who received hospital-based care: US$ 3.6 v US$ 1.6; and US$ 10.0 v 
US$ 6.4 respectively.  
 
On average, lost earnings experienced by patients in the hospital arm were 3.4 
times higher than those experienced by patients in the community arm. Patients in 
the community arm spent a mean of 17 days in hospital, whereas patients in the 
hospital arm spent a mean of 60 days in hospital. Guardians caring for patients in 
hospital lost a mean of 26.4 days earnings, whereas those in the community lost a 
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mean of only 12.2 days earnings during the time that their patient was admitted. 
There were 21 additional contacts with health care facilities after discharge in the 
group receiving community-based care, each visit taking an average of 5.5 hours for 
the patient, including travel and waiting times. Guardians accompanied patients on 
13 out of the 21 visits to health facilities post-discharge, and lost on average 8.6 
hours per visit.  Overall, lost earnings experienced by guardians were much lower 
than those experienced by patients, but were again higher in those who received 
hospital based care. Of note, 66.7% (124/186) of guardians had no regular income.  
 
 
 
Figure 33. Distribution of total user costs by study arm 
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Table 42. Total user costs of hospital-based and community-based management during the 
intensive phase of TB retreatment 
 Mean cost US Dollars (95% CI) 
 
Hospital-based 
management 
Community-based 
management 
Mean difference * 
Patient costs    
During admission    
  Direct medical    
  Direct non-medical 
      Food  
      Transport 
      Linen 
      Other out-of-pocket 
  Indirect 
 
0.7 (0.2-1.2) 
 
69.8 (58.4-81.2) 
3.6 (1.6-5.7) 
0.7 (0.1-1.3) 
11.9 (7.1-16.7) 
133.5 (111.6-155.4) 
 
0.4 (0.0-0.7) 
 
26.7 (21.5-31.8) 
1.6 (0.5-2.6) 
1.1 (-0.1-2.3) 
4.7 (3.2-6.2) 
37.0 (28.7-45.3) 
 
0.3 (-0.2-1.0) 
 
43.1 (30.5-55.7) 
2.1 (-0.1-4.3) 
-0.5 (-1.8-0.9) 
7.2 (2.1-12.4) 
96.5 (73.2-119.7) 
Health facility post discharge    
  Direct medical & non-medical 
  Indirect 
 
- 
- 
 
1.1 (0.3-2.0) 
0.3 (0.1-0.5) 
 
-1.1 (-2.0--0.3) 
-0.8 (-1.8-0.1) 
TOTAL PATIENT COSTS 220.2 (189.8-250.8) 72.9 (60.5-85.3) 147.4 (114.1-180.6) 
Guardian costs    
During admission 
  Direct non-medical 
      Food 
      Transport 
      Linen 
      Other out-of-pocket 
  Indirect 
 
 
17.7 (11.1-24.2) 
10.0 (5.6-14.3) 
0.1 (-0.1-0.2) 
2.9 (1.1-4.7) 
20.6 (8.4-32.9) 
 
 
13.6 (9.2-17.9) 
6.4 (4.1-8.8) 
0.1 (0.0-0.3) 
1.6 (0.7-2.5) 
5.2 (2.8-7.7) 
 
 
4.1 (-3.5-11.7) 
3.5 (-1.2-8.2) 
0.0 (-0.3-0.2) 
1.3 (-0.7-3.4) 
15.4 (3.1-27.7) 
Health facility post discharge 
  Direct non-medical 
  Indirect 
 
- 
- 
 
1.0 (-0.6-2.7) 
0.8 (-0.1-1.8) 
 
-1.0 (-2.7-0.6) 
-0.8 (-1.8-0.1) 
TOTAL GUARDIAN COSTS 51.3 (31.8-70-8) 28.6 (21.5-36.2) 22.4 (2.2-42.7) 
TOTAL USER COSTS 271.6 (234.4-308.7) 101.8 (85.1-118.4) 169.8 (128.9-210.7) 
* Bootstrapped  estimates of Mean differences and 95%CI   
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Costs were examined by wealth quartile. The characteristics of the participants in 
each wealth quartile are shown in table 43. The proportion of households owning a 
fridge and owning a television increased with increasing wealth quartile (chi2 test 
for trend p values <0.001); and the proportion with earth floors in their houses 
decreased with increasing wealth quartile (chi2 test for trend p-value <0.001). The 
mean monthly income increased as wealth quartile increased, but the mean 
monthly income in the ‘richest’ households was still only US$ 134.3 (95% CI US$ 
93.2 – US$175.4). 
 
 
Table 43. Characteristics of study population by wealth quartile 
 
Wealth quartile 
Household owns  
a fridge 
Household owns  
a TV 
Earth floor 
in house 
Mean monthly 
household income (US$) 
Fourth n=50 (%) 2 (4.0) 4 (8.0) 25 (50.0) 69.1 
Third n=50 (%) 6 (12.0) 14 (28.0) 9 (18.4) 96.7 
Second n=50 (%) 14 (28.0) 31 (62.0) 3 (6.1) 111.1 
First n=49 (%) 41 (83.7) 41 (83.7) 1 (2.0) 134.3 
 
 
 
In the study cohort as a whole, direct costs accounted for approximately half the 
total costs incurred during the first 2 months of TB retreatment, with lost earnings 
accounting for the other half (figure 34). The mean total costs for patients and 
guardians increased with increasing wealth quartile (chi2 test for trend p-value 
0.04), with the first quartile spending a mean of US$ 232 and the poorest quartile 
spending a mean US$ 149 (figure 34).  Similarly, the average direct costs to users, 
increased with increasing wealth quartile – the mean loss in the first quartile was 
US$ 112 compared to a mean loss in the poorest quartile of US$ 72 (chi2 test for 
trend p-value 0.07). 
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Figure 34. Mean user costs according to wealth quartile 
 
 
 
 
6.4.1.2 Provider costs 
 
 
Costs of community-based care 
 
Data on the provider costs for the intervention were available for 32 patients. The 
costs of community-based care are shown in table 44. The mean cost of 
community-based care was US$ 498.0 (95% CI 425.6-570.4) per patient. The 
majority of the cost of the intervention was accounted for by the costs of the 
patient being admitted to the ward whilst the guardian was being trained to 
administer injections. The mean number of days that patients remained on the 
ward prior to randomisation and discharge was 17 days (range 4 days – 53 days). 
Costs of TB drugs (US$ 85.4) and ART (US$ 20.5) combined were the second largest 
expense. In total, there were 12 adverse events, costing a mean of US$ 34 each. 
There were 2 readmissions, one lasting 15 days (cost US$ 217) and the other lasting 
34 days (cost US$ 492). 
 
 
 
 
 184 
 
Table 44.  Provider costs of community based care during the first 2 months of TB retreatment 
 
 
Mean costs (95% CI) 
2014 US dollars 
n=32 
  
Training guardians  
   Days of admission 301.0 (233.0-369.1) 
   Nurse time 7.5 (5.8-9.3) 
   Gloves 1.2 (0.8-1.5) 
   Syringes 0.4 (0.3-0.5) 
   Needles 0.8 (0.7-1.0) 
   Water for injection 0.7 (0.6-0.9) 
   Alcohol swabs 0.2 (0.2-0.3) 
   Training materials 1.2 
   Overhead costs 1.3 (1.0-1.6) 
   TOTAL TRAINING COSTS 314.3 (245-383.0) 
Routine follow up 
 
   HSA time 9.7 (7.8-11.6) 
   HSA transport 7.4 (5.4-9.5) 
   Gloves 5.6 (5.0-6.2) 
   Syringes 2.7 (2.4-3.0) 
   Needles 3.1 (2.8-3.4) 
   Water for injection 4.6 (4.2-5.1) 
   Alcohol swabs 1.2 (1.0-1.3) 
   Sharps boxes  4.6 (4.3-5.0) 
   Overhead costs 4.9 (3.9-5.9) 
   TOTAL FOLLOW UP COSTS 43.9 (38.0-49.7) 
Adverse events 
 
   HSA time 0.1 (0.0-0.2) 
   Nurse time 0.01 (0.0-0.1) 
   Junior clinician time 0.1 (-0.1-0.4) 
   Senior doctor time 0.5 (0.1-1.0) 
   Drugs 3.7 (-2.2-10.0) 
   Investigations & procedures 6.8 (-1.5-15.1) 
   Ward stay for readmission 22.2 (0.0-56.1) 
   Airtime 0.3 (0.0-0.6) 
   Overhead costs 0.1 (0.0-0.2) 
   TOTAL ADVERSE EVENT COSTS 34.0 (0.0-75.7) 
TB drugs 85.4 (80.9-89.8) 
ART 20.5 (19.4-21.6) 
TOTAL PROVIDER COSTS 498.0 (425.6-570.4) 
 
 
 
 
A summary of the costs of hospital-based care are shown in table 45. The mean cost 
to the health service of providing hospital based care was US$ 1100.3 (95%CI US$ 
1040.8 –US$ 1159.8) per patient. The bulk of the expense was accounted for by 
general costs of running the ward, which accounted for 81% of the total cost of 
hospital-based care during the intensive phase of retreatment.  
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Table 45. Provider costs for hospital-based care during the first 2 months of TB retreatment 
 
Mean costs (95% CI) 
2014 US dollars 
n=33 
Investigations & procedures 109.2 (68.5-149.9) 
Drugs 114.0 (110.1-117-9) 
Ward stay 895.6 (859.1-932.1) 
TOTAL PROVIDER COSTS 1100.3 (1040.8-1159.8) 
 
 
 
6.4.1.3 Cost effectiveness of the intervention 
 
It was possible to estimate total costs of care only for the 65 patients in whom data 
about health provider costs were available. Of the 33 patients who received 
hospital-based care, 31 successfully completed 2 months of treatment (1 default; 1 
death); and of 32 who received community-based care, 30 successfully completed 2 
months of treatment (2 deaths). User costs were not available for the three patients 
who died and one who defaulted prior to completion of the intensive phase of 
retreatment. For these patients, the mean user cost of either hospital or community 
based care respectively was used. In a limited sensitivity analysis, these costs were 
replaced with the minimum and maximum user costs for each group.  
 
Table 46 shows the total costs of community-based and hospital-based care during 
the intensive phase of TB retreatment. The total cost of care for 33 patients 
managed in the hospital was US$ 47,936.6, which amounted to a cost of US$ 1546.3  
per person successfully completing the intensive phase of treatment (range US$ 
833.8  – US$ 2764.1). This compares to a total cost of US$ 21,875.6 for treating 32 
patients in the community, equating to a cost of US$ 729.2 per person successfully 
completing the intensive phase of treatment (range US$ 341.5 – US$ 1589.1 ). The 
cost saved per person successfully completing the intensive phase of TB 
retreatment was therefore US$ 817.1.  
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If the unknown user costs were replaced with minimum values, cost per patient was 
US$ 1505.0 in the hospital arm and US$ 720.8 in the community arm. If these values 
were replaced with maximum values, cost per patient was US$ 1668.4 v US$ 760.8. 
 
 
Table 46. Cost-effectiveness of community-based care in the intensive phase of TB retreatment 
 Hospital-based 
management 
n = 33 
Community-based 
management 
n = 32 
Cost indicators 
Total cost 2014 US $ 
 
47,936.6 
 
21,875.6 
Effectiveness indicators 
Number of patients completing intensive phase retreatment 
 
31 
 
30 
Cost-effectiveness indicators 
Cost per patient completing intensive phase retreatment 2014 US$ * 
 
1546.3  
(833.8-2764.1) 
 
729.2  
(341.5-1589.1) 
Incremental cost-effectiveness ratio 
Cost per patient completing intensive phase retreatment 2014 US$ 
 
- 817.1 
* Mean cost & range 
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6.4.2 Health-related quality of life 
 
Health-related quality of life scores at the end of the intervention period for both 
groups are shown in table 47. There were no significant differences in patient’s 
overall EQ-5D scores, or in individual components of the score, between the two 
groups. The change in EQ-5D score from baseline was similar in both groups. There 
was also no difference in VAS scores  between patients managed in the community 
and those managed in the hospital. Overall, VAS scores were higher than EQ-5D 
scores, but the two scores were well correlated (Pearson correlation coefficient 
0.66).  
 
 
 
 
Table 47. Health-related quality of life scores at the end of the intensive phase of TB retreatment 
 
Total population     
n = 182 (%) 
Hospital-based 
management 
n = 89 (%) 
Community-based 
management 
n = 93 (%) 
 
p-
value* 
Effectiveness indicators 
EQ-5D: Utility score 
EQ-5D: Problems with mobility 
EQ-5D: Problems with self-care 
EQ-5D: Problems with usual activities 
EQ-5D: Problems with pain 
EQ-5D: Problems with anxiety 
Change in EQ-5D from baseline 
VAS score 
 
0.884 
19/172 (11.1) 
6/172 (3.5) 
18/172 (10.5) 
25/171 (14.6) 
16/172 (9.3) 
0.04 
96.7 
 
0.889 
9/85 (10.6) 
5/85 (5.9) 
12/85 (14.1) 
13/85 (15.3) 
9/85 (10.6) 
0.01 
96.1 
 
0.880 
10/86 (11.6) 
1/86 (1.2) 
6/86 (7.0) 
12/86 (14.0) 
6/86 (7.0) 
0.07 
97.3 
 
0.80 
1.00 
0.12 
0.14 
0.83 
0.43 
0.11 
0.23 
* Bootstrapped estimates of mean difference for continuous variables; Fishers exact test for categorical variables 
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6.4.3 Costs and outcomes of TB retreatment at 8 months 
 
User costs during continuation phase of retreatment 
 
Data on costs after completing the 8 month course of TB retreatment were 
available for 122 study participants. There was no significant difference in the 
overall costs incurred by users after the intensive phase of treatment, with a mean 
difference of US$ 36.2 (US$ -28.5 - US$ 100.9) (table 48).  
 
 
Table 48. User costs during the continuation phase of TB retreatment 
 
Mean cost US dollars (95%CI) 
 
Hospital-based 
management 
Community-based 
management 
Mean difference* 
 
Patient costs    
  Direct medical & non-medical    
     Re-admission 5.3 (-0.8-11.4) 11.0 (2.6-19.5) -5.7 (-16.1-4.6) 
     Visits to TB office 33.4 (16.2-50.7) 27.1 (19.3-35.0) 6.3 (-12.4-25.0) 
     Visits to ARV clinic 26.5 (-6.0-58.9) 8.3 (5.3-11.4) 18.1 (-14.2-50.5) 
     Visits to health centre 0.4 (0.0-0.7) 1.4 (-0.1-3.0) -1.1 (-2.6-0.5) 
     Visits to hospital OPD 5.5 (-4.9-15.9) 0.7 (-0.3-1.6) 4.8 (-5.2-14.9) 
  Indirect costs 8.6 (5.9-11.3) 14.0 (7.3-20.7) -5.4 (-12.4-1.6) 
TOTAL PATIENT COSTS 79.7 (30.7-128.6) 62.6 (44.9-80.3) 17.1 (-35.1-69.2) 
Guardian costs    
  Direct medical & non-medical    
     Re-admission 16.7 (0.8-32.6) 5.3 (-0.5-11.2) 11.4 (-5.4-28.2) 
     Visits to TB office 4.4 (0.1-8.8) 6.2 (-.08-13.2) -1.7 (-9.7-6.1) 
     Visits to ARV clinic 1.8 (-0.3-3.9) 0.6 (0.0-1.2) 1.2 (-0.9-3.3) 
     Visits to health centre 0.2 (-0.1-0.4) 0.4 (-0.2-1.0) -0.2 (-0.9-0.4) 
     Visits to hospital OPD 5.3 (-5.1-15.7) 0.5 (-0.5-1.4) 4.9 (-5.2-15.0) 
  Indirect costs 5.4 (-0.2-11.1) 1.7 (0.8-2.7) 3.7 (-1.8-9.2) 
TOTAL GUARDIAN COSTS 33.9 (9.6-58.2) 14.8 (2.1-27.4) 19.2 (-7.5-45.8) 
TOTAL USER COSTS 113.6 (55.3-171.9) 77.4 (48.6-106.1) 36.2 (-28.5-100.9) 
* Bootstrapped estimates of mean difference and 95% CI 
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Health care usage during continuation phase of retreatment 
 
Eleven patients were readmitted after completing streptomycin injections – 8/63 
(12.7%) in the community arm and 3/59 in the hospital arm (5.1%) (Risk Ratio 2.50, 
95%CI 0.70-8.97; p-value 0.21).  The mean number of admission days during the 
continuation phase for patients in the hospital arm was 1.32 (95% CI -0.75-3.39), 
compared a mean number of admission days in the community arm of 2.49 (95%CI 
0.05-4.93) (t-test p-value 0.47). There were no significant differences in the number 
of visits to the TB office, health centre or hospital outpatient department (table 49). 
There is a suggestion that patients who had been managed in hospital attended 
ARV clinic more often than those who had been managed in the community (mean 
number of visits 3.61 v 2.81, p-value 0.08).  
 
Table 49. Mean number of contacts with health facilities  
during the continuation phase of TB retreatment 
 
Hospital-based 
management 
Community-based 
management 
p-value* 
Readmission 5.1 12.7 0.21 
TB office 5.24 5.24 0.99 
ARV clinic 3.61 2.81 0.08 
Health centre 0.26 0.41 0.48 
Hospital OPD 0.18 0.17 0.96 
   * Student t-test 
 
 
6.4.4 Catastrophic costs and dissaving 
 
6.4.4.1 Factors associated with incurring catastrophic household costs 
 
During the first two months of TB retreatment, 109/180 (60.6%) patients 
experienced health costs of ≥10% annual household income, and 67/180 (37.2%) 
experienced costs of ≥20% annual household income (table 50). In univariate 
analysis, being HIV positive was associated with increased odds of catastrophic 
costs at both the ≥10% and ≥20% thresholds. After controlling for age, gender, 
residence and wealth, HIV remained significantly associated with catastrophic costs.  
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Table 50. Catastrophic costs during the intensive phase of retreatment 
 
Catastrophic cost p-value OR p-value aOR * 
Cost ≥10% annual HH income     
   Age group 
      <30 
      30-35 
      36-45 
      >45      
 
25.44 (56.8) 
27/40 (67.5) 
39/61 (63.9) 
18/35 (51.4) 
 
 
0.32 
0.46 
0.63 
 
 
1.58 (0.6503.84) 
1.35 (0.61-2.98) 
.080 (0.33-1.96) 
 
 
0.53 
0.99 
0.40 
 
 
1.36 (0.52-3.57) 
0.99 (0.42-2.37) 
0.65 (0.25-1.74) 
   Gender 
      Male 
      Female 
 
72/127 (56.7) 
37/53 (69.8) 
 
 
0.10 
 
 
1.77 (0.90-1.50) 
 
 
0.28 
 
 
1.50 (0.72-3.12) 
 HIV status 
      Negative 
      Positive 
 
13/35 (37.1) 
96/145 (66.2) 
 
 
0.002 
 
 
3.32 (1.54-7.14) 
 
 
0.01 
 
 
3.01 (1.25-7.24) 
Residence 
      Urban 
      Rural 
 
97/158(61.4) 
11/20 (55.0) 
 
 
0.58 
 
 
0.77 (0.30-1.96) 
 
 
0.95 
 
 
1.05 (0.28-3.95) 
Wealth quartile 
      First 
      Second  
      Third 
      Fourth 
 
21/41 (51.2) 
31.45 (68.9) 
28/46 (60.9) 
27/44 (61.4) 
 
 
0.10 
0.37 
0.35 
 
 
2.11 (0.88-5.08) 
1.48 (0.63-3.47) 
1.51 (0.64-3.58) 
 
 
0.08 
0.41 
0.34 
 
 
2.27 (0.91-5.70) 
1.46 (0.60-3.53) 
1.70 (0.60-4.99) 
Cost ≥20% annual HH income     
   Age group 
      <30 
      30-35 
      36-45 
      >45      
 
13/44 (29.6) 
18/40 (45.0) 
23/61 (37.7) 
13/35 (37.1) 
 
 
0.15 
0.39 
0.48 
 
 
1.95 (0.79-4.79) 
1.44 (0.63-3.31) 
1.41 (0.55-3.62) 
 
 
0.26 
0.92 
0.61 
 
 
1.73 (0.66-4.52) 
1.05 (0.43-2.58) 
1.30 (0.48-3.55) 
   Gender 
      Male 
      Female 
 
42/127 (33.1) 
25/53 (47.2) 
 
 
0.08 
 
 
1.81 (0.94-3.47) 
 
 
0.16 
 
 
1.64 (0.82-3.27) 
 HIV status 
      Negative 
      Positive 
 
7/35 (20.0) 
60/145 (41.4) 
 
 
0.02 
 
 
2.82 (1.16-6.89) 
 
 
0.04 
 
 
2.79 (1.03-7.57) 
Residence 
      Urban 
      Rural 
 
59/158 (37.3) 
8/20 (40.0) 
 
 
0.82 
 
 
1.12 (0.43-2.90) 
 
 
0.18  
 
 
2.53 (0.66-9.72) 
Wealth quartile 
      First 
      Second  
      Third 
      Fourth 
 
13/41 (31.7) 
17/45 (37.8) 
22/46 (47.8) 
15/44 (34.1) 
 
 
0.56 
0.13 
0.82 
 
 
1.31 (0.54-3.19) 
1.97 (0.82-4.74) 
1.11 (0.45-1.76) 
 
 
0.56 
0.81 
0.26 
 
 
1.32 (0.52-3.13) 
2.02 (0.81-5.01) 
0.80 (0.26-2.46) 
* Adjusted for age, gender, HIV, residence and wealth 
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Table 51 Mean key costs for HIV positive and HIV negative patients 
 HIV negative HIV positive Mean difference*  
Patient food 35.52 (23.41-47.64) 51.6 (43.43-59.68) 16.03 (1.93-30.13) 
Guardian food 12.21 (3.58-20.85) 16.51 (12.09-20.94) 4.30 (-5.10-13.80) 
Patient lost earning 46.68 (25.93-67.42) 95.38 (79.48 -111.27) 48.70 (21.81-75.59) 
Guardian lost earning 7.89 (2.22-13.57) 14.25 (6.43-22.07) 6.36 (-3.15-15.86) 
* Bootstrapped estimates of mean difference and 95% CI 
 
The predominant costs for HIV positive and HIV negative patients are shown in 
table 51. Patients who were HIV positive spent significantly more on food (mean 
difference US$ 16.03) and lost significantly more earnings (mean difference US$ 
48.7).  
 
 
6.4.4.2 Association between care delivery method and catastrophic household 
costs 
 
Significantly fewer households incurred costs of ≥10% or ≥20% annual household 
income if patients received community-based care (tables 52 and 53). Community 
based care reduced the risk of incurring costs of ≥10% annual household income by 
60%. The risk of incurring costs of ≥20% annual household income was reduced 
even further (by 84%) in the group who received community-based care. As 
demonstrated by the stratified analyses, the effect of community-based care in 
reducing catastrophic costs was independent of the wealth status of the household, 
gender and HIV status of the patient.  
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Table 52. Risk of incurring costs of ≥10% of household income according to study arm 
 
Total population Hospital-based 
management 
Community-based 
management 
Risk Ratio 
All participants 109/180 (60.6) 79/92 (85.9) 30/88 (34.1) 0.40 (0.29-0.54) 
Wealth quartile 
      First 
      Second  
      Third 
      Fourth 
 
21/41 (51.2)  
31/45 (68.9) 
28/46 (60.9)) 
27/44 (64.3) 
 
17/19 (89.5) 
22/26 (84.6) 
20/25 (80.0) 
20/23 (87.0) 
 
4/22 (18.2) 
9/20 (45.0) 
8/21 (38.1) 
7/21 (33.3) 
 
0.20 (0.08-0.50) 
0.53 (0.32-0.89) 
0.48 (0.27-0.85) 
0.38 (0.21-0.72) 
Gender 
      Male 
      Female 
 
72/127 (56.7) 
37/53 (69.8) 
 
50/60 (83.3) 
29/32 (90.6) 
 
22/67 (32.8) 
8/21 (38.1) 
 
0.39 (0.27-0.57) 
0.42 (0.24-0.73) 
HIV status 
      Negative 
      Positive 
 
13/35 (37.1) 
96/145 (66.2) 
 
9/12 (75.0) 
70/80 (87.5) 
 
4/23 (17.4) 
26/65 (40.0) 
 
0.23 (0.09-0.60) 
0.46 (0.34-0.62) 
 
 
Table 53. Risk of incurring costs of ≥20% household income according to study arm 
 
Total study 
population 
Hospital-based 
management 
Community-based 
management 
Risk Ratio 
All participants 67/180 (37.2) 58/92 (62.0) 9/88 (11.4) 0.16 (0.08-0.41) 
Wealth quartile 
      First 
      Second  
      Third 
      Fourth 
 
13/41 (31.2) 
17/45 (37.8) 
22/46 (47.8) 
15/44 (34.1) 
 
13/19 (68.4) 
14/26 (53.9) 
16/25 (64.4) 
14/23 (60.1) 
 
0/22 (0.0) 
2/20 (10.0) 
6/21 (28.6) 
1/21 (4.8) 
 
NA 
0.17 (0.04-0.64) 
0.45 (0.20-0.93) 
0.07 (0.01-0.54) 
Gender 
      Male 
      Female 
 
42/127 (33.1) 
25/53 (47.2) 
 
36/60 (60.0) 
22/32 (68.8) 
 
6/67 (9.0) 
3/21 (14.3) 
 
0.15 (0.07-0.33) 
0.21 (0.07-0.61) 
HIV status 
      Negative 
      Positive 
 
7/35 (20.0) 
60/145 (41.4) 
 
7/12 (58.3) 
51/80 (63.8) 
 
0/23 (0.0) 
9/65 (13.9) 
 
NA 
0.22 (0.12-0.41) 
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6.4.4.3 Association between catastrophic costs and treatment outcome 
 
In univariate analysis, catastrophic costs were significantly associated with an 
increased risk of unsuccessful treatment outcome if catastrophic costs were defined 
as costs of ≥20% annual household income, but the association was weaker if they 
were defined as ≥10% of annual household income (table 54). After controlling for 
age, gender, wealth and HIV, the odds ratio for unsuccessful treatment outcome 
comparing households which incurred costs of ≥20% annual household income to 
those which did not was 2.74 (95% CI 1.06-67.08; p-value 0.04). A multivariate 
logistic regression model which included an interaction term between wealth 
quartile and costs ≥20% annual household income demonstrated that wealth 
quartile did not modify the effect of catastrophic cost on 8 month treatment 
outcome. The odds of unsuccessful treatment outcome were higher in those who 
incurred costs ≥20% annual household income, regardless of study arm, although 
confidence intervals around the estimates became wide (OR in community arm 3.43 
(95% CI 0.52-22.80); OR in hospital arm 3.50 (95% CI 0.68-17.91); Wald p-value for 
interaction 0.988). 
 
 
 
Table 54. Association of catastrophic cost with clinical outcome 
 
Unsuccessful 
outcome 
p-value OR p-value aOR* 
Cost ≥10% annual 
HH income 
   No 
   Yes 
 
 
6/57 (10.5) 
18/80 (22.5) 
 
 
 
 
0.08 
 
 
 
 
2.47 (0.91-6.68) 
 
 
 
 
0.08 
 
 
 
 
2.52 (0.89-7.17) 
Cost ≥20% annual 
HH income 
   No 
   Yes 
 
 
10/84 (11.9) 
14/53 (26.4) 
 
 
0.03 
 
 
2.66 (1.08-6.53) 
 
 
0.04 
 
 
2.74 (1.06-7.08) 
* Adjusted for age, gender, wealth and HIV status 
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6.4.4.4 Dissaving 
 
Overall, 77/187 (41.2%) households borrowed money to cover the costs of 
healthcare (table 55). Most commonly, money was borrowed from a 
friend/neighbour (48/77, 62%) or family member (22/77, 29%). Participants also 
took loans from employers (2), banks (2), a friend or relative’s employer (1) and 
other sources (2). There was no difference between participants in the two study 
arms in terms of the amount of money they borrowed or were required to repay. In 
the study population as a whole, 26% of households sold property in order to cover 
the costs of health care, usually a household item. The proportion of participants 
who sold property and the pattern of what was sold did not differ by study arm. 
 
 
Table 55. Dissaving during the intensive phase of retreatment according to study arm 
 
Total study 
population 
Hospital-based 
management 
Community-based 
management 
p-value 
Borrowed money 77/187 (41.2) 39/94 (41.5) 38/93 (40.9) 1.00 
Amount borrowed (mean US$) 12.2 10.6 14.1 0.52 
Amount repaid (mean US$) 12.5 10.3 15.0 0.39 
Sold property 
   Land 
   Livestock 
   Bicycle or vehicle 
   Household item 
   Farm Produce 
   Other 
48/185 (26.0) 
1/48 (2.1) 
4/48 (8.3) 
1/48 (2.1) 
33/48 (68.8) 
7/48 (14.6) 
2/48 (4.2) 
23/92 (25.0) 
1/23 (4.4) 
4/23 (17.4) 
0/23 (0.0) 
15/23 (65.2) 
2/23 (8.7) 
1/23 (4.4) 
25/93 (26.9) 
0/25 (0.0) 
0/25 (0.0) 
1/25 (4.0) 
18/25 (72.0) 
5/25 (25.0) 
1/25 (4.0) 
1.00 
 
 
0.13 
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Figure 35. Dissaving according to wealth 
 
 
 
The proportion of participants who employed any dissaving measure was lower in 
the  first wealth quartile compared to all other quartiles (33% v 52%; RR 1.6, 95% CI 
1.04-2.56; p-value 0.02) (figure 35). In all quartiles of wealth apart from the second, 
participants were more likely to borrow money than to sell property. Overall, 13.7% 
of participants had to sell property and borrow money, with participants in the first 
wealth quartile less likely than others to both sell and borrow (4% v 17%; RR 0.24, 
95% CI 0.06-0.99; p-value 0.03). Unlike catastrophic costs, dissaving was not 
associated with treatment outcome (table 56). 
 
 
Table 56. Association between dissaving and clinical outcome 
 
Unsuccessful outcome 
(%) 
p-value OR 
Any dissaving 
   No 
   Yes 
 
12/56 (21.4) 
12/81 (14.8) 
 
 
0.32 
 
 
0.64 (0.26-1.55) 
Borrowed money 
   No 
   Yes 
 
13/69 (18.8) 
11/68 (16.2) 
 
 
0.68 
 
 
1.2 (0.50-2.91) 
Sold property 
   No 
   Yes 
 
16/97 (16.5) 
7/39 (18.0) 
 
 
0.83 
 
 
0.90 (0.34-2.40) 
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Dissaving was not associated with costs of ≥10% annual household income (table 
57). Households which experienced costs of ≥20% annual household income were 
more likely to borrow money and to sell property (table 58), although neither of 
these associations were statistically significant. 
 
 
Table 57. Associations between dissaving and costs ≥10% annual household income 
 
 
 
 
 
 
 
 
 
 
 
Table 58. Associations between dissaving and costs ≥20% annual household income 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Costs ≥10% annual 
household income (%) 
p-value Risk Ratio 
Borrowed money 
   No 
   Yes 
 
61/103 (59.2) 
46/73 (63.0) 
 
 
0.61 
 
 
1.06 (0.84-1.34) 
Sold property 
   No 
   Yes 
 
80/129 (62.0) 
25/45 (56.3) 
 
 
0.45 
 
 
0.90 (0.67-1.20) 
 
Costs ≥20% annual 
household income (%) 
p-value Risk Ratio 
Borrowed money 
   No 
   Yes 
 
35/103 (34.0) 
32/73 (43.8) 
 
 
0.19 
 
 
1.29 (0.89-1.88) 
Sold property 
   No 
   Yes 
 
44/129 (34.1) 
24/45 (46.7) 
 
 
0.14 
 
 
1.37 (0.92-2.03) 
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6.5 Discussion 
 
This economic evaluation has demonstrated that community-based management 
during the intensive phase of TB retreatment is highly cost effective, with large cost 
savings for both providers and users. Community-based management significantly 
reduced the risk of catastrophic household expenditure on health, irrespective of 
wealth, HIV status or gender. 
 
6.5.1 Trial-based economic evaluation 
 
The total cost per patient successfully completing the intensive phase of TB 
retreatment was US$ 817.1 less for community-based management than hospital 
based management. Hospital-based management cost on average US$ 1546.3 (95% 
CI US$ 833.8 - US$ 2764.1) per person, whereas community-based management 
cost on average US$ 729.2 (US$ 341.5 - US$ 1589.1) per person. Provider costs 
accounted for the majority of the total costs (US$ 1100.3 for hospital-based care 
and US$ 498.0 for community-based care), and in both groups ward stay costs 
made up the bulk of the health-system costs. This highlights the fact that it is the 
cost associated with the day-to-day running a TB ward which impacts most on the 
cost of providing treatment, and is a strong argument in favour of moving care away 
from in-patient facilities. The finding that community-based models of delivering TB 
care are cost-effective is not new [278-280], and guidelines for the management of 
new patients [24] and patients on treatment for MDR-TB [26] both advocate 
community-based care based largely on this fact. However, the cost of managing 
patients on retreatment regimen has not specifically been addressed until now 
either in research or in practice recommendations.  
 
Aside from the expenses associated with periods of ward admission, the largest 
health system costs of community-based management were ART and TB drugs, 
which are not impacted by the intervention. The mean costs of additional staff time 
and overheads required for community-based management made up only a small 
proportion of the total cost of the intervention – the mean cost of staff time being 
US$ 17.9, transport US$ 7.4 and overheads US$ 6.3 during the entire period.  
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Although provider costs made up the majority of the total costs, the impact of the 
intervention on user costs was dramatic. Community-based care reduced user costs 
by a mean of  US$ 169.8 (US$ 128.9 – US$ 210.7). The greatest saving for patients 
was the reduction in lost earning, indicating that in this cohort of well patients on 
treatment it was possible for many to return to work once discharged from hospital. 
This is in keeping with a recent review by Tanimura et al which demonstrated that 
lost income accounted for 60% (16% - 94%) of patient costs  during TB treatment in 
low and middle income countries [33]. The other large benefit was seen in the 
lower cost of food for patients managed at home. These findings are in keeping 
with previous literature which report descriptions of having to provide ‘special food’ 
for patients who are sick as well as the increased expense of not being able to feed 
the whole household from a communal pot [436, 437]. The issues around costs of 
food are also supported by the accounts of patients in the qualitative evaluation of 
this intervention (chapter 7) in which having to provide food for patients in hospital 
is a key theme.  
 
The amount spent by users increased significantly with increasing wealth quartile, 
suggesting that households spend as much as they possibly can afford to on health, 
stretching their financial capacity to the limit, a feature which has been described in 
other studies [431]. It is worth noting that participants who fell into the ‘richest’ 
wealth quartile still only had a mean monthly household income of US$ 134.3 and 
even in the ‘rich’ group there was still a household with an earth floor. This implies 
that although there was a spectrum of wealth amongst study participants, this 
spectrum was fairly narrow and most households were still relatively poor.  
 
6.5.2 Catastrophic household costs  
 
The huge reduction in absolute costs seen in those who received  community-based 
management translated to a significant impact on catastrophic household costs. In 
the cohort as a whole, 60.6% of participants experienced health costs of ≥10% 
annual household income and 37.2% experienced health costs of ≥20% annual 
household income. After adjusting for age, gender, HIV, residence and wealth 
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quartile, only being HIV positive was significantly associated with incurring 
catastrophic costs. Factors which contributed to the increased costs for HIV positive 
patients were higher expenditure on food and greater lost earnings. The higher 
degree of lost earnings may be partly explained by the fact that the HIV positive 
group on average earned more than the HIV negative group prior to starting 
treatment (US$ 16.95 v US$ 11.89 per week). Spending more money on food might 
also have reflected the fact that HIV positive patients had more money available, 
however total annual incomes were comparable between households in which the 
patient was HIV positive (US$ 1322) and those in which the patient was HIV 
negative (US$ 1323). Instead, it is possible that families of patients who were HIV 
positive recognised the importance of nutrition, for example having been through 
counselling in ART facilities, and therefore prioritised providing good quality food 
for patients, or that HIV positive patients were more obviously malnourished and in 
need of feeding.   
 
It is surprising that catastrophic health costs were not associated with wealth 
quartile, as a number of studies have shown that health expenditure affects the 
poorest in society the most [5, 33, 436]. A possible reason for the different finding 
in the current study is that health spending increased with wealth, suggesting that 
households in this setting will spend maximally on looking after a sick member of 
the household – whatever is available will go to ensuring care for the patient.  More 
importantly, as has already been discussed, the cohort as a whole was very poor 
with little difference in the income between ‘richest’ and ‘poorest’. It is likely that a 
large number in even the ‘richest’ quartile in this study would have been classified 
as ‘poor’ in many other settings.  
 
The effects of catastrophic expenditure associated with TB treatment go beyond the 
immediate effects of driving households into poverty. Poverty is well known to be a 
risk factor for the development TB [29], delayed TB diagnosis [438] and poor 
adherence [293, 439]. If accessing TB care drives people even further into financial 
hardship, a vicious cycle is established in which families and communities are put at 
ever increasing risk of both TB and worsening poverty. Moreover, catastrophic 
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health costs have now been shown to correlate with clinical outcomes for patients 
on TB treatment [275]. This recent paper by Wingfield et al has demonstrated that 
catastrophic cost, defined at a threshold of ≥20% annual household income (but not 
at thresholds of ≥10% or ≥15%) was independently associated with poor clinical 
outcome. That finding has been replicated by this study: expenditure of ≥20% 
annual household income was associated with an adjusted odds ratio for adverse 
clinical outcome of 2.74 (1.06-7.08), but the association at a threshold of ≥10% was 
not statistically significant. A key feature of both the Wingfield paper and this study 
is that they recognise the contribution of direct non-medical costs and lost earnings. 
This is particularly important in settings where TB care is provided free and 
therefore to only focus on direct medical costs would be misleading and 
underestimate the financial impact of illness on households. The association 
between catastrophic cost and clinical outcome can be explained by a number of 
possible mechanisms including inadequate nutrition; more severe disease; and 
poorer adherence due to barriers in meeting costs of accessing health care during 
treatment.  
 
The serious consequences of catastrophic health expenditures are increasingly 
being highlighted. The WHO post-2015 Global TB Strategy emphasises that without 
both universal health coverage and social protection, improvements in TB care and 
prevention will not be possible. As such, one of the targets of the post-2015 
strategy is that “no TB affected families should experience catastrophic costs due to 
TB” [276]. Over recent years, strategies promoted in order to reduce catastrophic 
health costs have included universal health coverage (UHC), defined as “universal 
access to needed health services without financial hardship in paying for them”; as 
well as various social protection measures aiming to mitigate the effects of poverty 
associated with accessing health care [440]. Social protection measures evaluated 
in tuberculosis have included health insurance schemes, food assistance, cash 
transfers and micro-finance schemes [441, 442]. After a successful piloting phase, 
an exciting socioeconomic intervention to enhance TB control in Peru through a 
combination of conditional cash transfers and social support is currently being 
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evaluated and is showing great promise in reducing catastrophic costs and 
improving retention in care [443].  
 
This study has shown that community-based management during the intensive 
phase of retreatment reduced the risk of incurring costs ≥10% annual household 
income by 60%, and the risk of incurring costs ≥20% annual household income by 
84%. Of participants who received community-based management, only 11.4% 
experienced health costs of ≥20% annual household income, compared to 62.0% of 
patients managed in the hospital. This intervention therefore offers an alternative 
model of care for patients on TB retreatment which significantly reduces the risks of 
catastrophic household costs.  
 
It is possible that community-based management has varying impact on 
catastrophic health expenditure for different groups within the population. If this 
were the case, the intervention may address some of the issues surrounding 
equitable access to healthcare, and as such it was important to examine the effect 
of the intervention in key groups. The data clearly show a reduction in the risk of 
incurring catastrophic costs which is independent of wealth quartile, gender and 
HIV status, and these benefits were seen at the thresholds of both 10% and 20% 
annual household income.  As the overall risk of experiencing catastrophic costs 
was the same across these groups, it is useful to also know that the intervention is 
effective in reducing the risk  for all groups.  
 
6.5.3 Dissaving 
 
A large proportion of participants employed dissaving measures such as borrowing  
money (41.2%) or selling property (26.0%), most commonly a household item, 
which is a common finding [444]. These data are corroborated by descriptions of 
coping mechanisms seen in the qualitative evaluation of the intervention, in which 
it is seen that having to borrow money caused particular distress. Participants who 
fell into the least poor quartile were less likely to employ dissaving measures than 
other participants. This is an interesting finding because it indicates that the richest 
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quartile in this population are willing spend a proportion of their disposable income 
on health which is similar to all other participants, but unlike the poorer 
participants this amount is sufficient to cover the costs of illness without having to 
sell or borrow. Unlike catastrophic costs, dissaving was not associated with clinical 
TB outcome.  
 
As addressing the problems of catastrophic costs is moving up the health policy 
agenda, it will become more important to define and to measure them. Currently, 
determining user costs involves long and sometimes complex participant interviews 
[426], which are poorly standardised. If instead a simple indicator could be used to 
screen for catastrophic expenditure, it would allow for better comparisons and 
possibly mean that an assessment of catastrophic costs could be incorporated into 
the routine holistic management of people with TB. It is for this reason that the 
associations between household expenditure and dissaving were evaluated. At a 
10% threshold for defining catastrophic cost, there was no association between 
catastrophic cost and dissaving. At a 20% threshold however, more patients who 
borrowed money (43.8% v 34.0%) and who sold property (46.7% v 34.1%) 
experienced catastrophic costs, although these differences were not significant. 
Nevertheless, this is an interesting area which deserves further evaluation with 
larger populations.  
 
6.5.4 Health related quality of life 
 
Quality of life scores at the end of the intensive phase of retreatment were the 
same in both groups. This is in line with other functional measures that were 
evaluated (Karnofsky score and SRQ) which were also very high in both groups 
throughout the study. These findings are unsurprising because the study selected a 
sub-group of very well patients, as the protocol determined they all had to be 
clinically well enough to no longer require hospital admission. The modalities in 
which patients most frequently experienced problems were pain (14.6%), mobility 
(11.1%) and carrying out usual daily activities (10.5%). Given that these patients had 
all recently had a diagnosis of TB, it is not surprising that these are the areas of their 
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lives which were most affected. Overall, VAS scores were higher than EQ-5D 
questionnaire utility scores, which is a common finding. 
 
6.5.5 Costs and outcomes during the continuation phase of retreatment 
 
During the continuation phase of treatment, the costs to participants were 
comparable between those who had received community-based and hospital-based 
care during the intensive phase (mean difference US$ 36.2, 95% CI -28.5-100.9). 
There were no significant differences in the number of contacts with health facilities 
during the continuation phase of treatment, and there was no difference in overall 
treatment outcomes at 8 months. As both costs and healthcare usage were similar 
in the two groups, it is likely that there was no major increase in the long term cost 
of community-based care compared to hospital-based care.  
 
6.5.6 Study limitations 
 
A limitation of this study is the fact that user costs were not available for the 
patients who did not complete the intensive phase. It was not felt to be appropriate 
to question guardians about costs soon after a patient had died, and data were not 
available for those patients who had defaulted. It is quite possible that the costs 
incurred by patients who did not complete the intervention were different from 
those who did, however a sensitivity analysis using high and low costs did not 
meaningfully alter the estimate of total costs. Another weakness is that opportunity 
costs for patients and guardians who had no regular income were not estimated. 
This is a common problem in performing health economic evaluations, particularly 
in low income countries where a large proportion of study participants have no 
regular income, and particularly for women who are generally less likely to have 
formal employment. Alternative approaches include substituting the average cost 
of the lowest wealth quartile in the study population; estimating a value based on 
national survey data (e.g. Demographic Health Survey); or using total income rather 
than earning. It is worth noting that all consumables used as part of community-
based care such as needles and syringes were accounted for in the provider costs of 
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the intervention. This will have slightly over estimated the cost of community-based 
care as these will also have been included in the running costs of the ward. 
However, it was thought to be important that all the costs of the intervention were 
clearly presented. Finally, the inability to perform a formal assessment of provider 
costs at 8 months is also a limitation of this evaluation. It must be recognised that 
user costs were only estimated for the period after the start of TB treatment, as the 
costs associated with diagnosis were assumed to be the same in both arms of the 
trial. However, it is well recognised that a significant proportion of patient costs are 
incurred during the process of obtaining a diagnosis of TB, before treatment is 
started [274, 437, 445]. It cannot be claimed that the intervention would have any 
effect on reducing the pre-diagnosis costs, and therefore if total costs including all 
those from onset of symptoms until the end of treatment were included in this 
analysis, the overall difference in costs between the two study arms may have be 
lower.  
 
 
6.6 Conclusion 
 
Patients on retreatment only make up a small proportion of the total number of all 
patients treated for TB. However, the current necessity for in-patient care, and the 
association between hospital-based management and extremely high risks of 
catastrophic health expenditure mean that this group of patients deserve special 
attention if the post-2015 target of “no families experiencing catastrophic costs” is 
to be reached. This evaluation has demonstrated that community-based 
management during the intensive phase of retreatment is cost effective for both 
providers and users, and that the financial  benefits to households of community-
based care are seen across a spectrum of patients. Additionally, the study has 
contributed to the body of evidence showing that catastrophic health costs are 
associated with clinical outcomes on treatment, and that in order to improve TB 
care, interventions are required to reduce the economic hardships suffered by 
households as a result of illness.  
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7 Qualitative Evaluation of the TB-RROC Trial 
 
7.1 Introduction 
 
This chapter evaluates the TB-RROC intervention from a qualitative perspective. It 
aims to describe the experiences of people affected by recurrent TB, including 
patients, guardians, household members, and healthcare workers. Using qualitative 
methods allows for in-depth exploration of the context in which treatment is 
delivered and the opportunity is taken to explore how participants’ circumstances 
influence their experiences. Particular attention is therefore paid to participants’ 
pre-existing personal, social and financial situations, and how these factors impact 
on their experiences of treatment. The conditions in which care for patients with 
recurrent TB is currently delivered are also examined, before going on to explore 
the experiences of participants who received community-based management as 
part of the TB-RROC trial and evaluating the mechanisms by which community-
based management may affect care in different situations.   
 
 
7.1.1 Methodological perspectives in qualitative research 
 
Research is framed within a number of distinct paradigms. The ontological and 
epistemological beliefs of an investigator will determine their approach to a 
research question, therefore the paradigm within which a study is conducted 
influences it’s design, implementation and analysis [446, 447]. The TB-RROC study 
was conducted from a realist perspective (see chapter 2), employing a combination 
of methodologies to inform a broad evaluation of the intervention [446, 448]. In 
keeping with this framework and considering the research question of interest, the 
qualitative evaluation used phenomenography – a method for examination of the 
‘lived experience’ [449].  
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Phenomenography 
 
The word ‘phenomenon’ originates from the Greek phainonenon, meaning ‘a thing 
appearing to view’, and can be defined as a ‘fact or situation that is perceived or 
observed to exist’. Phenomenography, a qualitative research methodology, must be 
differentiated from phenomenology, a philosophical theory [450]. Although both 
aim to examine human experience and awareness of phenomena, 
phenomenography is a research approach which aims to describe the different 
ways a group of people understand a phenomenon, whereas phenomenology aims 
to clarify the structure and meaning of a particular phenomenon [451]. 
 
Phenomenography was first developed as a methodological approach to qualitative 
research by a group of Swedish researchers in the 1970s, and is particularly 
associated with Ference Marton who describes it as “research which aims at 
description, analysis and understanding of experiences” [452]. Rather than focusing 
on the phenomenon itself and aiming to uncover the singular essence of that 
phenomenon, the emphasis in phenomenography is on the variation in the way 
people understand a given phenomenon. Conventional research is often described 
as ‘first order’, where the perspective is ‘from the outside’ and describes people 
and the world they experience in broadly the same way. However, 
phenomenography adopts a ‘second order’, or ‘from the inside’ perspective as it 
attempts to understand the world from the perspective of the subjects being 
studied [449]. 
 
A phenomenon can be experienced in an infinite number of different ways, and this 
experience is a product of the interaction between the subject and the 
phenomenon itself. Therefore, in phenomenography, analysis compares data 
obtained from a particular group of people and leads to the identification of 
different interpretations, known as ‘categories of description’ [451, 452]. These 
refer to descriptions of the various ways in which the phenomenon can be 
understood at a collective level, and together form the ‘outcome space’. Categories 
of description are usually related to each other, so that higher level analysis 
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examines the structures and interactions between categories within the outcome 
space [453].  
 
Interviewing and Thematic Content analysis 
 
Interviewing is the most commonly used tool for data collection in 
phenomenographic studies [454]. As the aim of research is to understand the 
variation in participant experience and understanding, a broad range of subjects are 
sampled in order to obtain data not just about the most common experiences, but 
to ensure many different perspectives are represented [449]. In depth interviews 
are conducted in which the interviewer sets the topic and guides discussion around 
the phenomenon of interest, but the participant is able to control the agenda and 
determine which information they provide. The aim is to encourage the participant 
to speak freely of their experiences and to gather data that represent the 
participants’ own understanding [455, 456]. This technique is in keeping with the 
realist approach, where by theories are developed by the researcher, and then 
tested through interviews with study participants [301].  
 
Thematic content analysis (TCA) is not a specific method for conducting qualitative 
research, but rather a tool for the inductive analysis of data which is systematic and 
transparent [457, 458]. According to Attride-Sterling it is: “simply a way of 
organising a thematic analysis of qualitative data… as such, thematic networks 
analysis is not in any way a new method, but one that shares the key features of 
any hermeneutic analysis… it makes explicit the procedures that may be employed 
in going from text to interpretation.” She outlines six specific steps in content 
analysis: (i) code material, (ii) identify themes, (iii) construct thematic networks, (iv) 
describe and explore thematic networks, (v) summarise thematic networks, and (vi) 
interpret patterns [459]. By allowing the organisation and description of the data, 
Thematic Content Analysis facilitates the inductive analysis of data at descriptive 
and ‘higher’ network levels; it is therefore an appropriate choice of analysis tool for 
phenomenographic studies. It is crucial to recognise that in both the collection and 
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analysis of qualitative transcripts, there is always a degree of subjectivity on the 
part of the researcher, and there may be multiple interpretations of a text [460].  
 
7.1.2 TB-RROC qualitative analysis 
 
 
The TB-RROC trial was conceived because it had been recognised that there were 
many potential disadvantages of hospital-based management during TB 
retreatment, which may be alleviated by community-based care. It introduced an 
entirely new method of delivering care by training guardians to do injections at 
home. The success or failure of a new approach such as this cannot simply be 
judged on the numeric efficacy outcomes of the trial, but must be interpreted in the 
light of the experiences of those involved. An understanding of the perspectives of 
those affected by the new intervention could help to identify whether the approach 
is acceptable to users, the community, and the health service; to adapt the 
intervention to maximise it’s potential benefit; and to improve it’s eventual 
implementation.  
 
 
7.2 Research questions 
 
This study aimed to answer two research questions: 
 
1. What are the experiences of adult patients and their guardians in Malawi during 
the intensive phase of TB retreatment?  
 
2. How are these experiences affected by an intervention that facilitates 
community-based management through teaching guardians to deliver daily 
streptomycin injections at home?  
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7.3 Conceptual framework 
 
In addition to being based on existing theory and research, construction of the 
conceptual framework for this study was informed by the researchers own 
experimental knowledge and exploratory research. It is necessary to acknowledge 
that the intervention being assessed was devised following the researcher’s 
personal experiences as a physician caring for patients receiving TB retreatment 
regimen. This experience inevitably plays a role in the development of ideas and 
theories to explore patient and guardian experiences of treatment.  Additionally, 
the study was conducted after completion of a pilot study to assess the feasibility of 
the intervention, and some months into trial recruitment. Furthermore, during 
these initial stages, a community advisory board (CAB) consisting of health care 
workers, patients, guardians and lay members of the public met on a number of 
occasions. Hence, the framework also draws from conversations with, and 
observations of, a variety of people who were likely to have insight into the issues 
being explored. 
 
Figure 36. Conceptual framework 
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Figure 1 depicts the basis of the conceptual framework. It is recognised that at the 
centre of the TB treatment event is the patient him or herself, but that the event is 
experienced not by the patient alone. Closest to the patient is the guardian, who is 
almost always nested within the household, which itself forms part of the wider 
community. Not only does TB treatment affect each of these layers independently, 
it is also important to explore how, if at all, the experience of TB treatment affects 
inter-relationships between these entities. It is also recognised that an important 
aspect of TB care, and an aspect which may well be affected by the intervention, is 
the relationship that patients, guardians, households and the wider community 
have with healthcare systems, and hence their willingness and ability to engage 
with health care facilities and interventions. The theoretical basis underpinning this 
framework and driving the design of the qualitative study is now explored. Many of 
the issues discussed pertain to the theories about which mechanisms are working in 
which contexts to influence the experiences of a wide range of study participants, 
as outlined in chapter 2.   
 
Patient experience 
 
Prolonged hospital admissions have the potential to have profound effects on 
patients. These effects may be influenced by the reason for the admission, and by 
the severity of the illness. A proportion of patients admitted to hospital in order to 
receive TB retreatment are not acutely unwell, and, were it not for the need for 
daily injections as part of this regimen, many would be managed in the community.  
 
In a systematic review of qualitative research, Munro et al identified factors 
influencing patients adherence to TB treatment and in so doing described 
experiences of receiving treatment [293]. A major theme was the financial burden 
experienced by patients on TB treatment, to the extent that patients felt the need 
to choose between going to work and attending treatment. The financial costs of TB 
treatment have been described for both inpatient and outpatient care in a number 
of settings and are consistently higher for hospitalised patients [279, 281, 461]. In 
addition to financial consequences, prolonged hospital admissions can have 
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negative impact on social and psychological well being, including isolation, rejection 
and boredom [462]. 
 
Guardian experience 
 
In many instances, when a patient is admitted to hospital in Malawi their guardian 
either stays with them in the hospital or visits on an almost daily basis. The effects 
of hospitalisation can therefore directly impact not only on the patient, but also on 
their guardian [463].  The experience of guardians is likely to vary substantially, and 
may be affected by factors such as their relationship to the patient and the gender 
of both patient and guardian [464].  
 
A concern expressed by the CAB was the potential for the intervention to affect the 
relationship between patient and guardian. Some members of the board felt that if 
the patient (usually a man) refused to have an injection, the guardian (usually the 
wife) would not have the authority to give the injection in the same way a nurse 
would. Tensions between patients and treatment supporters have previously been 
described in the realm of TB care – where DOT supporters have been viewed by 
patients as either constraining or facilitating empowerment [293, 464].  
 
Effects on Households  
 
There exists a body of literature demonstrating the catastrophic effects of illness 
and hospital admission on the household economic situation of patients, 
particularly the poor [465]. In previous years, all patients with TB were routinely 
admitted to hospital for the first two months of treatment, a practice which is no 
longer standard, in part due to the clear financial burden that this placed on 
patients and their families [277, 280]. It is important also to recognise that 
economic costs are not limited to the direct costs of treatment, and that there may 
be broader socio-economic consequences of illness within a household, for example 
having to take loans or sell possessions and being unable to send children to school 
[426].  
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Capacity to access health care frequently depends on the ability to call upon family 
members for assistance, and social capital plays a crucial role in this [284]. The 
strain on households however is not limited to financial and practical hardship - the 
family is often also a source of emotional and practical support [466].  
 
Community interactions 
 
Data have consistently shown that TB stigma exists within communities and that 
this can have a profound effect on health seeking behaviour and on patient 
experience during treatment [200, 467, 468]. Stigma can be defined as ‘a mark of 
disgrace associated with a particular circumstance, quality or person’. It is shaped 
and perpetuated by institutional and community norms and attitudes, and often 
results in individuals internalising feelings of shame, disgust and guilt. Two types of 
stigma have been distinguished: ‘enacted’ stigma that is external to the person and 
often concerns discrimination and social inferiority; and ‘perceived’ or ‘internalized’ 
stigma which often arises at least in part from enacted stigma [469]. Within the TB 
literature, a number of themes recur including fear of infection and transmission; 
impact on marriage prospects (mainly women) or the ability to provide for a family 
(mainly men); and the concept that TB is a ‘bad disease’, which happens to ‘bad 
people’ [470, 471].  
 
In more recent years, this issue has been compounded by the ‘double stigma’ of TB-
HIV co-infection, particularly within the context of the HIV epidemic in Sub-Saharan 
Africa [472-474]. Both qualitative and quantitative evaluations have described that 
people co-infected with TB and HIV are more likely to have perceived stigma 
compared to patients not co-infected [475].  Feedback from the TB-RROC CAB has 
suggested that this stigma is compounded in patients who are being treated for the 
second or third time for TB. Members of the CAB reported that many people in the 
Blantyre community believe that multiple episodes of TB is indicative of HIV 
infection; and that the 2-month admission to hospital in order to receive 
retreatment regimen makes it hard for patients to keep their diagnosis private. This 
essentially results in disclosure of both TB and HIV to their community.  
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 Interactions with healthcare services 
 
Some of the effects that TB retreatment in hospital and at home may have on 
interactions with healthcare services have been touched upon in the previous 
sections. However, a particular issue that needs further exploration is the specific 
role that injections (and people who administer injections) play in communities. It 
has been reported that in low resource settings, injections are frequently purchased 
without prescription and administered by unqualified people in pharmacies and in 
market places [476]. This practice is in part driven by beliefs surrounding the 
benefits of injections, which are viewed a ‘strong’ form of medication [477, 478]. An 
important part of the evaluation of the TB-RROC intervention was to assess what 
the effect was of training lay people to perform injections on community 
perceptions and expectations of injections and ‘injectionists’. Particular attention 
needed to be paid to whether trained people expected or were expected to 
administer injections to members of the community other than the patient 
receiving TB retreatment.  
 
More broadly, the shift of responsibility of care away from the healthcare system to 
guardians raises the issue of who is responsible for healthcare. Where is the division 
of responsibility between patients themselves, family and social networks, and 
health care systems? It has sometimes been seen as the community’s role to 
promote recommended health behaviours, influence social norms regarding health 
and contribute resources where feasible; whereas the health service is seen as 
providing human resources, infrastructure, equipment and medications [479]. In 
recent decades however, the role of community members in delivering or 
supporting care for patients has been increasing, especially in the field of TB-HIV 
management [154, 271, 480], which is generally seen as a positive development. 
However, a concept which is less well explored, is the possibility that task-shifting to 
family members, particularly a high level responsibility such as administering 
injections, carries with it more problematic issues for the community. For example, 
communities may view this as blurring the lines between the duties of healthcare 
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systems and societal duty, and it may place an undue burden on communities which 
they believe should remain with formal healthcare structures.   
 
7.4 Methods 
 
7.4.1 Overview of data collection methods 
 
In-depth interviews with trial participants were conducted. This was chosen as the 
most appropriate data collection method because the experiences of participants 
were likely to be very personal in nature, both in terms of sensitive medical 
information and in terms of relationships with others. It was felt that one-to-one 
interviews would be the environment best suited to allow participants to speak 
freely and therefore provide the most useful data. Triangulation of the primary data 
was achieved by conducting a number of key informant interviews as well as 
observations of patients at home and in the ward. Key informant interviews were 
done with a range of people including nurses, TB officers, and other members of the 
community. Although not directly relevant to the research questions, a small 
number of focus group discussions were held in order to obtain more detailed data 
about community attitude to guardians providing injections. Overall, the methods 
were designed to provide a comprehensive assessment, which took account of 
perspectives from a wide range of people potentially affected by the intervention.  
 
7.4.2 The study team 
 
The study team consisted of six investigators. Each had varying degrees of 
involvement in the TB-RROC trial and in collection of the primary qualitative data. 
All had previous research experience in the field of TB and HIV research in Malawi; 
some but not all were clinically trained; half the team were female; and there was a 
mixture of Malawian and UK born researchers (see responsibilities table on page v).  
 
MP conducted the primary data collection with support from DC; and DC performed 
the initial coding with input from MP. DC was the primary investigator on the TB-
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RROC trial. She is originally from the UK, but has worked for a number of years as a 
doctor in the adult medical wards and clinics at QECH. She therefore had personal 
relationships with a number of the study participants, both as the physician in 
charge of their medical care, and as the investigator responsible for the study in 
which they were enrolled. MP is a Malawian born social scientist with extensive 
experience performing data collection in the field; he had no involvement in the 
main TB-RROC trial. SBS is a senior clinician and professor at LSTM; he has worked 
in applied health research in Malawi since the 1990s, and is the overall supervisor of 
the TB-RROC Study. Other members of the team had no involvement in the trial, 
but were involved in the design, supervision and analysis of the qualitative 
evaluation. HB is a Malawi trained clinician with an interest in chronic lung disease 
and access to health care, and is the Research Manager at the REACH Trust – a 
multi-disciplinary research NGO based in Lilongwe. ND is a British Medical 
Anthropologist and Senior Lecturer at LSTM who has worked in Tanzania and 
Malawi for over a decade in mixed methods applied research and leads the Social 
Science Programme at MLW. IN is a senior social scientist with an interest in 
promoting equity in access to health care for the poor, and is Executive Director of 
the REACH Trust. 
 
 
7.4.3 In-depth interviews with trial participants 
 
Study population & sampling framework 
 
Study participants had previously been enrolled in the TB-RROC trial at QECH or 
Bwaila hospital. Purposive sampling of trial participants was employed to ensure 
that a broad range of perspectives was covered, and that the views of patients and 
guardians managed both in hospital and in the community were obtained (see table 
59). Depending on the sampling framework and willingness to participate, both 
members of a patient-guardian pair or only one member of the pair were recruited. 
As described in the conceptual framework, the roles and experiences of both 
patient and guardian may be affected by gender. This is reflected in the sampling 
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matrix that aimed to ensure representation of both genders in each role. An 
attempt was also made to interview at least 2 guardians who cared for patients who 
either died or had adverse clinical events, because these extreme cases may have 
different experiences (e.g. feelings of guilt or responsibility) from those who did not 
experience complications during treatment. Data was collected until it was felt that 
saturation had been reached and no new concepts were arising. The PI and the 
research assistant continuously assessed whether saturation had been reached, 
with input from other co-investigators when necessary.  
 
The trial was conducted in two central hospitals that provide comparable care in 
similar settings. It was therefore unlikely that the experiences of participants were 
going to differ vastly between the two sites. It is for this reason that the majority of 
data collection took place at QECH. However it was also recognised that there may 
have been some inconsistencies across the two sites, such as cultural diversity (for 
example the influence of Yao and Chewa traditions4), and varying distances 
between home and hospital. Therefore, a number of interviews were conducted in 
Bwaila, according to the general sampling framework. Once it was established that 
there were no new themes emerging from participants in Lilongwe, no further 
interviews were conducted at that site.  
 
Table 59. Sampling matrix 
Patients 
20 
Guardians 
20 
Home 
10 
Community 
10 
Home 
10 
Community 
10 
Male 
5 
Female 
5 
Male 
5 
Female 
5 
Male 
5 
Female 
5 
Male 
5 
Female 
5 
 
 
                                                     
4 Both the Chewa and Yao are Bantu tribes of Malawi. Chewa is the largest group in the country, and 
Chewa society is matrilineal. The Yao are predominantly Muslim and live mainly in the  central and 
southern lakeshore areas. There are a larger number of Yao people living in Lilongwe than in 
Blantyre.  
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Recruitment strategy  
 
Patients in the TB-RROC trial were approached as they completed the intervention 
(i.e. after 2 months of TB treatment). A member of the trial study team initially 
asked if they would be willing to be interviewed by an independent researcher 
about their experiences during treatment. If participants agreed to take part, they 
were introduced to the qualitative research assistant (MP), who was somebody not 
previously involved in their care or in the trial.  
 
Interview schedule, setting and process 
 
Participants were interviewed individually. They were given a choice whether to be 
interviewed in their home or at the hospital. This was because some may have 
preferred the privacy offered by an interview at the healthcare facility, whereas 
others may have been more comfortable in their own home. If participants chose to 
be interviewed at the hospital, the interview was conducted in a quiet room close 
to, but not on, the TB ward at QECH. Interviews were conducted within the first two 
weeks after completing the intensive phase of TB retreatment. This time point was 
chosen because participants still on intensive phase treatment under the care of the 
study team may not yet have felt able to talk freely and reflectively about the 
experience; but it was a time point not too far from the event which should have 
meant that participants were still able to recall clearly their experiences.  
 
Prior to conducting each interview, basic demographic details were recorded on an 
anonymised front sheet. All interviews were conducted by a single research 
assistant (MP) in Chichewa, the local language. A prepared interview guide was 
designed to answer the research questions within the structure of the conceptual 
framework and test theories about which mechanisms were operating to generate 
clinical, social and economic experiences of study participants (appendix 8). The 
interview guide was adapted iteratively as the study progressed. Interviews were 
recorded using a digital dictaphone. Following each interview the research assistant 
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was debriefed by the PI, who systematically compiled field notes based on these 
discussions. 
 
7.4.4 Key informant interviews 
 
In order to provide further information from a broad range of people who have 
contact with patients receiving TB retreatment, and to triangulate the data 
collected from study participants, a number of key informant interviews were 
conducted. Key informants were selected on the basis of their specific ability to 
provide information about the experiences of people who may have been affected 
by the intervention being assessed. Key informants included a variety of health care 
workers (nurses, TB officers); other members of the community, for example 
household members who did not directly participate in the study; and patients who 
declined to participate in the trial. Key informants were asked to provide informed 
consent. The interviews were conducted at a place and time that was convenient 
for the participant, ensuring privacy and confidentiality at all times. Participants 
were interviewed individually with reference to a prepared topic guide (appendix 
8). As with the in depth interviews of participants, interviews were recorded using a 
digital dictaphone and wherever possible following the interview the research 
assistant and PI had a debriefing interview from which field notes were made.  
 
7.4.5 Observations 
 
The research assistant performed a number of observations of activities during TB 
retreatment. The purpose of these observations was not only to provide further 
information in order to add to the triangulation of the data, but also to note any 
changes in behaviours, attitudes and feelings over time. The RA observed patients 
behaviours and interactions on the ward; and also accompanied the trial 
fieldworker on home visits to watch the dynamics and conditions within the 
households during those visits.  
 
For observations in the community, the research assistant accompanied the 
fieldworker on the home visit. He was introduced to the participant as a colleague 
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of the field worker. The study was discussed with the sister in charge of the TB ward 
prior to doing any observations on the ward. Patients on the ward were not 
formally introduced to the research assistant who carried out observation, as this 
would have significantly biased the results. Observations only took place in public 
places, and therefore did not result in additional breaches of privacy or 
confidentiality. The research assistant placed himself in an unobtrusive place within 
the ward in order to carry out his observations, and did not directly interfere with 
patient care.  During these periods of observation, the RA used a field guide 
(appendix 8) and took field notes, which were later formally written up. After the 
observations the PI debriefed the RA and made additional notes. 
 
7.4.6 Focus group discussions 
 
It was recognised that the attitude of the community towards guardians providing 
injections to patients at home not only affects the experience of patients and 
guardians, but may also play a key role in the potential acceptability of the 
intervention were it to be rolled out in the future. Therefore, an amendment was 
added to the initial protocol to do 2 focus group discussions (FGDs) in order to gain 
more in depth understanding of the response of people in the broader community. 
Focus groups composed 8-10 people with varying degrees of experience with TB 
and TB treatment, and included patients who had had TB, guardians and household 
members of people with TB, and other community members with no specific 
experience of TB. Patients, guardians and community members willing to 
participate were identified with the help of the TB officers at QECH and the MLW 
community liaison team. None had any experience of the TB-RROC study. 
Household members were identified by patients and guardians. The FGDs were 
facilitated by the research assistant (MP). They were conducted in neutral spaces 
not related to the TB ward at QECH – one in Ndirande Township and the other in 
Chilomoni Township, both urban areas of Blantyre near to where the majority of 
study participants reside. Both groups were conducted on a Saturday. Participants 
were asked to provide informed consent prior to participating.  As with the in depth 
interviews and key informant interviews, FGDs were recorded using a digital 
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Dictaphone and following the discussion, the research assistant and PI had a 
debriefing interview from which field notes were made.  
 
7.4.7 Participant feedback 
 
Two participant feedback sessions were organised after key themes had been 
identified from the data. One session involved patients and guardians in the trial 
and the other involved healthcare workers. The aim of these sessions was twofold. 
Firstly, they provided a means of validating the initial analysis of the data; and 
secondly they were an additional forum for participants to voice opinions and ideas 
that had not been expressed in their initial interview. The feedback sessions were 
conducted on hospital premises, but away from the TB ward. The session involving 
trial participants was conducted by MP in Chichewa, recorded using a digital 
dictaphone, transcribed and translated into English. The session for healthcare 
workers was conducted jointly by DC and MP in English and recorded and 
transcribed directly in English. Due to resource constraints, and the fact that only 
five participants were from Lilongwe, feedback sessions were only done in Blantyre.  
 
7.4.8 Data collection, management and analysis 
 
All interviews and group discussions were transcribed verbatim in Chichewa and 
then translated from the Chichewa transcripts directly into English. For quality 
control purposes, a second transcriber reviewed a random 20% sample of all 
transcripts. Anonymised transcripts were imported into Nvivo10 QSR software for 
organising, management and analysis of data. Transcripts were inductively coded 
and analysed using Thematic Content Analysis. The units of meaning for analysis 
were text in English (words or phrases), as DC did most coding and is not fluent in 
Chichewa. All transcripts were read and then re-read before applying free codes to 
text. Initially, two coders (DC and MP) coded the first 5 transcripts and each 
independently generated a coding structure, which was shared and discussed in 
order to produce a unified coding schedule. This coding schedule was used to code 
further transcripts as the study progressed, and was adapted iteratively as new data 
was collected. Free nodes within the final coding schedule were collapsed into tree 
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nodes and used to generate key descriptive themes that summarised the main 
findings. Data collection was stopped once the key descriptive themes had been 
identified and no new themes were emerging.  
 
In order to develop more in depth analytical themes, a full day workshop was held 
which was attended by all collaborators. Workshop participants who had not been 
involved in the initial coding were familiarised with the raw data by each taking 
time to read a selection of transcripts. This served two purposes. Firstly, it allowed 
those members of the study team not directly involved in data collection to become 
familiar with the data. Secondly, it acted as a check on the initial analysis, 
particularly as it was recognised that the bulk of the initial coding had been done by 
DC, who may have brought with her specific biases given her roles in the clinical 
care of patients and in the TB-RROC trial itself. The initial descriptive themes and 
coding framework were then presented by DC and MP and agreed upon by the 
whole group. Following this, more in depth analytical themes and were generated 
by discussion between the members of the research team. Initially, analytical 
themes were developed by discussion in pairs. Each pair evaluated two or three of 
the descriptive themes. Pairs were carefully chosen to ensure a balance between 
clinicians/non-clinicians and Malawian/Non-Malawian researchers. Following this, 
discussion between the whole group was used to develop the analytical framework.  
 
7.5 Results 
 
7.5.1 Characteristics of study participants 
 
A summary of the characteristics of study participants and details of in-depth 
interviews conducted is presented in table 60. In total there were 14 interviews 
with patients and 12 interviews with guardians who participated in the TB-RROC 
trial. Of the patients, 6 were in the community group, and of guardians 7 were in 
the community group. Two participants had experienced readmission after the 
patient became unwell in the community. Information regarding the 9 key 
informants is presented in table 61. Key informants were household members of 
trial participants (2); potential recruits to the trial who declined to participate (3); 
 222 
nurses (2) and TB Officers (2). Summaries of the observations, feedback sessions 
and focus group discussions are presented in tables 62, 63 and 64 respectively. All 
21 participants from Blantyre who gave an in-depth interview were invited to the 
first feedback session and 14 were able to attend. The second feedback session was 
conducted with healthcare workers. In addition to the nurses and TB Officers who 
were initially interviewed, 2 clinicians from the TB ward at QECH also attended the 
session.  
  
 223 
Table 60. Trial participants and interview details 
 
Participant 
ID 
Role Age TB care 
delivery 
Interview     
Setting 
Interview 
Duration  
1 Male patient with male guardian 35 Community Hospital, BT 54 
2 Male guardian of male patient 47 Community Hospital, BT 60 
3 Female guardian of female patient 40 Hospital Hospital, BT 58 
4 Male guardian of male patient 28 Community Hospital, BT 51 
5 Female guardian of male patient 30 Hospital Hospital, BT 59 
6 Male patient with male guardian 35 Community Hospital, BT 50 
7 Male patient with female guardian 36 Hospital Hospital, BT 74 
8 Female guardian of male patient 28 Hospital Hospital, BT 50 
9 Female patient with male guardian 34 Community Hospital, BT 60 
10 Female patient with female guardian 52 Hospital Hospital, LLW 50 
11 Male guardian of male patient 25 Community Hospital, BT 38 
12 Male patient with male guardian 42 Community Hospital, BT 36 
13 Female guardian of female patient 31 Hospital Hospital, LLW 39 
14 Male guardian of female patient 40 Community Hospital, BT 34 
15 Female guardian of female patient 54 Hospital Home, BT 45 
16 Female patient with female guardian 49 Hospital Home, BT 59 
17 Male patient with male guardian 18 Community Hospital, LLW 34 
18 Male guardian of male patient 20 Community Hospital, LLW 44 
19 Male guardian of male patient 21 Community Hospital, BT 55 
20 Male patient with male guardian 32 Community Home, BT 64 
21 Male patient with male guardian 20 Community Hospital, BT 54 
22 Male patient with male guardian 39 Hospital Hospital, BT 47 
23 Male guardian of male patient 21 Hospital Hospital, BT 54 
24 Female patient with no guardian 45 Hospital Hospital, BT 53 
25 Female patient with female guardian 29 Community Hospital, BT 45 
26 Female guardian of female patient 32 Community Hospital, BT 39 
 
 
Table 61. Key informants and interview details 
 
Participant 
ID 
Role Interview     
Setting 
Interview 
Duration  
27 Female household member of trial participants Hospital, BT 57 
28 Male patient who declined to participate in the trial  Hospital, BT 39 
29 Female nurse on the TB ward at QECH Hospital, BT 24 
30 Male patient who declined to participate in the trial Hospital, LLW 30 
31 Male TB officer at Blantyre DHO Hospital, BT 28 
32 Male TB officer at QECH Hospital, BT 28 
33 Female guardian who declined to participate in the trial Hospital, BT 26 
34 Female nurse on TB ward at QECH Hospital, BT 33 
35 Female household member of trial participants Hospital, BT 15 
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Table 62. Observations 
Observation Brief description Observation 
duration 
Community 1 
Male patient with female guardian visited at home. Guardian 
observed delivering injection, fieldworker assesses patient & 
exchanges equipment 
60 
Community 2 
Female patient with female guardian visited at home. Guardian 
observed delivering injection, fieldworker assesses patient & 
exchanges equipment 
45 
Hospital 1 
Male TB ward at QECH. Interactions between healthcare 
workers, guardians and patients observed. Casual conversations 
with patients on the ward 
91 
Hospital 2 
Female TB ward at QECH. Interactions between healthcare 
workers, guardians and patients observed. Casual conversations 
with patients on the ward 
60 
Hospital 3 
Nurses are observed preparing streptomycin for injection the 
evening before they are they are administered to patients  60 
Hospital 4 
Nurses are observed (at 5am) administering the pre-prepared 
syringes of streptomycin to patients on the ward 50 
 
 
Table 63. Participants in feedback sessions 
 
Participants Role 
Session 1: Trial participants (Duration 75 minutes) 
1 Male patient with male guardian 
3 Female guardian of female patient 
4 Male guardian of male patient 
6 Male patient with male guardian 
7 Male patient with female guardian 
8 Female guardian of male patient 
9 Female patient with male guardian 
11 Male guardian of male patient 
12 Male patient with male guardian 
14 Male guardian of female patient 
15 Female guardian of female patient 
21 Male patient with male guardian 
25 Female patient with female guardian 
26 Female guardian of female patient 
Session 2: Healthcare workers (Duration 46 minutes) 
31 Male TB officer at Blantyre DHO 
32 Male TB officer at QECH 
36 Male clinician on TB ward at QECH 
37 Female nurse on TB ward at QECH 
38 Male clinician at QECH 
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Table 64. Participants in Focus Group Discussions 
 
Participants  Role Age Occupation Education 
Session 1: Ndirande  (Duration 90 minutes) 
   
39 Woman who had had TB 40 Petty trader Standard 8 
40 Woman who had had TB 27 Marketer College 
41 Man who had been a guardian 61 Gardener Standard 8 
42 Man who lived with someone with TB 30 School leaver Form 4 
43 Woman who had been a guardian 35 Housewife Standard 8 
44 Woman who had been a guardian 30 Hawker owner Form 4 
45 Woman community member 23 Petty trader Standard 7 
46 Woman who had been a guardian 36 Hawker owner Form 2 
Session 2: Chilomoni (Duration 72 minutes)    
   
47 Man who had had TB 34 Minibus driver Standard 8 
48 Woman who had been a guardian 29 Petty trader College 
49 Man who had had TB 39 Gardener College 
50 Man community member 39 HSA Form 4 
51 Woman who had been a guardian 51 Petty trader None 
52 Man who lived with someone with TB 43 Businessman Form 4 
53 Woman who had been a guardian 42 Businesswoman Standard 8 
54 Man who had been a guardian 41 Crane operator Form 4 
55 Woman who had had TB 27 Clothes trader From 4 
 
 
 
7.5.2 Descriptive themes 
 
This section will present a brief summary of the initial descriptive themes that were 
developed from the coding framework and used as the basis for discussion during 
the analytical workshop. Following this, in the next section, the final analytical 
structure will be presented, in which concepts will be explored and discussed in 
detail. 
 
From 142 free nodes, 8 tree nodes were generated. These descriptive themes were 
developed inductively from the original data and are summarised as shown in 
Figure 37. Medical issues included descriptions of the symptoms people 
experienced; side effects of treatment; the process of accessing medical care and 
starting treatment; adherence; HIV; acquiring infections from hospital; and health 
issues for guardians. It was felt that issues relating directly to injections required 
specific attention, as this was the focus of the study. These issues included 
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complications of injections; the risks posed to others from injections; the process of 
training to do injections; guardians’ ability and willingness to do injections; choosing 
 
Figure 37. Descriptive Themes 
 
 
 
 
which patients should be injected at home; and the role of lay community injectors. 
Physical environments and routines were a major component of every interview, 
and common themes that arose were taking care of the physical needs of the 
patient (including providing food); disruption of daily routines; and the 
environments of the hospital and home. Emotional experiences were varied, both 
between individuals and within the same interview. They included feelings of 
sadness, fear, and acceptance. Participant descriptions of the sick role were also 
included in this theme.  Financial issues dominated many of the transcripts and had 
profound effects on people’s experience during retreatment. Issues discussed by 
participants related to the need for more money to cover costs associated with 
illness; the inability to earn money during treatment; mechanisms employed to 
overcome the lack of funds; and the effects of financial difficulties, for example 
being evicted from ones home. Considering the nature of the subject matter, it is 
perhaps unsurprising that many study participants focussed on their relationships 
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with others around them. Interpersonal relationships discussed included 
relationships between patients and guardians; relationships between patients, 
guardians and their families; and relationships between patients and guardians on 
the ward.  Beyond interpersonal relationships, interactions with the wider 
community also influenced experiences. Whilst some encounters with the 
community were negative, such as stigma and discrimination, it was also evident 
that the positive experience of support offered by the community played a crucial 
role. Finally, a key theme was the experience people had of the healthcare system 
itself. Topics discussed included the interactions with healthcare workers; views 
about the responsibility of the healthcare system; and beliefs about traditional 
medicine and witchcraft.  
 
7.5.3 Analytical themes 
 
During the analytical workshop, the study team examined these initial descriptive 
themes further. In depth assessment and examination of the relationships between 
items resulted in production of the final categories of description and eventual 
construction of the outcome space. Experiences revolved around three key 
categories: medical issues, the physical environment, and trust. Each of these 
experiences were influenced by the nature of participants’ prior role (the context in 
which they experienced TB), and in turn resulted in a broad range of emotional 
experiences. In some instances there were relationships between the central 
categories (figure 38). Each of the three main categories will now be discussed, 
referencing interactions between other categories within the network. Themes 
addressing the first research question (‘What are the experiences of patients and 
guardians on TB  retreatment?’) are illustrated using quotes within the body of the 
text. Examples of how the TB-RROC intervention affected these experiences are 
presented in tables 65 - 67. In line with the overall aims of the evaluation, the tables 
lay out which mechanisms were triggered by community-based management and 
how these produced certain outcomes, given the circumstances described by the 
study participants. Outcomes are focussed on medical, social and economic 
domains as outlined in chapter 2.  
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Figure 38. Experiences of patients and guardians during TB retreatment 
 
 
 
 
 
7.5.3.1 Medical issues 
 
7.5.3.1.1 Symptoms, treatment and adherence 
 
Illness, in particular recurrent TB, is the experience which links every participant in 
the study. Health problems that patients encountered were therefore at the 
forefront of their discourse. Participants described the symptoms from which 
patients suffer in relation to their TB in some detail. Classical symptoms of TB such 
as cough, shortness of breath, sweating at night and weight loss were frequently 
reported. Patients and guardians generally demonstrated good understanding and 
recognition of the symptoms of TB, which was often enhanced by their previous 
experiences of having had TB:  
 
“I had TB treatment for 6 months. When I had it for six months, they said it was 
enough and that I had been cured. Afterwards, I began to cough again. I began to 
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experience shortness of breath whenever I walked, the same experiences I had 
gone through before. Then I quietly sat down and spoke to myself: ‘What is 
happening to me? Does it mean that the disease is relapsing?” 
P24, female patient 
 
Participants’ experiences of accessing healthcare, going through the process of 
being diagnosed with TB and starting treatment varied. Delays in accessing care 
were common, although once again previous experience and quick recognition of 
TB symptoms often resulted in earlier presentation. In some cases, pre-existing 
relationships played a part in how patients accessed care. For example, family, 
community members or even work colleagues encouraged patients to seek medical 
attention: 
 
“Later on, the person I was working with, the foreman of the place said: ‘but we are 
noticing that your body is kind of losing weight and you are coughing from time to 
time, you need to go and submit sputum, it could be TB.” 
P1, Male patient 
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Table 65. Medical experiences: Symptoms, treatment and adherence 
Context Mechanisms Outcomes Illustrative experience  
Treatment 
   
Guardians have 
not previously 
done injections 
Guardians trained,  feel 
competent and deliver 
injections effectively   
Clinical outcomes in the 
community as good as 
hospital-based care  
 
“In my case, when I was just starting to undertake that responsibility, I declined. I said I would not 
manage. But because of encouragement that everyone would manage to train, we really trained and 
were able to inject on our own.” 
 
P13,  
Female 
guardian 
Guardians have 
not previously 
done injections 
Patients trust guardians 
are trained and allow 
them  to do injections   
 
Clinical outcomes in the 
community as good as 
hospital-based care 
“Ah, in my thinking I thought I was going to feel so much pain or the injected area was going to swell 
if he injected me because he was just learning. But I saw it was just the same as over the two weeks I 
had been in the hospital and was injected by a doctor. There wasn’t any difference.” 
P1,  
Male 
patient 
Guardian’s 
position within 
family (e.g. 
young age) 
means they are 
told what to do  
Guardian ‘forced’ to 
take on injecting job, 
does not feel 
comfortable in the role, 
and delivers injections 
poorly 
Clinical outcomes in the 
community as not good as 
hospital-based care; Social 
outcomes poorer from threat 
to family relationships;  
feelings of guilt and sadness 
“Ah, it really affected me. Even when I heard that they had taken him back to the hospital, it really affected 
my life. I felt I was responsible for the problem he had developed. I felt maybe I was the one at fault. I was 
sad and saying, ‘Maybe he is going to hold me responsible for whatever happened.’ But then my life rejoiced 
because … the doctor had told him: ‘The problem was not the injector’.” 
 
P19,  
Male 
guardian 
Patient is in 
good health 
Guardians provide TB 
medications at home 
and little additional 
medical care is required 
because patient is well 
Clinical outcomes in the 
community as good as 
hospital-based care; social 
outcomes better  
“The strategy should be executed depending on the condition of the patient ... people like these 
critically ill ones require being in the hospital for frequent monitoring by the doctors. But someone 
who does everything by herself, is strong, hasn’t complained about anything, gets out of the bed by 
herself and manages to move around, could be discharged to go and be injected at home if her 
guardian manages to inject so that she can perform other household chores.” 
 
“They come only to those who seem healthy. They don’t ask someone who is critically sick to be 
injected at home… that’s why they tell you” ‘We diagnosed him with TB, he has been admitted for 2 
weeks but he looks strong, would you accept to inject him at home?’” 
 
 
P9,  
Female 
patient 
 
 
 
P19, 
Male 
guardian 
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Context Mechanisms Outcomes Illustrative experience Participant 
Transmission of infections    
Overcrowded 
wards: risk of 
infection  
Fewer hospital acquired 
infections (for patients 
& guardians) at home 
Clinical outcomes better in 
the community; lower clinical 
risk to guardians; less anxiety 
  
“You would feel sad. It would affect the body… the ward accommodates people with different 
conditions that you could contract. Therefore you could be affected emotionally.” 
 
“You also think about how critically sick your fiend is, saying ‘Eeee! He is not in good shape.’ You start 
pitying yourself … you say ‘are we not going to contract diseases from here?’” 
 
P15,  
Female 
guardian 
P12, 
Male 
patient 
HIV positive 
patients in the 
community 
Guardians have needle 
stick injuries whilst 
doing injections 
Guardians contract HIV 
infection if not well trained & 
supported 
“From how they had taught me here, I knew I couldn’t contract this disease unless I had pricked 
myself with the same needle after injecting the patient. But if I injected him and handled the tools 
carefully and disposed of them I wouldn’t contract the virus from him. That’s why I completed 
injecting him without pricking myself or dropping the syringes at any time 
P23, Male 
guardian 
Adherence 
   
Guardian in a 
position of 
less influence 
than the 
patient 
Guardian unable to insist 
patient receives injection 
and therefore adherence 
poor 
Clinical outcomes in the 
community not as good as 
hospital-based care 
“… maybe like at home you’ve been injected by your madam but you’ve quarrelled on some story  
so how can that turn out? If your wife is refusing that I won’t inject you, what can be the advantage?” 
 
“I have stayed with him pretty well because he was co-operative in everything I could tell him. I don’t 
know if it’s because he was younger and I was older. He may he may have been saying ‘he is my 
senior brother I should listen to him’.’’ 
 
P30, Male 
patient, non 
participant 
 
P2,  
Male 
patient 
Strong 
existing 
relationship 
between 
patient & 
guardian 
Guardian able to deliver 
injections to patient, and 
gives encouragement to 
take TB treatment 
Clinical outcomes in the 
community as good as 
hospital-based care; Social 
outcomes good as patient -
guardian  relationships 
strengthened 
“The most encouragement also comes from you who are staying with him … I would know that 
maybe he was not going to take the oral medication if I just gave him the injection and departed 
going into town. I was therefore making sure he took the oral drugs. We just got used to offering one 
another encouragement and things were progressing without any challenges.” 
 
P4,  
Male 
guardian 
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Additionally, it was recognised that those from poorer backgrounds found it difficult 
to present to a health facility, often because of lack of money for transport: 
  
“Others come from remote areas and fail to go to the hospital because they have no 
means of transport. When they think about the place being very far away they fail 
to… get there though they are sick and deteriorating.” 
P16, Female patient 
  
Many participants described the side effects of treatment. They felt that TB tablets 
were ‘too strong’, or ‘very powerful’ and frequently talked about a relationship 
between the strength of the tablets and the importance of having food when on 
treatment. Although these issues applied to TB treatment in general, some 
participants were aware of, and concerned by, the potential for more serious side 
effects during retreatment because of the longer duration and the addition of 
injections compared to their previous treatment: 
 
“I started having concern after they had diagnosed me with TB for a second time 
because in the beginning I had tablets without injection for six months. Two or three 
years later, I am having the same treatment with additional 60 injections. When I 
complete these injections I will be on oral treatment for 6 months. So I was very 
worried right from the first day of the second treatment, wondering if I was not 
going to develop another problem of high level of drugs in my body.” 
P22, Male patient 
 
Other treatment related problems specifically concerned the physical experience of 
getting injections, both in hospital and in the community. Apart from feeling pain 
when the injection was being delivered participants did not frequently describe 
suffering complications from injections, however the majority were very aware of 
the potential complications such as swelling or infection at the site of injection, or 
paralysis of the leg. Most guardians were hesitant to do injections at first because 
they questioned their own ability and were concerned that they might hurt or cause 
damage to their patient, but all of them got over these fears once they had been 
trained to do the injections. Participants recognised the importance of guardians 
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being trained well before considering community-based management if treatment 
was to be successful (table 65, P13 & P1). 
 
Although these expressed concerns were extremely common, they were very rarely 
borne out. In fact, only one patient in the community described having had a 
complication that required readmission to hospital. The patient was intermittently 
experiencing swelling at the site of injection and had lost weight. There was no 
abscess at the site of injections and the patient was admitted for rehydration and 
treated empirically with antibiotics. As this is an outlying case of participants who 
had a negative experience, the circumstances of the event do deserve particular 
attention as they may provide valuable information about the potential for harm. 
The guardian administering injections was the patient’s younger brother. They 
came from a large family of 8 children. Both brothers described how the younger 
one was ‘forced’ to take on injections by the rest of the family. He initially showed 
reluctance but then accepted and embraced the role. Both described how the 
guardian drank alcohol, although the guardian said he was never drunk or hung 
over when doing the injection because of the responsibility he felt towards his 
brother, whilst the patient recalls a number of instances when he thought his 
brother was hung-over whilst administering injections. The guardian experienced a 
range of emotions, including fear, sadness and guilt; and also concern about how 
this would affect his relationship with his family (table 65, P19).  
 
Most participants describe an improvement in patients’ health on TB treatment, 
with a reduction in symptoms and gradual regaining of strength. ‘Becoming strong’ 
was a well recognised and well received benefit of being on TB treatment, and seen 
as a key factor when considering whether or not a patient should be cared for at 
home. Patients, guardians, household members and healthcare workers all 
recognised that home injections were not appropriate for all patients, and that 
being well enough was a prerequisite for discharge (table 65, P9 & P19). 
 
Despite seeing improvements in their health, a number of participants referenced 
TB being a ‘deadly’, or dangerous disease. Participants understood TB to be 
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dangerous for a number of reasons, including delayed presentation and poor 
adherence. Emotional experiences related to having what was seen as a potentially 
deadly disease fell into two broad categories. Many expressed fear about what may 
happen to them or to their patient, and worried about the future, however others 
accepted the situation and dwelt less on the potential for negative outcome: 
 
“I will take TB treatment that is provided by the hospital and see how far it is going 
to get me. If it’s time to die, I’m going to die. If the time is not yet, you can’t die.” 
P24, Female patient 
 
Some participants gave examples of how they had not adhered to TB treatment in 
the past, but none admitted non-adherence during the current episode. There was 
a good understanding of the consequences of non-adherence, with some going as 
far as explaining the concept of drug resistance: 
 
“If you stopped treatment and wanted to start again, the bacteria will have 
developed resistance. Even when the hospital gives you treatment, it doesn’t help 
and you just die eventually.” 
 P24, Female patient 
  
Participants perceived adherence, or lack of, as being related to treatment factors 
(such as length of treatment and side effects); health factors (such as feeling better 
and no longer seeing the need to take treatment); and personal factors, which were 
often affected by a patient’s pre-existing situation. For example, it was perceived 
that people commonly failed to adhere to treatment because of interactions within 
their social networks that involved alcohol (even when still admitted to hospital), 
but here gender did play a role, as alcohol was only discussed in reference to men:  
 
 “….there were a couple of people who I saw in the hospital. While they were getting 
injections, they were also going out to drink and return to the ward. Some of them 
even ran away from hospital without completing medication.” 
P20, Male patient 
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There were concerns expressed about the potential for non-adherence to injections 
for those managed at home, often by those who had not participated in the trial. A 
common reason offered for why doses might be missed in the community related 
to the interpersonal relationships between the patient, guardian and family. More 
specifically, it was perceived that guardians in certain positions – such as wives, or 
younger siblings – would be unable to insist on giving an injection to a patient who 
was refusing; or that arguments within families would mean that guardians could 
refuse to care for the patient properly (table 65, P30 & P2). However, these 
remained perceived problems. They were not realised in any of the accounts given 
by those in the community arm of the study, and none of the participants described 
a single missed injection. The closest situation in which an injection may have been 
missed was when a guardian (uncle to the patient) argued with his sister (mother of 
the patient) about an unrelated episode. He then threatened to walk away from the 
task of injecting, but after discussion did not follow through and gave all the doses 
according to schedule. This is an example of the potential for the injector role to be 
used as a control mechanism within a family, but it was related more to the existing 
relationships within the family than to caring for the patient, and did not result in 
actual harm. In fact, more often guardians played a positive role in supporting 
patients to adhere to treatment, with most reports recognising the importance of 
guardians (table 65, P4). 
 
7.5.3.1.2 HIV 
 
Most patients were HIV positive so that HIV infection as well as TB was an 
important component of peoples’ medical experiences. The majority of patients 
had already received their HIV diagnosis and were on ART prior to their current TB 
episode. In cases where the patient or guardian was finding out their status for the 
first time or the patient was failing ART, medical aspects of HIV featured more 
strongly. The interactions between TB and HIV in terms of increased risk of TB in 
HIV, reduced immunity and effects of drugs were well recognised.  
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“If you contract HIV then TB follows you too. It’s right behind you.” 
P10, Female patient 
 
“I feel that the main factor was decreased immunity in her body because her body 
did not accept the ARVs and they have now given her second line ARVs. The 
immunity was very low in her body and because of reduced immunity TB found the 
opportunity to relapse.” 
P15, Female guardian 
 
Issues around disclosure of TB-HIV status were related to interpersonal 
relationships and interactions with the community (see section 7.5.3.3.). 
 
7.5.3.1.3 Transmission of infections 
 
Concerns about contracting infections were common. These included getting TB 
from the patient, getting TB from the hospital, getting other infections from 
hospital, and risks of HIV transmission from injections. In this way ‘medical issues’ 
are closely related to the ‘physical environment,’ and reducing the risk of 
contracting infections from hospital was seen as a major advantage of community-
based care (table 65, P15).  Concerns about transmission of infection sometimes 
affected personal and community relationships (see section 7.5.3.3.). Emotional 
responses to the risk of infection were usually negative (‘fear’ and ‘sadness’) but 
trial participants had to deal with their concerns and always ended up accepting the 
risks. Participants were concerned about guardians acquiring TB: 
 
“The guardians are at risk of this same TB. I have seen a couple of women who 
came back to the hospital infected with TB two or three months after being 
guardians for their husbands.” 
P34, Female nurse 
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And also the risks of getting infections other than TB from the hospital: 
 
“I also felt at risk of other infections and was worried … You would have a critically 
ill patient struggling to get to the toilet and soiling himself on the bed just next to 
you. I felt I was in danger of other infections than the one I was in the hospital for. 
That’s what I was very much worried about. I feared I might develop another 
condition if I got well from the disease I already had.” 
P22, Male patient 
 
Some guardians expressed initial concerns about the risks of acquiring HIV from 
needle stick injury whilst doing injections, but they were more confident having 
received training (table 65, P23). Others were worried about having needles at 
home if there were children in the house, although by safely storing equipment, 
once again they all managed to find ways to avert the fears they had at the 
beginning. None of the participants reported a needle stick injury. Although it is 
possible that trial participants might not have reported needlestick injuries for fear 
of being seen to have failed, they were given opportunity to discuss this during 
interviews and none reported a needlestick injury.  
 
7.5.3.2 The physical environment 
 
7.5.3.2.1 The physical needs of the patient  
 
Attending to the physical needs of the patient formed a major component of the 
experiences of all those involved in caring for people with TB. Making sure that 
patients are able to wash, go to the toilet and have a clean, warm bed were key 
activities. Food has already featured heavily - as a side effect of treatment (reduced 
appetite, weight loss) and as being important for the recovery of the patient. 
Providing food was a central theme and consumed much time, money and energy. 
It is of interest that experiences of food depended very much on the hospital 
context - food on the ward in Blantyre was not thought to be adequate, and people 
felt the need to bring food for the patient and guardian from home, but in Lilongwe 
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food provided by the hospital was thought to be of high standard, and in some 
circumstances was even a reason for not wanting to be discharged.  
 
In the ward, one main guardian usually carried out the task of caring for a patient, 
but responsibility was often shared amongst family members and the community, 
and frequently depended on the availability of funds. Similarly, for those managed 
at home, these tasks tended to be done primarily by one main carer with the 
support of others at times, but more frequently the patient was able to take 
responsibility for their own care. Whether activities of daily living were an individual 
or collective responsibility was determined in large part by prior circumstances, 
such as existing economic situation, social support and existing relationships. 
Likewise current relationships with the community, healthcare workers and even 
other patients and guardians on the ward also affected the ability to deal with daily 
physical needs (see section 7.5.3.2.). The importance of having good pre-existing 
relationships is demonstrated by discussion about those patients who did not have 
a guardian: 
 
 “Challenges of being in a hospital appear if you the patient are not strong to get up 
from where you are sleeping because it becomes really hard if you depend on 
yourself for everything. How are you going to collect your porridge? How are you 
going to feed yourself if you have no guardian? Who is going to persuade you to 
take the medication because you need a guardian to collect the drugs and help you 
take them. This is a very big problem.” 
P24, Female patient with no guardian 
 
In contrast, those with strong social networks found support from their families and 
communities who provided assistance, for example bringing food. One of the main 
advantages of community-based care was relieving the burden of others having to 
come to the hospital to provide food (table 66, P12). 
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Table 66. The physical environment 
Context Mechanisms Outcomes Illustrative experience Participant 
Providing for the physical needs of the patient   
Those in hospital 
rely heavily on 
community  
Easier for people to visit 
and support patients at 
home as it is quicker 
and less expensive 
Strong community 
relationships are 
maintained; burden on 
community relieved   
“It’s a very helpful program because you also relieve other people. There are other 
disadvantaged people who can’t manage to travel from their homes daily coming to see 
you with food, or other people who want to come and see you every day.” 
 
P12,  
Male 
patient 
Poor hospital 
catering (Blantyre v 
Lilongwe) 
People have to bring 
food to hospital 
(burden on community) 
Bad hospital food is an 
incentive to go home, good 
food incentive to stay 
Food is available at the hospital, but it is not of good quality…the porridge that is offered 
in the morning is purely watery, it is not even porridge… a patient could not take that 
porridge only until lunch time. The ‘ndiwo*’ is not good for someone to eat… of course, 
someone could take it but they wouldn’t get the necessary vitamins or nutrients.” 
P15, Female 
guardian 
Daily routines    
Daily routines 
interrupted by 
hospital admission 
Patients and guardians 
at home are able to 
continue daily routines 
Patients and guardians able 
to maintain dignity and 
independence 
“My life was not affected because the job [injecting the patient] did not last many minutes. 
You perform it once right there and then you start carrying out other tasks. So there wasn’t 
any problem. It did not disturb me. It’s just the same.” 
 
P11, Male 
guardian 
Relationships 
disrupted by 
hospital admission 
Patients and guardians 
at home are able to 
continue social 
interactions 
Patients & guardians better 
able to maintain 
community relationships  
“I felt good about getting injected at home for you never feel anxious about how you are 
going to see your friends.”  
 
P17,  
Male 
patient 
Daily routines 
interrupted by 
hospital admission 
Patients and guardians 
at home are able to go 
to school and church 
Children are able to go to 
school (and church); 
relationships are 
maintained 
“… there is also time to go and worship … I would not have been able to write standard 8 
examinations if I stayed at hospital here … the reason he [my guardian] accepted to inject 
me was because he too is in school 
P17,  
Male 
patient 
Daily routines 
interrupted by 
hospital admission 
Patients at home feel 
more ‘normal,’ and 
therefore less ‘like a 
patient’ (sick role) 
Dignity and independence 
maintained 
“When you are taking medication at home it feels like you are not on medication. It feels like 
you are just staying. When someone sees you they say ‘Ah, he is not sick,’ when you are 
actually sick, because you are able to perform household work on your own. When you are 
in the hospital … all you think about its ‘I am in the hospital’ and the sickness worsens.” 
 
 
 
*Ndiwo = relish 
 
 
P12,  
Male 
patient 
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Context Mechanisms Outcomes Illustrative experience Participant 
Livelihoods     
People have to run 
two households 
when patient in 
hospital 
Food is shared and 
there are no transport 
costs when patients are 
at home 
Reduced costs to patients 
and households 
“If someone has been admitted to hospital transport costs can make them poor because it 
means they have two households: they should take care of home and come here to see the 
patient … at home they should fetch for food and also at the hospital, and also money for 
transport.” 
P29, Female 
nurse 
Inability to work 
when in hospital 
Patients and guardians 
at home are able to 
work 
Reduced lost earnings for 
patients and households 
“The problems I went through … because each time we came to the hospital here, the 
business also stopped” 
P4, Male 
guardian 
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7.5.3.2.2 Daily routines 
 
Trial participants found the ward environment distressing, and described in detail 
the unpleasant reality of daily life in hospital. The predominant feature for all 
participants was overcrowding, which affected people on many levels – the physical 
discomfort of not having enough space, the lack of privacy and dignity, the risk of 
infection, difficulty in getting care, and the anxiety associated with being in close 
proximity to seriously unwell people: 
 
“The disadvantage is where we stay. We stay in a place where we are squeezed in 
where people sleep, beds touch each other unaware of what the other is suffering 
from. That is what makes the hospital to become a problem.” 
P 28, Male patient who declined to participate in the trial 
 
“Now the ward is always full meaning that patients are sleeping on the floor maybe 
even failing to pass because it is full ... it becomes difficult for you to take care of 
someone who is under the bed.” 
P29, Female nurse  
 
Overcrowding was also related to a lack of hygiene on the ward, which was often a 
painful experience: 
 
“You find that they fail to mop because someone is sleeping on the floor. They fail to 
use disinfectants. In the end they just mop the corridors forgetting that they are 
supposed to mop under the bed.” 
P31, Male TB officer 
 
“This time their nostrils have detected a bad smell. As they enquire from one 
another where the smell is coming from, they discover it is from the patient just 
next to them, the one with a small baby. She has been soiling herself up since 
morning and can’t bathe because there is no water. 
‘The smell is too bad,’ one of them complains.  
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The woman doesn’t respond. She quietly walks to the sink just close to where 
I am to see if there is water, but still there is no water.  
‘So what do you do when it is like this?’ I ask her 
‘Nothing, we just wait until the water comes back,’ she replies’’ 
Hospital observation 2 
 
Guardians frequently expressed their unhappiness about not being allowed access 
to the ward, particularly in the morning when doctors did rounds or the ward was 
being cleaned. They felt that their patients might be neglected; that their time was 
being wasted being ‘idle’ outside the ward; and that they should be available during 
consultations with healthcare workers to provide and obtain information about the 
condition of their patient.  
 
“Life in hospital is challenging. The time I was in hospital, being a guardian, they 
had to wake me up at 5 am saying ‘wake up! Go outside, we want to clean the 
room! That means the patient had to stay alone. We had to stay outside until they 
had completed their work …. If the patient wanted something, there was no way 
she could communicate to you.” 
P26, Female guardian 
 
The ward environment at night was a particular discomfort for many. Guardians 
usually slept on the floor under the bed of their patient. This was particularly bad 
for women who often slept in the same ward with men, which many found 
extremely uncomfortable. However, in contrast to a situation outside the hospital, 
this was acceptable, because they were there to look after a patient.  
 
 “Where to sleep was so much of a problem because we used to spread chitenje on 
the cement floor and sleep there till morning, at times not even sleeping at all.” 
P5 Female guardian 
 
Admission to hospital caused massive, often disastrous, disruption to peoples’ usual 
daily routines. In addition to escaping the distressing living conditions on the ward, 
being able to continue normal activities such as going to school and church was a 
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major advantage for those managed at home (table 66, P11 & p17). Many trial 
participants described the phenomenon that ‘things just stopped’ during their time 
in hospital. Taking on the responsibility of caring for patients resulted in people 
‘being busy’, which was seen as a bad thing because it interrupted the pattern of 
peoples’ lives. Having a patient was especially bad if it caused many people to ‘be 
busy.’ The effects on daily routines depended on the circumstances of the patient 
or guardian, and was more significant for those who previously had provider or 
carer roles within the household. It was not clear that gender played a role in this 
effect per se, as it was not only men who had provider roles and many women 
worked too: 
 
“My family is also one of the areas that got affected. I was the one responsible for 
running the affairs of the household, and I was also the same person who got sick. 
Therefore everything seemed to stop.” 
P10, Female patient  
  
Many people attempted to continue normal routines whilst on the ward – 
guardians dividing their time between caring for the patient and maintaining their 
usual activities, and even patients themselves, who were often well enough, leaving 
the ward to visit family or to go to work.  
 
A consequence of being able to function more ‘normally’ at home was often a 
change in the emotional state of the patient. Many describe feeling less like a 
patient once they went home, and this was seen to aid their recovery, and changed 
their ‘sick role’ in the community (table 66, P12).  
 
7.5.3.2.3 Livelihoods  
 
Illness and admission to hospital often had catastrophic effects on peoples’ income 
and financial stability, and frequently left them extremely economically vulnerable. 
The increased costs to households were primarily costs of food and transport, 
 246 
which were a major feature of being in hospital. Costs were reduced for people at 
home as they no longer had to run two households (table 66, P29). 
 
The greater financial need during sickness was compounded in many cases by not 
being able to work, which again affected both guardians and patients. This was 
frequently dependent on their prior economic situation. Those who had fixed 
employment had variable experiences during their admission – many were not paid, 
some lost their jobs entirely, and others managed to continue going to work. Those 
running small informal enterprises sometimes lost their livelihood, but for others 
the increased flexibility meant that they were able to make arrangements to 
continue the business and often rearranged their schedules to fit around caring for 
the patient. This was also dependent on social networks, which, if strong, could be 
called upon to assist, but if weak meant no help:  
 
“On the side of the business, the time I was in hospital I had kept 25,000 kwacha at 
home. Since my senior sister also likes doing the business of trading textiles, I said to 
her ….  ‘use the money for ordering chitenje. She used the money and sold them on 
credit. When I got out of here, I resumed the business.’” 
P13, Female guardian  
 
Coping mechanisms for financial difficulties most often involved borrowing money, 
but trial participants also described having to sell items that they owned. 
Participants in both arms of the trial describe having to borrow money, but it was 
always related to the costs associated with hospital admission. Men and women 
both took loans, but, except for two students who had help from relatives, they 
were all people who had either employment or an existing small business. Yet 
again, patients and guardians relied heavily on their existing social support systems, 
rather than taking formal loans. People borrowed from relatives, friends, from their 
own businesses and in one case from a ‘community bank’ established in her village; 
and often struggled to repay the loans. The experience of having to employ financial 
coping mechanisms did not seem to be affected by gender or age. Both men and 
women, young and old borrowed frequently and there were no clear patterns 
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which differentiated different groups in terms of financial coping. The 
consequences of financial difficulties were sometimes devastating. Needless to say, 
where economic problems did arise they resulted in deep emotional experiences, 
causing fear and anxiety, irrespective of personal and social circumstances: 
 
“I was full of worries, saying to myself, ‘I obtained a loan just recently and they are 
saying I should be admitted.’ My life was sad all the time thinking about the loan 
and the sickness.” 
P24, Female patient 
  
7.5.3.3 Trust 
 
Issues around trust affected interpersonal relationships, relationships with the 
broader community and interactions with the health care system. These 
interactions lead to a range of emotions, such as sadness about leaving children at 
home, and anger at certain aspects of the healthcare system. In turn, this could 
affect peoples’ faith in those people and institutions around them.  
 
7.5.3.3.1 Interpersonal relationships 
 
In general, relationships between patients and guardians were strong and very 
positive in both the hospital and community groups. Most describe the love 
between them, with the guardian caring for the patient ‘wholeheartedly’. The job of 
the guardian was broad and multifaceted. It included practical activities such as 
washing, bathing and feeding; helping with medical care for example giving tablets 
(or injections), and monitoring the patients’ condition; as well as providing 
emotional support and companionship. Such close interactions often strengthened 
the relationship between the two, particularly if the guardian was injecting (table 
67, P23). 
 
Guardians showed enormous commitment, frequently demonstrating huge 
sacrifice in order to put the needs of their patients first. Particularly when patients 
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were in hospital, not only did guardians give up their time, they often also sacrificed 
money, work, school, their own security and dignity, and relationships with their 
families. In one extreme example, a young woman left four small children at home 
alone, lost her job, and was evicted from her house in order to care for her sick 
brother. Although this was a huge burden, she did not resent her brother in 
anyway. This was another area where ‘acceptance’ featured strongly, with people 
giving up a lot in order to look after their patient: 
 
“The 60 days hurt her more than me because it reached a point of her lying to me 
that she had eaten already just to ensure that I ate the little food that became 
available when actually she had not eaten. She would stay without eating.” 
P7, Male patient 
 
Much of this closeness derived from deep trust in one another. The patient was 
required to trust the guardian to care for them; and the guardian needed to trust 
that the patient would allow them to carry out their duties. This was especially 
important for those managed in the community. A suggestion from some 
participants in the community arm was for patients to be present when guardians 
were being trained to do injections, so that they would both be able to take on the 
responsibility of doing the injections correctly and their trust in each other would be 
even greater (table 67, P2). 
 
The respect and faith patients and guardians had in one another depended in part 
on the motivations people had for taking on the role of carer, and the process by 
which a guardian was chosen. There were both internal factors (the guardians’ own 
sense of duty), and external factors which affected peoples’ decision to become a 
guardian. Many felt an intrinsic sense of duty to care for a patient who was unwell. 
They volunteered themselves willingly because they loved their patient and 
because they simply wanted to see them get well. Commonly, people did not even 
question whether or not to be a guardian – the motivation for accepting the role 
was simply that the patient was sick and needed caring for; no other explanation 
was necessary. Factors external to people’s own sense of duty also affected who 
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became a guardian and included family pressure, a fear of being shunned by the 
community, and being instructed by healthcare workers. Some guardians were 
nominated by others, either family members or the patient themselves. It was 
recognised that the existing relationship between patient and guardian was crucial 
to how they would interact during treatment, and therefore how well the 
treatment would go, especially in situations where the guardian had taken on the 
responsibility of injecting (table 67 P14 & P34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 250 
 
 251 
Table 67. Trust 
Context Mechanisms Outcomes Illustrative experience Participant 
Interpersonal relationships    
Patients and 
guardians 
have good 
relationship 
Patients and guardians 
learn to depend more 
on each other, and 
develop deep trust 
Improved relationships 
between patient and 
guardian 
“It denotes love, the love that you have for that person, because it’s hard to help somebody you 
don’t love. But if you love that person and help him wholeheartedly, I think your relationship 
with that person improves. And that person accepts you because he knows you are going to 
help him.” 
P23, male 
guardian 
Patients 
present 
during 
training 
about giving 
injections 
Patients understand 
how to give injections, 
they check guardian 
technique, ensuring 
safe delivery & 
enhancing confidence  
Improved relationships 
between patient and 
guardian; Good clinical 
outcome 
“It could also be a good idea for doctors to ensure that when they are training this person to 
administer the treatment, the patient should be there too … so that when they go home, when 
one stops the other from doing something prohibited, the other shouldn’t disagree.”  
 
P2, male 
guardian 
Patients and 
guardians 
have bad 
relationship 
Extra burden of caring 
for the patient puts 
strain on the 
relationship  
Worsening of relationship 
between patient and 
guardian 
“The guardian needs to be someone who already relates well with the patient. You can’t take 
someone who doesn’t get along with the patient to be guardian. Then there is going to be some 
ill treatment between them … that is why the patient is given the opportunity to pick someone 
who should be caring for her.” 
“Others decline to be guardians because of lack of love for their patient. If they had disputes in 
their family or did not get along with her before, many find it hard to come and help her.” 
P14, male 
guardian 
 
P34, 
female 
nurse 
Families have 
children at 
home 
Patients and guardians 
able to look after 
children at home;  
reduced anxiety about 
neglecting children  
Children receive better 
support and care; emotional 
distress of parents is reduced 
“I had a small kid … the time I was in the hospital the kid looked like a child with no parents. She 
would go and wait for food in people’s homes. She would move around uncontrollably … it 
would bother me greatly in my life.” 
 
P16, 
female 
patient 
Community interactions    
Heavy 
reliance by 
patients & 
guardians on 
community 
 
Patients and guardians 
able to take care of 
their own households 
when at home 
Children receive better 
support; patient and guardian 
have better position in 
community; independence 
maintained 
“Children were being taken care of. Other people could support them for us: ‘oh, children what 
do you have in the house?’ ‘Ah, there is nothing.’ Then whoever had something would take the 
little they had and offer it to the children because they were all young.” 
 
P10, 
female 
patient 
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High level of 
TB-HIV 
awareness  
Community based care 
avoids disclosure of TB 
(and HIV) status 
Dignity and independence 
maintained as patient 
confidentiality protected 
“if you have been admitted to hospital for 2 months people know that you are also HIV positive” P10, 
female 
patient 
Guardian has 
good social 
network 
Community willing to 
accept new role, and 
recognises the benefits 
of guardians injecting 
Guardian gains respected 
position in the community 
“If I told them they would praise me saying ‘you did a great thing accepting to inject him 
because others would have remained in the hospital being afraid of learning to give injection,’ 
so many would encourage me.” 
 
P18, male 
guardian 
Experiences of healthcare system    
Under-
resourced 
health system 
& poor 
families 
Patients unable to 
access healthcare if 
they deteriorate at 
home due to lack of 
ambulances, phones, 
transport 
Poor clinical outcomes in the 
community; potential for 
anxiety  about what would 
happen if patient 
deteriorates at home (helped 
by understanding process to 
access care) 
“Admission to the hospital is good because at the hospital is where they know more. If you 
complain of something and they carry out an examination on you, they are able to determine 
the disease you are suffering from, but at home we wouldn’t be able to tell.” 
“When I was re-admitted to the hospital, the nurse asked me ‘are you going back home again?’ 
I told her ‘no, I should  complete the treatment here.’ I thought it was good to complete the 
treatment here because I could speak to a nurse if I felt something in my body.” 
P10, 
Female 
patient 
P20, Male 
patient 
 
Traditional 
model of 
healthcare, 
users are 
passive 
Patients and guardians 
feel empowered as they 
share responsibility of 
healthcare by doing 
injections at home 
Increased engagement with 
health care 
“They say doing injections is for healthcare workers, but when doing this work it is like we are 
saying that this problem is for everyone and everyone at home will receive it with both hands.” 
“This program could have good outcomes because through receiving the training we have 
known how TB works, what it does and what we need to do. This can spread the message so 
that it reaches other people.’ 
P29, 
Female 
nurse 
P5, female 
guardian 
Sick people in  
community 
unable or 
unwilling to 
access care 
Guardians trained 
become ‘lay injectors’ 
in the community and 
deliver injections 
without supervision 
Unsafe injections by lay 
injectors in the community 
lead to medical complications 
“No. I was only trained to inject the patient from whom I was a guardian. You are responsible 
only for your patient... Unless healthcare workers themselves instruct you to go somewhere and 
inject somebody … you can’t do that on your own. It would be an offense for you are not sure 
about the medications required for that person … You could even have somebody suffering 
from the same disease as your patient, but I learnt that if you are to inject somebody, you need 
to know how much they are weighing and their weight determines their dosage.” 
P23, male 
guardian 
Under-
resourced 
health system 
Guardians trained to 
give injections take on 
supervised volunteer 
role in the community 
Safely delivered injections in 
the community relieves 
burden on health system & 
users; Guardians sense of 
achievement in sharing 
responsibility for care 
“I think I have found a certain life fulfilment that people have. And I have been fighting hard, 
that if possible, if God pleases, I should join this medical field and be one of the people doing 
this work because this work is good. Whenever I was helping the patient I felt I was doing 
something great … if they ask me to go and inject somewhere, I can do that provided they tell 
me how to prepare the medicine.” 
 
P23, Male 
guardian 
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It was often the case that a family decided together which one of them should take 
primary responsibility. There were some guardians who declined to participate in 
the study because of fear that if something went wrong during the course of 
injections they would be blamed by the rest of the family. As previously seen 
(section 7.5.3.1), sometimes younger family members were instructed to be the 
guardian based on a decision made by the rest of the family. Whilst age played 
some role in choice of guardian, the data do not suggest that gender did. Although 
being a guardian is often associated with a caring role traditionally taken on by 
women, men and women both took on the role frequently and just as willingly. Not 
only performing injections (which may have been seen as having higher status), but 
taking care of the daily needs of the patient seemed to be entirely compatible with 
masculinity. Many of these issues around deciding who should be a guardian were 
similar when choosing who should care for a patient in hospital, and who should 
take on the role of injecting. One difference was that older women sometimes felt 
less confident to learn how to inject.  
 
Finally, some people were motivated to take on the role of guardian in the hope 
that it would be reciprocated if they got sick at some time in the future:  
 
“The love you have for that person is what motivates you to be a guardian, because 
everyone falls sick. Today it’s him, tomorrow it’s you. If you become sick yourself, 
the person you helped will say ‘this person helped me so I should help him too,’ 
because sickness knows no age or status.” 
P19, Male guardian  
 
In general, relationships within families were maintained. The family usually pulled 
together to support both guardian and patient in hospital. However, family 
dynamics often suffered, primarily because those in hospital felt that they were 
neglecting their children during the long admission. Sadness and worries about 
children who were left unsupported at home were common. This became part of 
the difficulty of being in hospital, and was one of the major attractions of 
community-based management (table 67, P16).  
 254 
Effects on interpersonal relationships were not limited to families. In many 
instances strong relationships developed between those living on the ward, where 
a short-term community of patients and guardians was seen to develop. Patients 
looked out for each other, sometimes filling the gap for those without strong 
existing social support mechanisms by caring for those patients without guardians. 
Guardians likewise shared the burden of responsibility by seeing to each other’s 
patients if one had to be away from the ward.  
 
“He did not have a guardian, and once I bathed him. And the example I 
demonstrated influenced all the other people around to follow suit. When it was 
morning, one would go and warm some water for him … we kept doing that until 
things started improving for him.” 
P7, Male patient 
 
The members of the ward community described comfort from the discussions they 
had amongst themselves about medical problems, medications, families, food, 
healthcare workers, and even about this study. Food was shared between those on 
the ward, and some guardians described praying together or having informal church 
services in the shelters. Furthermore, the accounts of friendships that developed on 
the ward were some of the times when happiness and even having fun were most 
evident: 
 
“There is a video song playing on the television and the thin patient starts dancing 
to it. She dances whilst sitting on her bed and others in the room laugh with her.” 
Hospital observation 2 
 
Although no participants in the community described a feeling of missing out on 
being part of the ‘ward community,’ nevertheless, this support structure may have 
offered the benefits of camaraderie and shared experience which patients at home 
would not benefit from.  
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7.5.3.3.2 Community interactions 
 
 
The vast majority of interactions within society were overwhelmingly positive, 
with those affected by illness relying heavily on the support of their communities. 
Occasionally, patients and guardians felt themselves to be a burden, but almost 
always they gained comfort from the people around them. Community members 
were trusted to support children left alone at home, visit those in hospital, and 
even provide financial help. These responsibilities were greatest when patients 
were admitted to hospital and relieved for patients managed at home (table 67, 
P10).  Frequently, the onus was shared amongst many in the community who often 
took on many of the same responsibilities as family members.  
 
“Many people knew of my problem and it pleased them to offer me a hand. My 
friends, neighbours and some of my relatives were the ones who played the role of 
helping me, paying house rentals for me, even looking after my children. It was a 
challenge for me and I don’t know how it would have been dealt with if it were not 
for these people.” 
P7, Male patient 
 
Yet again, peoples’ previous roles within their communities often influenced the 
support they received. Some community support came from friends and 
neighbours, but for those who had weaker social networks on which they could not 
rely, more formal networks were sometimes able to step in. For example, many got 
help from the religious groups to which they belonged, or even from communities 
established within a work environment: 
 
“My job stopped the moment I got sick. But with the committee we formed, we 
don’t forget one another. If a member has been admitted to a hospital maybe for 2 
or 3 weeks, drivers as well as conductors go there to see him … they formed this 
committee because previously if one of us minibus drivers got admitted, he would 
stay in hospital without being visited until he passed on or was discharged.” 
P20, Male patient 
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Despite the heavy reliance on community members during illness, issues around 
disclosure of health status and stigma still featured. In general, people felt more 
comfortable disclosing their TB diagnosis than their HIV diagnosis, but there was 
recognition of the link between HIV and TB. It was often felt that admission to the 
medical ward was in effect a disclosure of HIV status. In one case a participant 
claimed that “if you have been admitted to hospital for two months people know 
that you are also HIV positive,” demonstrating his perception that the significance 
of a two-month admission for retreatment TB was well recognised in the 
community as being associated with HIV. By shortening admission time to the TB 
ward to less than two months, the problem of disclosure by this mechanism can 
potentially be avoided. Not all participants expressed concerns about discrimination 
in the community, and for those who did it was almost always related to people’s 
fear of contracting TB. 
 
Most participants at home did not disclose beyond the household that the guardian 
was administering injections. However there were concerns, mainly from health 
care workers and attendees at FGDs rather than study participants, that injecting at 
home would cause problems in the community. They feared that even if patients 
did not tell people they were being injected at home, gossip in the neighbourhood 
would lead to people finding out and stigmatising patients because they associate 
injections with severe forms of TB. Once again, this abstract experience was not 
borne out in concrete experience - none of the concerns about gossip were realised 
by any of those who received community based care. In reality, when participants 
informed others about home injecting, guardians seemed to get great respect from 
the community for the helping role they were playing (table 67, P18). 
   
7.5.3.3.3 Experiences of the Healthcare System 
  
 
Trial participants described mixed experiences of their interactions with healthcare 
workers. A small number complained of negative interactions with nurses, including 
feeling that their patients were being neglected (e.g. delays in changing a drip); and 
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being shouted at for complaining or asking for help. However, it was well 
recognised by patients and guardians as well as the healthcare workers that the 
overcrowded environment on the ward made the job delivering care harder, and 
affected the ability of nurses in particular to look after patients well.  
 
Views about where the responsibility lies for the care of the sick varied. Although it 
was seen that responsibility for diagnosis and prescription of treatment lay clearly 
with the healthcare system, care for patients after this point was seen mostly as a 
shared responsibility. This was the view of both trial participants and healthcare 
workers; in fact there was a clear understanding from all perspectives about the 
division of labour and the responsibilities of the guardian. Guardians took on the 
majority of the care in terms of hygiene and nutrition, but some participants also 
felt this should be the responsibility of the health care system, especially when 
patients do not have a guardian. Conversely, most people felt that the health 
system should be primarily responsible for the health needs of patients, but that 
guardians, family members and even patients themselves also shared this 
responsibility. For example patients, guardians and nurses described the clear role 
that guardians played in monitoring the condition of the patient and reporting  to 
the nurses if a patient became unwell, as well as encouraging patients to take 
medication. In this example, patients are expected to take on the responsibility of 
registering themselves for TB treatment and submitting sputum, rather than the 
healthcare worker knowing who on the ward needed to be registered, a situation 
which may well have resulted in patients not registering if they were too unwell or 
not in the ward at the time: 
 
“A male TB officer enters the room. He is looking for patients who have been on the 
ward since a week ago. Four patients raise their hands. He sees them one by one. 
He gives to each one two small glass bottles. He first labels the bottles and then 
says, ‘these bottles are for sputum collection.” 
Hospital observation 1 
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Specifically relating to community-based management of injections, people 
believed it was the responsibility of doctors and nurses, but most recognised that 
guardians could take on the job if they were properly trained, because they saw the 
advantages of home-based care. However there were concerns about what would 
happen if a patient became unwell whilst at home. It was clearly felt that one 
advantage of hospital-based over community-based management was being close 
to doctors and nurses and being able to access help quickly if the patient’s 
condition deteriorated (table 67, P10 & P20). This is made worse by the fact that 
the circumstances in Malawi mean there is little access to emergency services such 
as ambulances, and patients with little income have to finance their own transport 
and communication with healthcare facilities. However, once again this theoretical 
concern was not realised in any actual experience, as no participants describe a 
situation in which they were, or even felt as if they were, stuck in the community 
with no access to care.  
 
There were no instances where guardians administered injections to people other 
than the patient they were trained to inject, and all said that they would not 
consider doing so without instruction from the hospital. Not only did all guardians 
deny injecting members of their communities, they were able to give very clear 
reasons why they would never do so (table 67, P23). However, in one community 
observation the guardian enrolled into the trial was a nurse and had taught the 
patient’s wife how to administer the injections. This was picked up by the trial 
fieldworker during the visit, and was the only example of such an incident 
throughout the trial. The wife was then formally trained by the study team, officially 
became the patient’s guardian and successfully completed injections. Most 
guardians were proud of their accomplishments and were keen to offer their help in 
future if it were needed, and properly supervised. 
 
Only one participant, who declined to participate in the trial, expressed concern 
that if she took a patient home for injections, she might be bewitched “so that they 
can claim if he is sick it is because of this research idea of discharging somebody to 
receive injections at home,” (P33) but this seemed related more to research per se 
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than injecting in the community. There were very few other references to 
traditional medicine or witchcraft, other than the acknowledgement that delays in 
accessing hospital care caused by first going to traditional healers may worsen a 
patient’s condition.  
 
Overall, feelings about community-based management of patients receiving 
injections as part of TB treatment were extremely positive. The advantages in terms 
of medical care, daily routines, financial stability, family relationships (especially 
with children), and burden on the community were overwhelming. However, it was 
recognised that successful home-based care depended very strongly on two factors: 
firstly, adequate training of guardians and support from the hospital when needed; 
and secondly that only patients who are well enough to be at home are selected.  
 
“They discharged us such that we got relieved of other things after we had 
gone home. We were now spending less money than when we used to come 
here because transport and food costs used to be high. For some of the 
relatives who were unable to come and see him because of lack of transport, 
it became lighter. Many people have been coming to the house to see him. 
The patient too transformed in his life because he was able to differentiate 
being at home from being here. At home, he had the sensation of being 
healed because he was able to meet with everyone.” 
P4, Male guardian 
 
 
7.6 Discussion 
 
Evaluation of the lived experiences of patients and their guardians during the 
intensive phase of TB retreatment produced three main categories of description: 
medical issues, the physical environment and trust. Experiences were often 
influenced by context of the patients’ and guardians’ prior roles within their 
communities and households, and resulted in a range of emotional responses.  
Community-based management affected experiences in all three categories of 
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description, and again these experiences were impacted on by previous roles and 
backgrounds.  
 
The data have important implications for the interpretation of the TB-RROC trial, 
and add to the overall evaluation of the intervention. The categories of description 
that have been identified, and the interactions between them, highlight some of the 
advantages and disadvantages of community versus hospital-based care during TB 
retreatment in terms of medical, financial, social and emotional outcomes. 
Additionally, the data provide information which helps to address some of the 
concerns initially raised by stakeholders such as the community advisory board, 
medical ethics boards, and the National TB Control Programme. Finally, they 
provide useful insights into ways in which the intervention could be improved to 
maximise benefit and improve experiences. 
 
7.6.1 Financial consequences 
 
A striking finding is the disastrous effect that admission to hospital has on peoples’ 
ability to continue normal daily life, and in particular the catastrophic consequences 
of this on their livelihoods. Once discharged, those in the community were relieved 
of many of their expenses and more easily able to return to their usual routines, 
thus relieving some of the economic pressures and associated emotional stress. 
However, it is important to acknowledge that financial burden was felt by those in 
both arms of the study with higher costs and reduced ability to earn money being 
primarily, but not exclusively, limited to the period of hospitalisation.  
 
It is of note that the economic burden of hospital admission and the financial 
advantage offered by community-based care did not appear to be particularly 
affected by age or gender. The economic vulnerability of women has often been 
reported, but the data in this study are reproduced in the qualitative and economic 
evaluations which both demonstrate that the intervention was cost saving for 
households, irrespective of the gender of the patient. This difference may be 
explained by the fact that most trial participants did have some income, even if it 
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was not in the form of  a regular salary therefore they still felt the financial effects 
of illness, and by the fact that the evaluation focussed on effects on the household, 
not simply on the individual recruited.  
 
7.6.2 Social experience 
 
Socially, the advantages of a community-based model were also evident. Patients, 
guardians, family members and the wider community were all affected by the 
necessity for care to be provided for those in hospital. Social capital is widely 
recognised to be a crucial component of peoples’ ability to access care, engage with 
health systems and remain in treatment [481-483]. Although solidarity from social 
networks or ‘the clanship system’ [466] have traditionally been seen as 
fundamental to the structure of many African societies, it has also been reported 
that the main source of assistance (and therefore duty) lies within the household 
rather than with the wider community. For example, in an ethnographic study in 
the Ivory Coast, Bossart reports that household members play a key role in the 
management of illness, but that their help is often taken for granted, considered an 
obligation and based on traditional gender roles [484]. In the context of strong 
social networks, those admitted to hospital in this study were able to rely on both 
families and broader social groups to help with the practicalities of being sick, 
whereas those with weaker social networks suffered. In contrast to previous studies 
[485-487], the role of guardian was not particularly gendered with men and women 
taking equal responsibility for all aspects of care. It is unclear why this intervention 
did seem to override gendered household norms. It may have been that the task of 
administering injections was seen as more important (and therefore more 
appropriate for men to take on) than other traditional roles played by guardians 
such as washing and cleaning. However, approximately one third of guardians in 
each group were male, and the interviews demonstrate that, by and large, male 
guardians enrolled into the trial continued in their guardian roles even after being 
randomised to hospital-based care. Once again, the burdens of care on family and 
social support structures were relieved to a large extent, but not entirely, by being 
in the community.  
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The commitment and sacrifice shown by carers was often staggering. The 
motivations for people to volunteer as community health workers have previously 
been well described and include both financial and non-financial reward [488, 489] 
[283]. However, the factors that influence how a family member or friend becomes 
a volunteer carer, or ‘guardian’, are less well understood. This study goes some way 
to describing those factors. Although a few guardians felt pressure from the patient 
or other family members to take on the role, the vast majority felt some duty to 
care for the person who was sick which was instinctive and entirely intrinsic within 
themselves. Occasionally, guardians were motivated by the fear that the 
community would think badly of them if they did not step up to the task; or the 
hope that their good deed would be reciprocated in the future.   
 
There were a few instances where people encountered discrimination, but this was 
not a central theme and the examples were all related to fears around TB being 
associated  with HIV, which have been well illustrated in previous studies [467, 469, 
472, 475, 490-492]. Specifically related to TB retreatment, it was acknowledged that 
admission to hospital often disclosed HIV as well as TB status, particularly if the 
admission was long. The situations of the communities in this study is likely to be of 
significance in understanding this  - the research was conducted in two urban areas 
with high burdens of HIV and TB where awareness about the two conditions is high. 
Therefore the understanding and assumptions which people are able to make may 
apply less so in settings where the prevalence of HIV is lower. Importantly, there 
was only perceived, but not realised, discrimination around guardians delivering 
injections in the community, and there was no perceived or realised stigma 
attached to injecting at home.   
 
7.6.3 Emotional experience 
 
Emotionally, there was a broad range of experiences, which arose from medical, 
practical and social factors. Experiences of people on the ward were often 
distressing, with issues around overcrowding, lack of space, and hygiene being 
paramount. Other common feelings were the sadness and anxiety around financial 
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issues and the neglect of children at home, which is consistent with previous 
literature [493].  
 
The psychological effect of illness and hospitalisation on patients was clear. 
Although essentially a social phenomenon, ‘the sick role’ has been categorised as an 
emotion in this context because it is being used to refer to the patient’s feeling of 
being maintained within a sick role. The concept was first described by Talcott 
Parsons in 1951 [494], and developed since then [495-497]. He described illness as 
not simply a biological or physiological phenomenon, but also a social and cultural 
one, in which the sick person adheres to a specific role within society. This role 
brings with it certain rights and responsibilities. The rights of the sick person are 
that they are exempted from certain social duties and responsibilities, and that they 
should not be seen as responsible for their illness. Obligations of people who have 
adopted the sick role include recognising that the state of illness is not desirable 
and wanting to get well, as well as actively seeking help and engaging in a 
relationship with medical professionals. Data from this study clearly demonstrate 
patients taking on a sick role, as the nature of their position in society and 
relationships with others are completely changed by their illness. There is a clear 
difference in the extent to which patients in hospital and in the community take on 
this role. Moreover, one of the aspects of community-based care which contributed 
most to patients emotional well being (and, according to some, physical well being) 
was the ability to practically and psychologically move away from this role.  
 
7.6.4 Medical care and the health system 
 
Experience of medical care varied. Participants described well known barriers and 
facilitators to accessing care such as previous experience of TB [200], costs [274], 
accessing informal providers [473], stigma [468], and HIV [498].  
 
For both hospital and community-based care, trust in the health system is crucial. 
Theories of trust, as described by Giddens and Luhmann, can be framed around 
both trust in the individual (interpersonal trust) and in the system (institutional 
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trust)[499, 500]. The importance of trust in the health system is that it increases a 
patient’s willingness to seek care, enhances ability to engage with treatment, 
improves relationships between patient and clinicians, facilitates disclosure by 
patients, enables necessary behaviour change and may grant patients more 
autonomy in decision-making [501]. Gilson argues that trust underpins the co-
operation amongst people necessary to achieve a common goal [502]. She goes on 
to suggest that respectful treatment of patients by healthcare professionals is 
crucial in developing trust, and that central components of that respect include 
positive attitudes and behaviours, thoroughness and technical competence [503]. 
Similarly, Mechanic reports that ‘interpersonal competence,’ comprising caring, 
concern and compassion, is the most common aspect of trust in health care 
amongst patients with serious illness [504].  In the current study we see that indeed 
trust in the healthcare system was primarily determined by interactions with 
healthcare workers, and that failure of these representatives to earn the respect of 
trial participants, for example by not changing a drip in time or by ‘shouting’ at 
guardians, impaired the relationship between the two. Conversely, the feeling of 
security generated by being in hospital represented the trust that people had in the 
ability of clinicians and nurses to provide help if a patient was unwell. Likewise the 
fact that participants agreed to take part in the trial demonstrates that not only did 
participating patients and guardians have trust in each other, but also that a 
relationship had been developed in which they trusted that they would be able to 
access care from health workers should they need it. In fact, some of the reasons 
provided for non-participation came from those who did not trust that the system 
would come to their assistance if there was a problem at home.  
 
One of the major advantages of community-based care was the opportunity to 
escape the overcrowded and often unclean conditions on the ward. The distress 
that this caused to patients and guardians is in keeping with previous literature in 
which patients with MDR-TB have expressed a preference for home-based care, 
siting transmission of infection and lack of psychosocial support as problems with 
hospital-based care [505].  
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7.6.5 Study limitations 
 
The study had some limitations. Data were collected almost exclusively at a single 
time point, just after completion of injections. It may have been that experiences 
changed during the period of the intervention and also that community-based 
management may have longer term effects on participants beyond the completion 
of injections. Although observations were conducted during the intervention phase, 
longitudinal data throughout the intensive phase of treatment and after it’s 
completion may have provided additional insights, allowing the development of 
increased rapport between participants and researchers, and thereby enabling 
more detailed exploration of experience. Additionally, although every attempt was 
made to sample participants who experienced adverse events during the trial, only 
two participants (one patient and his guardian) were interviewed who had 
complications whilst in the community. Particular focus was paid to the data 
provided by these participants however it may have been possible to get more 
understanding of the potential negative consequences of community-based care 
had there been other interviewees who had experienced significant difficulties. The 
impact of urban or rural residence and  was not specifically examined in this study. 
Only three of the interviewees were from rural areas and their experiences did not 
seem to differ significantly from other participants, although data from other 
participants not living in the city may have revealed more subtle differences in 
experience. This study was not exempt from the inherent difficulties of collecting 
observational data, including the observer altering behaviour by their mere 
presence and the ethics of collecting data without full informed consent. However, 
data were collected in the most unobtrusive way possible without misleading 
patients, guardians and staff.  
 
7.6.6 Stakeholder concerns addressed 
 
There had been a number of concerns raised by those consulted at the start of the 
TB-RROC trial, which this evaluation have helped address. Firstly, there was a fear 
that guardians simply would not deliver the injections at home. These qualitative 
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data back up the quantitative data from the trial, which suggest that adherence to 
injections was exemplary. Not only did trial participants report excellent adherence, 
this was made more convincing by the (often in-depth) explanations they were able 
to provide as to why they would not miss doses; and clear descriptions of the duty 
they felt to complete the task they had taken on. There were however, a small 
number of instances where situations developed in which a dose might have been 
missed, but in each case the issues were resolved and injections were delivered on 
schedule.  
 
Secondly, there had been a worry that guardians would not be competent to deliver 
injections. Indeed, many patients and guardians were also initially apprehensive. 
However, all of those who took part in the study were able to overcome these 
concerns, embrace the responsibility, and even be proud of what they had 
achieved. This experience has been reported in other settings, for example 
Livermore et al [506] quote a parent taught to administer injections for rheumatoid 
arthritis to their child as saying “I felt a sense of achievement. I have never wanted 
to be a nurse or give injections, but to keep him in his normal pattern of school, I 
will do anything.” The one occasion where complications around injections did arise 
seemed not to be directly related to the ability of the guardian to do the injection, 
but more to the condition of the patient. All other accounts from patients as well as 
guardians demonstrated that, once trained, guardians giving injections was ‘just the 
same.’ 
 
Thirdly, the issue of access to medical care during treatment at home had been 
raised. Very few participants described needing to access care whilst in the 
community but those who did were able to contact the study team, and in the one 
situation where admission was necessary, this was easily arranged and the ultimate 
outcome was positive. There was, however, a clear recognition that community-
based management was not for everyone, and only those well enough should be 
selected for discharge.  
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Finally, it had been suggested that training people to do injections might create a 
cadre within society of ‘lay injectors’ who would be expected to provide injections 
for people within their communities. The data from this study strongly suggest that 
the risk of that happening would be very low. Guardians had a very clear 
understanding of the limitations of their role, and strongly rejected the idea of 
injecting people other than their own patient without instruction from the hospital. 
On the other hand, they would be keen to put their newfound skills to use by 
helping others in the future, under supervision from the health system.  
 
7.6.7 Conclusion 
 
Overall, these data demonstrate that the experience of community-based 
management offers many advantages over hospital-based management. Concerns 
raised by participants as well as stakeholders have been both recognised and 
addressed. Although there were abstract worries about issues in the community 
such as adherence, relationships between patients and guardians and the ability of 
lay people to deliver injections safely, none of these were borne out in real 
experiences. Community-based management offers a number of benefits, including 
fewer financial difficulties, improved emotional well-being, and the ability to 
continue social interactions and daily activities. 
 
“That part [performing injections] needs to be fulfilled by the nurses because 
it is their job. But a guardian does this job because people can’t stay in the 
hospital for 2 months … it is a place where you end up getting other infections 
instead of getting well … you find that most of your relatives are not able to 
go there because of financial constraints … they saw it was possible for a 
guardian to go and inject a patient at home if properly trained. They saw it 
was a good idea.” 
P15, Female guardian 
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8 Final discussion and recommendations 
 
This thesis presents an in-depth assessment of the serious issues facing people with 
recurrent TB and their households in Malawi, and offers new approaches to 
alleviate some of those problems. People prescribed retreatment regimen make up 
only 11% of the total number of those prescribed TB treatment each year, and are 
therefore often overlooked in the clinical, research and policy arenas. The issue of 
tuberculosis recurrence features in the medical literature, but research falls almost 
exclusively into one of three categories: strategies to reduce the rate of relapse 
after initial treatment; how to identify patients at risk of MDR-TB; and, less 
frequently, presentation of data demonstrating the high proportion of unsuccessful 
treatment outcomes on WHO Category II regimen. These are no doubt central 
issues facing TB control and management, and should remain a focus of attention, 
however this thesis clearly demonstrates that TB retreatment is associated with a 
hugely disproportionate burden of clinical, social and economic problems. If targets 
to reduce death from TB and eliminate catastrophic costs associated with treatment 
are to be met, it will therefore be necessary to broaden the agenda and begin to 
address the specific issues faced by people on retreatment.  
 
The final chapter of the thesis will summarise the key findings of the research, 
discuss their implications, and present ideas for future work. Two main issues facing 
adults on TB retreatment were identified and addressed. Firstly, clinical outcomes 
on retreatment are poor. Although this issue is frequently reported, there are few 
data examining the reasons for poor outcomes, so ideas about how to improve 
outcomes are lacking. Secondly, patients on retreatment regimen require injections 
of streptomycin daily for the first two months of treatment, and so currently in 
Malawi have to suffer the consequences of long term hospital admissions. Although 
many models exist for community-based management of patients on first-line 
treatment and treatment for MDR-TB, few specifically address the issue of how to 
deliver injectables during the intensive phase.  
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It was intended that this piece of work provide a comprehensive evaluation of the 
management of TB retreatment in Malawi, therefore the approach was informed by 
realist theories of evaluation [301]. As such, chapter 3 reports a cohort study which 
describes the clinical context of retreatment, following which four chapters 
evaluate the new model of delivering care within that context. After  reviews of the 
literature and development of the model with relevant stakeholders, the evaluation 
of this complex intervention began with a pilot study, and then employed a mixed 
methods approach to examine the mechanisms and outcomes of the new model of 
community-based care.   
 
8.1 The clinical context:                 
Exploring reasons for poor clinical outcomes on TB retreatment in 
Malawi 
 
A prospective cohort study was conducted at QECH in order to investigate why 
treatment outcomes on TB retreatment in Malawi are poor. The study recruited 158 
patients and the key messages are summarised in Box 1. The findings of the study 
are in keeping with previous reports of low rates of successful completion on the 
WHO Category II regimen (see chapter 1). They also suggest that factors other than 
drug resistance are responsible for these poor outcomes, such as chronic lung 
disease, HIV, ART failure, renal disease and anaemia.  
 
There are a number of areas where interventions may have the potential to reduce 
morbidity and mortality. Firstly, the issue of chronic lung disease needs to be 
addressed. This was recently highlighted by Metcalfe et al, who reported that 74% 
of patients on retreatment regimen had abnormalities on plain chest x-ray 
consistent with chronic lung disease, and concluded that “retreatment of 
tuberculosis in the modern era represents a common pathway for individuals with 
chronic lung disease who remain symptomatic after repeated interactions with the 
public health system … empiric treatment exposes patients to drug toxicities and 
increased health-care costs without benefit” [507]. One of the main obstacles in 
tackling chronic lung disease in resource limited settings is the lack of available 
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diagnostic tools. Even in the most affluent settings, the diagnosis of bronchiectasis 
is complex and can only be made accurately using CT [508]. This study has shown 
once again that CXR is an inadequate method for diagnosing bronchiectasis, but 
suggests that spirometry may be useful. Spirometry can now easily be used away 
from central hospitals and its use is advocated in the WHO’s ‘Practical Approach to 
Lung Health’ for the diagnosis of respiratory disease at all levels of the healthcare 
system [509]. Postural drainage of respiratory secretions is a technique which 
requires no equipment and could be easily implemented with very limited 
requirement for materials and some basic training. A slightly more complicated 
issue to address is the problem of antibiotic management of bronchiectasis. This 
depends very much on the spectrum of pathogens involved in colonisation of the 
airways and infective exacerbations [510, 511]. Further information concerning the 
microbiology of bronchiectasis in post-tuberculous lung disease in high TB burden 
settings would help to design appropriate algorithms for the management of 
infection where sputum culture is not routinely available for bacteria implicated in 
bronchiectasis.  
 
 
Box 1: Key findings in the TB-RROC cohort study 
 
 Clinical outcomes on TB retreatment regimen in Malawi are still poor: 
only 68.4% successfully complete treatment, and mortality is 24.1%. 
 
 Drug resistance in patients with recurrent TB in Malawi is 
uncommon: 90.4% of patients are infected with a fully sensitive 
strain of M. tuberculosis. 
 
 Hypotension at baseline is associated with poor clinical outcome. 
 
 Medical co-morbidity is common in patients on TB retreatment in 
Malawi. Chronic lung disease, HIV, ART failure, renal impairment and 
anaemia are highly prevalent. 
 
 Streptomycin toxicity is common in patients on TB retreatment in 
Malawi: 35.9% of patients develop ototoxicity and 14.6% develop 
nephrotoxicity. 
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The second area for targeting interventions to improve mortality in patients with 
recurrent TB is HIV. Although the interaction between TB and HIV is well studied 
and routinely addressed in the delivery of care, the management of patients with 
recurrent TB poses specific challenges. The burden of HIV seems to be higher in this 
group of patients. Because HIV positive people will be living longer on ART they will 
be at increased risk of recurrent episodes of TB. In high TB high HIV burden settings, 
this may result in both increasing numbers of people getting recurrent TB, and 
increasing HIV prevalence in that group. Additionally, as people live longer on ART 
they will be at increased risk of both ART failure and recurrent TB, which is likely to 
result in a high prevalence of ART failure in patients on retreatment, as was seen in 
this study. Key recommendations for settings such as Malawi therefore reiterate 
the importance of testing all patients with TB for HIV, but also that viral load testing 
and second-line ART are made easily available at centres treating patients with 
recurrent TB.  
 
The incidence of streptomycin toxicity was high, with ototoxicity being particularly 
common. Streptomycin is the oldest anti-tuberculous drug, yet surprisingly little is 
known about it. Very few data exist about the pharmacokinetics of the drug, and 
dosing schedules are not based on good evidence [512]. Monitoring for toxicity and 
taking steps to reduce the impact of hearing loss and kidney damage are important. 
However, it is also necessary to explore possible avenues to reduce the risks of 
adverse drug reactions all together by understanding their mechanisms and 
devising regimens which limit the risk of toxicity.  
 
Patients with recurrent TB are a sick group, presenting with hypotension, renal 
impairment, severe lung disease and anaemia. Therefore the management of 
patients on TB retreatment relies on many of the same resources which are 
required to manage all acutely sick patients. In order to properly care for any 
severely unwell patient, it is necessary to have access to basic blood tests such as 
serum creatinine, to have the facilities to give blood transfusions to patients with 
severe anaemia, to resuscitate hypotensive patients, and provide oxygen to 
patients in respiratory distress. This requires not only material, but human resource. 
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Once again, it is seen that disease specific interventions can only go some way to 
improving treatment, and that without approaches which strengthen and develop 
whole health systems it will be hard to deliver better care [513, 514].  
 
 
 
8.2 A new mechanism:                                                                                                        
Community-based management for delivering injectables in TB 
retreatment 
 
 
In order to reduce the burdens of in-patient management for TB retreatment, an 
intervention which involved training guardians to deliver streptomycin to patients 
in the community was evaluated. Mixed methods used to assess the intervention 
included a pragmatic clinical trial of hospital versus community-based care; a health 
economic evaluation; and a qualitative study examining the experiences of study 
participants.  The main findings of the evaluation are summarised in Box 2.  
 
 
Box 2: Key findings in the evaluation of the TB-RROC trial 
 
 Of patients who received community-based management during the 
intensive phase of TB retreatment, 93% successfully completed 2 
months of treatment, compared to 96% who received hospital-based 
management (risk difference -3%; 95% CI -9% - 3%). 
 
 The proportion of patients who successfully completed TB treatment 
at 8 months did not differ according to model of care received during 
the intensive phase. 
 
 There were no deaths or serious adverse events in the community 
directly related to guardians administering streptomycin. 
 
 Community-based management during the intensive phase of TB 
retreatment was cost effective for both providers and users. 
 
 Community-based management during the intensive phase of TB 
retreatment significantly reduced the risk to households of 
catastrophic health expenditure. 
 
 Community-based management offered many social advantages to 
patients, guardians and households affected by recurrent TB. 
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The first domain which the evaluation aimed to examine was the clinical one, in 
which health outcomes were assessed in patients who received streptomycin from  
guardians at home. The randomised clinical trial demonstrated that outcomes at 
two months were similar for community-based and hospital-based management, 
but that community-based management was not statistically non-inferior at a 6% 
margin. Although there were some serious adverse events in the community arm, 
the number was similar to that in the hospital arm and none were directly related 
to guardians giving injections – there were no infections, sciatic nerve palsies or 
needle stick injuries in the community. Descriptions provided in the qualitative 
evaluation also suggested that once trained, guardians were entirely competent to 
administer injections safely:  “… but I saw it was just the same as over the two 
weeks I had been in hospital and was injected by the doctor. There wasn’t any 
difference.”  
 
Nevertheless, the TB-RROC cohort study has already emphasised that this 
intervention was delivered in the context of patients with multiple and complex 
medical problems. It must therefore be acknowledged that a possible disadvantage 
of community-based care is that these patients benefit from being in hospital 
precisely because they have multiple clinical needs beyond simply their current TB 
episode.  A strong message from study participants and healthcare workers was 
that community-based management should only be offered to patients who are 
well enough to be managed away from the hospital and that clear procedures are in 
place for readmission should a patient deteriorate whilst at home. During the trial   
there were a total of 11 readmissions to hospital from the community  and only one 
patient died at home (after an acute severe illness lasting less than one day), 
suggesting that overall participants were able to access care if they did become 
unwell in the community.  
 
Methods of care delivery during the intensive phase did not seem to affect overall 8 
month treatment outcomes, with 77.2% of patients managed in hospital having 
successful treatment outcome and 80.7% of patients managed in the community 
having successful treatment outcome.  Default rates were low in both arms of the 
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study, but the qualitative evaluation did provide evidence to support the theory 
that participants became more engaged with their care if given the responsibility of 
having injections at home, as one study participant described: “They say doing 
injections is for healthcare workers, but when doing this work it is like we are saying 
that this problem is for everyone and everyone at home will receive it with both 
hands.” 
 
The concern that adherence to injections in the community would be a problem 
was expressed by members of the NTP, CAB and other researchers. However, the 
data from the trial show that there were no patients who defaulted from treatment 
in the community, and very few missed doses of streptomycin. Once again, this 
experience is backed up by the qualitative evaluation, in which it was found that 
although concerns were expressed about adherence, particularly if the guardian 
was in a position of less influence than the patient, there were no instances where 
patients or guardians did not adhere to treatment.  
 
The second domain which was evaluated was the economic impact of retreatment 
in the hospital and in the community. The repercussions of hospital-based care for 
already precarious financial situations of households was a major theme in the 
qualitative evaluation, and reducing these consequences was seen as a major 
advantage of community-based care. Admission to hospital frequently had 
devastating consequences for peoples livelihoods: “I was the one responsible for 
running the affairs of the household, and I was also the same person who got sick. 
Therefore everything seemed to stop.” The quantitative economic evaluation 
demonstrated that community-based management reduced the absolute user costs 
during the intensive phase from US$ 271.6 to US$ 101.8, and the risk of incurring 
costs >20% annual household income from 62% to 11%. It was also shown that the 
benefits of community-based care in terms of reducing catastrophic health 
expenditure were seen in different groups and were independent of wealth, HIV 
status or gender. Overall, the intervention was cost effective, reducing the cost per 
patient successfully completing 2 months of treatment by US$ 817.   
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Finally, social impacts of the intervention were examined, primarily by the 
qualitative evaluation of the trial. The qualitative evaluation provided data which 
illustrated the huge sacrifices made by families and communities in order to care for 
patients admitted to the hospital. Escaping the overcrowded and often unhygienic 
conditions on the ward in order to go home and be able to go to work, look after 
children, socialise with friends, attend school and church was a major theme and 
highlighted some of the advantages of community-based care.  
 
Limitations of the individual components of the evaluation have been addressed in 
the relevant chapters, however there are some general issues which are worth 
discussing. Firstly, the evaluation was carried out in only two sites, both of which 
are urban centres in Malawi. Although Bwaila hospital is technically a district 
hospital, it is very much situated in the context of the capital city and therefore has 
many similarities with a central hospital, such as access to investigations and levels 
of staffing. Further information may be gained from additional sites based in truly 
more district settings. Secondly, the evaluation was done mostly at a limited time 
point. This applies to the trial whose primary endpoint was at 2 months, although 
data were also collected for a large group (162/204 patients) who completed 
treatment during the time that the study was still open. However, it also applies to 
the economic evaluation in which it was not possible to formally estimate provider 
costs at 8 months; as well as to the qualitative evaluation which only interviewed 
participants at a single time point soon after completion of the intervention. 
Thirdly, although some of the issues of ‘what worked for who and why?’ were able 
to be addressed in the economic and qualitative pieces, the clinical trial was not 
large enough to examine these questions by performing sub-group analyses.  
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8.3 Research outcomes:                                                                              
Recommendations and future work 
 
Drawing on the findings from all aspects of this evaluation, it is possible to suggest 
some modifications to the model of community-based management, which may 
improve it’s implementation: 
 
1. Eligibility of patients for community-based care 
In the intervention, patients were considered for community-based care if they 
were ‘declared fit by a clinician,’ with no criteria more specific than that a clinical 
assessment was required. Stakeholders, trial participants and key informants all 
recognised the importance of discharging people only once they were ‘strong 
enough.’ Data from the cohort study highlight the complex medical problems which 
patients have. Discussion with clinicians and nurses involved in the trial and working 
on the wards during the period the trial was running also highlighted the 
importance of ensuring patients were well selected for community-based 
management. Together, these experiences suggest that the criteria for discharge 
should be more specific and not rely solely on the judgement of a single clinician. 
For example, a checklist could be developed which would make sure that certain 
basic medical criteria are met prior to discharge. Such medical criteria might include 
having had certain investigations (full blood count, CXR, HIV test, HIV viral load if 
appropriate, sputum GXP), as well as meeting basic clinical criteria such as having 
normal blood pressure, respiratory rate and body temperature. This would go some 
way to both ensure and document patients’ fitness, and also to reassure patients 
and guardians.   
 
2. Eligibility of guardians for community-based care 
During the trial, the choice of guardian was left entirely up to the patient. It was felt 
that a patient would be the best judge of who would be able to look after them, and 
that if the patient chose their guardian the relationship between the two would be 
strong. However, it is clear, particularly from the qualitative data that the process of 
choosing a guardian and the factors that influence motivation to become a guardian 
were varied and complex. Most patient-guardian relationships worked extremely 
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well, but there were a small number of situations where the relationship broke 
down, even if only temporarily. Ultimately, the process of recruiting participants in 
a community-based intervention will begin with identifying a patient on treatment. 
Therefore, they will remain the first and primary point of contact with healthcare 
workers. Nevertheless, the data suggest that a more structured approach to 
supporting patients in identifying a suitable guardian may be useful. Healthcare 
workers might encourage patients to examine certain issues in their choice of 
guardian, for example: 
 
- What is the relationship between patient and guardian?  
- What is the age difference between patient and guardian? 
- Where does the guardian live in relation to the patient?  
- How will taking on injections affect the guardian’s work?  
- Does the guardian drink alcohol? 
- What will happen if something goes wrong?  
 
A checklist for choosing a guardian is unlikely to be successful because individual 
situations are specific, very varied, and often dependent on people other than the 
patient. However, the patient remains at the centre of the experience, and an 
informal process may help to ensure they chose the most appropriate guardian 
wherever possible.  
 
3. Training of guardians 
The training to do injections seemed to work well for all guardians. Initial fears were 
laid to rest during the process of learning how to do injections. The only suggestion 
for improvement of the training process came from a number of patients who 
requested that they should be present during the training. This recommendation 
should easily be implemented, and in fact was applied as an adaptation to the 
training process during the course of the trial.  
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4. Accessing medical care from the community 
The problem of accessing healthcare if a patient’s condition deteriorates is a 
disadvantage of community-based management that must be acknowledged and 
accepted. However, it is important to both minimise the risks and to allay the fears 
which being out of hospital generate. Not only is it crucial to ensure adequate 
mechanisms for community follow up and medical management, it is essential that 
patients and guardians understand that they are still under the care of the health 
system, and that there are clear, practical and realistic processes by which they can 
access care.   
 
The results of the TB-RROC evaluation can be summarised by saying that in the 
Malawian context clinical outcomes are probably not worse for patients who 
receive community-based care during the intensive phase of TB retreatment, that 
community-based care offers a cost-effective alternative to hospital-based care, 
and that there are economic and social benefits for a broad range of participants. 
The next stage involves considering the application of these findings within an 
operational situation. Ultimately, it is up to decision-makers to determine if 
community-based management is of benefit to the populations they provide for. 
Discussions with the Malawi NTP are on-going, and it has been suggested that the 
intervention should be evaluated under operational, rather than trial conditions, by 
performing a limited ‘post implementation’ study in Blantyre and Lilongwe.  
 
The TB-RROC intervention offers an entirely new model for delivering intramuscular 
injections as part of long-term treatment for tuberculosis in low resource settings, 
and has the potential to have application in different contexts. Currently, many 
NTPs are struggling with the issue of how to deliver care to the growing number of 
people requiring treatment for MDR-TB. Although the recommendation is for 
community-based management [157], there is not an obvious approach to the 
component of community-based care which involves providing daily intramuscular 
injections. Published schemes have involved either nurses travelling to patients 
homes, or patients travelling to the health facility [288], both of which require 
significant expenditure for either the health system or  the patient on transport and 
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time. This new model, which involves training people who are in regular close 
contact with patients in the community to administer injections, has the potential 
to offer a more efficient and  less costly alternative for patients with MDR-TB as 
well as those on retreatment regimen.  
 
 
8.4 Final conclusion 
 
 
As a whole, this piece of work has demonstrated the broad range of difficulties 
posed by the current ‘retreatment regimen.’ Category II regimen has no clinical trial 
evidence base, is associated with poor treatment outcomes, high rates of toxicity 
and the problems which accompany having to provide intramuscular injections. Yet 
it is still recommended by the WHO and used in the majority of low and middle 
income countries worldwide which have high burdens of recurrent TB in 
conjunction with the poor access to DST. There is an urgent need for this regimen to 
be re-evaluated, particularly with respect to the use of streptomycin. Few data exist 
on which to base decisions about the use of streptomycin, however those available 
do suggest that patients infected with an isoniazid resistant strain of M. 
tuberculosis have better clinical outcome if they receive streptomycin as part of 
their regimen [67]. As isoniazid resistance is the commonest non-MDR resistance 
pattern globally as well as in the recent MDR-TB survey in Malawi, and that it 
probably has the most impact on clinical outcome, streptomycin is still 
recommended for patients with recurrent TB in whom the prevalence of isoniazid 
resistance is of greatest concern. It is for these reasons that at a meeting of the 
Malawi TB technical working group in May 2015 it was decided to continue using 
the WHO category II regimen, and that WHO guidelines still recommend the 
regimen where access to DST is poor and the prevalence of MDR-TB is low.  
 
In summary, this thesis has drawn attention to the broad range of challenges faced 
by patients in Malawi with recurrent tuberculosis. It presents a comprehensive, 
prospective cohort study which, for the first time examines the burden of co-
morbidity in patients entering care at the point of a recurrent TB episode, and in so 
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doing identifies areas in which interventions may improve clinical outcomes for this 
group of patients. It also evaluates an entirely new method of delivering injectable 
agents as part of TB care in low resource settings. In the Malawian context, clinical 
outcomes are probably similar for patients who received hospital and community-
based management. However, community based management is associated with 
lower costs to the health system and better economic outcomes for users through 
mechanisms such as limiting food expenditure and reducing lost earnings; and with 
improved social outcomes through mechanisms such as maintaining dignity, 
independence and the ability to continue playing useful roles within family and 
community groups. Community-based management in which injections are 
delivered by trained guardians offers a new model of care which has the potential 
to benefit patients with MDR-TB as well as the thousands of patients treated for 
recurrent tuberculosis each year.  
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10 Appendices 
 
10.1 TB-RROC Community Advisory Board  
 
10.1.1 TB-RROC CAB Terms of Reference 
 
 
1. What is a Community Advisory Board (CAB)? 
 
A CAB is a group of volunteers whose role is to act as a liaison between a 
research organisation (such as MLW) and participant communities. The 
members of the board provide perspectives from the participant communities 
on the research work that is carried out by the organisation.   
 
2. What are the functions of the CAB? 
 
A CAB has the following major functions: 
 Assisting in the planning and implementation of research activities including 
study feasibility, recruitment, community education and community 
acceptability. 
 Providing feedback about community concerns and opinions. 
 Advising on best outreach and education methods to ensure communication 
between the research organisation and study participants. 
 
3. Who are the members of the CAB? 
 
 Membership of a CAB is strictly voluntary.  
 The members of a CAB should consist of members of the community in which 
the research is carried out.  
 Members should: 
- Be active in the community 
- Be chosen by the community members 
- Have an interest in health related issues 
- Be culturally sensitive 
 The CAB will consist of 6 – 8 members.  
 The CAB will elect one chairperson.  
 Introductory training will be provided for all members of the CAB.  
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4. What responsibilities do CAB members have? 
 
 Members of the CAB agree to strictly adhere to all legal and ethical standards 
regarding medical confidentiality. Membership of the CAB may be terminated 
if there is any breach in confidentiality.  
 Members of the CAB agree to give attention to mail and telephone calls from 
the responsible research team.  
 Members of the CAB agree to serve for the duration of participant 
recruitment into the study (from 2013 until 2015). 
 Members of the CAB should attend all meetings. A member may be dropped 
from the Board if they miss three consecutive meetings.  
 
5. How often does the CAB meet? 
 
 The CAB will meet approximately once every three months.  
 There will be a seating allowance for each meeting attended. This will be in-
line with MLW rates and policies.  
 
6. How does the CAB make decisions? 
 
 Not every issue discussed at CAB meetings requires a decision to be made; 
however when a decision is required, voting may be carried out.  
 In the event of a vote, each member will have one vote and the outcome will 
be decided based on a simple majority. At least five members will be need to 
be present for any formal decisions to be made by the group.  
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10.1.2 TB-RROC CAB minutes of first meeting 
 
Date:  16th January 2013 
Venue: MLW 
Present: All 6 CAB members, Trial PI, Trial nurse, MLW Science 
Communication officer 
 
The following questions were raised by members of the CAB and discussed: 
 
 How will guardians be identified?  
Patients will identify a guardian who they would like to be trained. The guardian 
must be available to inject daily for 60 days. The patient can chose to have a 
guardian who is not the one currently staying with them in the hospital. If the 
guardian is not competent to do the injection, the patient will have to stay in 
hospital. If the guardian goes away, the patient will have to come back into 
hospital. It will not be practical to train more than one guardian at the moment, 
but this suggestion will be kept in mind.  
 
 What are the training procedures? 
The CAB was shown the training materials and reviewed the training 
procedures.  
 
 How will streptomycin be stored and supplied?  
Streptomycin does not require refrigeration. It is not appropriate for the study 
to provide streptomycin, as drug procurement through the NTP is a key principle 
of the DOTS approach to TB control.  
 
 How will the safety of guardians be ensured? 
In the unlikely event of a needlestick injury PEP will be provided if necessary. 
Practical and emotional support will also be provided during regular reviews by 
the study team. The intervention poses no additional risk in terms of TB 
transmission, but standard contact tracing procedures under the existing TB 
systems will be followed.  
 
 How will the community be sensitised to the study? 
Suggestions included posters in health centres and meeting with TB officers, 
both of which are in the process of being organised.  
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10.1.3 TB-RROC CAB minutes of second meeting 
 
Date:  19th June 2013 
Venue: MLW 
Present: All 6 CAB members, Trial PI, Trial nurse, MLW Science 
Communication officer 
 
Results of the pilot study and plans for the next stages were presented to the CAB, 
following which a number off issues were discussed:  
 
 If 17 guardians successfully completed training in the pilot study, why were 
only 10 patients sent home?  
This was a pilot study which was trying to ask 2 questions: 1. Can guardians be 
trained to do injections? 2. Is it unsafe for guardians to give injections at 
home. In order to answer the first question, we trained all the guardians who 
were on the ward at the time. In order to answer the second question, we 
specified beforehand that only 10 patients would be discharged.  
 
 What challenges were faced in the pilot study?  
The biggest challenge was the inconsistent supply of streptomycin. This made 
it difficult to predict what was going to happen day to day. Stocks have been 
good for the past few months and we are confident that this will not be a 
continuous problem.  
 
 What changes have you made to the main study following the pilot study?  
1. Because recruitment was slower than we predicted, we have slightly 
changed the way we recruit patients. Initially patients were going to be 
recruited to the trial and the cohort study at the same time. Now patients 
can be recruited to one or both. If a patient does not have a guardian this 
does not mean that they should be excluded from the cohort study 
because the cohort study is trying to describe the clinical problems of ALL 
patients who get TB retreatment regimen.  
2. Because recruitment was slower, we have also reduced the target sample 
size to 268. 
3. We have made some small changes to the data collection forms so that is 
easier to collect accurate data for the main trial.  
 
 What were the qualifications and education levels of the guardians in the pilot 
study? Can illiterate people be trained to do injections?  
We did not formally document the education level of the guardians (but will 
do so in the main study – see the point above!). However we know from 
talking to the guardians that most were illiterate and had not completed 
school. This did not seem to affect their ability to learn how to do the 
injections. Practical instruction is given with visual aids. 
 
 Did you visit those 10 people who went home in the pilot study?  
Yes, we visited 1, 3 and 5 weeks after they were discharged home.  
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 Will you be providing food for patients who go home? In hospital, people 
are provided with food, but if they go home they will miss out on this.  
We are very aware of the problems of food for TB patients. However, many 
patients in hospital chose to have their own food rather than hospital food. 
This was not a concern raised by any of the participants in the pilot study. 
The benefits of being at home seem to far outweigh the benefits of hospital 
provided food.  
 
 Question from the study team to the CAB: What is the best option for 
reimbursing transport money? Should it be a flat rate to avoid confusion, or 
according to distance travelled?  
Definitely according to distance travelled, plus a bit more (which should be 
the same for all distances). The study team will draw up standard travel 
costs.  
 
 After the meeting, refreshments were provided and the CAB had a chance to 
talk informally to one of the patients who participated in the pilot study 
about her experiences of receiving injections given to her daily at home by 
her sister.  
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10.2 Radiology reporting proformae 
 
10.2.1 Chest x-ray: descriptive 
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10.2.2 Chest x-ray: diagnostic 
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10.2.3 CT Thorax: descriptive 
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10.2.4 CT Thorax: diagnostic 
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10.3 Competency assessment form 
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10.4 Instruction card 
 
 
 
 
 
 
 
1	 2	 3	
4	5	6	
7	 8	 9	
10	12	 11	
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Back of instruction card: 
 
 
 
 
 
 
 
 
 
 
Kumbukirani: 
 
Kusamba mmanja, musanabaye  ndi mukamaliza kupeleka Jakisoni. 
 
Kuvala ma gulovesi nthawi zonse pamene mukupeleka jakisoni. 
 
Kutaya masingano ndi masilinji mu bokosi la chikasu, pamene 
mwamalizira kugwiritsa ntchito. 
 
Kupeleka Jakisoni kwa odwala tsiku liri lonse 
 
Musapeleke jakisoni kwa wina aliyense kupatula odwala yekha. 
 
Woyang’anira odwala yekhayo amene waphunzitsidwa, ndi amene 
ayenera kupeleka jakisoni. 
 
Ngati pangakhale  zovuta: 
Lolemba kufikira Lachisanu 8 koloko mpaka 5 koloko, phone: 
 
Helen Mangochi: 0998654382 
Jimmy  Chavula: 0998654383 
George Musowa: 0998654384 
 
Nthawi ina ili yonse: 
Pitani ku Ngozi kapena ku Wodi 3A ku chipatala cha  
Queen Elizabeth central Hospital. 
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Back of instruction card in English: 
 
 
 
 
 
Remember to: 
 
Wash your hands before and after giving the injection. 
 
Wear gloves at all times when giving the injection. 
 
Throw away all needles and syringes into the yellow box when you have 
finished using them. 
 
Give the injection to the patient every day. 
 
Do not give the injection to anybody else apart from the patient. 
 
Only the trained guardian should give the injection.  
 
 
In case of problems: 
Monday – Friday 8am – 5pm phone: 
 
Helen Mangochi: 0998654382 
Jimmy  Chavula: 0998654383 
George Musowa: 0998654384 
 
All other times: 
Attend AETC or ward 3A at  
Queen Elizabeth central Hospital. 
 
 
 
 328 
10.5 Home monitoring form 
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10.6 Adverse Event form 
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10.7 TB-RROC DSMB 
 
10.7.1 TB-RROC DSMB Terms of Reference 
 
The DSMB reports to the trial sponsor, the research ethics committees, the PI and TSG.  
The DSMB  are an advisory group, they do not have the power or the authority to stop a 
trial or change a protocol.  The DSMC report their findings to the sponsor, the relevant 
IRB(s) and TSG who make the decision whether to continue, suspend, modify or stop a trial 
or amend the protocol.  
The DSMB has access to data for the trial so that they can see any emerging risks such as 
frequency or severity in adverse events.   
Their monitoring should also include considering external factors to the study such as 
therapeutic or scientific developments that may have an impact on the safety of 
participants or the ethics of the study. 
Confidentiality is paramount. The DSMB must protect the confidentiality of the trial data 
and the results of monitoring. 
Their role and responsibilities are: 
 To review the research protocol and the plans therein for data and safety monitoring; 
 To review any proposed modifications to the study prior to their implementation;   
 To review serious adverse events and adverse event reports provided by the PI at 
monthly intervals; 
 To review the planned interim analysis of study data after recruitment of 130 patients, 
as outlined in the protocol; 
 To inform the Sponsor, Research Ethics Committee and Site Investigators on the 
acceptability of continued recruitment to the Trial. If the DSMB makes a 
recommendation that a trial should be stopped or suspended, the sponsor will take the 
necessary action to ensure that new recruitment to the trial is stopped whilst the 
DSMB’s report is evaluated and the research ethics committee is informed.  If there is 
disagreement between the DSMB and the trial steering group and/or the research 
ethics committee on a recommendation to stop or suspend a trial, the sponsor may 
convene an independent external advisory committee to arbitrate.  During any such 
process, recruitment of new participants to the trial will be suspended;  
 To consider any requests for the release of interim trial data and to recommend to the 
Trial Steering Group on the advisability of this; 
 To consider any issues or concerns raised by local investigators, funding bodies etc that 
the Trial Steering Group has not been able to resolve; 
 To review and approve primary trial abstracts and manuscripts to give an assurance 
that the results are fairly presented and that the conclusions are appropriate. 
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10.7.2 TB-RROC DSMB interim report 
 
TB-RROC study DSMB meeting 12th September 
 
1. The meeting took place in the Wellcome Trust Tropical Centre seminar 
room. Professor Stephen Gordon, Dr Mas Chaponda, Professor Neil French 
(chair), Dr Danielle Cohen (investigator), Professor Bertie Squire 
(investigator) were present. Dr Cohen provided an overview of the trial to 
date. Key areas discussed were 
a. Errors in counting recruits into each arm explained and corrected 
b. Lower than expected number of end-points with 7 deaths and one 
treatment default. 
c. Review of case histories of all deaths in the two arms: 5 in 
community group, 2 in hospital group. 
2. The DSMB commended the investigators on the conduct of the study to 
date. 
3. The DSMB recommend the continuation of the study. 
4. The lower than expected end-points are the principal threat to the study 
and under current end-point accumulation there is a risk that the study may 
be underpowered to provide a conclusive result. Consequently the DSMB 
recommend 
a. Review with the other investigators whether additional analytical 
methods could be applied to the data 
b. Consider whether it is feasible to extend recruitment to increase 
end-point ascertainment. 
5. The DSMB has no formal plan to meet prior to the termination of the study 
unless requested by the investigators. We will continue to monitor monthly 
mortality data. 
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10.8 Qualitative topic guides 
 
10.8.1 Patient interviews 
 
Thank you for agreeing to talk to me. I am interested in learning about what it’s been like 
getting treatment for TB. I will be recording the interview, just so that I can make sure I 
have an accurate record of our conversation. If you feel uncomfortable at any time we can 
stop, and if we are talking about something you don’t want to talk about just tell me and 
we can skip it.  
 
 What does the participant know about TB 
 
 What are the participant’s experiences of TB treatment 
- Describe your treatment to me. 
- Tell me about your injections. 
- What is it like being in hospital. 
- What is it like getting treatment at home. 
- What is it like being in your community when you are taking TB treatment. 
- How do you feel about having TB treatment. 
- Did you feel differently about TB at the beginning of your treatment compared 
to now. Tell me more about that.  
 
 I would like to hear more about the healthcare workers you met during treatment. Can 
you tell me about them 
- How often did you have contact with healthcare workers.  
- What role did they play in your treatment. 
 
 How, if at all, has having TB treatment affected your life.  
- Work 
- Relationships – spouse, children, friends 
- Financial situation 
 
 What things influence people to continue taking TB treatment. 
- What things help somebody to take TB treatment. 
- What things make it difficult for somebody to take TB treatment. 
- What things would make it easier for you to take TB treatment.  
 
 Do you talk to anyone about your TB treatment. 
- Who do you talk to.  
- Tell me what it’s like talking to other people about TB 
 
 What do you think will happen to your health in the future.  
 
 Those are the main topics I had planned to cover, but is there anything else you would 
like to tell me about? Is there something we have missed that you think I should know? 
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10.8.2 Guardian interviews 
 
Thank you for agreeing to talk to me. I am interested in learning about what it’s been like 
being a guardian for a patient being treated for TB. I will be recording the interview, just so 
that I can make sure I have an accurate record of our conversation. If you feel 
uncomfortable at any time we can stop, and if we are talking about something you don’t 
want to talk about just tell me and we can skip it.  
 
 Can you tell me what you know about TB. 
 
 Tell me about your experiences of being a guardian for a patient with TB 
- Describe the treatment to me.  
- Tell me about the injections your patient received. 
- Tell me about learning to do the injections.  
- What is it like being in hospital. 
- What is it like looking after your patient at home.  
- Describe what your community thinks about people who are on TB treatment 
- Tell me about your position in the community since you started giving 
injections to your patient 
- Did you feel differently about TB at the beginning of your patient’s treatment 
compared to now. Tell me more about that.  
 
 I would like to hear more about the healthcare workers you met during your patient’s 
treatment. Can you tell me about them 
- How often did you have contact with healthcare workers.  
- What role did they play in the treatment of your patient. 
- What were the interactions you had with healthcare workers as a guardian. 
 
 How, if at all, has being a guardian for a TB patient affected your life.  
- Work  
- Relationships – spouse, children, friends 
- Financial situation 
 
 What influences people to continue taking TB treatment.  
- What things help somebody to take TB treatment.   
- What things make it difficult for people to take TB treatment. 
- What things do you think would make it easier for people to take TB treatment.  
 
 Do you talk to anyone about TB.  
- Who do you talk to. 
- Tell me what it’s like talking to other people about TB 
 
 Those are the main topics I had planned to cover, but is there anything else you would 
like to tell me about. Is there something we have missed that you think I should know.  
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10.8.3 Focus Group Discussions 
 
Tell me what you know about TB? 
- Transmission / causes 
- Diagnosis 
- Treatment (formal & informal) 
 
How, if at all, does TB affect your community? 
- Individual people 
- Households 
- Socially 
- Economically 
- Adults & children 
 
Why do you think some people are given TB treatment at home and others have to be in 
hospital?  
 
How, if at all, does being in hospital for TB treatment affect people?  
 
What do you think about people taking TB treatment in the community?  
 
Have you heard about people who get injections as part of TB treatment?  
- Tell me what you have heard about 
- What do you think about injections for TB?  
(If they have heard about CMB but they have the wrong idea about what it involves, probe 
further e.g. where did they hear about it? What have they been told?) 
 
Some people with TB are in hospital because they need to have injections every day for TB, 
but many of them are well enough to be at home. There is an idea that guardians can be 
trained by the nurses in the hospital to give injections to their patients. This would mean 
that if patients were well enough, they could go home. What do you think of that?  
- Patient 
- Guardian 
- Household 
- Friends 
- Wider community 
- Health care service (responsibility of community v health care workers) 
 
- How would you feel if you had a TB patient and the hospital offered to teach 
you to give injections to your patient, so that you could give them treatment at 
home?  
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10.8.4 Key informant interviews 
 
 
 Role of the Key Informant in TB care 
 
 Views of inpatient care for TB patients 
- Possible problems & advantages for patients 
- Possible problems & advantages for guardians/friends/relatives 
- Possible problems & advantages for Health care systems 
 
 Opinions about the intervention 
- Effects for patients 
- Effects for guardians/friends/relatives 
- Effects for communities 
- Effects for health care systems 
 
 General view of the intervention 
 
 
 
10.8.5 Hospital observations 
 
 Setting and environment of the hospital – male & female wards, nursing station, TB 
office 
 
 General condition of the patients – physical and psychological 
 
 Behaviours of patients on the ward 
 
 Relationships between patients – interactions, discussions  
 
 Behaviours of guardians – on and around the ward 
 
 Interactions between patients and guardians 
 
 Relationships between patients, guardians and healthcare workers 
 
 The process of injection administration on the ward 
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10.8.6 Community observations 
 
 Setting and environment of the household 
 
 General condition of the patient – physical and psychological 
 
 Interaction between patient and guardian 
 
 Interaction between patient and the rest of the household/community 
 
 Interaction between guardian and the rest of the household/community 
 
 The process of the guardian administering the injection 
 
 Reaction of the patient, guardian, household members, wider community to the 
fieldworker 
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